0001558370-24-01489310-Q Rezolute, Inc. 20241107202411071647041647041647041

into license, co-development, collaboration or similar arrangements.Any or all of our forward-looking statements may turn out to be wrong. They can be affected by inaccurate assumptions or by known and unknown risks, uncertainties and other factors including, but not limited to, â€œRisk Factorsâ€ described in (i) Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended June 30, 2024 (the â€œ2024 Form 10-Kâ€), filed with the Securities and Exchange Commission (â€œSECâ€) on September 19, 2024.In addition, there may be other factors that could cause our actual results to be materially different from the results referenced in the forward-looking statements, some of which are included elsewhere in this Report, including â€œManagementâ€™s Discussion and Analysis of Financial Condition and Results of Operations.â€ Many of these factors will be important in determining our actual future results. Consequently, no forward-looking statement can be guaranteed. Our actual future results may vary materially from those expressed or implied in any forward-looking statements. All forward-looking statements contained in this Report are qualified in their entirety by this cautionary statement. Forward-looking statements speak only as of the date they are made, and we disclaim any obligation to update any forward-looking statements to reflect events or circumstances after the date of this Report, except as otherwise required by applicable law.â€‹â€‹ii Table of ContentsPARTÂ IÂ - FINANCIAL INFORMATIONITEMÂ 1. FINANCIAL STATEMENTS.Rezolute, Inc.Unaudited Condensed Consolidated Balance Sheets(In thousands, except per share amounts)â€‹â€‹â€‹

comprehensive loss (in thousands):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹2024Â Â Â Â 2023Research and developmentâ€‹$ 119â€‹$ 131General and administrativeâ€‹Â 48â€‹Â 42Totalâ€‹$ 167â€‹$ 173â€‹As of September 30, 2024, the weighted average remaining lease term under operating leases was 3.0 years, and the weighted average discount rate for operating lease liabilities was 7.1%. Future cash payments under all operating lease agreements as of September 30, 2024 are as follows (in thousands):â€‹â€‹â€‹â€‹â€‹â€‹Fiscal year ending JuneÂ 30,Â Â Â Â Â Â Â Â â€‹Remainder of fiscal year 2025â€‹$ 5642026â€‹â€‹ 7702027â€‹â€‹ 750Thereafterâ€‹â€‹ 224Total lease paymentsâ€‹â€‹ 2,308Less imputed interestâ€‹Â (225)Present value of operating lease liabilitiesâ€‹$ 2,083â€‹â€‹NOTE 5 â€” LICENSE AGREEMENTSXOMA License AgreementIn December 2017, the Company entered into a license agreement (â€œXOMA License Agreementâ€) with XOMA Corporation (â€œXOMAâ€), through its wholly-owned subsidiary, XOMA (U.S.) LLC, pursuant to which XOMA granted an exclusive global license to the Company to develop and commercialize XOMA 358 (formerly X358 or RZ358, now ersodetug) for all indications. In January 2022, the Company was required to make a milestone payment under the XOMA License Agreement of $2.0 million that became due upon the dosing of the last patient in the Companyâ€™s Phase 2b Clinical Trial for ersodetug. In April 2024, the Company was required to make a milestone payment under the XOMA License Agreement of $5.0 million that became due upon dosing of the first patient in the Companyâ€™s Phase 3 Clinical Trial for ersodetug. Upon the achievement of certain clinical and regulatory events under the XOMA License Agreement, the Company will be required to make additional milestone payments to XOMA up to $30.0 million. After the clinical and regulatory milestones, the Company will be required, upon the future commercialization of ersodetug, to pay royalties to XOMA based on the net sales of the related products and additional milestone payments to XOMA up to $185.0 million related to 8 Table of ContentsRezolute,Â Inc.NotesÂ to Unaudited Condensed Consolidated Financial Statementsannual net sales amounts. There have been no events that would result in any royalty payments owed under the XOMA License Agreement to date. The Company records a liability and corresponding expense for milestone payments under license agreements in the period that the milestone event is achieved. The next milestone payment of $5.0 million will be due upon dosing of the last patient in either of the Phase 3 clinical trials for ersodetug.ActiveSite License AgreementIn August 2017, the Company entered into a Development and License Agreement (the â€œActiveSite License Agreementâ€) with ActiveSite Pharmaceuticals, Inc. (â€œActiveSiteâ€) pursuant to which the Company acquired the rights to ActiveSiteâ€™s Plasma Kallikrein Inhibitor program (â€œPKI Portfolioâ€). The Company is initially using the PKI Portfolio to develop an oral PKI therapeutic for diabetic macular edema (RZ402) and may use the PKI Portfolio to develop other therapeutics for different indications. The ActiveSite License Agreement requires various milestone payments up to $46.5 million, if all milestones are achieved. The first milestone payment for $1.0 million was paid in December 2020 after clearance was received for an Initial Drug Application, or IND, filed with the U.S. Food and Drug Administration (â€œFDAâ€). The second milestone payment of $3.0 million was paid in February 2023 after dosing of the first patient in a Phase 2 clinical trial for RZ402. The next milestone payment of $5.0 million will be due upon dosing of the first patient in a Phase 3 clinical trial. The Company is also required to pay royalties equal to 2.0% of any sales of products that use the PKI Portfolio. There have been no events that would result in any royalty payments owed under the ActiveSite License Agreement to date.NOTE 6 â€” EMBEDDED DERIVATIVE LIABILITYOn April 14, 2021, the Company entered into a $30.0 million Loan and Security Agreement (the â€œLoan Agreementâ€) with SLR Investment Corp. and certain other lenders (collectively, the â€œLendersâ€). The Lenders agreed to loan up to $30.0 million but the actual amount borrowed by the Company amounted to $15.0 million. The maturity date of the outstanding borrowings was April 1, 2026 (the â€œMaturity Dateâ€), but the Company elected to repay the entire amount and terminated the Loan Agreement on June 30, 2022.Concurrently with the execution of the Loan Agreement, the Company entered into an exit fee agreement (the â€œExit Fee Agreementâ€) that provides for a fee of 4.00% of the funded principal balance for a total of $0.6 million in the event certain transactions (defined as â€œExit Eventsâ€) occur prior to April 13, 2031. The Exit Fee Agreement was not impacted by the termination of the Loan Agreement discussed above. The Company is accounting for the Exit Fee Agreement as an embedded derivative liability with an estimated fair value of $0.5 million as of September 30, 2024 and June 30, 2024. Exit Events include, but are not limited to, sales of substantially all assets, certain mergers, change of control transactions, and issuances of common stock that result in new investors owning more than 35% of the Companyâ€™s shares. Fair value of this embedded derivative liability is reassessed at the end of each reporting period with changes in fair value recognized as a non-operating gain or loss.NOTE 7 â€” SHAREHOLDERSâ€™ EQUITYPre-Funded WarrantsBetween October 2021 and June 2024, the Company issued fully vested pre-funded warrants (â€œPFWsâ€) exercisable to purchase an aggregate of 21.3 million shares of common stock. As of September 30, 2024, all outstanding PFWs meet the requirements to be classified in shareholdersâ€™ equity under the caption additional paid-in capital. The PFWs do not entitle the holders thereof to any voting rights or any of the other rights or privileges to which holders of common stock are entitled. The exercise prices of the PFWs are subject to adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting holders of common stock. In the event of certain fundamental corporate transactions, the holders of the PFWs are entitled to receive the kind and amount of securities, cash or other property that the holders would have received had they exercised the PFWs immediately prior to such transaction. The PFWs are exercisable at any time, subject to the then effective ownership blocker percentage (the â€œOBPâ€) as elected by each of the holders of PFWs. The OBP is a percentage designated by the holders whereby the PFWs cannot be exercised if, after giving effect thereto, the holder would beneficially own more than the designated OBP. However, upon at leastÂ 61 daysâ€™ prior notice to the Company, any holder of PFWs may elect to increase or decrease the OBP to any other percentage not to exceedÂ 19.99%. Assuming the holders 9 Table of ContentsRezolute,Â Inc.NotesÂ to Unaudited Condensed Consolidated Financial Statementscomply with the respective OBP terms, all of the PFWs may be exercised at any time by paying the respective exercise price or electing to exercise on a cashless basis. As of June 30, 2024, the Company had an aggregate of 15,020,371 PFWs that were outstanding. The following table summarizes PFW activity for the three months ended September 30, 2024:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹2021â€‹2022â€‹Exchangeâ€‹2024â€‹â€‹â€‹PFWsâ€‹PFWsâ€‹PFWsâ€‹PFWsâ€‹TotalOutstanding, June 30, 2024 123,000(1) 8,147,371(2) 3,000,000(3) 3,750,000(4) 15,020,371Cashless exercise of PFWs:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Shares surrendered for exercise price â€”â€‹ â€”â€‹ (131)â€‹ â€”â€‹ (131)Shares of common stock issued â€”â€‹ â€”â€‹ (610,273)â€‹ â€”â€‹ (610,273)Outstanding, September 30, 2024 123,000â€‹ 8,147,371â€‹ 2,389,596â€‹ 3,750,000â€‹ 14,409,967(1)In connection with an underwritten offering in October 2021, PFWs were issued to purchase 1,661,461 shares of common stock at an issuance price of $6.49 per share (the â€œ2021 PFWsâ€). The exercise price of the 2021 PFWs is $0.01 per share.(2)In connection with a registered direct offering in May 2022, the Company issued 1,973,684Â Class A PFWs and 10,947,371 Class B PFWs to purchase an aggregate of 12,921,055 shares of common stock at an issuance price of $3.799 per warrant (the â€œ2022 PFWsâ€). The exercise price of the 2022 PFWs is $0.001 per share. For the fiscal year ended June 30, 2024, the holders elected cashless exercises for a total of 4,773,684 of the 2022 PFWs resulting in 8,147,371 shares that remained outstanding as of June 30, 2024. The 2022 PFWs were classified within shareholdersâ€™ equity for the entirety of the fiscal quarter ended September 30, 2024 and the fiscal year ended June 30, 2024.(3)As discussed below under the caption Exchange Agreement, the Company issued 3,000,000 Exchange PFWs on March 8, 2024. The exercise price of the Exchange PFWs is $0.001 per share. The Exchange PFWs were initially classified as a derivative liability until May 13, 2024 when the terms were amended to permit reclassification within shareholdersâ€™ equity.(4)As discussed below under the caption 2024 Underwritten Offering, the Company issued 2024 PFWs for the purchase of 3,750,000 shares of common stock on June 17, 2024. The exercise price of the 2024 PFWs is $0.001 per share.2024 Private PlacementIn June 2024, the Company entered into a securities purchase agreement (the â€œ2024 SPAâ€) with Handok, Inc. and one other investor relating to a private placement (the â€œ2024 Private Placementâ€), pursuant to which 1,500,000 shares of common stock were issued at a purchase price of $4.00 per share. Closing of the 2024 Private Placement occurred in July 2024, resulting in net proceeds of $6.0 million after deduction of offering costs.2024 Underwritten OfferingOn June 13, 2024, the Company entered into an underwriting agreement with Jefferies LLC and Cantor Fitzgerald & Co. (the â€œUnderwritersâ€) for the planned issuance and sale of equity securities in an underwritten public offering (the â€œ2024 Underwritten Offeringâ€). The 2024 Underwritten Offering provided for the issuance of (i) 11,250,000 shares of common stock at a price of $4.00 per share for gross proceeds of $45.0 million, and (ii) pre-funded warrants to purchase 3,750,000 shares of common stock at a public offering price of $3.999 per pre-funded warrant (the â€œ2024 PFWsâ€) for gross proceeds of $15.0 million. The Company granted the 2024 Underwriters a 30-day option to purchase up to an additional 2,250,000 shares of its common stock in the 2024 Underwritten Offering at a public offering price of $4.00 per share, less underwriting commissions (the â€œ2024 Underwritersâ€™ Optionâ€). The Underwritersâ€™ Option was partially exercised for 1,786,589 shares of common stock for gross proceeds of $7.1 million. Closing occurred on June 24, 2024, whereby the aggregate gross proceeds from the 2024 Underwritten Offering amounted to $67.1 million before deductions for underwriting commissions of 6.0% of the gross proceeds and other offering costs of approximately $0.5 million. After deducting total offering costs of $4.5 million, the net proceeds of the 2024 Underwritten Offering amounted to approximately $62.6 million.10 Table of ContentsRezolute,Â Inc.NotesÂ to Unaudited Condensed Consolidated Financial StatementsExchange AgreementOn MarchÂ 8, 2024, the Company entered into a securities exchange agreement (the â€œExchange Agreementâ€) with certain of its stockholders (the â€œExchanging Shareholdersâ€), whereby the Company purchased 3,000,000 shares of common stock representing approximately 7% of outstanding shares with an aggregate fair value of $5,700,000 (the â€œRetired Sharesâ€) from the Exchanging Shareholders. The Retired Shares were immediately cancelled whereby they will remain as authorized shares for future issuance in accordance with Nevada law. Consideration for the acquisition of the Retired Shares consisted of (i) a cash payment to the Exchanging Shareholders of $3,000, and (ii) the issuance of pre-funded warrants (the â€œExchange PFWsâ€) to the Exchanging Shareholders with an estimated fair value of $5,697,000. The Exchange PFWs do not expire and are exercisable to purchase an aggregate of 3,000,000 shares of the Companyâ€™s outstanding common stock at an exercise price of $0.001 per share. As required pursuant to the Exchange Agreement, the Company filed a registration statement in August 2024 to register the shares issuable upon the exercise of the Exchange PFWs.The Exchange PFWs originally required approval by the Companyâ€™s shareholders if the exercise of the Exchange PFWs resulted in aggregate beneficial ownership by the holders in excess of 19.99%. Even though the Exchange PFWs only entitled the holders to purchase 7% of the Companyâ€™s outstanding shares of common stock, the requirement to obtain shareholder approval for ownership in excess of 19.99% resulted in the treatment of the exchange PFWs as a warrant derivative liability of $5.7 million as of the issuance date. The fair value of this warrant derivative liability increased by approximately $2.9 million, for a total of approximately $8.5 million as of May 13, 2024 when the Exchange PFWs were amended to permit equity classification. Accordingly, the derivative liability was reclassified to shareholdersâ€™ equity on May 13, 2024. Jefferies Open Market Sales AgreementOn November 14, 2023, the Company and Jefferies LLC (the â€œAgentâ€) entered into an open market sales agreement (the â€œSales Agreementâ€) that provides for an â€œeat the marketâ€ offering for the sale of up to $50.0 million in shares of the Companyâ€™s common stock (the â€œPlacement Sharesâ€) through the Agent. The Agent is acting as sales agent and is required to use commercially reasonable efforts to sell all of the Placement Shares requested to be sold by the Company, consistent with the Agentâ€™s normal trading and sales practices, on mutually agreed terms between the Agent and the Company. The Sales Agreement will terminate when all of the Placement Shares have been sold, or earlier upon the election of either the Company or the Agent.The Company has no obligation to sell any of the Placement Shares under the Sales Agreement. The Company intends to use the net proceeds, if any, from amounts sold under the Sales Agreement for general corporate purposes, including working capital. Under the terms of the Sales Agreement, the Company agreed to pay the Agent a commission equal to 3.0% of the gross sales price of the Placement Shares plus certain expenses incurred by the Agent in connection with the offering.For the three months ended September 30, 2024, the Company did not elect to sell any shares of its common stock pursuant to the Sales Agreement. Accordingly, the maximum amount remaining for sale under the Sales Agreement amounts to $50.0 million as of September 30, 2024.11 Table of ContentsRezolute,Â Inc.NotesÂ to Unaudited Condensed Consolidated Financial StatementsNOTE 8 â€” SHARE-BASED COMPENSATION AND WARRANTSStock Option PlansPresented below is a summary of the number of shares outstanding, authorized, and available for future grants under the Companyâ€™s stock option plans and an inducement grant not associated with a stock option plan as of September 30, 2024 (in thousands):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â Number of Shares as of September 30, 2024DescriptionÂ Â Â Â AuthorizedÂ Â Â Â OutstandingÂ Â Â Â Available2015 PlanÂ 17Â 17Â â€”2016 PlanÂ 123Â 123Â â€”2019 PlanÂ 200Â 200Â â€”2021 Planâ€‹ 10,580â€‹ 10,160â€‹ 420Inducement Grantâ€‹ 275â€‹ 275â€‹ â€”TotalÂ 11,195Â 10,775Â 420â€‹2022 Employee Stock Purchase PlanOn June 16, 2022, the Companyâ€™s shareholders approved the adoption of the 2022 Employee Stock Purchase Plan (the â€œ2022 ESPPâ€). The 2022 ESPP provides an opportunity for employees to purchase the Companyâ€™s common stock through accumulated payroll deductions.The 2022 ESPP has consecutive offering periods that begin approximately every 6 months commencing on the first trading day on or after July 1 and terminating on the last trading day of the offering period ending on December 31 and commencing on the first trading day on or after January 1 and terminating on the last trading day of the offering period ending on June 30. The 2022 ESPP reserves 0.5 million shares for purchases. There have been no offering periods under the 2022 ESPP through September 30, 2024.Stock Options OutstandingFor the three months ended September 30, 2024, the following table sets forth a summary of the combined activity under the Companyâ€™s stock option plans and an inducement grant not associated with a stock option plan (shares in thousands):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â SharesÂ Â Â Â PriceÂ (1)Â Â Â Â TermÂ (2)Outstanding, June 30, 2024Â 10,891â€‹$ 3.82â€‹8.1Grants to employeesâ€‹ 240â€‹â€‹ 4.73â€‹â€‹Exercisesâ€‹ (38)(3)â€‹ 2.44â€‹â€‹Forfeitedâ€‹ (318)â€‹â€‹ 2.61â€‹â€‹Outstanding, September 30, 2024Â 10,775(4)Â 3.88Â 7.7Vested, September 30, 2024Â 5,525(5)Â 5.07Â 7.2(1)Represents the weighted average exercise price.(2)Represents the weighted average remaining contractual term for the number of years until the stock options expire.(3)The total intrinsic value (the amount by which the fair market value exceeded the exercise price) of stock options exercised during the three months ended September 30, 2024, was $0.1 million.(4)As of September 30, 2024, the intrinsic value of outstanding options was approximately $19.2 million.(5)As of September 30, 2024, the aggregate intrinsic value of vested stock options was approximately $7.5 million.For the three months ended September 30, 2024, the aggregate fair value of stock options granted for approximately 0.2 million shares of common stock amounted to $0.8 million or approximately $3.45 per share as of the grant dates. Fair value was computed using the Black-Scholes-Merton (â€œBSMâ€) option-pricing model and will result in the recognition of compensation cost ratably over the expected vesting period of the stock options. 12 Table of ContentsRezolute,Â Inc.NotesÂ to Unaudited Condensed Consolidated Financial StatementsFor the three months ended September 30, 2024, the fair value of stock options was estimated on the respective dates of grant, with the following weighted-average assumptions: â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Market price of common stock on grant dateâ€‹ 4.73â€‹Expected volatilityÂ Â Â Â â€‹ 84%Risk free interest rateÂ â€‹ 3.7%Expected term (years)Â â€‹ 6.1â€‹Dividend yieldÂ â€‹ 0%â€‹Share-based compensation expense for the three months ended September 30, 2024 and 2023 is included under the following captions in the unaudited condensed consolidated statements of operations and comprehensive loss (in thousands):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹2024Â Â Â Â 2023â€‹Research and developmentâ€‹$ 712â€‹$ 840â€‹General and administrativeâ€‹Â 688â€‹Â 1,009â€‹Totalâ€‹$ 1,400â€‹$ 1,849â€‹â€‹Unrecognized share-based compensation expense is approximately $10.4 million as of September 30, 2024. This amount is expected to be recognized over a weighted average period of 1.8 years.Pre-Funded WarrantsPFWs are outstanding for a total of 14.4 million shares as of September 30, 2024. Please refer to Note 7 for additional information about outstanding PFWs.Legacy WarrantsIn connection with an equity financing in October 2020, the Company issued warrants entitling the holders to purchase approximately 0.8 million shares of common stock. The warrants are exercisable at $19.50 per share for a period of seven years, may be exercised on a cash or cashless basis at the election of the holders, and the holders are entitled to share in any dividends or distributions payable to holders of common stock on an as-converted basis (â€œthe Participating Warrantsâ€). Additionally, the Company has issued warrants in conjunction with various debt and equity financings and for services. As of September 30, 2024, all of the warrants were vested. The Participating Warrants and other warrants are collectively referred to as the â€œLegacy Warrants.â€For the three months ended September 30, 2024, no Legacy Warrants were granted or exercised. The following table sets forth a summary of all Legacy Warrants for the three months ended September 30, 2024 (shares in thousands):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â SharesÂ Â Â Â PriceÂ (1)Â Â Â Â TermÂ (2)Outstanding, June 30, 2024Â 861Â Â $ 20.28Â 3.2ExpirationsÂ (10)Â Â Â 52.00Â Â Â Outstanding, September 30, 2024Â 851Â Â Â 19.90Â 3.0(1)Represents the weighted average exercise price.(2)Represents the weighted average remaining contractual term for the number of years until the warrants expire.13 Table of ContentsRezolute,Â Inc.NotesÂ to Unaudited Condensed Consolidated Financial StatementsNOTE 9 â€” COMMITMENTS AND CONTINGENCIESLicensing CommitmentsPlease refer to Note 5 for further discussion of commitments to make milestone payments and to pay royalties under license agreements with XOMA and ActiveSite.Legal MattersFrom time to time, the Company may be involved in litigation relating to claims arising out of operations in the normal course of business. At each reporting period, the Company evaluates known claims to determine whether a potential loss amount or a potential range of loss is probable and reasonably estimable under ASC 450, Contingencies. As of September 30, 2024, there were no pending or threatened lawsuits that could reasonably be expected to have a material effect on the Companyâ€™s results of operations. Legal fees are expensed as incurred.NOTE 10 â€” RELATED PARTY TRANSACTIONSRelated Party Licensing AgreementOn September 15, 2020, the Company and Handok entered into an exclusive license agreement (the

â€œHandok Licenseâ€) for the territory of the Republic of Korea. The Handok License relates to pharmaceutical products in final dosage form containing the pharmaceutical compounds developed or to be developed by the Company, including those related to ersodetug and RZ402. The Handok License is in effect for a period of 20 years after the first commercial sale of each product and requires (i) milestone payments to the Company of $0.5 million upon approval of a New Drug Application (â€œNDAâ€) for each product in the territory, and (ii) the Company will sell products ordered by Handok at a transfer price equal to 70% of the net selling price of the products. To date, no milestone payments have been earned by the Company.Investors in 2024 Private PlacementHandok was an investor in the 2024 Private Placement discussed in Note 7 for which the Company issued 1,250,000 shares of common stock at a purchase price of $4.00 resulting in gross proceeds of $5.0 million.NOTE 11 â€” INCOME TAXESIncome tax expense during interim periods is based on applying an estimated annualized effective income tax rate applied to the respective quarterly periods, adjusted for discrete tax items in the period in which they occur. The computation of the annualized estimated effective tax rate for each interim period requires certain estimates and significant judgment including, but not limited to, the expected operating results for the year, projections of the proportion of income earned and taxed in various jurisdictions, permanent and temporary differences, and the likelihood of recovering deferred income tax assets generated in the current year. The accounting estimates used to compute the provision for income taxes may change as new events occur, more experience is obtained, additional information becomes known or as the tax environment changes.For the three months ended September 30, 2024 and 2023, the Company did not recognize any income tax benefit due to a full valuation allowance on its deferred income tax assets. The Company did not have any material changes to its conclusions regarding valuation allowances for deferred income tax assets or uncertain tax positions for the three months ended September 30, 2024 and 2023.14 Table of ContentsRezolute,Â Inc.NotesÂ to Unaudited Condensed Consolidated Financial StatementsNOTE 12 â€” NET LOSS PER SHAREBasic net loss per share is computed by dividing net loss by the weighted average number of outstanding shares of common stock and PFWs during periods when the PFWs are accounted for as equity instruments. Common shares associated with PFWs that are accounted for as equity instruments are included in the computation of basic and diluted net loss per share since the exercise price is negligible and all of the PFWs are fully vested and exercisable. Accordingly, the weighted average number of shares outstanding for basic and diluted net loss per share is computed as follows for the three months ended September 30, 2024 and 2023 (in thousands):â€‹â€‹â€‹

patient with ersodetug. Dr. Patti reported that the patient safely achieved correction of hypoglycemia with ersodetug, enabling the patient to wean off continuous intravenous dextrose and several other medications for hypoglycemia, leave the hospital after a prolonged stay, and resume receiving concurrent treatment for his cancer with tumor-directed therapies. The patient remained on ersodetug for more than a year until he eventually passed away due to progression of his underlying malignant/metastatic insulinoma.We have received and approved several additional requests to date for use of ersodetug in patients with tumor HI caused by metastatic insulinomas and other insulin secreting metastatic cancer (cervical). In the U.S., these requests have all been approved by the Division. These patients have been refractory to usual standard of care therapies for chronic management of hypoglycemia and required continuous high volume/concentration intravenous dextrose or nutritional infusion and were hospitalized and in life-threatening or hospice-bound condition because of uncontrollable hypoglycemia. Further treatment with tumor-directed therapies (e.g., embolization, radiotherapy, chemotherapy) was often deferred as a result of the debilitating hypoglycemia.Generally, dosing for tumor HI patients has been either 6 mg/kg or 9 mg/kg every 1-2 weeks. In all cases to date, ersodetug has led to substantial improvement in hypoglycemia and has been well tolerated. Within a relatively short period of time after administration of ersodetug, continuous intravenous dextrose was discontinued or substantially reduced and hospitalized patients were able to be discharged and receive maintenance ersodetug doses on an outpatient basis, with durable benefit. In most cases, other background medical therapies for hypoglycemia were able to be weaned or stopped, and patients were able to resume tumor-directed therapies for treatment of their underlying cancer. Patients with metastatic tumor HI often have underlying hepatic injury (abnormal enzymes) at baseline due to hepatic metastases or previous tumor-directed treatments (e.g., partial liver resection or embolization). The patients with hepatic injury that have been treated under the EAP have not exhibited any indication of hepatic toxicity with the use of ersodetug. RZ402 for diabetic macular edema (DME)Our second clinical asset, RZ402, is an oral plasma kallikrein inhibitor (â€œPKIâ€) and potential therapy for the chronic treatment of diabetic macular edema (â€œDMEâ€). DME is a vascular complication of diabetes and a leading cause of blindness in the U.S. and elsewhere. Chronic exposure to high blood sugar levels can lead to inflammation, cell damage, and the breakdown of blood vessel walls. Specifically, in DME, retinal blood vessels at the back of the eye become porous and permeable leading to the unwanted infiltration of fluid into the macula. This fluid leakage creates distorted vision, and if left untreated, blindness. In May 2024, we completed a Phase 2 multi-center, randomized, double-masked, placebo-controlled, parallel arm study to evaluate the safety, efficacy, and pharmacokinetics of RZ402 administered as a monotherapy over a 12-week treatment period in participants with DME who are naÃ¯ve to, or have received limited anti-VEGF injections. The study met both primary endpoints, demonstrating a significant reduction in central subfield thickness (â€œCST") in the study eye at all RZ402 dose levels compared to placebo (up to approximately 50 micron improvement), as well as good safety and tolerability. The program is available for partnering and we are actively engaged in conversations with potential partners to take RZ402 into further development.Recent Developments2024 Underwritten OfferingOn June 13, 2024, we entered into an underwriting agreement for the planned issuance and sale of equity securities in an underwritten public offering (the â€œ2024 Underwritten Offeringâ€). The 2024 Underwritten Offering provided for the issuance of (i) 11,250,000 shares of common stock at a price of $4.00 per share for gross proceeds of $45.0 million, and (ii) pre-funded warrants to purchase 3,750,000 20 Table of Contentsshares of common stock at a public offering price of $3.999 per pre-funded warrant (the â€œ2024 PFWsâ€) for gross proceeds of $15.0 million. The Company grantedÂ the underwriters a 30-day option to purchase up to an additional 2,250,000 shares of its common stock at a public offering price of $4.00 per share, less underwriting discounts of 6.0% of the gross proceeds. The underwritersâ€™ option was partially exercised for 1,786,589 shares of common stock for gross proceeds of $7.1 million. Closing occurred on June 24, 2024, whereby the aggregate gross proceeds amounted to $67.1 million. The net proceeds of the 2024 Underwritten Offering amounted to approximately $62.6 million. In July 2024, we utilized approximately $59.7 million of the net proceeds from the 2024 Underwritten Offering to purchase investments in marketable debt securities with maturities that range from October 2024 through December 2025.2024 Private PlacementIn June 2024, we entered into a securities purchase agreement (the â€œ2024 SPAâ€) with Handok, Inc. and one other investor relating to a private placement (the â€œ2024 Private Placementâ€), pursuant to which we agreed to sell 1,500,000 shares of common stock at a purchase price of $4.00 per share. Closing of the 2024 Private Placement occurred in July 2024, whereby we received proceeds of $6.0 million.Exchange PFW ExercisesOn July 23, 2024, an investor from our March 2024 Exchange Agreement provided notice of cashless exercise of their Exchange PFWs. We issued 610,273 shares of our common stock on July 24, 2024, and we did not receive any cash proceeds from the exercise. Subsequently, in October 2024, additional holders of Exchange PFWs provided notice of cashless exercise of their PFWs. We issued 2,389,111 shares of our common stock in October 2024 and did not receive any cash proceeds from the exercise.Factors Impacting our Results of OperationsWe have not generated any meaningful revenues since our inception in March 2010. Over the last several years, we have conducted private placements and public offerings to raise additional capital, adopted a licensing model to pursue development of product candidates, conducted pre-clinical and clinical trials, and conducted other research and development activities on our pipeline of product candidates.Due to the time required to conduct clinical trials and obtain regulatory approval for our product candidates, we anticipate it will be several years before we generate substantial revenues, if ever. We expect to incur operating losses for the foreseeable future; therefore, we expect to continue efforts to raise additional capital to maintain our current operating plans over the next several years. We cannot assure you that we will secure such financing or that it will be adequate for the long-term execution of our business strategy. Even if we obtain additional financing, it may be costly and may require us to agree to covenants or other provisions that will favor new investors over our existing shareholders. Key Components of Consolidated Statements of Operations and Comprehensive LossResearch and development expenses.Â Research and development (â€œR&Dâ€) expenses consist primarily of compensation and benefits for our personnel engaged in R&D activities, clinical trial costs, licensing costs, and consulting and outside services. Our R&D compensation costs include an allocable portion of our cash and share-based compensation, employee benefits, and consulting costs related to personnel engaged in the design and development of product candidates and other scientific research projects. We also allocate a portion of our facilities and overhead costs based on the personnel and other resources devoted to R&D activities.General and administrative expenses.Â General and administrative (â€œG&Aâ€) expenses consist primarily of (i) an allocable portion of our cash and share-based compensation and employee benefits related to personnel engaged in our administrative, finance, accounting, and executive functions, and (ii) an allocable portion of our facilities and overhead costs related to such personnel. G&A expenses also include travel, legal, auditing, consulting, investor relations and other costs primarily related to our status as a public company.Interest and other income. Interest and other income consist primarily of interest income earned on marketable debt securities and temporary cash investments, amortization of investment premiums and accretion of investment discounts, and realized gains on investments in marketable debt securities.Loss from change in fair value of derivative liability. We recognize liabilities for financial instruments that are required to be accounted for as derivatives, as well as embedded derivatives in our debt agreements. Derivative liabilities are adjusted to fair value at the end of 21 Table of Contentseach reporting period until the contracts are settled, expire, or otherwise meet the conditions for equity classification. Changes in fair value are reflected as a gain or loss in our unaudited condensed consolidated statements of operations and comprehensive loss.Critical Accounting Policies and Significant Judgments and EstimatesOverviewThe discussion herein is based on our unaudited condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these unaudited condensed consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, as well as the reported revenue and expenses during the reporting periods. These items are monitored and analyzed for changes in facts and circumstances, and material changes in these estimates could occur in the future. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Changes in estimates are reflected in reported results for the period in which they become known. Actual results may differ from these estimates under different assumptions or conditions.With respect to our significant accounting policies that are described in Note 1 to our consolidated financial statements included in Item 8 of our 2024 Form 10-K, we believe that the following accounting policies involve a greater degree of judgment and complexity. Accordingly, these are the policies we believe are the most critical to aid in fully understanding and evaluating our consolidated financial condition and results of operations.Investments in Marketable Debt SecuritiesWe account for investments in marketable debt securities as available-for-sale securities whereby they are recorded in our consolidated balance sheets at fair value. Interest income consists of accrued interest earned based on the coupon rate of the security, plus the impact of accreting discounts and amortizing premiums to maturity using the straight-line method which approximates the interest method. Unrealized gains and losses due to subsequent changes in fair value of the investments are reported in shareholdersâ€™ equity as a component of accumulated other comprehensive income (loss). The individual debt securities in our portfolio are subject to credit risk in the event of default by the issuers. We review the components of our portfolio of available-for-sale debt securities, using both quantitative and qualitative factors, to determine if declines in fair value below amortized cost have resulted from a credit-related loss or other factors. To the extent that declines in fair value are due to a deterioration of credit quality of the issuer, we will recognize an allowance for credit losses related to such investments with a corresponding loss in the consolidated statements of operations. Allowances for credit losses may be reversed in subsequent periods if conditions improve and credit-related losses are no longer expected. For a decline in fair value that is solely due to changes in interest rates, impairment is not recognized if we have the ability and intent to hold the investment until maturity. The cost basis of any securities sold prior to maturity will be determined using the specific identification method.Research and DevelopmentR&D costs are expensed as incurred. Intangible assets related to in-licensing costs under license agreements with third parties are charged to expense unless we are able to determine that the licensing rights have an alternative future use in other R&D projects or otherwise.Clinical Trial AccrualsClinical trial costs are a component of R&D expenses. We accrue and recognize expenses for clinical trial activities performed by third parties based upon estimates of the percentage of work completed over the life of the individual study in accordance with agreements established with clinical research organizations and clinical trial sites. We determine the estimates through discussions with internal clinical personnel and external service providers as to the progress or stage of completion of trials or services and the agreed-upon fee to be paid for such services. Nonrefundable advance payments for goods and services that will be used or rendered in future R&D activities are deferred and recognized as expense in the period that the related goods are delivered, or services are performed.22 Table of ContentsShare-Based Compensation ExpenseWe measure the fair value of services received in exchange for grants of stock options based on the fair value of the award as of the grant date. We compute the fair value of stock options with time-based vesting using the BSM option-pricing model and recognize the cost of the equity awards over the period that services are provided to earn the award. For awards that contain a graded vesting schedule, and the only condition for vesting is a service condition, compensation cost is recognized on a straight-line basis over the requisite service period as if the award was, in substance, a single award. We recognize the impact of forfeitures in the period that the forfeiture occurs, rather than estimating the number of awards that are not expected to vest in accounting for share-based compensation. For stock options that are voluntarily surrendered by employees, all unrecognized compensation is immediately recognized in the period the options are cancelled.Results of OperationsThree months ended September 30, 2024 and 2023Revenue. As a late-stage rare disease company, we did not generate any revenue for the three months ended September 30, 2024 and 2023. We are at a late stage of clinical development and do not currently have any commercial products. Our existing product candidates will require extensive additional clinical evaluation, regulatory review, significant marketing efforts and substantial investment before they generate any revenues. We do not expect to be able to generate revenue from any of our product candidates for several years.Research and development expenses. R&D expenses for the three months ended September 30, 2024 and 2023 were as follows (in thousands, except percentages):â€‹â€‹â€‹

of our contractual obligations and conduct all planned activities to advance our clinical trials at least through the next 12 months.Long-term Liquidity RequirementsOur most significant long-term contractual obligations consist of additional clinical and regulatory milestone payments up to $30.0 million payable to XOMA and additional milestone payments up to $25.0 million payable to ActiveSite. Of these amounts, we expect 24 Table of Contentsthat $5.0 million will be payable to XOMA during the 12-month period ending September 30, 2025 as discussed above under the caption Short-term Liquidity Requirements. Up to $50.0 million of the remaining milestone payments that may become payable are considered a long-term liquidity requirement. Due to uncertainties in the timing associated with clinical trial activities and regulatory approvals, there is even greater uncertainty in forecasting the timing of future clinical and regulatory milestone payments to XOMA and ActiveSite that may extend beyond the next 12 months.In addition to the clinical and regulatory milestone payments discussed above, upon the future commercialization of ersodetug and RZ402 we will be obligated to pay additional milestone payments and royalties based on the net sales of the related products and alternative indication regulatory approvals to XOMA and ActiveSite for an aggregate up to $202.5 million. These future milestones include $185.0 million in potential payments to XOMA and $17.5 million to ActiveSite for various sales-based milestones and alternative indication regulatory approvals. No assurance can be provided that commercialization will ever be achieved for ersodetug and RZ402, in which case none of these future payments may ever be required.In addition to our licensing obligations, we also have long-term contractual obligations under existing operating lease agreements of $0.8 million for each of the fiscal years ending June 30, 2026 and 2027. Based on our current forecast, we expect that our existing cash, cash equivalents and investments in marketable debt securities will be sufficient to fund our long-term contractual obligations and conduct all planned activities to advance our clinical trials at least through the third quarter of calendar year 2025. In November 2023 we entered into the Sales Agreement that provides for an â€œat-the-marketâ€ offering for the sale of up to $50.0 million in shares of our common stock. The net proceeds under the Sales Agreement, if any, will be used to fund a portion of our long-term liquidity requirements including payments for general corporate purposes and to meet our working capital requirements. To date, we have not elected to sell any shares of our common stock pursuant to the Sales Agreement. Even if we elect to sell the entire $50.0 million of shares under the Sales Agreement, we will need to obtain additional equity or debt financing in order to fund all of our long-term liquidity requirements. Accordingly, no assurance can be given that we will be able to obtain sufficient sources of equity and debt financing on terms that are acceptable to our Board of Directors and stockholders.Presented below is an additional discussion about the ongoing requirements pursuant to our license agreements with XOMA and ActiveSite, along with additional information about our ongoing financing activities that impacted our liquidity and capital resources through September 30, 2024.XOMA License AgreementIn December 2017, we entered into a license agreement (the â€œXOMA License Agreementâ€) with XOMA through its wholly-owned subsidiary, XOMA (US) LLC, pursuant to which XOMA granted an exclusive global license to develop and commercialize XOMA 358 (formerly X358 or RZ358, now ersodetug) for all indications. In January 2019, the XOMA License Agreement was amended with an updated payment schedule, as well as revised the amount we were required to expend on development of ersodetug and related licensed products, and revised provisions with respect to our diligence efforts in conducting clinical studies.Upon the achievement of certain clinical and regulatory events, we will be required to make up to $37.0 million in aggregate milestone payments to XOMA. Milestone payments made to date include a $2.0 million payment in January 2022 for the enrollment of the last patient of the Phase 2 clinical study and $5.0 million paid in May 2024 related to the first patient enrollment in a Phase 3 study. We record a liability for milestone payments in our financial statements on the date that we achieve the milestone event. The next milestone payment of $5.0 million will be due upon the enrollment of the last patient in a Phase 3 study, which we believe will occur in the next twelve months. Additionally, upon the future commercialization of ersodetug, we will be required to pay royalties to XOMA based on the net sales of the related products, and milestone payments up to an additional $185.0 million if future annual sales related to ersodetug exceed targets ranging from $100.0 million to $1.0 billion. Through September 30, 2024, no events have occurred that would result in the requirement to make additional milestone payments and no royalties have been incurred. ActiveSite License AgreementIn August 2017, we entered into a Development and License Agreement with ActiveSite (â€œActiveSite License Agreementâ€) pursuant to which we acquired the rights to ActiveSiteâ€™s PKI portfolio. We are planning to use the PKI Program to develop, file, manufacture, market and sell products for diabetic macular edema and other therapeutic indications. The ActiveSite License Agreement requires various milestone payments ranging from $1.0 million to $10.0 million when milestone events occur, up to an aggregate of $46.5 million 25 Table of Contentsof aggregate milestone payments. The first milestone payment for $1.0 million was paid in December 2020 after completion of preclinical work and submission of an IND to the FDA for RZ402. The second milestone payment for $3.0 million became due upon dosing of the first patient in a Phase 2 study in February 2023. Remaining milestone payments under the ActiveSite License Agreement for various clinical and regulatory milestones amount to $25.0 million and milestones after commercial success or alternative indication approvals amount to $17.5 million. We will also be required to pay royalties equal to 2.0% of any sales of products that use the PKI Program. Through September 30, 2024, no events have occurred that would result in the requirement to make additional milestone payments and no royalties have been incurred.Cash Flows SummaryPresented below is a summary of our operating, investing, and financing cash flows for the three months ended September 30, 2024 and 2023 (in thousands):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â 2024Â Â Â Â 2023Â Â Â Â ChangeNet cash provided by (used in):â€‹Â Â â€‹â€‹Â Â â€‹â€‹Â Â â€‹Operating activitiesâ€‹$ (16,014)â€‹$ (10,585)â€‹$ (5,429)Investing activitiesâ€‹Â (49,410)â€‹Â 2,606â€‹Â (52,016)Financing activitiesâ€‹Â 5,500â€‹Â â€”â€‹Â 5,500Cash Used in Operating ActivitiesFor the three months ended September 30, 2024 and 2023, cash used in operating activities amounted to $16.0 million and $10.6 million, respectively. The key components in the calculation of our cash used in operating activities are as follows (in thousands):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â 2024Â Â Â Â 2023Â Â Â Â ChangeNet lossâ€‹$ (15,378)â€‹$ (14,524)â€‹$ (854)Non-cash expensesÂ â€‹ 1,550Â â€‹ 1,995Â â€‹ (445)Accretion of discounts and amortization of premiums on marketable debt securities, netÂ â€‹ (832)Â â€‹ 973Â â€‹ (1,805)Changes in operating assets and liabilities, netÂ â€‹ (1,354)Â â€‹ 971Â â€‹ (2,325)Totalâ€‹$ (16,014)â€‹$ (10,585)â€‹$ (5,429)For the three months ended September 30, 2024, our net loss was $15.4 million compared to $14.5 million for the three months ended September 30, 2023. For further discussion about changes in our operating results for the three months ended September 30, 2024 and 2023, please refer to Results of Operations above.For the three months ended September 30, 2024 and 2023, our non-cash expenses of $1.6 million and $2.0 million, respectively, were primarily attributable to share-based compensation expense, and non-cash lease expense. Â For the three months ended September 30, 2024 and 2023, amortization of premiums exceeded accretion of discounts on marketable debt securities by $0.8 million. For the three months ended September 30, 2023, accretion of discounts exceeded amortization of premiums on marketable debt securities by $1.0 million. Accretion of discounts and amortization of premiums on marketable debt securities are a component of interest income that results from investing in marketable debt securities at premiums and discounts. For the three months ended September 30, 2024, net changes in operating assets and liabilities decreased operating cash flow by $1.4 million, primarily driven by a net decrease of $1.3 million in accounts payable and other accrued liabilities, and an increase in prepaid expenses and other assets of $0.1 million. For the three months ended September 30, 2023, net changes in operating assets and liabilities increased operating cash flow by $1.0 million, primarily driven by a net increase of $1.9 million in accounts payable and other accrued liabilities. This amount was partially offset by cash outflows resulting from an increase in prepaid expenses and other assets of $0.9 million.Cash Provided by or Used in Investing ActivitiesFor the three months ended September 30, 2024, our net cash used in investing activities amounted to $49.4 million. For the three months ended September 30, 2024, we received proceeds of $23.8 million upon the maturity of certain marketable debt securities. Â These cash proceeds from maturities, along with certain proceeds from the 2024 Public Underwritten Offering in June 2024 and 2024 Private Placement in July 2024, were used to purchase a total of $73.2 million of marketable debt securities. 26 Table of ContentsFor the three months ended September 30, 2023, our net cash provided by investing activities amounted to $2.6 million, primarily related to the maturity of marketable debt securities $18.6 million partially offset by $16.0 million of purchases of marketable debt securities.Cash Provided by or Used in Financing ActivitiesFor the three months ended September 30, 2024, our net cash provided by financing activities was $5.5 million. Â Cash inflows amounted to $6.1 million consisting of $6.0 of proceeds from the 2024 Private Placement and proceeds of $0.1 million of proceeds the exercise of employee stock options. These amounts were partially offset by cash outflows related to the payments of offering costs of $0.6 million incurred in connection with the 2024 Public Underwritten Offering. Â There was no net cash provided by or used in financing activities for the three months ended September 30, 2023. Recent Accounting PronouncementsPlease refer to Note 1 to our unaudited condensed consolidated financial statements in Part I, Item 1 of this Report regarding the impact of recent accounting pronouncements.Off-Balance Sheet ArrangementsWe did not have any off-balance sheet transactions for the periods covered by this Report.Item 3. Quantitative and Qualitative Disclosures About Market Risk.Not applicable.Item 4. Controls and Procedures.Evaluation of Disclosure Controls and ProceduresAs of the end of the period covered by this Quarterly Report on Form 10-Q, we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer (our Principal Executive and Financial Officer), of the effectiveness of our disclosure controls and procedures as defined in Rule 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (â€œExchange Actâ€). Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the Companyâ€™s management, including its Principal Executive and Principal Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable, not absolute assurance of achieving the desired objectives. Also, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Based on that assessment under those criteria, our management has determined that our internal control over financial reporting was effective as of September 30, 2024. Changes in Internal Controls over Financial ReportingDuring the period covered by this Quarterly Report on Form 10-Q, there were no changes in our internal control over financial reporting that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.â€‹27 Table of ContentsPART II â€” OTHER INFORMATIONItem 1. Legal Proceedings.None.Item 1A. Risk Factors.Our Risk Factor disclosures are set forth in Item 1A of our Annual Report on Form 10-K for the fiscal year ended June 30, 2024 filed with the Securities and Exchange Commission (â€œSECâ€) on September 19, 2024. As of the date of this Report, there have been no material changes with respect to the Risk Factor disclosures.Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.None.Item 3. Defaults Upon Senior Securities.None.Item 4. Mine Safety Disclosures.Not applicable.Item 5. Other Information.None.Item 6. Exhibits. The following exhibits are incorporated by reference or filed as part of this Quarterly Report on Form 10-Q:Exhibit NumberÂ Â Â Â DescriptionÂ ofÂ Exhibits31.1*â€‹Certification of Chief Executive and Principal Financial Officer as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*32.1*â€‹Certification of Chief Executive and Principal Financial Officer as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002*101.INS*â€‹Inline XBRL Instance Document101.SC*â€‹Inline XBRL Taxonomy Extension Schema101.CA*â€‹Inline XBRL Taxonomy Extension Calculation Linkbase101.DEF*â€‹Inline XBRL Taxonomy Extension Definition Linkbase101.LA*â€‹Inline XBRL Taxonomy Extension Label Linkbase101.PRE*â€‹Inline XBRL Taxonomy Extension Presentation Linkbase104â€‹Cover Page Interactive Data File, formatted in Inline XBRL (included as Exhibit 101)* Filed herewith.â€‹28 Table of ContentsSIGNATURESIn accordance with Section 12 of the Securities Exchange Act of 1934, the Registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.â€‹â€‹â€‹â€‹â€‹â€‹REZOLUTE, INC.â€‹â€‹â€‹Date: November 7, 2024By:/s/ Nevan Charles Elamâ€‹â€‹Nevan Charles Elamâ€‹â€‹Chief Executive Officerâ€‹â€‹(Principal Executive and Financial Officer)â€‹â€‹29 EX-31.1 2 rzlt-20240930xex31d1.htm EX-31.1 EXHIBIT 31.1CERTIFICATION OF PERIODIC REPORT UNDER SECTION 302OF THE SARBANES-OXLEY ACT OF 2002I, Nevan Charles Elam, certify that:1.I have reviewed this quarterly report on Form 10-Q of Rezolute, Inc.;2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects, the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report.4.As the Registrant's certifying officer, I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have:a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;c)Evaluated the effectiveness of the Registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; andd)Disclosed in this report any change in the Registrant's internal control over financial reporting that occurred during the Registrant's most recent fiscal quarter (fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant's internal control over financial reporting; and5.As the Registrant's certifying officer, I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the Registrant's auditors and the audit committee of the Registrant's board of directors:a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant's ability to record, process, summarize and report financial information; andb)Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant's internal control over financial reporting.Date:November 7, 2024â€‹â€‹â€‹â€‹By:/s/ Nevan Charles Elamâ€‹â€‹Nevan Charles Elamâ€‹â€‹Chief Executive Officerâ€‹â€‹(Principal Executive and Financial Officer)â€‹ EX-32.2 3 rzlt-20240930xex32d2.htm EX-32.2 EXHIBIT 32.1CERTIFICATION PURSUANT TO18 U.S.C. SECTION 1350,AS ADOPTED PURSUANT TOSECTION 906 OF THE SARBANES-OXLEY ACT OF 2002In connection with the quarterly report of Rezolute, Inc. (the â€œCompanyâ€) on Form 10-Q for the period ended September 30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the â€œReportâ€), I, Nevan Elam, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and (2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.Date:November 7, 2024By:/s/ Nevan Charles ElamÂ Nevan Charles Elamâ€‹â€‹Chief Executive OfficerÂ (Principal Executive and Financial Officer)â€‹A signed original of this written statement required by Section 906 has been provided to Rezolute, Inc. and will be retained by Rezolute, Inc. to be furnished to the Securities and Exchange Commission or its staff upon request. EX-101.SCH 4 rzlt-20240930.xsd EX-101.SCH 99900 - Disclosure - Standard And Custom Axis Domain Defaults link:presentationLink link:calculationLink link:definitionLink 995200100 - Statement - Unaudited Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 995200200 - Statement - Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 995200400 - Statement - Unaudited Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 99940301 - Disclosure - INVESTMENTS IN MARKETABLE DEBT SECURITIES - Investments in Marketable Securities (Details) link:presentationLink link:calculationLink link:definitionLink 99940303 - Disclosure - INVESTMENTS IN MARKETABLE DEBT SECURITIES - Cash and Cash Equivalents and Marketable Securities Held (Details) link:presentationLink link:calculationLink link:definitionLink 99940401 - Disclosure - OPERATING LEASES - Assets and Operating Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 99940404 - Disclosure - OPERATING LEASES - Future Operating Lease Payments (Details) link:presentationLink link:calculationLink link:definitionLink 40404 - Disclosure - OPERATING LEASES - Future Operating Lease Payments (Details) (Calc 2) link:presentationLink link:calculationLink link:definitionLink 995200105 - Statement - Unaudited Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 995200300 - Statement - Unaudited Condensed Consolidated Statements of Shareholders' Equity link:presentationLink link:calculationLink link:definitionLink 99930703 - Disclosure - SHAREHOLDERS' EQUITY (Tables) link:presentationLink link:calculationLink link:definitionLink 99930803 - Disclosure - SHARE-BASED COMPENSATION AND WARRANTS (Tables) link:presentationLink link:calculationLink link:definitionLink 99940101 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) link:presentationLink link:calculationLink link:definitionLink 99940201 - Disclosure - LIQUIDITY (Details) link:presentationLink link:calculationLink link:definitionLink 99940402 - Disclosure - OPERATING LEASES - Operating Lease Expense (Details) link:presentationLink link:calculationLink link:definitionLink 99940403 - Disclosure - OPERATING LEASES - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 99940501 -

Disclosure - LICENSE AGREEMENTS (Details) link:presentationLink link:calculationLink link:definitionLink 99940601 - Disclosure - EMBEDDED DERIVATIVE LIABILITY (Details) link:presentationLink link:calculationLink link:definitionLink 99940701 - Disclosure - SHAREHOLDERS' EQUITY - Pre-Funded Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 99940702 - Disclosure - SHAREHOLDERS' EQUITY - 2024 Private Placement (Details) link:presentationLink link:calculationLink link:definitionLink 99940703 - Disclosure - SHAREHOLDERS' EQUITY - 2024 Underwritten Offering (Details) link:presentationLink link:calculationLink link:definitionLink 99940704 - Disclosure - SHAREHOLDERS' EQUITY - Exchange Agreement (Details) link:presentationLink link:calculationLink link:definitionLink 99940705 - Disclosure - SHAREHOLDERS' EQUITY - Jefferies Open Market Sales Agreement (Details) link:presentationLink link:calculationLink link:definitionLink 99940801 - Disclosure - SHARE-BASED COMPENSATION AND WARRANTS - Stock Option Plans (Details) link:presentationLink link:calculationLink link:definitionLink 99940802 - Disclosure - SHARE-BASED COMPENSATION AND WARRANTS - 2022 Employee Stock Purchase Plan (Details) link:presentationLink link:calculationLink link:definitionLink 99940803 - Disclosure - SHARE-BASED COMPENSATION AND WARRANTS - Stock Options Outstanding (Details) link:presentationLink link:calculationLink link:definitionLink 99940804 - Disclosure - SHARE-BASED COMPENSATION AND WARRANTS - Weighted Average Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 99940805 - Disclosure - SHARE-BASED COMPENSATION AND WARRANTS - Share Based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 99940806 - Disclosure - SHARE-BASED COMPENSATION AND WARRANTS - Pre-Funded Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 99940807 - Disclosure - SHARE-BASED COMPENSATION AND WARRANTS - Summary of Legacy Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 99941001 - Disclosure - RELATED PARTY TRANSACTIONS (Details) link:presentationLink link:calculationLink link:definitionLink 99941201 - Disclosure - NET LOSS PER SHARE - Weighted Average Number of Shares Outstanding (Details) link:presentationLink link:calculationLink link:definitionLink 99941202 - Disclosure - NET LOSS PER SHARE - Anti-dilutive (Details) link:presentationLink link:calculationLink link:definitionLink 99941301 - Disclosure - FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS - Fair Value on a Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 99941302 - Disclosure - FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS - Summary of Changes in the Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 99941303 - Disclosure - FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS - Significant Concentrations (Details) link:presentationLink link:calculationLink link:definitionLink 99941401 - Disclosure - SUBSEQUENT EVENTS (Details) link:presentationLink link:calculationLink link:definitionLink 995200090 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink 995210101 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 995210201 - Disclosure - LIQUIDITY link:presentationLink link:calculationLink link:definitionLink 995210301 - Disclosure - INVESTMENTS IN MARKETABLE DEBT SECURITIES link:presentationLink link:calculationLink link:definitionLink 995210401 - Disclosure - OPERATING LEASES link:presentationLink link:calculationLink link:definitionLink 995210501 - Disclosure - LICENSE AGREEMENTS link:presentationLink link:calculationLink link:definitionLink 995210601 - Disclosure - EMBEDDED DERIVATIVE LIABILITY link:presentationLink link:calculationLink link:definitionLink 995210701 - Disclosure - SHAREHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 995210801 - Disclosure - SHARE-BASED COMPENSATION AND WARRANTS link:presentationLink link:calculationLink link:definitionLink 995210901 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 995211001 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 995211101 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 995211201 - Disclosure - NET LOSS PER SHARE link:presentationLink link:calculationLink link:definitionLink 995211301 - Disclosure - FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS link:presentationLink link:calculationLink link:definitionLink 995211401 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 99920102 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 99930303 - Disclosure - INVESTMENTS IN MARKETABLE DEBT SECURITIES (Tables) link:presentationLink link:calculationLink link:definitionLink 99930403 - Disclosure - OPERATING LEASES (Tables) link:presentationLink link:calculationLink link:definitionLink 99931203 - Disclosure - NET LOSS PER SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 99931303 - Disclosure - FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS (Tables) link:presentationLink link:calculationLink link:definitionLink 99940302 - Disclosure - INVESTMENTS IN MARKETABLE DEBT SECURITIES - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 5 rzlt-20240930_cal.xml EX-101.CAL EX-101.DEF 6 rzlt-20240930_def.xml EX-101.DEF EX-101.LAB 7 rzlt-20240930_lab.xml EX-101.LAB Document And Entity Information [Abstract] Document Type Document Quarterly Report Document Period End Date Document Transition Report Entity File Number Entity Registrant Name Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Address, Address Line One Entity Address, City or Town Entity Address, State or Province Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security Trading Symbol Security Exchange Name Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Entity Shell Company Entity Common Stock, Shares Outstanding Entity Central Index Key Current Fiscal Year End Date Document Fiscal Year Focus Document Fiscal Period Focus Amendment Flag Unaudited Condensed Consolidated Balance Sheets Assets [Abstract] Assets Assets, Current [Abstract] Current assets: Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Marketable Securities, Current Investments in marketable debt securities Short-term investments Prepaid Expense and Other Assets, Current Prepaid expenses and other Assets, Current Total current assets Assets, Noncurrent [Abstract] Long-term assets: Marketable Securities, Noncurrent Investments in marketable debt securities Long-term investments Deposits Assets, Noncurrent Deposits and other Operating Lease, Right-of-Use Asset Right-of-use assets Property, Plant and Equipment, Net Property and equipment, net Assets Total assets Liabilities and Equity [Abstract] Liabilities and Shareholders' Equity Liabilities, Current [Abstract] Current liabilities: Accounts Payable, Current Accounts payable Accrued Liabilities, Current [Abstract] Accrued liabilities: Employee-related Liabilities, Current Compensation and benefits Amount of accrued for clinical liabilities. Accrued Clinical, Current Accrued clinical and other Operating Lease, Liability, Current Current Current portion of operating lease liabilities Liabilities, Current Current liabilities Total current liabilities Liabilities, Noncurrent [Abstract] Long-term liabilities: Operating Lease, Liability, Noncurrent Long-term Operating lease liabilities, net of current portion Fair value as of the balance sheet date of the warrants derivative classified as a liability. Warrant Derivative Liability, Non-Current Warrant derivative liability Embedded Derivative, Fair Value of Embedded Derivative Liability Embedded derivative liability Liabilities Total liabilities Total liabilities Commitments and Contingencies Commitments and contingencies (Notes 5, 9 and 10) Equity, Attributable to Parent [Abstract] Shareholders' equity: Preferred Stock, Value, Issued Preferred stock, $0.001 par value; 400 shares authorized; no shares issued Common Stock, Value, Issued Common stock, $0.001 par value; 100,000 shares authorized; issued and outstanding 55,394 and 53,246 shares as of September 30, 2024 and as of June 30, 2024, respectively Additional Paid in Capital Additional paid-in capital Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive income (loss) Retained Earnings (Accumulated Deficit) Accumulated deficit Equity, Attributable to Parent Balance ending Balance beginning Total shareholders' equity Liabilities and Equity Total liabilities and shareholders' equity Statement [Table] Statement [Line Items] Preferred Stock, Par or Stated Value Per Share Preferred stock, par value (in dollars per share) Preferred Stock, Shares Authorized Preferred stock, shares authorized Preferred Stock, Shares Issued Preferred stock, shares, issued Common Stock, Par or Stated Value Per Share Common stock, par value (in dollars per share) Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Outstanding Common stock, shares outstanding Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss Operating Expenses [Abstract] Operating expenses: Research and Development Expense Research and development General and Administrative Expense General and administrative Operating Expenses Total operating expenses Operating Income (Loss) Operating loss Nonoperating Income (Expense) [Abstract] Non-operating income (expense): Interest and Other Income Interest and other income, net Gain (Loss) on Derivative Instruments, Net, Pretax Loss from change in fair value of embedded derivative liability Loss from change in fair value of embedded derivative liability Nonoperating Income (Expense) Total non-operating income, net Net loss Net loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract] Other comprehensive income (loss): OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax Net unrealized gain (loss) on marketable debt securities Net change in accumulated other comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Comprehensive loss Earnings Per Share, Basic Net loss per common share - basic (in dollars per share) Earnings Per Share, Diluted Net loss per common share - diluted (in dollars per share) Weighted Average Number of Shares Outstanding, Basic Weighted average number of common shares outstanding - basic (in shares) Weighted Average Number of Shares Outstanding, Diluted Weighted average number of common shares outstanding - diluted (in shares) Unaudited Condensed Consolidated Statements of Shareholders' Equity Equity Components [Axis] Equity Component [Domain] Common Stock [Member] Common Stock Additional Paid-in Capital [Member] Additional Paid-in Capital AOCI Attributable to Parent [Member] Accumulated Other Comprehensive Loss Retained Earnings [Member] Accumulated Deficit Sale of Stock [Axis] Sale of Stock [Domain] Private Placement [Member] Private Placement Private Placement Represents the information pertaining to underwritten Public Offering. Underwritten Public Offering [Member] Underwritten Public Offering Underwritten Public Offering Shares, Outstanding Balance ending (in shares) Balance beginning (in shares) Stock Issued During Period, Value, New Issues Gross proceeds from issuance of common stock for cash Stock Issued During Period, Shares, New Issues Number of shares issued Gross proceeds from issuance of common stock for cash (in shares) Number of shares issued Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs Payment of commissions and other offering costs Stock Issued During Period, Value, Stock Options Exercised Issuance of common stock upon exercise of stock options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Exercises Issuance of common stock upon exercise of stock options (in shares) APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Share-based compensation Value of stock issued upon exercise of pre-funded warrants Stock Issued During Period, Value, Exercise of Pre-funded Warrants Cashless exercise of pre-funded warrants Number of shares issued upon exercise of pre-funded warrants. Stock Issued During Period, Shares, Exercise of Pre-funded Warrants Cashless exercise of pre-funded warrants (in shares) Unaudited Condensed Consolidated Statements of Cash Flows Net Cash Provided by (Used in) Operating Activities [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES: Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net loss Share-Based Payment Arrangement, Noncash Expense Share-based compensation expense Amount representing the non cash lease expense. Non Cash Lease Expense Non-cash lease expense Accretion (Amortization) of Discounts and Premiums, Investments Accretion of discounts and amortization of premiums on marketable debt securities, net Depreciation, Depletion and Amortization, Nonproduction Depreciation expense Debt Securities, Available-for-Sale, Realized Gain Realized gain from investments Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Increase (Decrease) in Prepaid Expense and Other Assets Increase in prepaid expenses, deposits, and other assets Increase (Decrease) in Accounts Payable Decrease in accounts payable Increase (Decrease) in Accrued Liabilities Increase in accrued liabilities Net Cash Provided by (Used in) Operating Activities Net Cash Used in Operating Activities Net cash used in operating activities Net Cash Provided by (Used in) Investing Activities [Abstract] CASH FLOWS FROM INVESTING ACTIVITIES Payments to Acquire Marketable Securities Purchase of marketable debt securities Investment in marketable securities Proceeds from Sale and Maturity of Marketable Securities Proceeds from maturities of marketable debt securities Net Cash Provided by (Used in) Investing Activities Total Cash Provided by (Used in) Investing Activities Net Cash Provided by (Used in) Financing Activities [Abstract] CASH FLOWS FROM FINANCING ACTIVITIES: Proceeds from Stock Options Exercised Proceeds from exercise of stock options Payments for Repurchase of Common Stock Net cash payment pursuant to Exchange Agreement Cash payment to exchanging shareholders Proceeds from Issuance of Private Placement Gross proceeds from issuance of common stock in 2024 Private Placement Payments of Stock Issuance Costs Payment of offering costs Net Cash Provided by (Used in) Financing Activities Net Cash Provided by Financing Activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Net decrease in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Cash and cash equivalents at end of period Cash and cash equivalents at beginning of period SUPPLEMENTAL FINANCIAL INFORMATION SUPPLEMENTARY CASH FLOW INFORMATION: Operating Lease, Payments Cash paid for amounts included in the measurement of operating lease liabilities Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] NON-CASH INVESTING AND FINANCING ACTIVITIES: The amount of payables accrued for offering costs in the period. Payables for offering costs Payables for offering costs Amount of receivable from exercise of stock options in non-cash investing or financing transactions. Receivable From Exercise of Stock Options Receivable from exercise of stock options NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block] NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES No definition available. LIQUIDITY Substantial Doubt about Going Concern [Text Block] LIQUIDITY INVESTMENTS IN MARKETABLE DEBT SECURITIES Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] INVESTMENTS IN MARKETABLE DEBT SECURITIES OPERATING LEASES Lessee, Operating Leases [Text Block] OPERATING LEASES n/a LICENSE AGREEMENTS The entire disclosure for information about License agreements. LICENSE AGREEMENTS [Text block] LICENSE AGREEMENTS EMBEDDED DERIVATIVE LIABILITY Discussion of Hybrid Instruments and Embedded Derivatives [Text Block] EMBEDDED DERIVATIVE LIABILITY SHAREHOLDERS' EQUITY Equity [Text Block] SHAREHOLDERS' EQUITY SHARE-BASED COMPENSATION AND WARRANTS Share-Based Payment Arrangement [Text Block] SHARE-BASED COMPENSATION AND WARRANTS COMMITMENTS AND CONTINGENCIES. Commitments and Contingencies Disclosure [Text Block] COMMITMENTS AND CONTINGENCIES RELATED PARTY TRANSACTIONS Related Party Transactions Disclosure [Text Block] RELATED PARTY TRANSACTIONS INCOME TAXES Income Tax Disclosure [Text Block] INCOME TAXES NET LOSS PER SHARE Earnings Per Share [Text Block] NET LOSS PER SHARE FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS Financial Instruments Disclosure [Text Block] FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS SUBSEQUENT EVENTS Subsequent Events [Text Block] SUBSEQUENT EVENTS Nature of Operations [Text Block] Nature of Operations Basis of Accounting, Policy [Policy Text Block] Basis of Presentation Consolidation, Policy [Policy Text Block] Consolidation Use of Estimates, Policy [Policy Text Block] Use of Estimates Disclosure of accounting policy for the risks and uncertainties during the reporting period. Risks and Uncertainties [Policy Text Block] Risks and Uncertainties Significant Accounting Policies [Text Block] Significant Accounting Policies New Accounting Pronouncements, Policy [Policy Text Block] Recent Accounting Pronouncements Not Yet Adopted Marketable Securities [Table Text Block] Schedule of investments in marketable debt securities Schedule of Available-for-Sale Securities Reconciliation [Table Text Block] Summary of unrealized gains and losses that result in differences between the amortized cost basis and fair value of the Company's marketable debt securities The tabular disclosure of carrying value of ROU assets and operating lease liabilities. Lessee, Operating Lease, Right Of Use Assets And Operating Lease Liabilities Schedule of carrying value of right-of-use assets and operating lease liabilities Lease, Cost [Table Text Block] Schedule of operating lease expense Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Schedule of future payments under operating lease agreements Class of Warrant or Right [Table] Class of Warrant or Right [Axis] Class of Warrant or Right [Domain] Represents information pertaining to pre-funded warrants. Pre Funded Warrants [Member] Pre-funded warrants Class of Warrant or Right [Line Items] Class of warrant or right SHARE-BASED COMPENSATION AND WARRANTS Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Schedule of warrant activity Represents the information pertaining to legacy warrants. Legacy Warrants [Member] Legacy warrants The tabular disclosure of the number of shares authorized, outstanding, and available for future grants under stock option. Share-based Payment Arrangement, Option, Shares Authorized, Outstanding, and Available for Future Grants Schedule of the number of shares authorized, outstanding, and available for future grants under stock option Share-Based Payment Arrangement, Option, Activity [Table Text Block] Schedule of the stock option plans Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Schedule of the fair value of stock options Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Schedule of share-based compensation expense Schedule of Weighted Average Number of Shares [Table Text Block] Schedule of weighted average shares outstanding Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of potential common stock equivalents were excluded from the computation of diluted net loss per share Fair Value, Assets Measured on Recurring Basis [Table Text Block] Schedule of financial assets measured at fair value on a recurring basis Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Schedule of changes in the fair value of the company's derivative liabilities, fair value, level 3 inputs Represents the number of wholly owned subsidiaries. Number of Wholly Owned Subsidiaries Number of wholly owned subsidiaries Counterparty Name [Axis] Counterparty Name [Domain] XOMA Corporation [Member] XOMA Corporation [Member] XOMA Corporation XOMA (US) LLC

[Member] XOMA (US) LLC [Member] XOMA (US) LLC Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Research and Development Arrangement, Contract to Perform for Others, Type [Domain] License Agreement Terms [Member] License agreement Phase 3 Clinical Trial Rz 358 [Member]. Phase 3 Clinical Trial RZ 358 (ersodetug) Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement [Member] Collaborative Arrangement Xoma License Agreement [Member] Xoma License Agreement [Member] Xoma License Agreement Scenario [Axis] Scenario [Domain] Scenario, Plan [Member] Scenario, Plan Plan Represents information pertaining to dosing of the last patient milestones. Scenario, Upon Dosing Of The Last Patient [Member] Scenario, Upon Dosing Of The Last Patient Sale of Stock, Consideration Received on Transaction Sale of stock received on transaction The number of warrants issued. Class of Warrant or Right, Issued Warrants issued Amount of milestone payment made during the period. Milestone Closing Payment Milestone closing payment Marketable Securities Marketable debt securities Total investments Debt Securities, Available-for-Sale, Term Debt securities, available-for-sale, term Weighted average period of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Debt Securities, Available-for-Sale, Weighted Average Term Debt securities, available-for-sale, weighted average term Debt Securities, Available-for-Sale, Accrued Interest, after Allowance for Credit Loss, Current Interest receivable Debt Securities, Available-for-Sale, Amortized Cost, Allowance for Credit Loss, Excluding Accrued Interest, Current Allowance for credit losses related to investments in marketable debt securities Debt Securities, Available-for-Sale [Table] Financial Instrument [Axis] Financial Instruments [Domain] Commercial Paper [Member] Corporate commercial paper US Government Agencies Debt Securities [Member] U.S. Government agencies Obligations of U.S. government agencies US Treasury Securities [Member] U.S. Government treasuries U.S. Treasury obligations Corporate Debt Securities [Member] Corporate notes and bonds Corporate notes and bonds Debt Securities, Available-for-Sale [Line Items] INVESTMENTS IN MARKETABLE DEBT SECURITIES Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, before Allowance for Credit Loss Amortized Cost Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Gross Unrealized Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Gross Unrealized Losses Debt Securities, Available-for-Sale, Excluding Accrued Interest Fair Value Property, Plant and Equipment [Table] Property, Plant and Equipment [Line Items] Assets and Liabilities, Lessee [Abstract] Carrying value of right-of-use assets and operating lease liabilities Operating Lease, Liability [Abstract] Operating lease liabilities: Operating Lease, Liability Total Present value of operating lease liabilities Lessee, Lease, Description [Table] Statement of Income Location, Balance [Axis] Statement of Income Location, Balance [Domain] Research and Development Expense [Member] Research and Development Expense Research and development General and Administrative Expense [Member] General and Administrative Expense General and administrative Lessee, Lease, Description [Line Items] Operating Lease, Expense Operating lease expense Operating Lease, Weighted Average Remaining Lease Term Weighted average remaining lease term under operating leases Operating Lease, Weighted Average Discount Rate, Percent Weighted average discount rate for operating lease liabilities Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract] Future lease payments related to operating lease agreements Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Remainder of fiscal year 2025 Lessee, Operating Lease, Liability, to be Paid, Year One 2026 Lessee, Operating Lease, Liability, to be Paid, Year Two 2027 Amount of lessee's undiscounted obligation for lease payment for operating lease due after second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). Lessee, Operating Lease, Liability, Payments Due after Two Thereafter Lessee, Operating Lease, Liability, to be Paid Total lease payments Lessee, Operating Lease, Liability, Undiscounted Excess Amount Less imputed interest Research and Development, Contract to Perform for Others [Table] Represent the information pertaining to ActiveSite Pharmaceuticals, Inc. ActiveSite Pharmaceuticals, Inc N/A. Phase 1 Clinical Trial RZ402 N/A. Phase 2 Clinical Trial RZ402 N/A. Phase 2 Clinical Trial RZ358 (ersodetug) Phase 3 Clinical Trial Rz 402 [Member]. Phase 3 Clinical Trial RZ 402 Development And License Agreement [Member] Development And License Agreement [Member] Development And License Agreement Represents information pertaining to upon the clinical and regulatory milestones. Scenario, Upon Clinical and Regulatory Milestones [Member] Upon Clinical and Regulatory Milestones Represents information pertaining to after the clinical and regulatory milestones. Scenario, After Clinical and Regulatory Milestones [Member] After Clinical and Regulatory Milestones Statistical Measurement [Axis] Statistical Measurement [Domain] Maximum [Member] Maximum Research and Development Arrangement, Contract to Perform for Others [Line Items] License Agreements The maximum amount of milestone event which need to occur for making specific range of milestone payment. Maximum Amount of Milestone Events Maximum amount of milestone events Represents the percentage of royalties. Development and License Agreement, Royalties Percentage Royalties percentage Schedule of Long-Term Debt Instruments [Table] Derivative Instrument [Axis] Derivative Contract [Domain] Embedded Derivative Financial Instruments [Member] Embedded derivative Embedded Derivative Financial Instruments Debt Instrument [Line Items] Line of Credit Facility, Maximum Borrowing Capacity Maximum borrowing capacity Proceeds from Issuance of Debt Gross proceeds from issuance of debt Represents the exit fee on the funded principal balance. Debt Instrument, Exit Fee Exit fee on the funded principal balance Amount of expenses associated with exit fees on the funded principal balance. Debt Instrument, Exit Fee Amount Exit fee amount Represents the percentage of entity's shares held by investors. Percentage Of Entity's Shares Held By Investors Percentage of entity's shares held by investors Stock, Class of Stock [Table] Represents information relating to pre-funded 2021 warrants. Pre Funded Warrants 2021 [Member] 2021 Pre-Funded Warrants 2021 PFWs Represents information relating to pre-funded 2022 warrants. 2022 Pre-Funded Warrants 2022 PFWs Represents information relating to Class A pre-funded warrants. Class A Pre-Funded Warrants Class A pre-funded warrants Represents information relating to Class B pre-funded warrants. Class B pre-funded warrants Class B Pre-Funded Warrants Represents information relating to exchange pre-funded warrants. Exchange Pre Funded Warrants [Member] Exchange Pre-Funded Warrants Exchange PFWs Represents information relating to pre-funded 2024 warrants. Pre Funded Warrants 2024 Pre Funded Warrants 2024 2024 PFWs Information of agreement. Agreement [Axis] Information of agreement. Agreement [Domain] Represents information pertaining to securities exchange agreement. Securities Exchange Agreement [Member] Securities exchange agreement Class of Stock [Line Items] Class of Warrant or Right, Number of Securities Called by Warrants or Rights Warrants to purchase shares of common stock Pre-funded warrants to purchase shares of common stock Number of shares of common stock called by warrants issued Represents the designated ownership percentage by holder not exceeding the specified percentage for exercise of warrants. Warrants Exercisable, Ownership Blocker Percentage Warrants exercisable, ownership blocker percentage Class of Warrant or Right, Outstanding Warrants outstanding, ending (In shares) Warrants outstanding, beginning (In shares) Warrants outstanding (In shares) Number of warrants or rights surrendered. Class of Warrant or Right, Warrants Surrendered Shares surrendered for exercise price Number of warrants or rights exercised. Class of Warrant or Right, Exercised Shares of common stock issued Warrants exercised Shares Issued, Price Per Share Shares issue price Issuance price (in dollars per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Warrants Outstanding, Ending Price (in dollars per share) Warrants Outstanding, Beginning Price (in dollars per share) Warrant price (per share) Warrants exercise price Underwriters Option. Underwriters Option [Member] Underwriters Option Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the additional shares option of a stock transaction. Sale of stock, Additional Shares Option, price per share Proceeds from Issuance of Common Stock Proceeds from issuance of common stock Proceeds from Issuance of Warrants Proceeds from warrants issued Represent the maximum number of additional shares offered. Maximum Number Of Additional Shares Issued Maximum number of additional shares issued Proceeds from Issuance or Sale of Equity Gross proceeds from sale of equity The percentage of underwriting discounts and commissions. Underwriting Discounts and Commissions Underwriting discounts and commissions (In percentage) Related to other offering costs Other Offering Costs Other offering costs The costs for underwriter discounts, commissions and other fees. Underwriting Discounts And Commissions Expense Underwriting discounts and commissions expense The cash inflow from the additional capital contribution to the entity net of underwriting discounts, commissions and other fees. Proceeds From Issuance Of Common Stock, Net Of Underwriting Discounts And Commissions Net cash proceeds Treasury Stock, Shares, Acquired Purchased shares of common stock The percentage of stock acquired to the total of outstanding shares. Percentage of Treasury Stock Acquired, of Shares Outstanding Outstanding shares percentage Treasury Stock, Value, Acquired, Cost Method Fair value of shares Warrants and Rights Outstanding Estimated fair value of warrants The amount of change in fair value of warrant derivative liability. Change in Fair Value of Warrant Derivative Liability Change in fair value of derivative liability Represents the information pertaining to at the market offering. At the Market Offering [Member] At the Market Offering Maximum amount agreed to sell as per open market sales agreement. Sale of Stock, Maximum Amount Agreed to Sell as Per Open Market Sales Agreement Amount agreed to sell as per open market sales agreement Percentage of commission agreed to pay as a percentage on gross sales price. Sale of Stock, Commission Agreed to Pay as a Percentage on Gross Sales Price Percentage of commission agreed Sale of Stock, Number of Shares Issued in Transaction Common stock to sales agreement Maximum amount remaining for sale as per open market sales agreement. Sale of Stock, Maximum Amount Remaining for Sale as Per Open Market Sales Agreement Sales agreement amounts Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Plan Name [Axis] Plan Name [Domain] Represents information pertaining to 2015 plan. 2015 Plan Represents information pertaining to 2016 plan. 2016 Plan Represents information pertaining to year 2019 plan. 2019 Plan Represents information pertaining to year 2021 plan. 2021 Plan Represents information pertaining to the inducement grant. Inducement Grant Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Number of shares authorized Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Outstanding, ending Outstanding, beginning Number of shares outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Number of shares available Employee Stock [Member] Employee Stock Purchase Plan Common Stock, Capital Shares Reserved for Future Issuance Shares reserved for purchase Stock Issued During Period, Shares, Employee Stock Purchase Plans Shares purchases Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Number of Options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Grants to employees Shares Issued, Shares, Share-Based Payment Arrangement, Forfeited Forfeited Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares Vested, ending Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Outstanding, ending Outstanding, beginning Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Granted Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Exercises Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Forfeited Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value Vested, ending Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract] Weighted Average Remaining Contractual Life Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Remaining contractual term (years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Vested (years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value Total intrinsic value of exercised Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Intrinsic value of outstanding options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value Aggregate intrinsic value of vested stock options Fair value of options granted. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock. Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grant in Period, Fair Value Fair value of options granted Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Weighted average grant date fair value, granted Represents information pertaining to stock options time based vesting. Time-Based Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price Market price of common stock on grant date Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Expected volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Risk free interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Expected term (years) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Dividend yield Share-Based Payment Arrangement, Expense Compensation cost Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Unrecognized share-based compensation expense Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Expected to be recognized over a remaining weighted average period Number of warrants or rights expired. Class of Warrant or Right, Expirations Warrant expirations (In shares) Exercise price per share or per unit of warrants or rights expired. Class of Warrant or Right, Expiration, Exercise Price of Warrants or Rights Warrant expirations, Price (in dollars per share) Warrants and Rights Outstanding, Term Weighted average remaining contractual term Number of warrants exercised, granted or expired. Warrants Exercised, Granted Or Expired Warrants granted, exercised or expired Related Party Transaction [Table] Related and Nonrelated Parties [Axis] Related and Nonrelated Parties [Domain] Related Party [Member] Related Party Related Party Transaction [Axis] Related Party Transaction [Domain] Represents the information pertaining to Handok License agreement Handok License Agreement [Member] Handok License Agreement Handok, Inc. [Member] Handok, Inc. [Member] Handok, Inc. Related Party Transaction [Line Items] Term of pharmaceutical license agreement in years. Pharmaceutical License Agreement, Term License term (in years) The amount of milestone payments to be incurred for the approval of license. Pharmaceutical License Agreement, Milestone Payment Milestone payments The percentage of transfer price on sale of products. Pharmaceutical License Agreement, Transfer Price Transfer price (in percent) The amount of milestone payments earned by the entity. Pharmaceutical License Agreement Milestone Payment Earned Milestone payments earned Antidilutive Security, Excluded EPS Calculation [Table] Class of Stock [Axis] Class of Stock [Domain] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] NET LOSS PER SHARE Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Total Fair Value, Recurring and Nonrecurring [Table] Measurement Frequency [Axis] Measurement Frequency [Domain] Fair Value, Recurring [Member] Recurring Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Domain] Fair Value, Inputs, Level 1 [Member] Level 1 Fair Value, Inputs, Level 2 [Member] Level 2 Money Market Funds [Member] Money Market Mutual Fund Money market funds Asset-Backed Securities [Member] Asset-backed securities Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS Cash and Cash Equivalents, Fair Value Disclosure Cash and cash equivalents Assets, Fair Value Disclosure Financial assets measured at fair value Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Balance at the end Balance at the beginning Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Changes in fair value Industry Sector [Axis] Industry Sector [Domain] Financial Services Sector [Member] Banking and Financial Services Industries Concentration Risk, Credit Risk, Uninsured Deposits Concentration risk, credit risk, uninsured deposits Subsequent Event [Table] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event [Member] Subsequent Event Subsequent Event [Line Items] EX-101.PRE 8 rzlt-20240930_pre.xml EX-101.PRE XML 10 R1.htm IDEA: XBRL DOCUMENT v3.24.3 Document And Entity Information - shares 3 Months Ended Sep. 30, 2024 Nov. 05, 2024 Document And Entity Information [Abstract] Â Â Document Type 10-Q Â Document Quarterly Report true Â Document Period End Date Sep. 30, 2024 Â Document Transition Report false Â Entity File Number 001-39683 Â Entity Registrant Name REZOLUTE, INC. Â Entity Incorporation, State or Country Code NV Â Entity Tax Identification Number 27-3440894 Â Entity Address, Address Line One 275 Shoreline Drive, Suite 500 Â Entity Address, City or Town Redwood City Â Entity Address, State or Province CA Â Entity Address, Postal Zip Code 94065 Â City Area Code 650 Â Local Phone Number 206-4507 Â Title of 12(b) Security Common Stock, par value $0.001 per share Â Trading Symbol RZLT Â Security Exchange Name NASDAQ Â Entity Current Reporting Status Yes Â Entity Interactive Data Current Yes Â Entity Filer Category Non-accelerated Filer Â Entity Small Business true Â Entity Emerging Growth Company false Â Entity Shell Company false Â Entity Common Stock, Shares Outstanding Â 57,943,066 Entity Central Index Key 0001509261 Â Current Fiscal Year End Date --06-30 Â Document Fiscal Year Focus 2025 Â Document Fiscal Period Focus Q1 Â Amendment Flag false Â

X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei_CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCover page. + ReferencesNo definition available. + Details Name: dei_CoverAbstract Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli:gMonthDayItemType Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a + Details Name: dei_DocumentQuarterlyReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a transition report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + ReferencesNo definition available. + Details Name: dei_DocumentType Namespace Prefix: dei_ Data Type: dei:submissionTypeItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCode for the postal or zip code + ReferencesNo definition available. + Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the state or province. + ReferencesNo definition available. + Details Name: dei_EntityAddressStateOrProvince Namespace Prefix: dei_ Data Type: dei:stateOrProvinceItemType Balance Type: na Period Type: duration X - DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_ Data Type: dei:centralIndexKeyItemType Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + ReferencesNo definition available. + Details Name: dei_EntityFileNumber Namespace Prefix: dei_ Data Type: dei:fileNumberItemType Balance Type: na Period Type: duration X - DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityFilerCategory Namespace Prefix: dei_ Data Type: dei:filerCategoryItemType Balance Type: na Period Type: duration X - DefinitionTwo-character EDGAR code representing the state or country of incorporation. + ReferencesNo definition available. + Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_ Data Type: dei:edgarStateCountryItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405 + Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityRegistrantName Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityShellCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicates that the company is a Smaller Reporting Company (SRC). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityTaxIdentificationNumber Namespace Prefix: dei_ Data Type: dei:employerIdItemType Balance Type: na Period Type: duration X - DefinitionLocal phone number for entity. + ReferencesNo definition available. + Details Name: dei_LocalPhoneNumber Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionTitle of a 12(b) registered security. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b + Details Name: dei_Security12bTitle Namespace Prefix: dei_ Data Type: dei:securityTitleItemType Balance Type: na Period Type: duration X - DefinitionName of the Exchange on which a security is registered. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1 + Details Name: dei_SecurityExchangeName Namespace Prefix: dei_ Data Type: dei:edgarExchangeCodeItemType Balance Type: na Period Type: duration X - DefinitionTrading symbol of an instrument as listed on an exchange. + ReferencesNo definition available. + Details Name: dei_TradingSymbol Namespace Prefix: dei_ Data Type: dei:tradingSymbolItemType Balance Type: na Period Type: duration XML 11 R2.htm IDEA: XBRL DOCUMENT v3.24.3 Unaudited Condensed Consolidated Balance Sheets - USD ($) $ in Thousands Sep. 30, 2024 Jun. 30, 2024 Current assets: Â Â Cash and cash equivalents $ 10,472 $ 70,396 Investments in marketable debt securities 97,801 56,478 Prepaid expenses and other 1,905 1,779 Total current assets 110,178 128,653 Long-term assets: Â Â Investments in marketable debt securities 9,552 263 Deposits and other 1,838 1,838 Right-of-use assets 1,751 1,880 Property and equipment, net 95 103 Total assets 123,414 132,737 Current liabilities: Â Â Accounts payable 2,176 4,901 Accrued liabilities: Â Â Compensation and benefits 2,652 1,812 Accrued clinical and other 2,579 2,325 Current portion of operating lease liabilities 584 568 Total current liabilities 7,991 9,606 Long-term liabilities: Â Â Operating lease liabilities, net of current portion 1,499 1,660 Embedded derivative liability 483 468 Total liabilities 9,973 11,734 Commitments and contingencies (Notes 5, 9 and 10) Shareholders' equity: Â Â Preferred stock, $0.001 par value; 400 shares authorized; no shares issued Common stock, $0.001 par value; 100,000 shares authorized; issued and outstanding 55,394 and 53,246 shares as of September 30, 2024 and as of June 30, 2024, respectively 55 53 Additional paid-in capital 457,919 450,473 Accumulated other comprehensive income (loss) 289 (79) Accumulated deficit (344,822) (329,444) Total shareholders' equity 113,441 121,003 Total liabilities and shareholders' equity $ 123,414 $ 132,737 X - DefinitionAmount of accrued for clinical liabilities. + ReferencesNo definition available. + Details Name: rzlt_AccruedClinicalCurrent Namespace Prefix: rzlt_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_AccountsPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AccruedLiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14AReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14 + Details Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AdditionalPaidInCapital Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting

Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_AssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AssetsNoncurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRepresents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommitmentsAndContingencies Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_CommonStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_DepositsAssetsNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as a liability. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B + Details Name: us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_EmployeeRelatedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -

Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details Name: us-gaap_Liabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_LiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesNoncurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of investment in marketable security, classified as current. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_MarketableSecuritiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of investment in marketable security, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_MarketableSecuritiesNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_PreferredStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -

Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 12 R3.htm IDEA: XBRL DOCUMENT v3.24.3 Unaudited Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares shares in Thousands Sep. 30, 2024 Jun. 30, 2024 Unaudited Condensed Consolidated Balance Sheets Â Â Preferred stock, par value (in dollars per share) $ 0.001 $ 0.001 Preferred stock, shares authorized 400 400 Preferred stock, shares, issued 0 0 Common stock, par value (in dollars per share) $ 0.001 $ 0.001 Common stock, shares authorized 100,000 100,000 Common stock, shares issued 55,394 53,246 Common stock, shares outstanding 55,394 53,246 X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_PreferredStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfFinancialPositionAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 13 R4.htm IDEA: XBRL DOCUMENT v3.24.3 Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands 3 Months Ended Sep. 30, 2024 Sep. 30, 2023 Operating expenses: Â Â Research and development $ 12,754 $ 12,214 General and administrative 4,187 3,700 Total operating expenses 16,941 15,914 Operating loss (16,941) (15,914) Non-operating income (expense): Â Â Interest and other income, net 1,578 1,404 Loss from change in fair value of embedded derivative liability (15) (14) Total non-operating income, net 1,563 1,390 Net loss (15,378) (14,524) Other comprehensive income (loss): Â Â Net unrealized gain (loss) on marketable debt securities 368 67 Comprehensive loss $ (15,010) $ (14,457) Net loss per common share - basic (in dollars per share) $ (0.22) $ (0.28) Net loss per common share - diluted (in dollars per share) $ (0.22) $ (0.28) Weighted average number of common shares outstanding - basic (in shares) 69,736 51,409 Weighted average number of common shares outstanding - diluted (in shares) 69,736 51,409 X - DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5 + Details Name: us-gaap_ComprehensiveIncomeNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_ComprehensiveIncomeNetOfTaxAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-

04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A + Details Name: us-gaap_GainLossOnDerivativeInstrumentsNetPretax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap_GeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business). + ReferencesNo definition available. + Details Name: us-gaap_InterestAndOtherIncome Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_NonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NonoperatingIncomeExpenseAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionGenerally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. + ReferencesNo definition available. + Details Name: us-gaap_OperatingExpenses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OperatingExpensesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11 + Details Name: us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 14 R5.htm IDEA: XBRL DOCUMENT v3.24.3 Unaudited Condensed Consolidated Statements of Shareholders' Equity - USD ($) shares in Thousands, $ in Thousands Common Stock Private Placement Common Stock Additional Paid-in Capital Private Placement Additional Paid-in Capital Accumulated Other Comprehensive Loss Accumulated Deficit Private Placement Total Balance beginning at Jun. 30, 2023 Â $ 37 Â $ 377,471 $ (351) $ (260,985) Â $ 116,172 Balance beginning (in shares) at Jun. 30, 2023 Â 36,827 Â Â Â Â Â Â Share-based compensation Â Â Â 1,849 Â Â Â 1,849 Net change in accumulated other comprehensive loss Â Â Â Â 67 Â Â 67 Net loss Â Â Â Â Â Â (14,524) Â (14,524) Balance ending at Sep. 30, 2023 Â $ 37 Â 379,320 (284) (275,509) Â 103,564 Balance ending (in shares) at Sep. 30, 2023 Â 36,827 Â Â Â Â Â Â Balance beginning at Jun. 30, 2023 Â $ 37 Â 377,471 (351) (260,985) Â 116,172 Balance beginning (in shares) at Jun. 30, 2023 Â 36,827 Â Â Â Â Â Â Net loss Â Â Â Â Â Â Â (68,500) Balance ending at Jun. 30, 2024 Â $ 53 Â 450,473 (79) (329,444) Â 121,003 Balance ending (in shares) at Jun. 30, 2024 Â 53,246 Â Â Â Â Â Â Gross proceeds from issuance of common stock for cash $ 1 Â $ 5,999 Â Â Â $ 6,000 Â Gross proceeds from issuance of common stock for cash (in shares) 1,500 Â Â Â Â Â Â Â Payment of commissions and other offering costs Â Â Â (45) Â Â Â (45) Issuance of common stock upon exercise of stock options Â Â Â 93 Â Â Â $ 93 Issuance of common

stock upon exercise of stock options (in shares) Â 38 Â Â Â Â Â Â 38 Share-based compensation Â Â Â 1,400 Â Â Â $ 1,400 Cashless exercise of pre-funded warrants Â $ 1 Â (1) Â Â Â Â Cashless exercise of pre-funded warrants (in shares) Â 610 Â Â Â Â Â Â Â Net change in accumulated other comprehensive loss Â Â Â Â 368 Â Â 368 Net loss Â Â Â Â Â (15,378) Â (15,378) Balance ending at Sep. 30, 2024 Â $ 55 Â $ 457,919 $ 289 $ (344,822) Â $ 113,441 Balance ending (in shares) at Sep. 30, 2024 Â 55,394 Â Â Â Â Â Â Â X - DefinitionNumber of shares issued upon exercise of pre-funded warrants. + ReferencesNo definition available. + Details Name: rzlt_StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants Namespace Prefix: rzlt_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionValue of stock issued upon exercise of pre-funded warrants + ReferencesNo definition available. + Details Name: rzlt_StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants Namespace Prefix: rzlt_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12 + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11 + Details Name: us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares issued which are neither cancelled nor held in the treasury. + ReferencesNo definition available. + Details Name: us-gaap_SharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue of stock issued as a result of the exercise of stock options. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-

gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 15 R6.htm IDEA: XBRL DOCUMENT v3.24.3 Unaudited Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands 3 Months Ended 12 Months Ended Sep. 30, 2024 Sep. 30, 2023 Jun. 30, 2024 CASH FLOWS FROM OPERATING ACTIVITIES: Â Â Â Net loss $ (15,378) $ (14,524) Â Share-based compensation expense 1,400 1,849 Â Loss from change in fair value of embedded derivative liability 15 14 Â Non-cash lease expense 129 122 Â Accretion of discounts and amortization of premiums on marketable debt securities, net (832) 973 Â Depreciation expense 8 10 Â Realized gain from investments (2) Â Â Changes in operating assets and liabilities: Â Â Â Increase in prepaid expenses, deposits, and other assets (108) (902) Â Decrease in accounts payable (2,194) (836) Â Increase in accrued liabilities 948 2,709 Â Net Cash Used in Operating Activities (16,014) (10,585) $ (57,400) CASH FLOWS FROM INVESTING ACTIVITIES Â Â Â Purchase of marketable debt securities (73,238) (15,989) Â Proceeds from maturities of marketable debt securities 23,828 18,595 Â Total Cash Provided by (Used in) Investing Activities (49,410) 2,606 Â CASH FLOWS FROM FINANCING ACTIVITIES: Â Â Â Proceeds from exercise of stock options 76 Â Â Gross proceeds from issuance of common stock in 2024 Private Placement 6,000 Â Â Payment of offering costs (576) Â Â Net Cash Provided by Financing Activities 5,500 Â Â Net decrease in cash and cash equivalents (59,924) (7,979) Â Cash and cash equivalents at beginning of period 70,396 16,036 16,036 Cash and cash equivalents at end of period 10,472 8,057 $ 70,396 SUPPLEMENTARY CASH FLOW INFORMATION: Â Â Â Cash paid for amounts included in the measurement of operating lease liabilities 184 $ 171 Â NON-CASH INVESTING AND FINANCING ACTIVITIES: Â Â Â Payables for offering costs 18 Â Â Receivable from exercise of stock options $ 17 Â Â X - DefinitionAmount representing the non cash lease expense. + ReferencesNo definition available. + Details Name: rzlt_NonCashLeaseExpense Namespace Prefix: rzlt_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of payables accrued for offering costs in the period. + ReferencesNo definition available. + Details Name: rzlt_PayablesForOfferingCosts Namespace Prefix: rzlt_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of receivable from exercise of stock options in non-cash investing or financing transactions. + ReferencesNo definition available. + Details Name: rzlt_ReceivableFromExerciseOfStockOptions Namespace Prefix: rzlt_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9 + Details Name: us-gaap_DebtSecuritiesAvailableForSaleRealizedGain Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_DepreciationAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A + Details Name: us-gaap_GainLossOnDerivativeInstrumentsNetPretax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccruedLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeasePayments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow for cost incurred directly with the issuance of an equity security. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsOfStockIssuanceCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow for purchase of marketable security. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11 + Details Name: us-gaap_PaymentsToAcquireMarketableSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow associated with the amount received from entity's raising of capital via private rather than public placement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfPrivatePlacement Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period. + ReferencesNo definition available. + Details Name: us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from exercise of option under share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Subparagraph (a) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A + Details Name: us-gaap_ProceedsFromStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting

Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_SupplementalCashFlowInformationAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 16 R7.htm IDEA: XBRL DOCUMENT v3.24.3 NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES 3 Months Ended Sep. 30, 2024 NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Â NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES NOTE 1 â€” NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIESNature of OperationsRezolute, Inc. (the â€œCompanyâ€) is a late-stage rare disease company focused on significantly improving outcomes for individuals with hypoglycemia caused by hyperinsulinism. The Companyâ€™s primary clinical assets consist of (i) ersodetug (formerly known as RZ358), which is a potential treatment for all forms of hyperinsulinism, including congenital hyperinsulinism, an ultra-rare pediatric genetic disorder characterized by excessive production of insulin by the pancreas, and (ii) RZ402, which is an oral plasma kallikrein inhibitor (â€œPKIâ€) being developed as a potential therapy for the chronic treatment of diabetic macular edema.Basis of Presentation The accompanying unaudited interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (â€œGAAPâ€), the rules and regulations of the SEC for interim financial information, and the instructions to Form 10-Q and Article 8 of Regulation S-X.The condensed consolidated balance sheet as of June 30, 2024, has been derived from the Companyâ€™s audited consolidated financial statements. The unaudited interim financial statements should be read in conjunction with the Companyâ€™s 2024 Form 10-K, which contains the Companyâ€™s audited financial statements and notes thereto, together with Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations for the fiscal year ended June 30, 2024.Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all information and footnote disclosures necessary for a comprehensive presentation of financial position, results of operations, and cash flows. It is managementâ€™s opinion, however, that all material adjustments (consisting of normal recurring adjustments) that are necessary for a fair financial statement presentation have been made. The interim results for the three months ended September 30, 2024, are not necessarily indicative of the financial condition and results of operations that may be expected for any future interim period or for the fiscal year ending June 30, 2025.ConsolidationThe Company has two wholly owned subsidiaries consisting of Rezolute (Bio) Ireland Limited, and Rezolute Bio UK, Ltd. The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.Use of EstimatesThe preparation of financial statements in conformity with GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts in the unaudited condensed consolidated financial statements and the accompanying notes. The Company bases its estimates and assumptions on current facts, historical experience, and various other factors that it believes are reasonable under the circumstances, to determine the carrying values of assets and liabilities that are not readily apparent from other sources. The Companyâ€™s significant accounting estimates include, but are not necessarily limited to, determination if an allowance for credit losses is required for marketable debt securities, the fair value of an embedded derivative liability, fair value of share-based compensation, managementâ€™s assessment of going concern, and estimates related to clinical trial accrued liabilities. Actual results could differ from those estimates.Risks and UncertaintiesThe Company's operations may be subject to significant risks and uncertainties including financial, operational, regulatory and other risks associated with a clinical stage company, including the potential risk of business failure discussed in Note 2.Significant Accounting PoliciesThe Companyâ€™s significant accounting policies are described in Note 1 to the financial statements in Item 8 of the 2024 Form 10-K.Â Recent Accounting Pronouncements Not Yet AdoptedIn November 2023, the Financial Accounting Standards Board (â€œFASBâ€) issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (â€œASU 2023-07â€), which improves reportable segment disclosure requirements through enhanced disclosures about significant segment expenses. ASU 2023-07 expands public entitiesâ€™ segment disclosures by requiring disclosure of significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items and interim disclosures of a reportable segmentâ€™s profit or loss and assets. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods in fiscal years beginning after December 15, 2024. Early adoption is permitted and the amendments should be applied on a retrospective basis to all periods presented. The Company is evaluating the effect of adopting ASU 2023-07 and does not expect the amendments to have a material impact on its consolidated financial statements.In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (â€œASU 2023-09â€), which expands income tax disclosures including changes in the rate reconciliation and income taxes paid information. Â This ASU is intended to enhance the transparency and decision usefulness of income tax disclosures. ASU 2023-09 is effective for annual periods beginning after December 15, 2024, and early adoption is permitted. The Company has not determined the timing for adoption of this standard.Other accounting standards that have been issued or proposed by the FASB or other standards-setting bodies that do not require adoption until a future date are not currently expected to have a material impact on the Companyâ€™s financial statements upon adoption. X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContentReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 275 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/275/tableOfContentReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/810/tableOfContentReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 250 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/250/tableOfContent + Details Name: us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 17 R8.htm IDEA: XBRL DOCUMENT v3.24.3 LIQUIDITY 3 Months Ended Sep. 30, 2024 LIQUIDITY Â LIQUIDITY NOTE 2 â€” LIQUIDITYAs a clinical stage business, the Company has not yet generated any revenues and had an accumulated deficit of $344.8 million as of September 30, 2024. For the three months ended September 30, 2024, the Company incurred a net loss of $15.4 million and net cash used in operating activities amounted to $16.0 million. For the fiscal year ended June 30, 2024, the Company incurred a net loss of $68.5 million and net cash used in operating activities amounted to $57.4 million. As of September 30, 2024, the Companyâ€™s capital resources consist of cash and cash equivalents of $10.5 million, short-term investments in marketable debt securities of $97.8 million and long-term investments in marketable debt securities of $9.6 million.As discussed in Note 7, the Company completed the 2024 Private Placement in July 2024 that resulted in the sale of 1.5 million shares of common stock for net cash proceeds of $6.0 million. As of September 30, 2024, the Company has total liabilities of $10.0 million, including current liabilities of $8.0 million. As discussed in Note 5, the Company is subject to license agreements that provide for future contractual payments upon achievement of various milestone events. Pursuant to the XOMA License Agreement (as defined below), a $5.0 million milestone payment will be due upon dosing of the last patient in a Phase 3 clinical trial for ersodetug. The commitment to pay the last patient dosing milestone of $5.0 million for the ersodetug Phase 3 clinical trial is expected to be recognized as a liability and corresponding expense within 12 months. Management believes the Companyâ€™s existing cash and cash equivalents and investments in marketable debt securities will be adequate to meet the Companyâ€™s contractual obligations and carry out ongoing clinical trials and other planned activities through November 2025, at a minimum. X - ReferencesNo definition available. + Details Name: rzlt_LiquidityAbstract Namespace Prefix: rzlt_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 40 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/205-40/tableOfContent + Details Name: us-gaap_SubstantialDoubtAboutGoingConcernTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 18 R9.htm IDEA: XBRL DOCUMENT v3.24.3 INVESTMENTS IN MARKETABLE DEBT SECURITIES 3 Months Ended Sep. 30, 2024 INVESTMENTS IN MARKETABLE DEBT SECURITIES Â INVESTMENTS IN MARKETABLE DEBT SECURITIES NOTE 3 â€”INVESTMENTS IN MARKETABLE DEBT SECURITIESInvestments in marketable debt securities are accounted for as available-for-sale investments at fair value and consist of the following (in thousands):â€‹â€‹â€‹

the 12-month period ending September 30, 2026.During the three months ended September 30, 2024, marketable debt securities for $23.8 million matured and were reinvested in additional marketable debt securities. The Company used $73.2 million of cash and cash equivalents to purchase investments in marketable debt securities of the proceeds during the three months ended September 30, 2024. The Company did not sell any marketable debt securities prior to the scheduled maturity dates for the three months ended September 30, 2024. Accrued interest receivable on all marketable debt securities amounted to $0.5 million and $0.4 million as of September 30, 2024 and June 30, 2024, respectively. Accrued interest receivable is included in other current assets in the accompanying condensed consolidated balance sheets.For the three months ended September 30, 2024, the Company did not recognize any allowance for credit losses or other than temporary impairment related to investments in marketable debt securities. The following table summarizes the cumulative unrealized gains and losses that result in differences between the amortized cost basis and fair value of the Companyâ€™s marketable debt securities held as of September 30, 2024 (in thousands):â€‹â€‹â€‹

available. + Details Name: us-gaap_StockholdersEquityNoteAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/505/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18 + Details Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 23 R14.htm IDEA: XBRL DOCUMENT v3.24.3 SHARE-BASED COMPENSATION AND WARRANTS 3 Months Ended Sep. 30, 2024 SHARE-BASED COMPENSATION AND WARRANTS Â SHARE-BASED COMPENSATION AND WARRANTS NOTE 8 â€” SHARE-BASED COMPENSATION AND WARRANTSStock Option PlansPresented below is a summary of the number of shares outstanding, authorized, and available for future grants under the Companyâ€™s stock option plans and an inducement grant not associated with a stock option plan as of September 30, 2024 (in thousands):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â Number of Shares as of September 30, 2024DescriptionÂ Â Â Â AuthorizedÂ Â Â Â OutstandingÂ Â Â Â Available2015 PlanÂ 17Â 17Â â€”2016 PlanÂ 123Â 123Â â€”2019 PlanÂ 200Â 200Â â€”2021 Planâ€‹ 10,580â€‹ 10,160â€‹ 420Inducement Grantâ€‹ 275â€‹ 275â€‹ â€”TotalÂ 11,195Â 10,775Â 420â€‹2022 Employee Stock Purchase PlanOn June 16, 2022, the Companyâ€™s shareholders approved the adoption of the 2022 Employee Stock Purchase Plan (the â€œ2022 ESPPâ€). The 2022 ESPP provides an opportunity for employees to purchase the Companyâ€™s common stock through accumulated payroll deductions.The 2022 ESPP has consecutive offering periods that begin approximately every 6 months commencing on the first trading day on or after July 1 and terminating on the last trading day of the offering period ending on December 31 and commencing on the first trading day on or after January 1 and terminating on the last trading day of the offering period ending on June 30. The 2022 ESPP reserves 0.5 million shares for purchases. There have been no offering periods under the 2022 ESPP through September 30, 2024.Stock Options OutstandingFor the three months ended September 30, 2024, the following table sets forth a summary of the combined activity under the Companyâ€™s stock option plans and an inducement grant not associated with a stock option plan (shares in thousands):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â SharesÂ Â Â Â PriceÂ (1)Â Â Â Â TermÂ (2)Outstanding, June 30, 2024Â 10,891â€‹ $ 3.82â€‹8.1Grants to employeesâ€‹ 240â€‹â€‹ 4.73â€‹â€‹Exercisesâ€‹ (38)(3)â€‹ 2.44â€‹â€‹Forfeitedâ€‹ (318)â€‹â€‹ 2.61â€‹â€‹Outstanding, September 30, 2024Â 10,775(4)Â 3.88Â 7.7Vested, September 30, 2024Â 5,525(5)Â 5.07Â 7.2(1)Represents the weighted average exercise price.(2)Represents the weighted average remaining contractual term for the number of years until the stock options expire.(3)The total intrinsic value (the amount by which the fair market value exceeded the exercise price) of stock options exercised during the three months ended September 30, 2024, was $0.1 million.(4)As of September 30, 2024, the intrinsic value of outstanding options was approximately $19.2 million.(5)As of September 30, 2024, the aggregate intrinsic value of vested stock options was approximately $7.5 million.For the three months ended September 30, 2024, the aggregate fair value of stock options granted for approximately 0.2 million shares of common stock amounted to $0.8 million or approximately $3.45 per share as of the grant dates. Fair value was computed using the Black-Scholes-Merton (â€œBSMâ€) option-pricing model and will result in the recognition of compensation cost ratably over the expected vesting period of the stock options. For the three months ended September 30, 2024, the fair value of stock options was estimated on the respective dates of grant, with the following weighted-average assumptions: â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Market price of common stock on grant dateâ€‹ $ 4.73â€‹Expected volatilityÂ Â Â Â â€‹ 84%Risk free interest rateÂ â€‹ 3.7%Expected term (years)Â â€‹ 6.1â€‹Dividend yieldÂ â€‹ 0%â€‹Share-based compensation expense for the three months ended September 30, 2024 and 2023 is included under the following captions in the unaudited condensed consolidated statements of operations and comprehensive loss (in thousands):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹2024Â Â Â Â 2023â€‹Research and developmentâ€‹ $ 712â€‹ $ 840â€‹General and administrativeâ€‹Â 688â€‹Â 1,009â€‹Totalâ€‹ $ 1,400â€‹ $ 1,849â€‹â€‹Unrecognized share-based compensation expense is approximately $10.4 million as of September 30, 2024. This amount is expected to be recognized over a weighted average period of 1.8 years.Pre-Funded WarrantsPFWs are outstanding for a total of 14.4 million shares as of September 30, 2024. Please refer to Note 7 for additional information about outstanding PFWs.Legacy WarrantsIn connection with an equity financing in October 2020, the Company issued warrants entitling the holders to purchase approximately 0.8 million shares of common stock. The warrants are exercisable at $19.50 per share for a period of seven years, may be exercised on a cash or cashless basis at the election of the holders, and the holders are entitled to share in any dividends or distributions payable to holders of common stock on an as-converted basis (â€œthe Participating Warrantsâ€). Additionally, the Company has issued warrants in conjunction with various debt and equity financings and for services. As of September 30, 2024, all of the warrants were vested. The Participating Warrants and other warrants are collectively referred to as the â€œLegacy Warrants.â€For the three months ended September 30, 2024, no Legacy Warrants were granted or exercised. The following table sets forth a summary of all Legacy Warrants for the three months ended September 30, 2024 (shares in thousands): â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â SharesÂ Â Â Â PriceÂ (1)Â Â Â Â TermÂ (2)Outstanding, June 30, 2024Â 861Â Â $ 20.28Â 3.2ExpirationsÂ (10)Â Â Â 52.00Â Â Â Outstanding, September 30, 2024Â 851Â Â Â 19.90Â 3.0(1)Represents the weighted average exercise price.(2)Represents the weighted average remaining contractual term for the number of years until the warrants expire. X - DefinitionThe entire disclosure for share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 24 R15.htm IDEA: XBRL DOCUMENT v3.24.3 COMMITMENTS AND CONTINGENCIES 3 Months Ended Sep. 30, 2024 COMMITMENTS AND CONTINGENCIES. Â COMMITMENTS AND CONTINGENCIES NOTE 9 â€” COMMITMENTS AND CONTINGENCIESLicensing CommitmentsPlease refer to Note 5 for further discussion of commitments to make milestone payments and to pay royalties under license agreements with XOMA and ActiveSite.Legal MattersFrom time to time, the Company may be involved in litigation relating to claims arising out of operations in the normal course of business. At each reporting period, the Company evaluates known claims to determine whether a potential loss amount or a potential range of loss is probable and reasonably estimable under ASC 450, Contingencies. As of September 30, 2024, there were no pending or threatened lawsuits that could reasonably be expected to have a material effect on the Companyâ€™s results of operations. Legal fees are expensed as incurred. X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for commitments and contingencies. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 405 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/405-30/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/450/tableOfContentReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 440 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/440/tableOfContent + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 25 R16.htm IDEA: XBRL DOCUMENT v3.24.3 RELATED PARTY TRANSACTIONS 3 Months Ended Sep. 30, 2024 RELATED PARTY TRANSACTIONS Â RELATED PARTY TRANSACTIONS NOTE 10 â€” RELATED PARTY TRANSACTIONSRelated Party Licensing AgreementOn September 15, 2020, the Company and Handok entered into an exclusive license agreement (the â€œHandok Licenseâ€) for the territory of the Republic of Korea. The Handok License relates to pharmaceutical products in final dosage form containing the pharmaceutical compounds developed or to be developed by the Company, including those related to ersodetug and RZ402. The Handok License is in effect for a period of 20 years after the first commercial sale of each product and requires (i) milestone payments to the Company of $0.5 million upon approval of a New Drug Application (â€œNDAâ€) for each product in the territory, and (ii) the Company will sell products ordered by Handok at a transfer price equal to 70% of the net selling price of the products. To date, no milestone payments have been earned by the Company.Investors in 2024 Private PlacementHandok was an investor in the 2024 Private Placement discussed in Note 7 for which the Company issued 1,250,000 shares of common stock at a purchase price of $4.00 resulting in gross proceeds of $5.0 million. X - ReferencesNo definition available. + Details Name: us-gaap_RelatedPartyTransactionsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(g)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(e)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/850/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1 + Details Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 26 R17.htm IDEA: XBRL DOCUMENT v3.24.3 INCOME TAXES 3 Months Ended Sep. 30, 2024 INCOME TAXES Â INCOME TAXES NOTE 11 â€” INCOME TAXESIncome tax expense during interim periods is based on applying an estimated annualized effective income tax rate applied to the respective quarterly periods, adjusted for discrete tax items in the period in which they occur. The computation of the annualized estimated effective tax rate for each interim period requires certain estimates and significant judgment including, but not limited to, the expected operating results for the year, projections of the proportion of income earned and taxed in various jurisdictions, permanent and temporary differences, and the likelihood of recovering deferred income tax assets generated in the current year. The accounting estimates used to compute the provision for income taxes may change as new events occur, more experience is obtained, additional information becomes known or as the tax environment changes.For the three months ended September 30, 2024 and 2023, the Company did not recognize any income tax benefit due to a full valuation allowance on its deferred income tax assets. The Company did not have any material changes to its conclusions regarding valuation allowances for deferred income tax assets or uncertain tax positions for

the three months ended September 30, 2024 and 2023. X - ReferencesNo definition available. + Details Name: us-gaap_IncomeTaxDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for income tax. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12CReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12BReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 270 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.5.Q1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/740/tableOfContentReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 11.C) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2 + Details Name: us-gaap_IncomeTaxDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 27 R18.htm IDEA: XBRL DOCUMENT v3.24.3 NET LOSS PER SHARE 3 Months Ended Sep. 30, 2024 NET LOSS PER SHARE Â NET LOSS PER SHARE NOTE 12 â€” NET LOSS PER SHAREBasic net loss per share is computed by dividing net loss by the weighted average number of outstanding shares of common stock and PFWs during periods when the PFWs are accounted for as equity instruments. Common shares associated with PFWs that are accounted for as equity instruments are included in the computation of basic and diluted net loss per share since the exercise price is negligible and all of the PFWs are fully vested and exercisable. Accordingly, the weighted average number of shares outstanding for basic and diluted net loss per share is computed as follows for the three months ended September 30, 2024 and 2023 (in thousands):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹2024Â Â Â Â 2023Common Stockâ€‹â€‹ 55,167â€‹â€‹ 36,8272021 PFWsâ€‹â€‹ 123â€‹â€‹ 1,6612022 PFWsâ€‹â€‹ 8,147â€‹â€‹ 12,921Exchange PFWsâ€‹â€‹ 2,549â€‹â€‹ â€”2024 PFWsâ€‹â€‹ 3,750â€‹â€‹ â€”Totalâ€‹â€‹ 69,736â€‹â€‹ 51,409â€‹For the three months ended September 30, 2024 and 2023, basic and diluted net loss per share were the same since all other common stock equivalents were anti-dilutive. As of September 30, 2024 and 2023, the following outstanding potential common stock equivalents were excluded from the computation of diluted net loss per share since the impact of inclusion was anti-dilutive (in thousands):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹2024â€‹2023Stock optionsâ€‹ 10,775â€‹ 9,109Legacy warrantsâ€‹ 851â€‹ 888Totalâ€‹ 11,626â€‹ 9,997â€‹ X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for earnings per share. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/260/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3 + Details Name: us-gaap_EarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 28 R19.htm IDEA: XBRL DOCUMENT v3.24.3 FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS 3 Months Ended Sep. 30, 2024 FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS Â FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS NOTE 13 â€” FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONSFair Value MeasurementsFair value is defined as the price that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants on the measurement date. When determining fair value, the Company considers the principal or most advantageous market in which it transacts and considers assumptions that market participants would use when pricing the asset or liability. The Company applies the following fair value hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement:Level 1â€”Quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date.Level 2â€”Other than quoted prices included in Level 1 that are observable for the asset and liability, either directly or indirectly through market corroboration, for substantially the full term of the asset or liability.Level 3â€”Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any market activity for the asset or liability at the measurement date.The following table presents information about the Companyâ€™s financial assets measured at fair value on a recurring basis and indicates the fair value hierarchy classification as of September 30, 2024 and June 30, 2024 (in thousands):â€‹Fair Value Measurement of Assets as of September 30, 2024â€‹â€‹Totalâ€‹Level 1â€‹Level 2â€‹Level 3Cash and cash equivalents:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Money market fundsâ€‹â€‹$ 5,894â€‹â€‹$ 5,894â€‹â€‹$ â€”â€‹â€‹$ â€”Marketable debt securities:â€‹Corporate commercial paperâ€‹â€‹ 31,522â€‹â€‹ â€”â€‹â€‹ 31,522â€‹â€‹ â€”U.S. Government agenciesâ€‹â€‹ 5,277â€‹â€‹ â€”â€‹â€‹ 5,277â€‹â€‹ â€”U.S. Government treasuriesâ€‹â€‹ 13,664â€‹â€‹ â€”â€‹â€‹ 13,664â€‹â€‹ â€”Corporate notes and bondsâ€‹â€‹ 56,890â€‹â€‹ â€”â€‹â€‹ 56,890â€‹â€‹ â€”Total â€‹$ 113,247â€‹$ 5,894â€‹$ 107,353â€‹$ â€”â€‹Fair Value Measurement of Assets as of June 30, 2024â€‹â€‹Totalâ€‹Level 1â€‹Level 2â€‹Level 3Cash and cash equivalents:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Money market fundsâ€‹$ 61,249â€‹$ 61,249â€‹$ â€”â€‹$ â€”Marketable debt securities:â€‹Corporate commercial paperâ€‹â€‹ 20,929â€‹â€‹ â€”â€‹â€‹ 20,929â€‹â€‹ â€”U.S. Government agenciesâ€‹â€‹ 1,997â€‹â€‹ â€”â€‹â€‹ 1,997â€‹â€‹ â€”U.S. Government treasuriesâ€‹â€‹ 2,720â€‹â€‹ â€”â€‹â€‹ 2,720â€‹â€‹ â€”Corporate notes and bondsâ€‹â€‹ 30,832â€‹â€‹ â€”â€‹â€‹ 30,832â€‹â€‹ â€”Asset-backed securitiesâ€‹â€‹ 263â€‹â€‹ â€”â€‹â€‹ 263â€‹â€‹ â€”Total â€‹$ 117,990â€‹$ 61,249â€‹$ 56,741â€‹$ â€”â€‹Marketable debt securities classified as Level 2 within the valuation hierarchy generally consist of U.S. government agency securities, corporate bonds, and commercial paper. The Company determines the fair value of marketable debt securities based upon valuations obtained from third-party pricing sources. Except for the amounts shown in the table above, the Company did not have any other assets measured at fair value on a recurring basis as of September 30, 2024 and June 30, 2024.The Companyâ€™s embedded derivative liability discussed in Note 6 is classified under Level 3 of the fair value hierarchy and is required to be measured and recorded at fair value on a recurring basis. Fair value is determined based on managementâ€™s assessment of the probability and timing of occurrence for the Exit Events discussed in Note 6 using a discount rate equal to the effective interest rate under the Loan Agreement.The following table sets forth changes in the fair value of the Companyâ€™s embedded derivative liability measured at fair value liability for the three months ended September 30, 2024 and 2023 (in thousands):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹2024â€‹2023Fair value, beginning of period$ 468â€‹$ 412Changes in fair valueâ€‹ 15â€‹â€‹ 14Fair value, end of period$ 483â€‹$ 426â€‹Except for the embedded derivative liability, the Company did not have any other liabilities measured at fair value on a recurring basis as of September 30, 2024 and June 30, 2024.Due to the relatively short maturity of the respective instruments, the fair value of cash, accounts payable, and accrued liabilities approximated their carrying values as of September 30, 2024 and June 30, 2024.The Companyâ€™s policy is to recognize asset or liability transfers among Level 1, Level 2 and Level 3 as of the actual date of the events or change in circumstances that caused the transfer. During the three months ended September 30, 2024 and 2023, the Company did not have any transfers of its assets or liabilities between levels of the fair value hierarchy.Significant ConcentrationsFinancial instruments that subject the Company to concentrations of credit risk consist primarily of cash, cash equivalents and investments in marketable debt securities. The Company maintains cash in demand deposit accounts at a high-quality financial institution. As of and for the three months ended September 30, 2024 and 2023, cash deposits have exceeded the amount of insurance provided on such deposits by the Federal Deposit Insurance Corporation. As of September 30, 2024, the Company has an aggregate of $41.3 million invested in the debt securities of issuers in the banking and financial services industries. While the Companyâ€™s investment policy requires investments in highly rated securities, a wide variety of broad economic factors and issuer-specific factors could result in credit agency downgrades below the Companyâ€™s minimum credit rating requirements that could result in losses regardless of whether the Company elects to sell the securities or hold them until maturity. To date, the Company has not experienced any credit losses or impairments of marketable debt securities due to credit rating agency downgrades. X - ReferencesNo definition available. + Details Name: us-gaap_FairValueDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures. + ReferencesNo definition available. + Details Name: us-gaap_FinancialInstrumentsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 29 R20.htm IDEA: XBRL DOCUMENT v3.24.3 SUBSEQUENT EVENTS 3 Months Ended Sep. 30, 2024 SUBSEQUENT EVENTS Â SUBSEQUENT EVENTS NOTE 14 â€” SUBSEQUENT EVENTSExchange PFW Warrant ExercisesIn October 2024, holders of Exchange PFWs provided notice of cashless exercises ofÂ the remaining 2,389,596Â Exchange PFWs outstanding, which resulted in the issuance ofÂ 2,389,111Â shares of common stock.2022 PFW Warrant ExerciseOn November 7, 2024, a holder of certain 2022 PFWs provided notice of cashless exercises ofÂ 2,526,318Â Class B PFWs, which will result in the issuance ofÂ 2,525,883Â shares of common stock in November 2024. X - ReferencesNo definition available. + Details Name: us-gaap_SubsequentEventsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/855/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2 + Details Name: us-gaap_SubsequentEventsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 30 R21.htm IDEA: XBRL DOCUMENT v3.24.3 Pay vs Performance Disclosure - USD ($) $ in Thousands 3 Months Ended 12 Months Ended Sep. 30, 2024 Sep. 30, 2023 Jun. 30, 2024 Pay vs Performance Disclosure Â Â Â Net Income (Loss) $ (15,378) $ (14,524) $ (68,500) X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details Name: ecd_PvpTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -

Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 31 R22.htm IDEA: XBRL DOCUMENT v3.24.3 Insider Trading Arrangements 3 Months Ended Sep. 30, 2024 Trading Arrangements, by Individual Â Rule 10b5-1 Arrangement Adopted false Non-Rule 10b5-1 Arrangement Adopted false Rule 10b5-1 Arrangement Terminated false Non-Rule 10b5-1 Arrangement Terminated false X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A + Details Name: ecd_TradingArrByIndTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 32 R23.htm IDEA: XBRL DOCUMENT v3.24.3 NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) 3 Months Ended Sep. 30, 2024 NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Â Nature of Operations Nature of OperationsRezolute, Inc. (the â€œCompanyâ€) is a late-stage rare disease company focused on significantly improving outcomes for individuals with hypoglycemia caused by hyperinsulinism. The Companyâ€™s primary clinical assets consist of (i) ersodetug (formerly known as RZ358), which is a potential treatment for all forms of hyperinsulinism, including congenital hyperinsulinism, an ultra-rare pediatric genetic disorder characterized by excessive production of insulin by the pancreas, and (ii) RZ402, which is an oral plasma kallikrein inhibitor (â€œPKIâ€) being developed as a potential therapy for the chronic treatment of diabetic macular edema. Basis of Presentation Basis of Presentation The accompanying unaudited interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (â€œGAAPâ€), the rules and regulations of the SEC for interim financial information, and the instructions to Form 10-Q and Article 8 of Regulation S-X.The condensed consolidated balance sheet as of June 30, 2024, has been derived from the Companyâ€™s audited consolidated financial statements. The unaudited interim financial statements should be read in conjunction with the Companyâ€™s 2024 Form 10-K, which contains the Companyâ€™s audited financial statements and notes thereto, together with Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations for the fiscal year ended June 30, 2024.Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all information and footnote disclosures necessary for a comprehensive presentation of financial position, results of operations, and cash flows. It is managementâ€™s opinion, however, that all material adjustments (consisting of normal recurring adjustments) that are necessary for a fair financial statement presentation have been made. The interim results for the three months ended September 30, 2024, are not necessarily indicative of the financial condition and results of operations that may be expected for any future interim period or for the fiscal year ending June 30, 2025. Consolidation ConsolidationThe Company has two wholly owned subsidiaries consisting of Rezolute (Bio) Ireland Limited, and Rezolute Bio UK, Ltd. The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. Use of Estimates Use of EstimatesThe preparation of financial statements in conformity with GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts in the unaudited condensed consolidated financial statements and the accompanying notes. The Company bases its estimates and assumptions on current facts, historical experience, and various other factors that it believes are reasonable under the circumstances, to determine the carrying values of assets and liabilities that are not readily apparent from other sources. The Companyâ€™s significant accounting estimates include, but are not necessarily limited to, determination if an allowance for credit losses is required for marketable debt securities, the fair value of an embedded derivative liability, fair value of share-based compensation, managementâ€™s assessment of going concern, and estimates related to clinical trial accrued liabilities. Actual results could differ from those estimates. Risks and Uncertainties Risks and UncertaintiesThe Company's operations may be subject to significant risks and uncertainties including financial, operational, regulatory and other risks associated with a clinical stage company, including the potential risk of business failure discussed in Note 2. Significant Accounting Policies Significant Accounting PoliciesThe Companyâ€™s significant accounting policies are described in Note 1 to the financial statements in Item 8 of the 2024 Form 10-K.Â Recent Accounting Pronouncements Not Yet Adopted Recent Accounting Pronouncements Not Yet AdoptedIn November 2023, the Financial Accounting Standards Board (â€œFASBâ€) issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (â€œASU 2023-07â€), which improves reportable segment disclosure requirements through enhanced disclosures about significant segment expenses. ASU 2023-07 expands public entitiesâ€™ segment disclosures by requiring disclosure of significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items and interim disclosures of a reportable segmentâ€™s profit or loss and assets. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods in fiscal years beginning after December 15, 2024. Early adoption is permitted and the amendments should be applied on a retrospective basis to all periods presented. The Company is evaluating the effect of adopting ASU 2023-07 and does not expect the amendments to have a material impact on its consolidated financial statements.In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (â€œASU 2023-09â€), which expands income tax disclosures including changes in the rate reconciliation and income taxes paid information. Â This ASU is intended to enhance the transparency and decision usefulness of income tax disclosures. ASU 2023-09 is effective for annual periods beginning after December 15, 2024, and early adoption is permitted. The Company has not determined the timing for adoption of this standard.Other accounting standards that have been issued or proposed by the FASB or other standards-setting bodies that do not require adoption until a future date are not currently expected to have a material impact on the Companyâ€™s financial statements upon adoption. X - DefinitionDisclosure of accounting policy for the risks and uncertainties during the reporting period. + ReferencesNo definition available. + Details Name: rzlt_RisksAndUncertaintiesPolicyTextBlock Namespace Prefix: rzlt_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). + ReferencesNo definition available. + Details Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1 + Details Name: us-gaap_ConsolidationPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 275 -Publisher FASB -URI https://asc.fasb.org/275/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1 + Details Name: us-gaap_NatureOfOperations Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact. + ReferencesNo definition available. + Details Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for all significant accounting policies of the reporting entity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContent + Details Name: us-gaap_SignificantAccountingPoliciesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 11 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 12 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8 + Details Name: us-gaap_UseOfEstimates Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 33 R24.htm IDEA: XBRL DOCUMENT v3.24.3 INVESTMENTS IN MARKETABLE DEBT SECURITIES (Tables) 3 Months Ended Sep. 30, 2024 INVESTMENTS IN MARKETABLE DEBT SECURITIES Â Schedule of investments in marketable debt securities Investments in marketable debt securities are accounted for as available-for-sale investments at fair value and consist of the following (in thousands):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹SeptemberÂ 30,Â â€‹JuneÂ 30,Â â€‹2024Â Â Â Â 2024Short-term investments$ 97,801â€‹$ 56,478Long-term investmentsâ€‹ 9,552â€‹â€‹ 263Total investments$ 107,353â€‹$ 56,741 Summary of unrealized gains and losses that result in differences between the amortized cost basis and fair value of the Company's marketable debt securities The following table summarizes the cumulative unrealized gains and losses that result in differences between the amortized cost basis and fair value of the Companyâ€™s marketable debt securities held as of September 30, 2024 (in thousands):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹

thousands):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹SeptemberÂ 30,Â â€‹JuneÂ 30,Â â€‹Â Â Â Â 2024Â Â Â Â 2024Right-of-use assetsâ€‹$ 1,751â€‹$ 1,880â€‹â€‹â€‹â€‹â€‹â€‹â€‹Operating lease liabilities:â€‹Â Â Â Â â€‹Â Â Â Â Currentâ€‹$ 584â€‹$ 568Long-termâ€‹Â 1,499â€‹Â 1,660Totalâ€‹$ 2,083â€‹$ 2,228 Schedule of operating lease expense For the three months ended September 30, 2024 and 2023, operating lease expense is included under the following captions in the accompanying unaudited condensed consolidated statements of operations and comprehensive loss (in thousands):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹

http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_FairValueDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 39 R30.htm IDEA: XBRL DOCUMENT v3.24.3 NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) 3 Months Ended Sep. 30, 2024 subsidiary NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Â Number of wholly owned subsidiaries 2 X - DefinitionRepresents the number of wholly owned subsidiaries. + ReferencesNo definition available. + Details Name: rzlt_NumberOfWhollyOwnedSubsidiaries Namespace Prefix: rzlt_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 40 R31.htm IDEA: XBRL DOCUMENT v3.24.3 LIQUIDITY (Details) - USD ($) $ in Thousands 1 Months Ended 3 Months Ended 12 Months Ended Jul. 31, 2024 Jun. 30, 2024 Apr. 30, 2024 Sep. 30, 2024 Sep. 30, 2023 Jun. 30, 2024 Accumulated deficit Â $ (329,444) Â $ (344,822) Â $ (329,444) Net Income (Loss) Â Â Â (15,378) $ (14,524) (68,500) Net cash used in operating activities Â Â Â (16,014) $ (10,585) (57,400) Cash and cash equivalents Â 70,396 Â 10,472 Â 70,396 Short-term investments Â 56,478 Â 97,801 Â 56,478 Long-term investments Â 263 Â 9,552 Â 263 Total liabilities Â 11,734 Â 9,973 Â 11,734 Current liabilities Â $ 9,606 Â 7,991 Â $ 9,606 Private Placement Â Â Â Â Â Â Â Number of shares issued 1,500,000 1,500,000 Â Â Â Â Â Sale of stock received on transaction $ 6,000 Â Â Â Â Â Â XOMA (US) LLC | Phase 3 Clinical Trial RZ 358 (ersodetug) | Xoma License Agreement Â Â Â Â Â Â Milestone closing payment Â Â $ 5,000 Â Â Â XOMA (US) LLC | Phase 3 Clinical Trial RZ 358 (ersodetug) | Xoma License Agreement | Scenario, Upon Dosing Of The Last Patient Â Â Â Â Â Â Milestone closing payment Â Â Â $ 5,000 Â Â X - DefinitionAmount of milestone payment made during the period. + ReferencesNo definition available. + Details Name: rzlt_MilestoneClosingPayment Namespace Prefix: rzlt_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details Name: us-gaap_Liabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_LiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of investment in marketable security, classified as current. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_MarketableSecuritiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of investment in marketable security, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_MarketableSecuritiesNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-

gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCash received on stock transaction after deduction of issuance costs. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockConsiderationReceivedOnTransaction Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=rzlt_XomaUsLlcMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=rzlt_Phase3ClinicalTrialRz358Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=rzlt_XomaLicenseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=rzlt_ScenarioUponDosingOfLastPatientMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 41 R32.htm IDEA: XBRL DOCUMENT v3.24.3 INVESTMENTS IN MARKETABLE DEBT SECURITIES - Investments in Marketable Securities (Details) - USD ($) $ in Thousands Sep. 30, 2024 Jun. 30, 2024 INVESTMENTS IN MARKETABLE DEBT SECURITIES Â Â Short-term investments $ 97,801 $ 56,478 Long-term investments 9,552 263 Total investments $ 107,353 $ 56,741 X - DefinitionAmount of investment in marketable security. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_MarketableSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_MarketableSecuritiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of investment in marketable security, classified as current. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_MarketableSecuritiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of investment in marketable security, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_MarketableSecuritiesNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 42 R33.htm IDEA: XBRL DOCUMENT v3.24.3 INVESTMENTS IN MARKETABLE DEBT SECURITIES - Additional Information (Details) - USD ($) $ in Thousands 3 Months Ended Sep. 30, 2024 Sep. 30, 2023 Jun. 30, 2024 INVESTMENTS IN MARKETABLE DEBT SECURITIES Â Â Â Debt securities, available-for-sale, term 2 years Â Â Debt securities, available-for-sale, weighted average term 1 year Â Â Short-term investments $ 97,801 Â $ 56,478 Long-term investments 9,552 Â 263 Proceeds from maturities of marketable debt securities 23,828 $ 18,595 Â Investment in marketable securities 73,238 $ 15,989 Â Interest receivable 500 Â $ 400 Allowance for credit losses related to investments in marketable debt securities $ 0 Â Â X - DefinitionWeighted average period of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: rzlt_DebtSecuritiesAvailableForSaleWeightedAverageTerm Namespace Prefix: rzlt_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionAmount, after allowance for credit loss, of accrued interest on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2AReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3A -Publisher FASB -URI https://asc.fasb.org/1943274/2147479106/326-30-50-3A + Details Name: us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount excluding accrued interest, of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterestCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPeriod between issuance and maturity of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_DebtSecuritiesAvailableForSaleTerm Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_MarketableSecuritiesAbstract Namespace Prefix: us-gaap_ Data Type:

xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of investment in marketable security, classified as current. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_MarketableSecuritiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of investment in marketable security, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_MarketableSecuritiesNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash outflow for purchase of marketable security. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11 + Details Name: us-gaap_PaymentsToAcquireMarketableSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period. + ReferencesNo definition available. + Details Name: us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 43 R34.htm IDEA: XBRL DOCUMENT v3.24.3 INVESTMENTS IN MARKETABLE DEBT SECURITIES - Cash and Cash Equivalents and Marketable Securities Held (Details) $ in Thousands Sep. 30, 2024 USD ($) INVESTMENTS IN MARKETABLE DEBT SECURITIES Â Amortized Cost $ 107,064 Gross Unrealized Gains 292 Gross Unrealized Losses (3) Fair Value 107,353 Corporate commercial paper Â INVESTMENTS IN MARKETABLE DEBT SECURITIES Â Amortized Cost 31,485 Gross Unrealized Gains 37 Fair Value 31,522 Obligations of U.S. government agencies Â INVESTMENTS IN MARKETABLE DEBT SECURITIES Â Amortized Cost 5,253 Gross Unrealized Gains 24 Fair Value 5,277 U.S. Treasury obligations Â INVESTMENTS IN MARKETABLE DEBT SECURITIES Â Amortized Cost 13,651 Gross Unrealized Gains 14 Gross Unrealized Losses (1) Fair Value 13,664 Corporate notes and bonds Â INVESTMENTS IN MARKETABLE DEBT SECURITIES Â Amortized Cost 56,675 Gross Unrealized Gains 217 Gross Unrealized Losses (2) Fair Value $ 56,890 X - DefinitionAmount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2 + Details Name: us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2 + Details Name: us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmortized cost excluding accrued interest, before allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aaa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3 + Details Name: us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 44 R35.htm IDEA: XBRL DOCUMENT v3.24.3 OPERATING LEASES - Assets and Operating Lease Liabilities (Details) - USD ($) $ in Thousands Sep. 30, 2024 Jun. 30, 2024 Carrying value of right-of-use assets and operating lease liabilities Â Â Right-of-use assets $ 1,751 $ 1,880 Operating lease liabilities: Â Â Current 584 568 Long-term 1,499 1,660 Total $ 2,083 $ 2,228 X - ReferencesNo definition available. + Details Name: us-gaap_AssetsAndLiabilitiesLesseeAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_OperatingLeaseLiabilityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 45 R36.htm IDEA: XBRL DOCUMENT v3.24.3 OPERATING LEASES - Operating Lease Expense (Details) - USD ($) $ in Thousands 3 Months Ended Sep. 30, 2024 Sep. 30, 2023 Lessee, Lease, Description [Line Items] Â Â Operating lease expense $ 167 $ 173 Research and development Â Â Lessee, Lease, Description [Line Items] Â Â Operating lease expense 119 131 General and administrative Â Â Lessee, Lease, Description [Line Items] Â Â Operating lease expense $ 48 $ 42 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeLeaseDescriptionLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of operating lease expense. Excludes sublease income. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4 + Details Name: us-gaap_OperatingLeaseExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 46 R37.htm IDEA: XBRL DOCUMENT v3.24.3 OPERATING LEASES - Additional Information (Details) Sep. 30, 2024 OPERATING LEASES Â Weighted average remaining lease term under operating leases 3 years Weighted average discount rate for operating lease liabilities 7.10% X - ReferencesNo definition available. + Details Name: us-gaap_LeasesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionWeighted average discount rate for operating lease calculated at point in time. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionWeighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant XML 47 R38.htm IDEA: XBRL DOCUMENT v3.24.3 OPERATING LEASES - Future Operating Lease Payments (Details) - USD ($) $ in Thousands Sep. 30, 2024 Jun. 30, 2024 Future lease payments related to operating lease agreements Â Â Remainder of fiscal year 2025 $ 564 Â 2026 770 Â 2027 750 Â Thereafter 224 Â Total lease payments 2,308 Â Less imputed interest (225) Â Present value of operating lease liabilities $ 2,083 $ 2,228 X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease due after second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesNo definition available. + Details Name: rzlt_LesseeOperatingLeaseLiabilityPaymentsDueAfterTwo Namespace Prefix: rzlt_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 48 R39.htm IDEA: XBRL DOCUMENT v3.24.3 LICENSE AGREEMENTS (Details) - USD ($) $ in Millions 1 Months Ended 3 Months Ended Apr. 30, 2024 Feb. 28, 2023 Jan. 31, 2022 Dec. 31, 2020 Aug. 31, 2017 Sep. 30, 2024 XOMA (US) LLC | Xoma License Agreement | Upon Clinical and Regulatory Milestones |

Maximum Â Â Â Â Â Â License Agreements Â Â Â Â Â Â Maximum amount of milestone events Â Â Â Â Â $ 30.0 XOMA (US) LLC | Xoma License Agreement | After Clinical and Regulatory Milestones | Maximum Â Â Â Â Â Â License Agreements Â Â Â Â Â Â Maximum amount of milestone events Â Â Â Â Â 185.0 XOMA (US) LLC | Phase 2 Clinical Trial RZ358 (ersodetug) | Xoma License Agreement Â Â Â Â Â Â License Agreements Â Â Â Â Â Â Milestone closing payment Â Â $ 2.0 Â Â Â XOMA (US) LLC | Phase 3 Clinical Trial RZ 358 (ersodetug) | Xoma License Agreement Â Â Â Â Â Â License Agreements Â Â Â Â Â Â Milestone closing payment $ 5.0 Â Â Â Â Â XOMA (US) LLC | Phase 3 Clinical Trial RZ 358 (ersodetug) | Xoma License Agreement | Scenario, Upon Dosing Of The Last Patient Â Â Â Â Â Â License Agreements Â Â Â Â Â Â Milestone closing payment Â Â Â Â Â 5.0 ActiveSite Pharmaceuticals, Inc | Development And License Agreement Â Â Â Â Â Â License Agreements Â Â Â Â Â Â Royalties percentage Â Â Â Â 2.00% Â ActiveSite Pharmaceuticals, Inc | Development And License Agreement | Scenario, Plan | Maximum Â Â Â Â Â Â License Agreements Â Â Â Â Â Â Maximum amount of milestone events Â Â Â Â $ 46.5 Â ActiveSite Pharmaceuticals, Inc | Phase 1 Clinical Trial RZ402 | Development And License Agreement Â Â Â Â Â Â License Agreements Â Â Â Â Â Â Milestone closing payment Â Â Â $ 1.0 Â Â ActiveSite Pharmaceuticals, Inc | Phase 2 Clinical Trial RZ402 | Development And License Agreement Â Â Â Â Â Â License Agreements Â Â Â Â Â Â Milestone closing payment Â $ 3.0 Â Â Â Â ActiveSite Pharmaceuticals, Inc | Phase 3 Clinical Trial RZ 402 | Development And License Agreement | Scenario, Plan Â Â Â Â Â Â License Agreements Â Â Â Â Â Â Milestone closing payment Â Â Â Â Â $ 5.0 X - DefinitionRepresents the percentage of royalties. + ReferencesNo definition available. + Details Name: rzlt_DevelopmentAndLicenseAgreementRoyaltiesPercentage Namespace Prefix: rzlt_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe maximum amount of milestone event which need to occur for making specific range of milestone payment. + ReferencesNo definition available. + Details Name: rzlt_MaximumAmountOfMilestoneEvents Namespace Prefix: rzlt_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of milestone payment made during the period. + ReferencesNo definition available. + Details Name: rzlt_MilestoneClosingPayment Namespace Prefix: rzlt_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 730 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1 + Details Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: srt_CounterpartyNameAxis=rzlt_XomaUsLlcMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=rzlt_XomaLicenseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=rzlt_ScenarioUponClinicalAndRegulatoryMilestonesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=rzlt_ScenarioAfterClinicalAndRegulatoryMilestonesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=rzlt_Phase2ClinicalTrialRz358Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=rzlt_Phase3ClinicalTrialRz358Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=rzlt_ScenarioUponDosingOfLastPatientMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=rzlt_ActivesitePharmaceuticalsIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=rzlt_DevelopmentAndLicenseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=us-gaap_ScenarioPlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=rzlt_Phase1ClinicalTrialRz402Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=rzlt_Phase2ClinicalTrialRz402Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=rzlt_Phase3ClinicalTrialRz402Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 49 R40.htm IDEA: XBRL DOCUMENT v3.24.3 EMBEDDED DERIVATIVE LIABILITY (Details) - USD ($) $ in Thousands Apr. 14, 2021 Sep. 30, 2024 Jun. 30, 2024 Debt Instrument [Line Items] Â Â Â Embedded derivative liability Â $ 483 $ 468 Embedded Derivative Financial Instruments Â Â Â Debt Instrument [Line Items] Â Â Â Maximum borrowing capacity $ 30,000 Â Â Gross proceeds from issuance of debt $ 15,000 Â Â Exit fee on the funded principal balance 4.00% Â Â Exit fee amount $ 600 Â Â Embedded derivative liability Â $ 500 $ 500 Percentage of entity's shares held by investors 35.00% Â Â X - DefinitionRepresents the exit fee on the funded principal balance. + ReferencesNo definition available. + Details Name: rzlt_DebtInstrumentExitFee Namespace Prefix: rzlt_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionAmount of expenses associated with exit fees on the funded principal balance. + ReferencesNo definition available. + Details Name: rzlt_DebtInstrumentExitFeeAmount Namespace Prefix: rzlt_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRepresents the percentage of entity's shares held by investors. + ReferencesNo definition available. + Details Name: rzlt_PercentageOfEntitySSharesHeldByInvestors Namespace Prefix: rzlt_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 26: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 + Details Name: us-gaap_DebtInstrumentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as a liability. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B + Details Name: us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionMaximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_EmbeddedDerivativeFinancialInstrumentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 50 R41.htm IDEA: XBRL DOCUMENT v3.24.3 SHAREHOLDERS' EQUITY - Pre-Funded Warrants (Details) - $ / shares 1 Months Ended 3 Months Ended Mar. 08, 2024 May 31, 2022 Sep. 30, 2024 Jun. 30, 2024 Jun. 24, 2024 Jun. 17, 2024 Oct. 31, 2021 Underwritten Public Offering Â Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Â Shares Issued, Price Per Share Â Â Â Â $ 4.00 Â Â Pre-funded warrants Â Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Â Number of shares of common stock called by warrants issued Â Â Â 21,300,000 Â Â Â Warrants outstanding, beginning (In shares) Â Â 15,020,371 Â Â Â Â Â Shares surrendered for exercise price Â Â (131) Â Â Â Â Shares of common stock issued Â Â (610,273) Â Â Â Â Warrants outstanding, ending (In shares) Â Â 14,409,967 Â Â Â Â Â Pre-funded warrants | Securities exchange agreement | Maximum Â Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Â Warrants exercisable, ownership blocker percentage Â Â 19.99% Â Â Â Â Â 2021 PFWs Â Â Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Â Number of shares of common stock called by warrants issued Â Â Â Â Â 1,661,461 Warrants outstanding, beginning (In shares) Â Â 123,000 Â Â Â Â Warrants outstanding, ending (In shares) Â Â 123,000 Â Â Â Â Shares Issued, Price Per Share Â Â Â Â Â $ 6.49 Warrant price (per share) Â Â Â Â Â Â $ 0.01 2022 PFWs Â Â Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Â Number of shares of common stock called by warrants issued Â 12,921,055 Â Â Â Â Â Warrants outstanding, beginning (In shares) Â Â 8,147,371 Â Â Â Â Shares of common stock issued Â Â Â 4,773,684 Â Â Â Warrants outstanding, ending (In shares) Â Â 8,147,371 Â Â Â Â Shares Issued, Price Per Share Â $ 3.799 Â Â Â Â Â Warrant price (per share) Â $ 0.001 Â Â Â Â Â Class A pre-funded warrants Â Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Â Warrants issued Â 1,973,684 Â Â Â Â Â Class B pre-funded warrants Â Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Â Warrants issued Â 10,947,371 Â Â Â Â Â Exchange PFWs Â Â Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Â Warrants outstanding, beginning (In shares) Â Â 3,000,000 Â Â Â Â Shares surrendered for exercise price Â Â (131) Â Â Â Â Shares of common stock issued Â Â (610,273) Â Â Â Â Warrants outstanding, ending (In shares) Â Â 2,389,596 Â Â Â Â Exchange PFWs | Securities exchange agreement Â Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Â Number of shares of common stock called by warrants issued 3,000,000 Â Â Â Â Â Â Warrants issued 3,000,000 Â Â Â Â Â Â Warrant price (per share) $ 0.001 Â Â Â Â Â Â Exchange PFWs | Securities exchange agreement | Maximum Â Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Â Warrants exercisable, ownership blocker percentage 19.99% Â Â Â Â Â Â Â 2024 PFWs Â Â Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Â Warrants outstanding, beginning (In shares) Â Â 3,750,000 Â Â Â Â Warrants outstanding, ending (In shares) Â Â 3,750,000 Â Â Â Â 2024 PFWs | Underwritten Public Offering Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Â Number of shares of common stock called by warrants issued Â Â Â Â 3,750,000 3,750,000 Â Shares Issued, Price Per Share Â Â Â Â $ 3.999 Â Â Warrant price (per share) Â Â Â Â Â Â $ 0.001 Â X - DefinitionNumber of warrants or rights exercised. + ReferencesNo definition available. + Details Name: rzlt_ClassOfWarrantOrRightExercised Namespace Prefix: rzlt_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe number of warrants issued. + ReferencesNo definition available. + Details Name: rzlt_ClassOfWarrantOrRightIssued Namespace Prefix: rzlt_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of warrants or rights surrendered. + ReferencesNo definition available. + Details Name: rzlt_ClassOfWarrantOrRightWarrantsSurrendered Namespace Prefix: rzlt_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionRepresents the designated ownership percentage by holder not exceeding the specified percentage for exercise

of warrants. + ReferencesNo definition available. + Details Name: rzlt_WarrantsExercisableOwnershipBlockerPercentage Namespace Prefix: rzlt_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 + Details Name: us-gaap_ClassOfStockLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of warrants or rights outstanding. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionPer share or per unit amount of equity securities issued. + ReferencesNo definition available. + Details Name: us-gaap_SharesIssuedPricePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=rzlt_UnderwrittenPublicOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=rzlt_PreFundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: rzlt_AgreementAxis=rzlt_SecuritiesExchangeAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=rzlt_PreFundedWarrants2021Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=rzlt_PreFundedWarrants2022Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=rzlt_ClassPreFundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=rzlt_ClassBPreFundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=rzlt_ExchangePreFundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=rzlt_PreFundedWarrants2024Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 51 R42.htm IDEA: XBRL DOCUMENT v3.24.3 SHAREHOLDERS' EQUITY - 2024 Private Placement (Details) - Private Placement - USD ($) $ / shares in Units, $ in Millions 1 Months Ended Jul. 31, 2024 Jun. 30, 2024 Class of Stock [Line Items] Â Â Gross proceeds from issuance of common stock for cash (in shares) 1,500,000 1,500,000 Shares issue price Â $ 4.00 Sale of stock received on transaction $ 6.0 Â X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 + Details Name: us-gaap_ClassOfStockLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionCash received on stock transaction after deduction of issuance costs. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockConsiderationReceivedOnTransaction Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPer share or per unit amount of equity securities issued. + ReferencesNo definition available. + Details Name: us-gaap_SharesIssuedPricePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 52 R43.htm IDEA: XBRL DOCUMENT v3.24.3 SHAREHOLDERS' EQUITY - 2024 Underwritten Offering (Details) - USD ($) $ / shares in Units, $ in Millions Jun. 24, 2024 Jun. 17, 2024 Underwritten Public Offering Â Â Class of Stock [Line Items] Â Â Number of shares issued 11,250,000 Â Shares issue price $ 4.00 Â Proceeds from issuance of common stock $ 45.0 Â Gross proceeds from sale of equity $ 67.1 Â Underwriting discounts and commissions (In percentage) 6.00% Â Other offering costs $ 0.5 Â Underwriting discounts and commissions expense 4.5 Â Net cash proceeds $ 62.6 Â Underwritten Public Offering | Pre Funded Warrants 2024 Â Â Class of Stock [Line Items] Â Â Shares issue price $ 3.999 Â Pre-funded warrants to purchase shares of common stock 3,750,000 3,750,000 Proceeds from warrants issued $ 15.0 Â Underwriters Option Â Â Class of Stock [Line Items] Â Â Number of shares issued 1,786,589 Â Sale of stock, Additional Shares Option, price per share $ 4.00 Â Proceeds from issuance of common stock $ 7.1 Â Maximum number of additional shares issued 2,250,000 Â X - DefinitionRepresent the maximum number of additional shares offered. + ReferencesNo definition available. + Details Name: rzlt_MaximumNumberOfAdditionalSharesIssued Namespace Prefix: rzlt_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionRelated to other offering costs + ReferencesNo definition available. + Details Name: rzlt_OtherOfferingCosts Namespace Prefix: rzlt_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow from the additional capital contribution to the entity net of underwriting discounts, commissions and other fees. + ReferencesNo definition available. + Details Name: rzlt_ProceedsFromIssuanceOfCommonStockNetOfUnderwritingDiscountsAndCommissions Namespace Prefix: rzlt_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPer share amount received by subsidiary or equity investee for each share of common stock issued or sold in the additional shares option of a stock transaction. + ReferencesNo definition available. + Details Name: rzlt_SaleOfStockAdditionalSharesOptionPricePerShare Namespace Prefix: rzlt_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe percentage of underwriting discounts and commissions. + ReferencesNo definition available. + Details Name: rzlt_UnderwritingDiscountsAndCommissions Namespace Prefix: rzlt_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe costs for underwriter discounts, commissions and other fees. + ReferencesNo definition available. + Details Name: rzlt_UnderwritingDiscountsAndCommissionsExpense Namespace Prefix: rzlt_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 11:

http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 + Details Name: us-gaap_ClassOfStockLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfWarrants Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 + Details Name: us-gaap_ProceedsFromIssuanceOrSaleOfEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPer share or per unit amount of equity securities issued. + ReferencesNo definition available. + Details Name: us-gaap_SharesIssuedPricePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=rzlt_UnderwrittenPublicOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=rzlt_PreFundedWarrants2024Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=rzlt_UnderwritersOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 53 R44.htm IDEA: XBRL DOCUMENT v3.24.3 SHAREHOLDERS' EQUITY - Exchange Agreement (Details) - Securities exchange agreement - USD ($) May 13, 2024 Mar. 08, 2024 Purchased shares of common stock Â 3,000,000 Outstanding shares percentage Â 7.00% Fair value of shares Â $ 5,700,000 Cash payment to exchanging shareholders Â $ 3,000 Exchange Pre-Funded Warrants Â Â Outstanding shares percentage Â 7.00% Estimated fair value of warrants Â $ 5,697,000 Warrants to purchase shares of common stock Â 3,000,000 Warrants exercise price Â $ 0.001 Change in fair value of derivative liability $ 2,900,000 Â Warrant derivative liability $ 8,500,000 $ 5,700,000 Exchange Pre-Funded Warrants | Maximum Â Â Warrants exercisable, ownership blocker percentage Â 19.99% X - DefinitionThe amount of change in fair value of warrant derivative liability. + ReferencesNo definition available. + Details Name: rzlt_ChangeInFairValueOfWarrantDerivativeLiability Namespace Prefix: rzlt_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe percentage of stock acquired to the total of outstanding shares. + ReferencesNo definition available. + Details Name: rzlt_PercentageOfTreasuryStockAcquiredOfSharesOutstanding Namespace Prefix: rzlt_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionFair value as of the balance sheet date of the warrants derivative classified as a liability. + ReferencesNo definition available. + Details Name: rzlt_WarrantDerivativeLiabilityNonCurrent Namespace Prefix: rzlt_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionRepresents the designated ownership percentage by holder not exceeding the specified percentage for exercise of warrants. + ReferencesNo definition available. + Details Name: rzlt_WarrantsExercisableOwnershipBlockerPercentage Namespace Prefix: rzlt_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe cash outflow to reacquire common stock during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsForRepurchaseOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares that have been repurchased during the period and are being held in treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_TreasuryStockSharesAcquired Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionEquity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1 + Details Name: us-gaap_TreasuryStockValueAcquiredCostMethod Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionValue of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_WarrantsAndRightsOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: rzlt_AgreementAxis=rzlt_SecuritiesExchangeAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=rzlt_ExchangePreFundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 54 R45.htm IDEA: XBRL DOCUMENT v3.24.3 SHAREHOLDERS' EQUITY - Jefferies Open Market Sales Agreement (Details) - At the Market Offering - USD ($) $ in Millions 3 Months Ended Nov. 14, 2023 Sep. 30, 2024 Class of Stock [Line Items] Â Â Amount agreed to sell as per open market sales agreement $ 50.0 Â Percentage of commission agreed 3.00% Â Common stock to sales agreement Â 0 Sales agreement amounts Â $ 50.0 X - DefinitionPercentage of commission agreed to pay as a percentage on gross sales price. + ReferencesNo definition available. + Details Name: rzlt_SaleOfStockCommissionAgreedToPayAsPercentageOnGrossSalesPrice Namespace Prefix: rzlt_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionMaximum amount agreed to sell as per open market sales agreement. + ReferencesNo definition available. + Details Name: rzlt_SaleOfStockMaximumAmountAgreedToSellAsPerOpenMarketSalesAgreement Namespace Prefix: rzlt_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionMaximum amount remaining for sale as per open market sales agreement. + ReferencesNo definition available. + Details Name: rzlt_SaleOfStockMaximumAmountRemainingForSaleAsPerOpenMarketSalesAgreement Namespace Prefix: rzlt_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 + Details Name: us-gaap_ClassOfStockLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe number of shares issued or sold by the subsidiary or equity method investee per stock transaction. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=rzlt_AtMarketOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 55 R46.htm IDEA: XBRL DOCUMENT v3.24.3 SHARE-BASED COMPENSATION AND WARRANTS - Stock Option Plans (Details) - shares shares in Thousands Sep. 30, 2024 Jun. 30, 2024 Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Number of shares authorized 11,195 Â Number of shares outstanding 10,775 10,891 Number of shares available 420 Â 2015 Plan Â Â Share-Based

Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Number of shares authorized 17 Â Number of shares outstanding 17 Â 2016 Plan Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Number of shares authorized 123 Â Number of shares outstanding 123 Â 2019 Plan Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Number of shares authorized 200 Â Number of shares outstanding 200 Â 2021 Plan Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Number of shares outstanding 10,580 Â Number of shares outstanding 10,160 Â Number of shares available 420 Â Inducement Grant Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Number of shares authorized 275 Â Number of shares outstanding 275 Â X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares authorized for issuance under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of options outstanding, including both vested and non-vested options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_PlanNameAxis=rzlt_Year2015PlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=rzlt_Year2016PlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=rzlt_Year2019PlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=rzlt_Year2021PlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=rzlt_InducementGrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 56 R47.htm IDEA: XBRL DOCUMENT v3.24.3 SHARE-BASED COMPENSATION AND WARRANTS - 2022 Employee Stock Purchase Plan (Details) - Employee Stock Purchase Plan 3 Months Ended Sep. 30, 2024 shares Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Shares reserved for purchase 500,000 Shares purchases 0 X - DefinitionAggregate number of common shares reserved for future issuance. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockCapitalSharesReservedForFutureIssuance Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares issued during the period as a result of an employee stock purchase plan. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 57 R48.htm IDEA: XBRL DOCUMENT v3.24.3 SHARE-BASED COMPENSATION AND WARRANTS - Stock Options Outstanding (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Millions 3 Months Ended Sep. 30, 2024 Jun. 30, 2024 Number of Options Â Â Outstanding, beginning 10,891 Â Grants to employees 240 Â Exercises (38) Â Forfeited (318) Â Outstanding, ending 10,775 10,891 Vested, ending 5,525 Â Weighted Average Exercise Price Â Â Outstanding, beginning $ 3.82 Â Granted 4.73 Â Exercises 2.44 Â Forfeited 2.61 Â Outstanding, ending 3.88 $ 3.82 Vested, ending $ 5.07 Â Weighted Average Remaining Contractual Life Â Â Remaining contractual term (years) 7 years 8 months 12 days 8 years 1 month 6 days Vested (years) 7 years 2 months 12 days Â Total intrinsic value of exercised $ 0.1 Â Intrinsic value of outstanding options 19.2 Â Aggregate intrinsic value of vested stock options 7.5 Â Fair value of options granted $ 0.8 Â Weighted average grant date fair value, granted $ 3.45 Â X - DefinitionFair value of options granted. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights,

restricted stock. + ReferencesNo definition available. + Details Name: rzlt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodFairValue Namespace Prefix: rzlt_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionGross number of share options (or share units) granted during the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionNumber of options outstanding, including both vested and non-vested options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price at which option holders acquired shares when converting their stock options into shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average per share amount at which grantees can acquire shares of common stock by exercise of options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (e)(1) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionFair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of options vested. + ReferencesNo definition available. + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionWeighted average grant-date fair value of options vested. + ReferencesNo definition available. + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares (or other type of equity) forfeited during the period. + ReferencesNo definition available. + Details Name: us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 58 R49.htm IDEA: XBRL DOCUMENT v3.24.3 SHARE-BASED COMPENSATION AND WARRANTS - Weighted Average Assumptions (Details) - Time-Based 3 Months Ended Sep. 30, 2024 $ / shares Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Market price of common stock on grant date $ 4.73 Expected volatility 84.00% Risk free interest rate 3.70% Expected term (years) 6 years 1 month 6 days Dividend yield 0.00% X - DefinitionThe estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe risk-free interest rate assumption that is used in valuing an option on its own shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24:

http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionExpected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionWeighted average grant-date fair value of non-vested options outstanding. + ReferencesNo definition available. + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_AwardTypeAxis=rzlt_StockOptionVestingTimeBasedMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 59 R50.htm IDEA: XBRL DOCUMENT v3.24.3 SHARE-BASED COMPENSATION AND WARRANTS - Share Based Compensation Expense (Details) - USD ($) $ in Thousands 3 Months Ended Sep. 30, 2024 Sep. 30, 2023 Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Compensation cost $ 1,400 $ 1,849 Unrecognized share-based compensation expense $ 10,400 Â Expected to be recognized over a remaining weighted average period 1 year 9 months 18 days Â Research and Development Expense Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Compensation cost $ 712 840 General and Administrative Expense Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Compensation cost $ 688 $ 1,009 X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionWeighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionAmount of cost to be recognized for option under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 60 R51.htm IDEA: XBRL DOCUMENT v3.24.3 SHARE-BASED COMPENSATION AND WARRANTS - Pre-Funded Warrants (Details) - shares Sep. 30, 2024 Jun. 30, 2024 Pre-funded warrants Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Warrants outstanding (In shares) 14,409,967 15,020,371 X - DefinitionNumber of warrants or rights outstanding. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=rzlt_PreFundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 61 R52.htm IDEA: XBRL DOCUMENT v3.24.3 SHARE-BASED COMPENSATION AND WARRANTS - Summary of Legacy Warrants (Details) - Legacy warrants - $ / shares shares in Thousands 3 Months Ended Sep. 30, 2024 Jun. 30, 2024 Oct. 31, 2020 Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Warrants outstanding, beginning (In shares) 861 Â Â Warrant expirations (In

shares) (10) Â Â Warrants outstanding, ending (In shares) 851 Â Â Warrants Outstanding, Beginning Price (in dollars per share) $ 20.28 Â Â Warrant expirations, Price (in dollars per share) 52.00 Â Â Warrants Outstanding, Ending Price (in dollars per share) $ 19.90 Â Â Weighted average remaining contractual term 3 years 3 years 2 months 12 days 7 years Pre-funded warrants to purchase shares of common stock Â Â 800 Warrants granted, exercised or expired 0 Â Â Warrants exercise price $ 19.90 $ 20.28 $ 19.50 X - DefinitionExercise price per share or per unit of warrants or rights expired. + ReferencesNo definition available. + Details Name: rzlt_ClassOfWarrantOrRightExpirationExercisePriceOfWarrantsOrRights Namespace Prefix: rzlt_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionNumber of warrants or rights expired. + ReferencesNo definition available. + Details Name: rzlt_ClassOfWarrantOrRightExpirations Namespace Prefix: rzlt_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of warrants exercised, granted or expired. + ReferencesNo definition available. + Details Name: rzlt_WarrantsExercisedGrantedOrExpired Namespace Prefix: rzlt_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of warrants or rights outstanding. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPeriod between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_WarrantsAndRightsOutstandingTerm Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=rzlt_LegacyWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 62 R53.htm IDEA: XBRL DOCUMENT v3.24.3 RELATED PARTY TRANSACTIONS (Details) - USD ($) $ / shares in Units, $ in Thousands 3 Months Ended Jun. 24, 2024 Sep. 15, 2020 Sep. 30, 2024 Underwritten Public Offering Â Â Related Party Transaction [Line Items] Â Â Number of shares issued 11,250,000 Â Issuance price (in dollars per share) $ 4.00 Â Related Party | Handok, Inc. | Underwritten Public Offering Â Â Related Party Transaction [Line Items] Â Â Number of shares issued 1,250,000 Â Issuance price (in dollars per share) $ 4.00 Â Sale of stock received on transaction $ 5,000 Â Related Party | Handok License Agreement | Handok, Inc. Â Â Related Party Transaction [Line Items] Â Â License term (in years) Â 20 years Â Milestone payments Â $ 500 Â Transfer price (in percent) Â 70.00% Â Milestone payments earned Â Â $ 0 X - DefinitionThe amount of milestone payments to be incurred for the approval of license. + ReferencesNo definition available. + Details Name: rzlt_PharmaceuticalLicenseAgreementMilestonePayment Namespace Prefix: rzlt_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of milestone payments earned by the entity. + ReferencesNo definition available. + Details Name: rzlt_PharmaceuticalLicenseAgreementMilestonePaymentEarned Namespace Prefix: rzlt_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionTerm of pharmaceutical license agreement in years. + ReferencesNo definition available. + Details Name: rzlt_PharmaceuticalLicenseAgreementTerm Namespace Prefix: rzlt_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionThe percentage of transfer price on sale of products. + ReferencesNo definition available. + Details Name: rzlt_PharmaceuticalLicenseAgreementTransferPrice Namespace Prefix: rzlt_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)(2)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(g)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap_RelatedPartyTransactionLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionCash received on stock transaction after deduction of issuance costs. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockConsiderationReceivedOnTransaction Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPer share or per unit amount of equity securities issued. + ReferencesNo definition available. + Details Name: us-gaap_SharesIssuedPricePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef - Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=rzlt_UnderwrittenPublicOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=rzlt_HandokInc.Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionAxis=rzlt_HandokLicenseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 63 R54.htm IDEA: XBRL DOCUMENT v3.24.3 NET LOSS PER SHARE - Weighted Average Number of Shares Outstanding (Details) - shares shares in Thousands 3 Months Ended Sep. 30, 2024 Sep. 30, 2023 Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Weighted Average Number of Shares Outstanding, Basic 69,736 51,409 Weighted Average Number of Shares Outstanding, Diluted 69,736 51,409 2021 PFWs Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Weighted Average Number of Shares Outstanding, Basic 123 1,661 Weighted Average Number of Shares Outstanding, Diluted 123 1,661 2022 PFWs Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Weighted Average Number of Shares Outstanding, Basic 8,147 12,921 Weighted Average Number of Shares Outstanding, Diluted 8,147 12,921 Exchange PFWs Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Weighted Average Number of Shares Outstanding, Basic 2,549 Â Weighted Average Number of Shares Outstanding, Diluted 2,549 Â 2024 PFWs Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Weighted Average Number of Shares Outstanding, Basic 3,750 Â Weighted Average Number of Shares Outstanding, Diluted 3,750 Â Common Stock Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Weighted Average Number of Shares Outstanding, Basic 55,167 36,827 Weighted Average Number of Shares Outstanding, Diluted 55,167 36,827 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type:

xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=rzlt_PreFundedWarrants2021Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=rzlt_PreFundedWarrants2022Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=rzlt_ExchangePreFundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=rzlt_PreFundedWarrants2024Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 64 R55.htm IDEA: XBRL DOCUMENT v3.24.3 NET LOSS PER SHARE - Anti-dilutive (Details) - shares shares in Thousands 3 Months Ended Sep. 30, 2024 Sep. 30, 2023 NET LOSS PER SHARE Â Â Total 11,626 9,997 Employee Stock Option Â Â NET LOSS PER SHARE Â Â Total 10,775 9,109 Legacy warrants Â Â NET LOSS PER SHARE Â Â Total 851 888 X - DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 - SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=rzlt_LegacyWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 65 R56.htm IDEA: XBRL DOCUMENT v3.24.3 FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS - Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands Sep. 30, 2024 Jun. 30, 2024 FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS Â Â Marketable debt securities $ 107,353 $ 56,741 Recurring Â Â FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS Â Â Financial assets measured at fair value 113,247 117,990 Recurring | Money market funds Â Â FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS Â Â Cash and cash equivalents 5,894 61,249 Recurring | Corporate commercial paper Â Â FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS Â Â Marketable debt securities 31,522 20,929 Recurring | U.S. Government agencies Â Â FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS Â Â Marketable debt securities 5,277 1,997 Recurring | U.S. Government treasuries Â Â FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS Â Â Marketable debt securities 13,664 2,720 Recurring | Corporate notes and bonds Â Â FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS Â Â Marketable debt securities 56,890 30,832 Recurring | Asset-backed securities Â Â FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS Â Â Marketable debt securities Â 263 Recurring | Level 1 Â Â FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS Â Â Financial assets measured at fair value 5,894 61,249 Recurring | Level 1 | Money market funds Â Â FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS Â Â Cash and cash equivalents 5,894 61,249 Recurring | Level 2 Â Â FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS Â Â Financial assets measured at fair value 107,353 56,741 Recurring | Level 2 | Corporate commercial paper Â Â FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS Â Â Marketable debt securities 31,522 20,929 Recurring | Level 2 | U.S. Government agencies Â Â FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS Â Â Marketable debt securities 5,277 1,997 Recurring | Level 2 | U.S. Government treasuries Â Â FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS Â Â Marketable debt securities 13,664 2,720 Recurring | Level 2 | Corporate notes and bonds Â Â FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS Â Â Marketable debt securities $ 56,890 30,832 Recurring | Level 2 | Asset-backed securities Â Â FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS Â Â Marketable debt securities Â $ 263 X - DefinitionFair value portion of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 - SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_AssetsFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_CashAndCashEquivalentsFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 - SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 - Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3 + Details Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of investment in marketable security. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_MarketableSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 66 R57.htm IDEA: XBRL DOCUMENT v3.24.3 FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS - Summary of Changes in the Fair Value (Details) - USD ($) $ in Thousands 3 Months Ended Sep. 30, 2024 Sep. 30, 2023 Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Â Â Balance at the beginning $ 468 $ 412 Changes in fair value 15 14 Balance at the end $ 483 $ 426 X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionFair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 67 R58.htm IDEA: XBRL DOCUMENT v3.24.3 FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS - Significant Concentrations (Details) - USD ($) $ in Thousands 3 Months Ended Sep. 30, 2024 Jun. 30, 2024 FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS Â Â Concentration risk, credit risk, uninsured deposits Financial instruments that subject the Company to concentrations of credit risk consist primarily of cash, cash equivalents and investments in marketable debt securities. The Company maintains cash in demand deposit accounts at a high-quality financial institution. As of and for the three months ended September 30, 2024 and 2023, cash deposits have exceeded the amount of insurance provided on such deposits by the Federal Deposit Insurance Corporation. Â Marketable debt securities $ 107,353 $ 56,741 Banking and Financial Services Industries Â Â FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS Â Â Marketable debt securities $ 41,300 Â X - DefinitionDescription of credit risk that arises from having significant balances in excess of the Federal Deposit Insurance Corporation or other insurance limits on deposits in financial institutions. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20 + Details Name: us-gaap_ConcentrationRiskCreditRiskUninsuredDeposits Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 - SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of investment in marketable security. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_MarketableSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_EquitySecuritiesByIndustryAxis=us-gaap_FinancialServicesSectorMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 68 R59.htm IDEA: XBRL DOCUMENT v3.24.3 SUBSEQUENT EVENTS (Details) - shares Nov. 07, 2024 Oct. 31, 2024 Sep. 30, 2024 Jun. 30, 2024 May 31, 2022 Exchange Pre-Funded Warrants Â Â Â Â Â Â Subsequent Event [Line Items] Â Â Â Â Â Â Warrants exercised Â Â Â 610,273 Â Â Â 2022 Pre-Funded Warrants Â Â Â Â Â Â Subsequent Event [Line Items] Â Â Â Â Â Â Warrants exercised Â Â Â (4,773,684) Â Pre-funded warrants to purchase shares of common stock Â Â Â Â 12,921,055 Subsequent Event | Exchange Pre-Funded Warrants Â Â Â Â Â Â Subsequent Event [Line Items] Â Â Â Â Â Â Warrants exercised Â 2,389,596 Â Â Â Pre-funded warrants to purchase shares of common stock Â 2,389,111 Â Â Â Â Subsequent Event | 2022 Pre-Funded Warrants Â Â Â Â Â Â Subsequent Event [Line Items] Â Â Â Â Â Â Warrants exercised 2,526,318 Â Â Â Â Â Pre-funded warrants to purchase shares of common stock 2,525,883 Â Â Â Â Â X - DefinitionNumber of warrants or rights exercised. + ReferencesNo definition available. + Details Name: rzlt_ClassOfWarrantOrRightExercised Namespace Prefix: rzlt_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionDetail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 - Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2 + Details Name: us-gaap_SubsequentEventLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=rzlt_ExchangePreFundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=rzlt_PreFundedWarrants2022Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember Namespace Prefix: Data Type: na Balance Type: Period Type: EXCEL 69 Financial_Report.xlsx IDEA:

XBRL DOCUMENT begin 644 Financial_Report.xlsx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

"]SE5G/&B&V*K)_ VZ/185+&_72P< MC#$4"4*4(^29?TD+;64ZY?V\4L(Z4N(D8\BT:9S/KP^'%NYBZH80C.&,,I&(M*7@PY")/MV;OB0XS(Y4OYA])<_\UFLL4)])\+\?!*Q2_5$X482PI;RJ30C2.
MYB*$E30GD\%IKH33%'C:FE*&O\9NQ6E$D:BM<5P424XNTO/"@Y9W>?0\X\>W M@][*6QT83EQIP293:T2[W9KV(J,FNLW0DX(QB!Q6\Y@LK](RTO)K0W('(
M'J^R=K;!4)O(^BXLQE))PBWZDR&EY/>(\QN?,P_&2;K&"X7J%VW<5B60H9$Z M*@CQ>@'AJ8*T59I'A74I/KLU-;M:DE6F;"C'U8Z#-"[(SO)K58=U>CJN0[M: MB$-_QAM)A^O'W#"?
TI']2]%W7C1_+\8.?@FVP]+E[-JF=7G\-782(SI4M1@[MYD-5=96&G7H<+C;6 "*MNP+7!1U&?[\LX14LC3R<"/M%$DH\&R=57 M:2S'DLJ9=X")@WV,O"#'4..AT$9T!8&=^[_V>L&NCT0B6MNUZ%]ZC30 M;0D_F5"4?7XU)C&SV9HX96^S\"2H-'*[MJ]*GK+WOK-?97P;Y,3/_47O!&%P MI7J*,?2R?-C@M_UF_='PS(3D'&T>UX(>"-^]0X6"3CHAEF,U1&
(4%8I95\\WWY#7IOX/F4M;*Z*:3NMN/MW&990& M_]1?N2W-*!JAQ;VT?EO?ZH?%97:QO?A)X$:8J4PM*)R0:*_S8;]5]+9JX73F MK[9C[>BB[!]C%$2!-]#WB=:N6K""^K>.DW\ 4$L#!!0 (-V%9UF6F>_< MP@0 .* 9 >&PO=V]R:W-H965TG3K@:N MLBCRH%2JP2A-CP:ED#J9GH6]>SL],[574N.]!5>7I;"OEZC,YCP9)NW&@UP5 MGC<&T[-*K/
1_1_5O:6O08>2RQ*UDT:#Q>5Y/>7Z>I&P0*LP\(PCZ6^,5*L5 9,;?#6;27YL\SN)U??,YOYT]_G0T\7<&"@ZR!NXQPHP_@QG!GM"\< MS'2.^:[^@$SK[!NU]EV.]@(^8M6'<=J#43J:[,$;=_Z.]
[X__(WPDW>A^.2 M.7&5R/ \H9IP:-:>83#]_&AZEIWN,G73&3O:A_W=C]\/]_NUI!D?P^=/Q:#@Z MA;WH\$W#166E@N$D!'_8 U\@7)FR$OH54'NTF(/4WH" @W':3XF?2G&IW1I!
M]:9S>,2M4#_PL7*(E(M>_C"*&S"*#T- DP5X MXO'V N5ZC\T'M MRE@B F-F:#TU&S $9$$A$HUFMI>$B5:]#X\T5FS*8(OSX%\ M4&Q+7?%RUYE%[0,<]8]:#'["EJA;&43%=0.
[$)1Y'R(/AX0^<>"^UD1B0 M7'@$LPRZU"N=)]>D7C6XM'*P$:Y-0MUUG9YXJ!$*B(D Y$1DWZ: M_M1:LZRY*9&DU)FL*)<+H83.L%'QQM,>R1ZD_:,N_<2TX-J:#6JYYZW03H1W
MA:A'CP!56@Z4KVUC9ZS2\0Y,1A'CR^DR\KC])@C.AY&=KSU,9! &P^2@A82 MV?"M3=B'P89<.GH_'-NU,&N,-[3!ET3]+./T,^G8?__^_70]YZ9<6,ZQHZ*1
M:\%5!DJ*A53,P)!_EG)>EH%#2R$MK(6JL8GG81=/ J0M:NN>06W7VP,-MUDV MZ<-6&"D/F:ISC P7Q%Z.BI*EC.SN@1,* [:K%UQ.7@I%Y*0?NM.A=[TN?27: M%54 _;11"KX*-&3U;EE[?[AYU+#-
<[UWWO;!EM#2 @PCUH. LGB/-+M=M/<11QB?HC'4?!.V)6DRE*X M)-6T__4P 1O'J_CA315&FH7Q-""%94$3*5H6H/.E,;[]X NZ&7?Z+U!+ P04 M " #=A6=9!CPD2PL- "O* &0
'AL+W=OYSY")"3A0A$L M %IQ?WUW%P)4I2TZ1M<3H9CL]/MUR6)V]>T;?[_>:5 MJFTA2W&GF:FW6ZX2*WXI"[5Z?I"?AQD>YWEB\GC91< M;D5II"[9P9JO7)U?IR[-$QBQ/AWD/Z.; =;EMR(:U7\(7.
[>7UR<<)RL>)U83^J MW7OA[3E#>9DJ#/W/=F[L!%;,:F/5UD^&ZZTLW5_^Q>,03;@8'Y@P\1,FI+=; MB+3\B5O^YI56.Z9Q-$C#'VQ0JS0;E9.E.N;<:GDJ89]_//^]I>?;C[>
M_X/=_//W#Y_^ _>K4@F1\?IIY*6^=E,D!*5/VJRKMQK";,A=Y=_XI:-2H-0EJ MO9T<%7@QJA&;CA,V&4]F1^1-&S.G)&_Z7YKII,R&I> &>6DJGHG7)[#C- / MXN3-C]^EY^/+(SK.&AUGQZ1_M8['I?
QV^^F&S=F/WUU,TLDEBX72O?FE%\WN MM'CQKD:'L3^XUKRTAKT5=B=$R6XSJY9"(_PIXV7.?JY+0V8,P%BX FAHROUUJLN15,K=@D'4TA]HL"M['9<(>;V=JN\4;5F6?1^R*
M[D'<6+%%S4/P)(P7!0,Z,A;LD.6:H0YLBX2'EFCQ9RVU)X!-4&+I6!9P8V1 M*PD&2+_@1A6YT"8@B'/L(T,C-4G)>.5()L\E N %J[C,7\!\>"0M7'^"8;0T
MB.N8SBU#*"UP70+DN/P/$!9J@G+A7\G$:B6(O)C:E:#%1E9L68#5L'@% LPDE:6)5$$H'$ZP)6 M$:58R4QRC"NPFFV51C0@-'!LI ^H.V+OU4X\")VPND(G6%8(;BP[3UG.'QNO M55HJS4 [F8D L
_DA%S@5?!P ,T^.N1PL"PS2'H0G2 B%_ZW]7C\!I4QL<:=D.G!]O3!=^*U5 H4"JT.YPU8+\" 8\3'59 M'/<>U"-^AV@A(#DM8A07T2>$G[8CR]_+_]):*,+B;-Q*GLX-R
M")YOO/BDD%]N6R23KG]8.IDFX &8/4N?LXLDG#4 \U>S MY['3KD,0M+'A]LC ,#MA[Q^NFUAJ]J#&K8&!V0S6DM7AV?/TLG8*-QY >#V:0 MD,J>7.$\'2>3^?
3(*LV(CDOVH[+Q2YC9^J:)E61ZL4C.%N?-G=9'X4XZ2V;C M1;(XGY.#/T#*467IJU[B$]B.E*IV6EH+"44! 6K<8K*;Z1,75[0Q/1QQ7DZ3 M_,TF0&K#B=A1SXTDY=9PRXK]OWY:+9 7G03.YF*-
DY<%C@:Z%.4X[QF,&:H M[\>C<=I*'5% #UD/U+>64)I@3.60ZX'08P1?.!0[%'3M8V:3)8CY-SB]F[!JK M G;E7>_;6D]N14B:=) O >7QV[LT83?SA0/15U5]&"?? N.D M V,7QW>>6E?29$
LCX)KSZP#M! R5R@QLCY5&-K"\&!!E@(-9LG<0[JG#@ " MW93W2[L;/%24-:!4@U83%HI+.KZ?E)S]K6@*ZJBRP] X7MV%# .Y'((&;GAU M/2Q_UEQC27,HYU",? 6,(Z)>2*LYC*L-
)O$E]LH#U6632JX@I*AD98-!V[)Z M,X,P4!CL$)D ;831<(QT9P[&R:>]88XY2BB!J7"+X.9848(]\H%3"5)(OI2% M*Z*M+&@3IE./W ZK7DKN6/4XJ7SKL,/=!7T#NQY^4%"D\Z<]TRXUZ!7WF(
&KQ30K5* @ M?"@/]7#PE*A1EEC&,B.R&DR6H&5+8TV\]3AGQN[OKII.@^CV/<2]^IS @AF(M]H"'''55UE+ML0$?+0H>RDV.UI&R5:/LWBI[]H0U$U02N9(*[=U&0GZGR=$M*-
IQ@D.^;0UMZ78&N,:P7A?*H,8=)^RAK+(,"QAJ'^NBT9M*/I4&7>=714$Q"%-BXF+_XL M2":]\LOU^3&:\ 87/=.VK_60G-HTGD[DV^H2I(\Z_FHT\]N/(J/9% 6TAZA" MR&\HV?"",/>\&P4@H-
6O7:IZ6:O10,5WVROBOC:9BR!J.)GOK]1-ZYG0%@KOL,THOD+M/R 'K;SO%6(N7\?! M%+0..STN70^$M!9T]%ZZI-7!;D[Q$/<%7D9H@MO877&IV0,O:K?-SY)Y. :) M3/DHL/#/_8%!2WPAT
^8ZK9T=[(O.;9;D4NG;(9)I2B0;EM \/RO*R/0S5S M;3<*3[_R8 MNBU5M:QVE)AR;94KG=$76_B8>>,Y9P7>PPV"0$[3KDH.B8UG MD&Z-#%6&W=ET;ZT@, MA(8C%)+B32-
'(B!TZF[CAF6HB1P*&V(;_$>IK;&%-C4XBW5)HH$N[N^87#V] ML"^_757>>JM]QQ"_5^F^WI E'=X;\F,XO[]YH/94U>O-P&*]+(B&I2U\L1.$ MQ7$S_^%K(F.8
Y/^BRN4K)9SQX+9"XY5L3!VSJ($2-MQ;1O7RYV2T:%-S[^2I M- 2BS>)>O^%3B($SCOW3"-^\=(D8),2+X,OB\?$O[H:, B+O/8XP\D]?H2"YA[[*="N"W]2#.Z5*77$W[=("O>GM='XQ&5^MXZJ@
MWTWB=R)LZU8WM//)PH='3JB5U/-WS[9<_,RS#'.[>U3KI?D9;EX6,%OI(URY\ M?S:.^FI9/D'(1*.]6V;^UX=8#>ZH0"''Q@4$ _:0WJ*Z(:!-<&./ !0BPCY@9- M:^ #7!XIS%,A-
]#D(+6",Y1V39^!VRCBKQ'HDF3U$.C MWVC?(%'BURX%4 !W9ZN^0\?Z&DT"YD@P K=0A)"VY.;%A,ANDU'X\@>/%B2U W&L M^Z")/-
>^"R400@%$+N>:A&77HEX\'56K'$'O&=87#=@'],,'O >8AP8Q&C](R MTS4*QKGRX JNSX-TIL%OP#>5TG2>5L,O@^X"PBQJ\B9^(T4UA_LJ8>0:E.BP MU9O76Z%'$][C"DO!V-51CX9%VY_]
("P:":-]H?-7+XJZMN*;OP%02P,$% @ W85G6=G<]T:3^0 0!P !D !X M;"]W;W)K&ULS5G[<]LV$OY7,*K;L6=DBJ0D2XX? M,W+LM.E<;(WE-C]#")"3A3!(L %K6_?6WN^!#+]MQVMS<3!P1)+#8%
[YOESQ? M*OUH%D)8]IPFF;EH+:S-/W0Z)EJ(E!M/Y2*#)S.E4VYAJ.<=DVO!8UJ4)IW0 MJT\Z*9=9Z_*<[HWUY;DJ;"(S,=;,%&G*]>I*)&IYT0I:U8U[.5]8O-&Y/,_Y
M7R_2,?:QAU:BFQ3$5FI,J8%K.+UBCX<-7#^33A3RF69NV:H253I1YQ\#F^ M:/FHDA9%$"AY\G\5$D"0H"-?XJ9;;J+7'A^G4E_1/9#K9,N1$?5?)5QG9Q
MT1JV6"QFO$CLO5K^)DI[^B@0AHFA_]G2S>W"Y*@P5J7E8M @E9G[Y<^E']86 M#/T7%H3E@I#T=AN1EM?<\LMSK99,XVR0AA=D*JT&Y62&09E8#4\EK+.7D]]& M]S?'5Z/)S37[>/=E?',
[&3U\OKMEH]MK]G5T?S^Z?9B<=RQLA0LZ42GVRHD- M7Q#;95]49A>&W62QB#?7=T#%6L^PTO,J?%7@1.0>Z_IM%OIA[Q5YW=KN+LGK M_M-V.[&]_6+Q"'TP.8_$10O.B!'Z2;0N?
_DI./'/7E&Z5RO=>TWZ]RO]NMC; MNX<;-F2__#0,@_",?=,N;&)5],CN"944Z%1'9L%A/@.@),9GLET'=7*8W>-7]FH=F/H!WV*%@L&^*^.=P_*>^'!?I;>W+J MG@#.TU_S) SZ^KS1Z4Y0D+
M@G9PVD?! YB# NLU?ABRFS1/U$J(,CG'A8X6@<A.R;N,_5YD@@4GY+BPO3]W MT-L+E4!N@<_S7*LG<';.Y'&9$&4FO[WC(4Y#R:%_YF9/QF,:!V='GNHA!)PT$]8ZJ ?
=1%9A$M51MK.I#:66A8ZD65MZV!T>P7]'C2ROU]M9!PDQ M$Q*]VJP+AD<[\T+O)-BYN6'V'B8K8?VP=X16#]G &[_A;%8#>R9WF_W0YC= M/V)]SQ_ []\?"]R5X<8RJ,EU>688X!.T&8P49H.B
N!\2@@;ZW1 OL;3&I M1CCQD2V C1 2Z'QN%C8KP34>0BL3>K*>>'!ZGG.I<5MP-:*)6*3(%5"IQ.Q M)YX4PE$'3Q5(8=,,56RYDM'#*BTL-];]^A'[-217/D1!Q25*;QAU1G;6UO9L0
ML[@@T'C'\5X",QSXD((E1'D4JM$+A8F#@VW#8.I:Q5>KA:(WR>0@.(6 -COU MW]J)S^=:S&'QOCV?*(VV?+%GTT$#P-[WH%^C! 6JWG]S8X(ID(*YLZF W]A< M%\BS359W68'Q5AB-
83U_1]A!U^OUD163R*HBX0Y_B*TA>T.R\KF:O*EJFE* X\Q^7!MJF*1$$PO04>D M.>B5'=SBF8K4'$J'C3#:*[Q:VG4 MAH^_*WJOQ0Q=@]NFQ"FJLL&@2E@FD3-Q&?FV[5AGDQ K6#FN8
5(JDB=_/?3 MSA<' G30=Y(S(+I#%8K[')!AG^YG=2_/(9N@^.%)0=[B@ M-/*Z -_V((#P\)_AI&./$:(KB66.)"JRD2!H*\4'(!FD>XWN6>#,E,/A0 ME-9X^TUAI=R#BR[VHC+*D@+G-
45&$YN(EW$NL[/(>!$3T0'BQ[@S71F5R)@[M*(&?E"@#,0U2D3L!9:D)A++_=U>0&HDRYHV V#@4D:19# MD9ZHG*JE)BT&0;@V&JY5$;^*#"QSAYC'4 %+8]'2IR8+3H;#IN5K^_YI/7)-
M6R,X:/=\?V,\[)WN6/!'5D(#MK'FK7R0N\3A>[T:%%]JF[&2QJ6.8J5IP 5@ M=5JC$ZI ^,-WBX(&?0) 84I[#]^!"\]*!V_4[4U15:@5:.1O]-+@35-@W5W) MA%R3^#;8D4G57*^WLMLD.'R#!%T#*56^
OBT+&^HYH#_%]'OKY&?\W<3,P,' M(7-1:T-!M<*@-\4!>@PPP2R05?$7B, @ZU _&>O8]JQ7-)/:9=[<;5N*&E' M+G#9Y?3!AE\%9>0:"'C& ^7G!8.2*!5)VM@225J#\S3RZECB!ED);UZ(QTK
MMLEMKVNBG/!WV\5[:-@I=[,C@B WA$U MY!<=&^V"P5W%7[IKZS1XI9/>6TM 4[Y]KDC_JN[#5SI5JCEKOK5K1M=LBWX? M(_[@IO=O-;]#:!H/X-(+AU!;A%A9R(I6#P,?&KW0 P)YJX\
<]@,&Q__4!R'^ M_V=/V&"C:P?W?1SHK'W5286>T[A9KK[M@:UXAPZ M(I:(&2SUO4&_Q;3[7N4&5N7TC6BJK%4I72X$!\S!"?!\IH!AR@%N4'\TO/PO M4$L#!!0 (-V%9UG$%,-?,0, ,L& 9
>&PO=V]R:W-H965T$B+]*BU[L%7B 2_M3)^G%1$]56:^KQ"+7S/ MUFCX9&.=%L2F+U-?.Q1%!&F59OW^FU0+:9+)*.[=N.K+"L*&^ED5(L25TC?ZC0'5GI@*:1&XZ4UX' S3J;G5]?#X!\=
MODML_=$:0B9K:Q^"<5.,DWX0A IS"@R"7UN+Q^9/\8 M<^=U\!QPQ;SQ9O0>S MK:7IWN+WO@Y'@,O^"X!L#\BB[BY05/E!D)B,G&W!!6]F"XN8:D2S.&G"1UF1
MXU/).)K,;A>+F_O%?'F_@NGR \QNE_QFOAJEQ"&"8YKOZ:X[NNP% MN@$LK*'*P]P46#S%IRSMH"][U'>=G21<8=V#0?\U9/UL>()O<,AW$/D&_Y-O M[[F$.
[[A\WRA9ZY\+7(<)]P4'MT6D\G9J_,W_?GV/_]ZYRF6[> MS^$=G+VZS,ZS]W"2\;[(//2>*6%FM9;$G4@>[A1R#X1V1 =D86JX0)X.L"F M<53Q;B$]7]S8M78#^1&8_;5X0+['"OEF&X1:
[+HC88IPS#8XNQ.*)'IH^!(Y M4%$(@B@=8N?=2JK@Y^UB&G'3V-DK2=B#+U@*!0M!A,[#1VKX$E MAH1J878L9@=K!&FV5FVQX 4'(UD*ZD:.X@7GSJA<";E9I9.Q(CS=0FX\&EWT
M]0$:F$V8%(J3;APK9I=UPP#TO@=3 A1YQ;2U=9&7T=(63R7A5JA&"$"?_8&QK M'@.SA (Y)9X "&V%L= "JZ^(Q:K!7& MXO$D]]:PR;$]ER@>=(6?KF8PO.#>FW%/LV T.7^5YZYU>C2 -+HRCED?
RF"H MFT6'W<,DGW8#[*][]QM8"%=*+JC"#4/[O;<7";ANM'8&V3J.L[4E'HYQ6?'? M"%UPX/.-Y&ULK5;;N,V$/V5@39=9(EA5[M$^1BP+D4&^QN8CANB_:-ED86$8G4DI0=_WT/*=GKM$F
GVQ16KFS)DSY(PN MUMH\V8+9T7-5*GL9%<[59_V^30NNA.WIFA7>Y-I4PF%IEGU;&Q99<*K*?A+' MG_N5D"H:7X2]J1E?Z,:54O'4D&VJ2IC-%9=Z?1D-HNW&3"X+YS?ZXXM:+/F1
MW6_UUWZ%DLF)EI59D.+^,)H.SJZ&W#P:_2U[;O6?RF2RT?O*+N^PRBCTA M+CEU'D'@;\777)8>"#1^=)C1+J1WW' >HO\:#=!@HL;X03XPNCUV2\-=#\0T@;\.(.<5+XHC\[@&K82
&\]NOTWFMSJI]V6%^2/0YXQ_]+LBW6\'4L?UG.;"U2OHQP&RR M%4?CCQ\&G^/S=Y@.=TR'[Z'_1Z;O8]T_S&]I$-/'#Z?)(#FGM[%IQJ5PG%4 M&+>A;S+UMT\M:,(TS+B*CAX4H2J.JP4;&HQ":5
@5S!=ZZH6:D-"9?0%/_J) MX,$&>%(YC7WBY[1L+*XAE0&;2>R0#SV&YYC$YYU[2X##YN#\$Z$'A4@ -=)I MLR&=AXT9U\T"D'[]5:,Y]6B.[9O! ^V#]\4Z2M&Y59-(,5FER-?#U/30O>VUIL]D4Z
M0B1(D;68>DRO89R\FH\,?#G/T>&"-H)EJ)G7H8DI@T+ M8TGDD"O$$J6QSO.MV*02U*THV=NR2(NM!B&FX1^-Q*FF0_D)7:=D]"&%S,7& MERHHN%]QO!S$O9&W+'VK;6K?;VL@KA
%;P7=HS_?&*0TJ6L42H26?-B5^_YF M\J+&+_@Q161G<=6D3><,FDQ-VRX=72O\>XD MB+HN)%3=ETQ:V\!L<)2,XJ,$CLGB9*/HR-4?$A0(X=).M;HQ:8'QJU./@V$/ M/G# /1"(=S2:&N]2"ES%H
.1KUX>RYZKS7&_M[LPKE0JUOX +M/H_'?4$L#!!0 (-V%9UGQ7-#K* 0 &H) 9 >&PO M=V]R:W-H965TW*[HD0-OK M<'WH5JR]VUX5FX[5RI)+R4FSQ_Y(*7&S0YL#]I)8,OGQXT>*\FSCZ-'7B &>
M&V/]/*M#:,_RW!CT<>\4=IFBUG< MNZ7%S'7!:(NW!+YK&D7"S1N,_&V7[CFU[503;RQ:Q5*[S#\'=[2[S*>Y12 M-VB]=A8(JWEV/CZ[.!':/"/QHT_> ;)9.GW^0MW^7P0 MO,(9'WJADVS'TPR*S@?
7[)R90:-M^E?/.QT.'$Y';SA,=@Z3R#L%BBS_5$$M M9N0V0&+-:/(04XW>3$Y;*PHVSH?9P94LL?_7/F4E/9[*K7 MK_=7,![#^W>GD_'D$QRBP;4M7(,0U#/@,Y]?CU!VI.T*M U(NH&6?UWI0?O8
MU"7("6E;LQ4C90%]T-SS_$)9VRFC?_(C5A7&4\0P?0!BJ^BJV2(X"#7R:?7M MSO*I4\0AS78?<@"J?.#&9FN>*5!J7Q"&A*4#-LS)11!D+ZM-K8M:]K;@BJ*C M(=SS>V;0=D'%P^VJZ'+
(M4_@A75/5P*C8LQ?Y6#>3YUF\E @!9YH/8IGZ!*\ M7EE=Z4+9]=N>+A%$0*TY4LVP"670#K AC=Z!*5&$1:4H-"-GB6\703N?^B65$??)KG6<]Z++2RPV M;]06BEK9%<-
YL#SN<4&F(I'5=]T4,9!DTWF019 MH@3P\&C=AN4E018:\=S8M29G8XE37#^$S[MJA9H0.62'NBY9T$H'/K$H^BBH.F.XO*9+K)7A MFU1)CKS0K,#;Q4GR_S=RK=8IJ!2"-
(NR2U#""6#AI*=];$/"E2)I[]<8I/X] MTAS\MK/[PR3[K?,Z]7?U6UH.7QN\^<']UR"MXBTO:7#3I:NPW^T_),[3_?EB MGKY";A2M-+,S6+'K:/C'APPHW>QI$5P;;].E"WPWQ\>:/X:0Q(#?5\Z%_4("
M])]7BW\!4$L#!!0 (-V%9UF@RT\.' 0 #@+ 9 >&PO=V]R:W-H 9M65T+L MJIF6QA812E1)RH[_?%YF3ESX9S1C#+=2>)D,T.%-QV[LWLU'FX9*NTZ10H*<^QT%P6 MH' Y\:
[#RYNNE7<"_W#=TX@76(128&(O Z&^-MRB$!2W M?C287FO2*NZO=^AW+G:*9<$TWDKQG:5' L_^F;ZU^P1OGR;S^%]C#@*S3]BG5,WT4G .987$ <^1$'4/8$7MT'& M#B _^7T'6&-
WC&)8]..'L!]$FA/YJ(Z3)Z!;N+_[MKB&ME!4C^URF&C89%@[>75I_6)+(JK"&J.\ TX _*FZVP MM5$5-@3H1W#;8 MM3&FM4PXLSH;K(:RV3,G OHY'B1B(JJF!;.HSHKS'40"F?A$FCC2+EPV3J2
M3$T@Z+3QX57"-4*I>.*R7.!*\!5?"'0H3 @+^RKV927$%M:H79YJ$%AI'0! MUQ2(LDD66_JG3()]AKV7L=&?%<1^15"ZEE)0_]9.WUHUF4*$O.8]6MX#L=:@ M,[VCKK-!BQA^<^F4E:83_?
NEJ]$@OOIE_\Z:L]04Q=P5W%NQ7L\/^X.#X[CO M#Z.!U0_K9W@K$!+PP9G?[X=6)SJN,_3#[J&I,/)'9&7VG&2L6.%QUU8O]02]X5^]1&B8.OLC?Q#W#$5,5^MW@Q8>[__3L_GFEMD%5TT6S M?,
<>1PPZ4Z\[B&7MF@E'5Z?&"L/_<-CT<2=VN*9STB5KJ*YFRX=];I32$#"G M))VVB<]-CU@JF1_K$F?
U!I[3U\18<==SW)2S(::]BNB7$\NUVY(=4#5]PQ9(M>:D4L]EH2[T7OJR'PS>5%A)3HOX>U&C4\N+8 MI[.S-\WDJ%9N9K/=B/IW/=BTI^U8>%U/0R_B]4SYE:D5=7@0N"35X&+0\T#5
M&PO=V]R:W-H965T01(2L28)!@ E*[)^NQL@ M1>]*DIU4S>Z+S0/H\^M&=U.72Z6?3"*$9<]9FINK3F)M\:K?-U$B,FYZJA Y MO)DIG7$+MWK>-X46/*9-6=H/!H/3?L9EWKF^I&K M-
R)5RZO.L%,]^"3GB<4' >O+@L %@["?BX\:[OHUE5AF(C=2Y4R+V57G9OCJ MS1C7TX+?I5B:QC5#34*EGO#F/K[J#% @D8K(((4._Q9B(M(4"8$87SS-3LT2 M-
S:O*^IWI#OH$G(C)BK]0\8VN>]<=U@L9KQ,[2>U_(?P^IP@O4BEAOZRI5M(M,NJP]#1697XS2)#)W/WGS]X.C0WG@ST; K\A(+D=(Y+R+;?\^E*K)=.X&JCA
M!:E*NT$XF:-3'JR&MQ+VV>N[^^G-=')_\X[=3Q\>/WU^?SM]?& WT[?LX?ZW MZ?W=_>1F^L@F'Z83>/'IYO'^P_3ALF^!,^[O1Y[+&\:Q MB-O[^R!Q+790B?TF.$CP010]-AIT63 (Q@?
HC6HSC(C>Z">;P7$9[^_" ?;* M%#P25QV(("/T0G2N?_UE>#IX?4"'<:W#^!#U/TV@UQVZS#\)'C+AB/VZR_G YM3!XS7Y$%';'16:_\[04[+W@IM0"@M\:]WQ!SZ7!B .)8L8-LXE@A9:1@"MN M(?S+-
&:A@%P1"0CUF)4%Q+WAJ6!JQCBD &,@S2G-"BYC9A6SFN=F)C3C+)4\ ME*FT*R9S7*MT+'2Z6A0*0 ;VQ9T 5F[WP,Y) M$WAI/L BC2KF[,N&8%%:0DY&";T"SA(<'*!"C&^R!8J[!@-
:ID9#EPE)Y&,) MD6F!7IBG#D$'_[.A MDW?D5?R<-\3UB&I+W=Q]"&S>UN+9HCG)&MNDT3ZYLFNX4#!K$8)/ZAA W:0M MN0N^.EAI(6(-)+&X4V)Z6E46(J2@C ?
$W^OWQU846A*9$C5&NSUV UF7//(6M8>BXQU$[I]E+M9/_D:!#3D07IF_OZ(S9S!Z_9?YO_L8 M0_5NG#7WZKI)Z5%9\$%U5T5G^S[8N!^Q"3>).P'P0GPI)=@>O?_S305%GJA1
M/"O!/_6K%^RD>WXQ/G!?U0[;3]X304)R+$+++#$*.,N3/5VFB=(&Y"HX8E65" M4U@4O "_;2X=#;LG0;"34E.O(Y=_[CWTV&]J(71.^(%S'V)2F*T-)W@.[.QH MKH=7;S*UFA"\B^UPU#T]W<;L/K[?
6+XV,^14X4]WU010K< IX&9PO+Z'E[=# M[4;@IS!^*SQ9!.FP\%9=W0R.@#O _GW6"0?44 MC2]#'CU!1;5&U;TIZ/C-3VP=CO'G8$[!HTG6U$!6?-L/&P\V.2[/SCJRL[U MZ%7&:'1D6
JZJF]=#@+,X!*K?^1;#:4MPL5\ XRK!J\N-A/>A^2YKF]]V'S M;E>K5GR[.@66V7Z]L-GT(X5: TBHH>4TCYAIE0%'J>.7V%BOZA;:]%)#I]5C
MM\\1U'SKHCY3)=;D)E'+G'G;.-90FB\VA@.QC*G=2/A"4*^@J.7ZD0+]Z%*[M93=" '8'N"O&CC$6&M(\-;7KOB26)BJ-<0WE%.**G6*CTP %I&C@6IT,@]Y5.-C) 60(MEI=M+ Q MU4GJ)C,JK-
LPD,'*#)G 6Q4A1P#INE^^?9:6W2ZH^]IEF]+@7D[O$ ^,P P: M WBK/G0V$VYV(',0&4<7M,@9$E>\4]#7W\RU(-%W]X#&#QULPJ*$YW,WE-B. M@%T-X6&7[P'?>D%E"S>_R=PD6.
D>!\,X6+TIS=ZK7]'-.PU)G&AF,L\]XZ$ MI"%5#'EO?'K>R(+C8< F:^,UE*T/NI/MLV_A\B"PF 9SJ5(^$RR- MW84P@C"2.BN5)]%PL]W(^Z&6QARGC^+PV] :ZT=3E*MV3/*K$;G M?GI[(.WWV$-
CYCI1H%=NM3]N[^K15 ,Q3FM3AO\&-+6D!==$;0((]H])&4M MS5-=;_3%=KM&VV,GZRM8#[F_EAVH%RH5USX-=1K!.,HRKQ@T"&]&)1 M*"/M&NHX>05;S:7> 10]FRI+&V)BO2@BG0?->(?
3*]>02^ <0X5D')$[+'C M"A0W((=<@0##LV\A8W=8FC)J[_=X/8.MD,AQ]YZQ>[KK56YW9!^6[PVV!)N MZ+/-'(ZVN8^#%^-A;\0RF:9803I_N!,5=VX6;2B\,27"TZ\(>?Y$1RY:KC8M M3G?]/#PN
5CDP3\2B9/W'<& AD&5!WR18C81@JX$5&G*1,W*E>.'BR&@9=+ M:%6/&:027*5R0AB(]*>]B1#B\Q76)@U.\B^FH#,,N4O@5Y:/M".8,"VS71]I^X]L[=!US^H4!>2:W[C-\ ;3^$<.- M^W: _7NY^
0%-U1QS1"IFL'70.SOI0):B7Q6X&ZL*^I(?*FM51I>) -$T+H#W M,P5%I;]!!O5/.Z[_ U!+ P04 " #=A6=9LW-0 \," "'!@ &0 'AL M+W=OY$+ M/?8R8\]+(-!)A@73'5FBH)655 4S-%7K0)<*6>I
11[$83@("L:%-QFYV%Q- M1G)C.3KS-A ,!F5;(T+-,_E7-$L:%E27]#0 M7 I0N!I[5]'%M&?S7<(+QTKOC<$Z64KY9B>WZ=@+K2#,,3&6@=%KB]>8YY:(M9'QO.+VVI 7NCW?L-
\X[>5DRC=T(,45VR3FT=9?<7&3]_R)3+7 M[@E5G1M1 V.FN'5F7S#QR\AD(]*>]B1#B\Q76)@U.\B^FH#,,N4O@5Y:/M+.8,"VS71]I^X]L[=!US^H4!>2:W[C-\ ;3^$<.- M^W: _7NY^ 0%-U1QS1"IFL'70.SOI0):B7Q6X&ZL*^I(?*FM51I>) -$T+H#W M,P5%I;]!!O5/.Z[_ U!+ P04 " #=A6=9LW-0 \," "'!@ &0 'AL M+W=OY$+ M/?8R8\]+(-!)A@73'5FBH)655 4S-%7K0)<*6>I
11[$83@("L:%-QFYV%Q- M1G)C.3KS-A ,!F5;(T+-,_E7-$L:%E27]#0 M7 I0N!I[5]'%M&?S7<(+QTKOC<$Z64KY9B>WZ=@+K2#,,3&6@=%KB]>8YY:(M9'QO.+VVI 7NCW?L-
\X[>5DRC=T(,45VR3FT=9?<7&3]_R)3+7 M[@E5G1M1 V.FN'5F7S#QR\AD(]*>]B1#B\Q76)@U.\B^FH#,,N4O@5Y:/M".8,"VS71]I^X]L[=!US^H4!>2:W[C-\ ;3^$<.- M^W: _7NY^

H"G>BOZ)H0/Z7,@^UR*%,@Y3)=5HE^U9PQ1F2TK]?<*0"+ M=R\(I*[N.01BRU)1#5-KL!JL/3%6ENSKIA"+G1OC27N"NB@U#ASE8 Z64*H' M%
VIOM;X375$:=\IN3;1H+/)M(='=T116E>"HRAS_T)E0 UCJ63WQ(C5P,]T MR<6V%+&A -7&,''\,3(.;I\)/W$$Q%DW^:)*4!4)"@QSP!Z2P9)SQ9 >?B
6#;^@KXWA&.K MXEHF^GD51V@1E=;2O<[:[4H4>.^EG7.I[;IPKYK<1C:3L0J56P>FMKM.3Y]8 MI4066M>0GU/"T&R&(FD1A95!I&J%-
*=@#"RE6:3.@E:S:*5"UCH(6)G))>&$ M^EI@NJ%")CNI7RJY*:O5IN[<'Z^4E?DPVYA'6VBRC<-5;[9R''C!A5?H)7,(V[1?=F#8JM]*39C6@@PA;B8?E?
A2Q@O>O2-4HGX#0#+K6=60A=U0RUW/U*8_$JA_J7.<2DNC)J\ ,%QRGQNJ;P M#L$=CPD(/:Q*D.+&\DA""(#$08*$='Y"&ID2FYBN:;VQE;':
(UE2#=AU#$S4 MQIMV(6>G7 MXFT:JEU0'U/;$G).SVE6 ?>89R9YPD@,-XBV &-R8%R=: %B,0X^*L\NB]7, M"T=$Q.:&-
IB)ACW#CD%A@A!B8@=N*0/JUTX"FZ^N=YC)U"ZE1,S4C&2K6N,U M3$I>=ZZ>>Q:F JE(V:J5;EU$L!<\T(ZR/E!M%-E2K<2-^@U?,LD&]HFX*8TU
M2L76';%!.3?R-R',28,P)QOQX4Z[QY!"#V0"=7:DS#J@^5."NKGU-]>ETXI) M <)?& K,2LK91ERY(JZ=QIORWVFETD75[1D;4#^D>B7..8,=%)(PG[5A"8]"
M*LSH#OT\>S>S,,FAL,]*!_N=HT1*R_#\A/KPP /7U/\--X7G;1.>MQN].NVX M9-168?W<;UV8_I) <;]!Z?U!^VQSL#D9 ,O#K F-Q3* -/PD/@%X^ H-C0
MKWU\^;\]0DPH+D^A443#=1" HQV2.I(P@.>QM+$3%P9?S?A]-9I>=!ZC.:K@ MT?2!Q>T.CG?0BC+_H;>IA@BQ=8_..Q+#D\'V.S'A9V>5?DCXL(Q1K=
[YH3,U M0.,/L/*EQE#BV\/?\H,_DREQ+[]B;W7N\>&Z<]N5*^?=<*ETP-XU?F!.:=N> MZG@ ,P1C2 E/LAKM:"P+#%,+V 53L?%'K!UZUUW=PUW_?
6=78,Q@:*+3FJ_V+OC M>7GFU=-;"_E5)0":?,L85WTGT3J_:395E$!&U97(@>.7A9 9U7B5RZ;*)=#8 M"F6LZ;MNNYG1E#N#GJ4]R4%/%)JE')XD44664?
E]"$RL^X[G; G/Z3+1AM < M]'*ZA"GHE_Q)XJU9:8G3#+A*!2<2%GWGSKL9AH;?,KRFL%:U,S&>S(7X:BZ3 MN.^X!A
PB+310/&U@A$P9A0AC+\V.IW*I!&LG[?:/UO?T9X2T,6Y2>JZ: GQ9I(PXW:S,&Z:J417,I-4J9:XM<4Y?1@\O@ZGLX>QH^S M*9D\DH>
[Y]_'L[OA_9A\&@]G9#H>O3Q/9I/QE)S/Z)R!NN@U-=HUTLUH8V-8 MVO#_Q49 '@37B2)C'D.\+]]$O!5H?PMZZ)]4.(7\B@1N@_BNWSJA+ZB"$%A]
MP<\&X9COI>K6<=6FIVY43B/H.]@T"N0*G,''#U[;O3T!O%4!;YW2/IABC\8% M R(6).4K4!K[12L\8XW(KZ!-RK!(YYHHB J9ZA34,2=.FYG\J&I")6"C1:+@
M&F*",X-0)*YHR@S[)1(N%46Y.EBJR8*FDJPH*U":QR02V/1*&Z]T JB&X>Q(M^9*#+0_XMVW4C#/T#5'X[(#.A*7MCPW,[MC2 ,]HUT6MZ)"@JK"@I/5U
YC$VH"XY3G:5_8^*6.,V530432F%>=8)9POK% M66\ILDP&+3.2BY7ZFV%O>Z MX">:X+]Z?
Y$84O*R"_9[%=Q501Z9('^QN;HO_39Q/G5QGG+/A(R%Y)JS+7(M,I!1BAV5TQQCN.N@P&NTNF&=T*E=;)+\VWW^T-^U[!]SEBZI62QLEEZNIE=D
M*58@N6E:@OL,CTPFW[H2-OQ:(U>-WSKJ>QU!34%GA]3:G6%@56&:N ;JK9P7 M--
JA=T@^M'SN71R5;K>.1)@+#67!SX69R0=PVXUV)SQTV.L7+SA#@ZC?VR*-FL;%5;0TNZ-BM@?6[E<5=1J M-;TK-[(=>[G7/E"Y-
/7*8(&B[E4')Y@L=\7RHD5N][.YT+CMV6."ZS5(PX#? M%P)CO+D8]7"/O@'4$L#!!0 (-V%9UGLW.($ P0 *0+ 9 >&PO M=V]R:W-H965TZ!-U@NS
3J]S10C@=EWP%%4/67/V[.X2T*\48A]G[7AKR7OW/'IV.C MU\R0-*+1P(?JM=$YH>A2YL[@KD]-_U^=S.[O/_RYR?V]>9R?C-G)_=\(<%^ M&
(<.X4DH3#=05S54_ I4PKYIY7++;E0&V:Y^B&XUOL5;WZ[BHX!S*,]8$G58 M',6](WA)$VOB\9(WQGHHQ!JA=QB!,N3"ECR%28 I8,$\0#!]_ZX[B#X>\:_7
M^-<[ACZ=8\9EE02FERSEQCP)M6(/7%9^Q1"_3O7RM++ N+7@+.,J8YB?ACL2 ME8#T9%+PA9#"";"' CSNPGT.+TQ;LLVE_!G[3*"(94LM,?C
MZ*>=^_[Z,>V?Q'5E#"C7,MX?]=JSP8A]U6IUZL 4S7JWTSL_;\T&@XC=:\=E M2S/N1*-D9Q['HR/<[3?<[;^9NR\9 8_XA%@XQ,;CH%AWD3" /P/ BKJZ
%67 M%W?M;Y/(B(.D\YH#1$>A4ED10(4P-7I-3Y).>4E/!4GY'9ZFNBBY\ME0*5YE MPJ%JJE$7\?S(:BDR3LO6X0??
*V=;AT!HY!@!&T\R>,"GN"QV^=7MGK=G29=] H412*_#,WQZA'44$;J_%>R-GH?Q'M6Z M@V%[-
DR.T&S0T&SP9IHM*U<98"5_J@^]OM&7=\]7R!TO<(A_QZW=UA92;O.7 M9J@BOFZ*JAYZ>(BD!GY%2;P5-L7#?L)KI80@'_;JW RH*?-G@H?54D!'^CO%
MQ--DL&=D.(QH8[B_T3V+U_WK-VY6 K-=PA)5H[,AUC93]X3UQ.G2]V$+[;"K\\,&ULM5=93R,Y$/XKII*]J)N[9,M9FHC,9961)IU0_9G<2
M1YU:RYREE"LF.$BZ&+?.O)SKMEO-_S-Z$HUOL%$,A/BR0QNYN.6:QRB"8VT MT4#P[X5>T"0QBM"-YU)GJS9I!)O?E?8K&SO&,B.*7HCD.YOK>-
P:M&!.%R1/ M]+U87=,R'NM@)!)E?V%5[W<%D2YTB(MA=&#E/'BG[R6.#0$!OL$_%+ MWX7 MAJR77XDFDY$4*Y!F-
VHS'S94*XW.,6Z2,M425QG*Z]0%\$UP'2NXY',ZWY;OH&NU M?W[EW[E_4.&49FT(7 =\UP\/Z OJ> .K+]RC[T[2WQ>Y<0Y61$K"M=H5Y4$E
MIE!.5$8B.FYA)2@J7VAK\N63UW-/#[@8UBZ&5GNPQ\6+A"@%8E$Y"$*"-.3:
MY6CX"QSMUHYV#V(YQ0XQSQ/:]-56&=/K7;X>UO804UB(!+L$XTO0AH%EJV#_ M4@5W5]]KY;A/@L;].I:40EI0CMJL(F$T36=4UJPY@2^?!KX;G/ZR?
[3B-0=^ M/;A\C6+"E[2Y&N[5@S&JCPX>A"8)W.9::<+G")T#?^2.Z[IPY!W# MP/'"OA/T/3CRC\'.%VN!&?6[Y2@\!J_KN+YKMUX0%6,W0(!?
J8R8LODV/OQ_ MP$YC@O3$=$MILB@QCR;%M<%,LJC T/.WI9OC(R_ & ^OEI8P@DBD2!S #AL] M 5,J1Z,_M-#S7,?O!P>LU#NV4O*>E75>*LE-
;FJN.,%@Z'2'O7IFDZ-JQ@N= MT!TZPU[?)OB&8URBND8" ?3[^1*,JTIQ] 75)H28QQN(RV,4X; 3L&K M%:)?P:$%9+E$!F,*/*?
7\YRPYX':#2'1QI21)#RJ4H:;/O?:X1 RM&(%X<@4 MKG'?=TJMX1BS=NR='K?!M($W>4C$;@L]MVO8W6MB7TKNCQYK!D2EM.
MS9G$M2T$OI&UK5C'FK@0:4;XNHK?(.+O=[H,4B069A9S"7+-P2O6T5RM8Q05A,ET(/0J=?0OK.'00$ MKU)E7C;54$*E8P1'4G//1$-B4UQ +
(Y;WA7Q;U1;4D_\>9V9C:E95=E[I.XW&04KFT3R"%'B#VQ3NAGJU?66?% MXV*SO7BB(7^6C"M(Z)%W78?;W2R>/84
RTR^]28"8T/%_L9XTN12K,!UQ=" MZ&I@#-1OS\E_4$L#!!0 (-V%9UFS KW6N@8 $86 9 >&PO=V]R M:W-H965TE9U^DDZ60]VJ.J.$A
MCA)UVIAKG1YU.BJ88\R4(U),Z,M4R)AI:LI91Z4266@GQ5''=]W#3LQXTC@[ML7W7\NQ$9#KB"5Y+4%D<,[DZQT@L3QM>H^RXX;.Y-
AV=LY.4S7""^J_T6E*K M4Z&$/,9$<9& Q.EI8^P=G7NNF6!'?.>X5&OO8RY^+>-+Z$IPOM*?:(01!MI M,'HL\"-&D4$B/?XN0!N53#-Q_;U$_]T:3\;<,84?1?
2#AWI^VA@V(,0IRR)] M(Y:?L3"H;_ "$2G['Y;%6+,D$QVC@6[US05;+ M"Z;9V8D42Y!F-*&9%VNJG4W*\<3LRD1+^LIIGCZ;?![?7'XX'T\N+^#CMZ_7
MEU>3\>V7;U1 MZ+F"RR3$<'-^AW2M%/9+A<_]O8 33!WHNFWP7;^W!Z];+4#7XG5_90%VV9W# M]G;#&F"\G_P; -Y(M*LR3DR:P-]
2V8#PR&PKDU3#-="819I(E M6D%&VT1.JT5P#R(UCK/+]OW:71N#$XTAW!FO!T[ZE&[_I,:;6JZI_S*-#>9' M$:A[@V.U806D$4M4#I8 3\(L0
HN.D>!1&A@2HF ,Z/WDNNYT?DQ M (TQ*A,'-5K]2R)"DR>D@\@425"M(S!*N-WC7WY>5>LT*7;V*0TN4 62Y[J.
MJ_6#;_6ZPKA:1M_U^G!M+/(&YL^NF7]L^@^+?K]K?VM?1OD7"OCV5W_QO?Q+ MJ;3GMOM#=[U)O*^:/=^%+_4&?+(;4'[T!_V=[Z6P6Z%9!)[7]D9]
SR@,02X MQZ?ZE4_U7^53V^S9Y0G[,2EQ6"P]EX@0YY$0323V[A>_;?.T"Q<]XVH7Q#^6O(H>FUX!9E#$V_M<[I M-OR1)5A[5%B./(JC
/H.D_:@X=+^>; BT XS02*R09%>-Z[I8:/6?0W>J\ M?$ 9<+4VM=D=MNA?J\9R>KVM>42(*7*SJO4\;]C:&N<[A]Y6YX;9.R) X0[-
M7LM8/82!,X#OJ+2)HCN&]]M]GT;W6]!WW &-]NTJWV":QV]E>;2T=8WAV (E MU6F A>F0FHUQ[(8\-T>B*1 -J0/R 4ETS$B=4)8(9,FK&L>;3DB M>
<]#RJ412TM]:US+!@1.J)Q*Q0 6+,J(+F8BBP6AP-T*EG,>S'/W8EQ2_23O MJ>#-A^)#@&@\TGS>-*YE\],C\?F $,),6B]]N7LO*78?N$3!F$<1H3EVJ\9/
M!/0\'#PVC(:N9$U&\WP ;9=AY6-R-^Z3.RA6&AS3 4:D,CV;XI$?&0Y3Y,C]C&:A-,4F):#F!$<ESLVIFR@; M":7>K++=2GG&;&MRV7-#*85)"MQ&LQ
7=)A(;9E2TW7@^6NMX5KZ_H0)61;E M14Y()V>NM+%T4;/SD')D5:.V77=4M?(JLP;VVCW7W6@/>]7H/=0<5M0<[B7/ MGQ1X TI33-KB9!?
[]@+\Y'%S5*DW>ILS\N@-E/;<^FK#?;'#%TM;56,B\M_5D4;&_+KJ\<>7^2Q7\D"K? M WIU_"'E#]]D#UZ&J*;G4K7J.^2,SQ7#P[X'5 *-7
)Q_Y^%;>GN94V[B_2= MM:N]&.7,7F JDD8P^2U?U5M=DH[SJ\%Z>'[#2O7 C,HZB'!*4UUG0&=7F5]: MY@TM4GM1>"">T%K%]G2.CE&,&T/>I$+IL&
'5U?'9OU!+ P04 " #=A6=9 M3]V2]H4# "K"0 &0 'AL+W=O84QU&00Z*Z"D^D)6('!F+U5)#7;5 M(="5 IH[4,F#. S'04F9\)9S-[91R[FL#6<"-
HKHNBRI>KH"+H\++_*>!V[9 MH3!V(%C.*WJ +9B_JXW"7M"QY*P$H9D41,%^X:VBRXO4KG<+_F%PU"=M8C/9 M27EO.U_SA1=:0<
A,Y:!XNL!KH%S2X0R?K:<7A?2 D_;S^Q?7.Z8RXYJN);\ M!\M-L?"F'LEA3VMN;N7Q!MI\G,!,Y-BN#3V2U=K(L@6C@I*)YDT?V^_P M%D#<
F*GNPGD5/Y!#5W.E3P295[.Z79,/=W3'07^+XDC=G.Y1DPS$:YK NN=05S6#A MH0TTJ ?PEN_?1>/P\QF%HT[AZ!S[]7307Z5J6J(ILC\O2U(_&D]YP,O:G
M\<3B([+Y\D/W%D1(W!OSQ^/(8N)AS-2/1OU04>S/,,KZ,2NHP,T:A,9^.IH- MYAK%;:Z#N,2?I.&KN#MI*._-CF?^)!GWOU3DC\+9&4.DG2'2-
QNBD@:$8:@B M:W9)NUV"GS5[H!RG-%8SUAX\9KRV);57LG3EUI0B=0MT.&.B]PI2WC MF>)M;-88P%KHU$[_0T9$,Y&!P[2_UO&+L\U]
MC)-.TII+5E;\2Q5&H3^9I%UWYD?AC'R# \V>4*52U'Z-SAUI]-*>3O]3G!&: M*QZ?4,UFG96&:C(X.4!+4 =W3; _L%J8YBSM1KN;R*HY@%^6-
]>8[U0=&&;% M88_0\&*"U:.:JT'3,;)RQ_%.&CS<7;/ VQ0HNP#G]Q)KHNW8 -W];/D+4$L# M!!0 (-V%9UEK_B=HIP0 /\1 9 >&PO=V]R:W-H965TJPA
D^])S-6@%FF=GC<:*H@@ MH>I,I,!Q92ED0C4.Y:JA4@DTM)N2N.$Y3KN14,9KP[Z=NY'#OLATS#C<2**R M)*'R\1)BL1[4W-K3Q"U;1=I,-
(;]E*Y@!OHNO9$X:A1:0I8 5TQP(F$YJ(W< M\\N6D;<"7QFL5>F9F$@60MR;P20&K)?OJ:;#OA1K(HTT:C,/-E2[
M&YUCW!S*3$M<9;A/#Z\FT]%T/!E])I/I;'Y[=_UA.I^1T?0]F4T^3B=7D_%H M.B?C+],Q+MR.YI,OTQEY.Z>+&-2[?D.C"T91(]B8N\S-><^8\\FUX#I2Y ,/
M(=S=WT#7"_^])_\OO4J%,TC/B._4B>=XS0I]?I$/W^KS?V(^CJ4AM](\;L54 MVKE*:0"#&I:2 OD M>&;5V[;N:B(H5G$T*S2/IQAY899#$0LR9)QR@-
&8T*5 M JU(E1E$D)"-5E2)LD#C3,4Q0+!(@LR*1E?&: S=2RN:LOS",A2Q%CI1HDV M*"$V0(Z6&<\YQ!;C @F":!0?BR2E_/'-JZ[G=B[4WW*84!ZBF9
%5(.RZDL[M(@:2RB!Z)$&,NMG2B%EGE,D4(DE#L@!9P,FJ^R/CL)UYRSBJ%9G")?7NG!BW M'?_BE_F_,N%^M>%>YWE# M4FO%&>S6=CW=V-
L;^V1, M5633%I@'^)8QS+TY_7\^54@L\(C4*._Q5;;,\'R*I=>D5>_VFA5C"S_OXLC, MM55HD1S"0A-E(,=U13.:X3 MQ>_.9F?DHW@
R2U^\/6,-0GJ8$.K[G4Z)UNMEMXWJJ5%\#&SKE]OMP\Q^YS= M%\2W:>;"\(;![T*4 50T;<.*?'6RV^6V*OB8M^>LU.:68?IJ[3J?LMOP*X
MOSCQ[++I_YMSVBZ>9J]JXC_/.IY3[WF]HYJ.@?(%\9-9QZWW>J>S3K7T#["[". M5^]XIQ=_M?3IG(/5TO5_@-
FKQ6TU_KZ@P3UV5%M4'7K?]D^/M$+VD.,Z>!Q. M:>:@*I U.TVW-+'15=$9MXK.N'5R9QQ$E*_ M*7[C2(NFID@[TQ_4UB"$CG%
M7!])S.B"Q39G]=*>.HDW;,1XFNFCK7.U:\=:9TN,/%J,JXSN_GQ6SQ=6.47^JWXOFG$7P;8* *,;;$KO!']:5 DMD,C('BF\_P+U!+ P04 " #=A6=9\^L? MA$<"
#\! &0 'AL+W=OBQ(K;8J#*RL!.+>@ MDKJ^YSVX)2;,"0-[MA)AP(^*$@8K@>2Q++%X'0/E]#-3D4RARX85#A M Z2@MM5*:,MM67)2 I.$,R1@/W*B[G#
<-_[6X2>!6E[MD5&RX_S9&'$^CG!!"@U1#J-/V=.IPUI@-?["_O<:M=:=EC"A--?)%?%R/GJH!SV M^$C5FM??X:QG8/@R3J7]HKKQ?
=3.V5$J7I[!.H.2L&;%+^QY,HV:!H,EENDTV,T@?RL; 7DKY89T8$G- MU)]"/W!/UWFX5QU9@CC8N9,HXT>FFN9L3]O1CIJ.?G-OWH4%%@?")**PUU"O
M\ZCCBF;6&D/QRO;WCBL]+79;Z.<)A''0]WO.U<4P =H'+_P+4$L#!!0 (M -V%9UE,-1?WD04 "\C 9 >&PO=V]R:W-H965TF/ MKWR)P<:(T-$7P)?W.9;?
XR/[X*M70E]8C! 'W],D8]>#F//UY7#(HABED%V0 M-1BD:Z&;$T17)2B-!D:FN8,4XBSP>2J7#>CDRN2\P1G:$8!R],4 MTA^W*"&OUP-
]\+;B"U[%O%@QG%RMX0K-$7]:SZA8&C:4!4Y1QC#) $7+Z\&- M?AGJ;B$H]_@3HU>V\QL40WDFY*58N%]<#[3BB%""(EX@H/C:H#N4) 5)',>W
M&CIH8A;"W=]O]* C 5B@)0[%I@OS>"4PNG^L#J[I34>Y'!R1@E;*/TMU<(1 MG!6I..=4;,5"QR?3^S^>[KW[QI_!F8 ,_ 8DYS! M;,&NAEQ$+'3#J*;?5G3C
%T'#R3C,0-^MD"+'KTOUYO'].&1^(8$,!2GJCE? MQMOYNC6DQ-_RY *8^D=@:(;5S:J#*HWQ?4LD:&T0X:J P: M'A]IRS2K,/<6Z;;JC MCJW6OA.Z91N=E
M[:,[(UK1^O^S&+_NH7Q%D,.IG?,">P>#S5[9'<\[*'9KG7(0Z?QT)%Z>%?X M)R;PRDCT+<<;F*",]_HF19WJF[,W'E^'U#7+[99*E2'#8Z-L
MF>8VIKE2T^8QH?P31S055]T&,9X>I=A4LRIAHWVAF(X9L7RHC MAO(AMKP:-UZ-I5X]$@X3D).#4Y@4<:I/X_VZI+MF][Y194A_/^1X['9R M(U
9,3PVR)97NK9]1M7D$UA.J;B8CODEIYQJ6$W;G;/'CM:=NY3&]&M::RH9 MC[NE4&G,\-@XVY[M]!5TJ6[U?+\3X?08KK+YX2FE^4II@5):J(K6SHIM-
TB7MX.^?GZX 6=/\W,PG=Z! M?\$LA@P!$]R)'7$D;M$>*1:?7_X!ICT"9X@RLD \7YV+?;^2%((ICE F)#P715QHS4$H+5=':F;!MA^GR?
ICZHB,VS,4J2#'Y")[6 M8E+SJA3[O 2/,0)3R#B80?'@];[^F50O;NQQ5>ODCQ NL(9 PE:BE#:A2LJ+ZW>SJ@6
M.%F7+P<\$\Y)6OZ,$5P@6NP@MB\)X6\+18#F'9G)?U!+ P04 " #=A6=9 M>3$RX8," "-!@ &0
'AL+W=ORSF]XV%DZ1ZR6E)1PSY&HBP+SWT.@;#.P7&N[,".K7.H% M.XXJO((SY$-US]7,[E06I(!2$%8B#LN!=>U>C4*--X!' ANQ,T8ZR9RQ)SV9
M+@:6HPT!A4QJ!:P>:Q@!I5I(V?C5:EK=*S5Q=[Q5_VJRJRQS+&#Z^RD/G MNK30 I:XIG+&-
M^@S6,,9HP*\XLV+=:Q4%8+R8J6K!P4I&R>^+FMPP[!#=X@ M>"W!>R_!;PF^"=HX,['&6.(XXFR#N$8K-3TPM3%LE8:4^A03R=4N43P93^\> M)TEZ.
[E+$S2]0[?7LQ^3]'IX,T'CR3!%R63T,)NFTTF"SM&T7(.0Z@BE0*1$ MMY@_@<1S"BB!K.9$$A#H=*S6"!5GBO"0C-'IR1DZT? T9[7 Y4)$ME3&]>OM
MK#4Y;$QZ;YA,H+I OO,)>8X7'*"/CM._U^5;=%N5JZN9U]7,,WK^O];L4-)& M.C@LK>_LE:AP!@-+74H!? U6_/&#VW.^',K]G\1>5,'OJN ?4X^3G'%Y+H$7
MZG2[/\:AR(U.S^CHKK*./_RU[M9]E%A+^A?=J@7)H/.9'#4Y TK5^_R MV,B$NQ[#T'ME<1_D]?S#!L/.8'C48,HDIG\S%^Z5QG7Z?NB_LK&PO=V]R M:W-
H965T=2>(7!I,%9GAURFZ3 MR<2D^UG8%_#$MEA)0/KO>V4[K@%'&UJ^@&7KG'O/T?/V]HP_BS6)"]IDHF^ ML99R%
HQR4)J9C66TSI7%F#'KYNP<^ MZ+&M3.('C@1VS2E_/L($K;O&[;Q^N(Q7JVE>F$.>ANZ@@#DT^:!8\NL6*(X MA4S$+", MX@M9(O)?
LB_[6@8)MT*RM 1C!FF<%?_TI32B!D">9H!3 IQC0.L-@%L"W/<" M6B6@E3M32,E]F%!)!SW.]H2KWLBF'G(SD-D]N1L^_C.=#T=?IV0R'2,ME]RQ

M3*X%F6811(=X$R56.IU7G2-'2QC YH:XUA5Q+*?5D,_X_7"W 3[1P__>9F]%
M/U#C5J/FYGSN[XY:D_,%=:N96NTSMV)#0^@;N)$(X#LP!G_^8;>MOYILNR39 MY$)D!Y:V*DM;.O;!!!:2" BW'.*J\Z:<^EIW[V62G%G>N
MG1*.Y7BCE;Q5Y:MWB6XH/'J@CW/.=*KC76NWM.(3MMM M5NM7:GVMV@?.0H!(D"5G*9[GLEPWA"VQQ9_Q1,6E@Q>8@U759(=_FISK._Z1 M'_]D-
F^U_4.>TVT.?_BC.]6CG2UCLRJ45=7AYH'>OG=$_D=%PTXDM\]E>]U M_>Z1?&V"ORC?MGY>Q*S_,0!G/UJ M^D0XIW2WGAOLDX4>Y9UI%88(U!\U"
('A D) #7BY)PH3 5< AH>JN8G5FFS/-NJ"[$5GIJU>WT*?)771X*$;)O)XNI;O:UJL&%>>1R]']FW MXZ*2^DE3%'9WE*_B3)
$EDAIW71P8O&B5BH:DFWRZF'!)-8B^>,:ZTO@J@-^ M7S(F7QLJ0%6Q#GX 4$L#!!0 (-V%9UGF,%]F"P0 $,2 9 >&PO M=V]R:W-
H965T1WQ49H'0)&I[G_X"4G +9&>UOE$"/,__GY#G1\A@S_BSV !(M]#T*8S$T-E(FUZ8I_ U$5+18 K&ZLF(\HE(U^=H4"0>ZS(*BT"26Y9@1#6+#
M'63G'K@[8%L9!C$\<"2V443YCQ&$;#\TL/'SQ&.PWLCTA.D.$KH&#^0\>>"J M9199ED$$L0A8C#BLAL8-OAZ17AJ0W?$4P%X<':.T*PO&GM/&=#DTK-
01A.#+ M- 55?SL80QBFF92/;WE2H]!, X^/?V;_E'5>=69!!8Q9^&^PE)NAT3/0$E9T M&\I'MO\">8?L>)_/0I']HGU^KV4@?RLDB_)@Y2 *XL,__9X/Q%$
(0T!) \@ MF>^#4.;REDKJ#CC;(Y[>K;*E!UE7LVAE+HC3I^))KJX&*DZZT_NGB3>[F]S/ M/#2]1WCKQ-T.QG-D#
<9SQ^GL^G$0U=H3,4&T7AY.)A\VP8[&D(L M17;RCO)GD'01 O+ W_) !B#0%PB7Z/VMNA*$X@-ZAX(8S39L*U2(&)A2=2$U
M8OJYW='!+FFPZT'20FWK(R(6Z:"Y=XO>O_OP,HVI1J 8!E(, \GRML\=ACK+ MA]2=^M1I65V+A/HP-%3=". [,-P__\".]9?
&>+LPWM9E=V\BQF7P'ZB'PH2L M(=[+XM$9W+K:ZEM,9F+L:W4ZAV]'J?N9,"#2/%0G"3/ZS(D#M SWDL8_T
M29_4B]N%N/TV\:^J#;7J=D7]JETO[A3BCE;\$PTX>J+A%NKTG(J>&NVVW:#9 M+32[6LTQXPGC5 +R610!]P,:HH0FP.L\:'.=.!][A=/>Y0JI=P'C_<)X_\Q"
MZE<>;1MW>G;]D\56"6#K-U52GNB%@VZ#_!'_\1G3.0]^V6F;--0O+G&+M5!T M_UF$P9JF[V6!V K-
6UX+K=D.>*$^!*I]4#L!_45K<]\XBS!)6]Q^W(3'&MA M?JKWDME8#^W7YSBNTMFH?3"):_Q&X'=/,>KP"8-KRI<$AN?@VQ<9;9-NDV%
M52(;ZYF=S>F9ZK'8\A^(E1.^UL,EF(U+:.,+4AM? MNXY#8^%]RX2F[<=FQ< M_X1)26[RN\A-
JN3&#;.:E.0F>G*_815$JAB_:NK^T9)9SW!J5>7!OPQZT[*3 ME/PE^@5ON12*F83#I\>"-7Q,Z'.=.#5)R5O2N>!7A9;EIWHOD4WTR'Z]K$@5
MU;;C=!L61*2D-='3^@UE524WP0W@)B6XB1[<;ZFK;K6N&M9&I(0QT0+SM;KJ M5;[G;*?7MWY1-8^V!-+M%?
5UOE:CB$)8J3BKU56>^6"XM"0+,EV"19,2A9E MAQN@2^#I#>KZBJERRQOIQD.Q;^3^#U!+ P04 " #=A6=9D7="KK<" #^ M!P &0 'AL+W=OK8F>U
^^]G)VE*:4![Z O8R3W'YYSKV-&6 MBT>9 BCTE%$FAU:J5#ZP;;E,(T M,TR8%4?ELZF((UXH2AA,!9)%EF'Q? F4;X>6:[T\F)%UJLP#.XYRO(8YJ(=\
M*O3,;EA6) ,F"6=(0#*T1NY@W#/U9<%O ENY,T;&R8+S1S.Y70TMQP@""DME M&+#^V\ 8*#5$6L;?FM-JEC3 W?$+^TWI77M98
EC3O^0E4J'5M]"*TAP0=6, M;[]#[:=K^):M:QT++0BJ>U6"M(".L^L=/=0X[#_ +\& M^*712EEIZPHK'$>";Y$PU9K-
#,IL2K1V0YCIXEP)_99HG(KOIM>ST?WMKV]H M/8^ MCS:_%4E8DIAS91.[O:X;V9M='RU%_;[3%+W1%S3Z@J,=O#OFYP<;$GJJ4H#
]LD%ZCJG=4U3U7F+8IZKW;C9[3]_<4M11YWGY.]L[I M;&[&GUBL"9-Z1R8:YISWM"-1W3;51/&\/+ 77.GCOQRF^H(&80KT^X1S]3(Q
M=T!SYF"@ICXP]JQ MT%>RS6/;&.ROA61)D8P,DBC-[_2Y*,1> N)4)SA%@G.$J&M'40-=&9Z.:*%6O<2$Y/HTP3WIWL\E\<'_S_9I,)X/%9$$^
MD[L,.)51NB)3P *1R3-Z!N_G8Y TBL4GC'E8C,GYV2=R1J*4W(=L+6@:B)XI MD9("-OUB^V&^O?/*]BZY9:D,!9FD 02'^29**?4X.SU#YR3@
K)+XEH7Q+&< M1@6?T?^GNR?HN&5Y78WGOH(W!2$ +O)*7I Q")]'F3;PKRG&DAL)B?A=5;@< MN%$-K+[N*Y%1'_H&?KX"^ 8,
[^,'NV5][J5)=$]A!#1IE#1JGT+T7/\7:3Y#[MJ4IS#M320.H VGAVJ]TS-_M2*F+:;AESP+!9,FR>9#A'S93[(4$3XQFPP<,M MPZ-*5E$\B?
36UU(3V('H5BFZ)5[6;-59@YK #FK0+FO0KLN:.5!SWW9V]\B: M%3&N76W-3LFP5-)JN],MR@M,WAK>4KZ*4H&:E@AI7;;Q@^%YMY5/),MTP_+(
M)+8_>AABAPI#S)6-R-U$;E#VO]P]02P,$% @ W85G625>)%\W @ M_00 !D !X;"]W;W)K&ULE53O;]HP$/U7+$^: M-FG#
(4GIRD(D:+L.:3\0;.MGDQQ@U;$SVX'VO]_9@8A.%&WYD/CL>^_>.<_. M=MH\V V (X^55'9$-\[50\9LL8&*VYZN0>'*2IN*.PS-FMG: "\#J)(LCJ(! MJ[A0-
,_"W,SDF6Z<% IFAMBFJKAYFH#4NQ'MT\/$7*PWSD^P/*OY&A;@?M8S M@Q'K6$I1@;)"*V)@-:+C_G"2^OR0\$O SAZ-B>]DJ?6##Z;EB$9>$$@HG&?@
M^-G"-4CIB5#&[STG[4IZX/'XP/XI](Z]++F%:RWO1>DV(_J!DA)6O)%NKG>? M8=_/A>C HJH=HO?]SOPQ&@G[X B/> ..AN"P65 M-]SQ/#-
Z1XS/1C8_"*T&-(H3RO^4A3.X*A#G\N^SV_GXQ_3;'?ER.U[<+LA[M,BY+X?>,2S)5[6_W^_?F!AP7TK[-F,/"'LZ*?9%)6R1^H<@"ZAY)HG:O7_4'T<]:++
MZ.K9D['ML6AVY&9_,7SE9BV4Q8(K9(EZEQ>4F/:PM8'3=3#X4CL\+F&XP?L) MC$_]976[A#X,]/=>/D?4$L#!!0 (-V%9UF2(Y M_P(.4) 9
M>&PO=V]R:W-H965TB2%/,7Z^ LO7(ZEB;!U.R3*1^8(?#'"]A!O(IGW ULVN6 MB*20"<(RQ"$>69>=B_% QYN 'P368FN,M),Y8\]Z-+$<+
@H+J1FPNJU@ M#)1J(B7C5\5IU2DU<'N\8;\UWI67.18P9O0GB60RLOH6BB#&!953MOX"E1]? M\RT8%>:*UE6L8Z%%(21+*[!2D)*LO..7J@Y;@$[W
,"M .Z_ KP*X!FCI3)C MZQI+' XY6R.NHQ6;'IC:&+1R0S*]BC/)U5NB<#)\F-Q,+Q_OOG[&]S>7LYL9 M.D.WA2PXH(<<.)8D6Z)[4'5"$_RJ5D*='H-
$A,J/JC8I]DU.CWY@$X0R=!C MP@J!LT@,;:FDZ03VHI)Q5RV3=YF3Z/[T0.5[MR%(_H@"^ BM_ZX3.)^:*O&?R-
[4Q:OKXK6QAU/0C2$"CEB,8B(6F*)7P%S7 MW6]R7M(%ADXWE%7H!VJ!5MN&6E,>::A;&^JV&E*Z@R;=)XUZ?;W=?N[NEN9C]0=U+J#5MV/"':B])I;
F]0'>^I==_=K:>4_ M4GVO5M]K5\^D^N#?=H4F'[U]'Y[3WS'2FNI((_W:2+_5R#T(@4B:%[J=D4PM
M!PC9Y*2_Y^3,U7_Z&R>MN8YT,JB=#%J=3#1E)M$*TP)T5]KMS)3@.:%$$FA< MJL%>@W*=OK=CL"'(=?^L9RG&PO=V]R:W-H965T!'ZB8AZ3H,9?)T
MH8+X\;SC=)YWW/J+99;OZ([.5G*A)BJ[6]TD>JM;469^J*+4CR.2J/EY9^R< M"L_-"XHS_O+58[KUFN276ZO0Z;K-
(O#LECW(/2CS;/\6KX16P6:TUS@E@7NRX+^C@*O+/#V M+>B7!?U]"P9EP6#?@F%9,-SWHH_+@N/B9FW>W>+64)G)T5D2/Y(D/UO3\A?%
M_2VJ]1WQHUR*DRS11WU=EXVNWE^R#Q-&QN*6L6OVX=.$'%"523](#\EOY&Y" MR<&;0_*&^!&Y]H-
RR<]ZV:ZY;R^.RU;N=BTXNYHQ2'7<90M4*BF9HUU M[MO6>I[^HKKB[;?;[L"]<*'*^2(^+UWA*WY_8;^G-I+^?J_HBX)T6YUU!.[>5_
MRDBW[A3E;D,YLY=3-:W*>PWE_!O7OEX\ESO'3??"7CY1JUUOG7KOJ!7L'K M[^!]_G@])@=WDT-R=75)_B.?XU"2*W^JASM%QHM$*3WR9?K
W4H/79>ZW)_* M@,AH1F[58AW(+$Z>2V_^IM2_YN':KN14G7?TP)ZJ MY$%U1K_^X@Q[OS>)! FC2!A#PC@2)D
P0VK]2FK]@N[M&NQ>JJIQ*.LC)8*$ M422,(6$<"1,@F"&10261@74T*H<.(L-XK4>=>*Y-MQQ9B'K8)1DKLZUDD#"* MA#$DC"-A8@,;%K#\T_?#R-/.^-
@A&$EA"'&EL;S3"4_[$O6SK15$!)&D3"& MA'$D3(!@AM:.*ZT= WSI&"D1)(PB80P)XTB8 ,$,B9Q4$CGY";YD9;:5#!)& MD3"&A'$D3&Q@@RU?NAP:P?
ZE/CZ\?8?;W!"#E22 MQC.5K1>'.SVL23C6+K05#A)&D3"&A'$D3(!@AL*<7AT*]0"&5$) *H'2*)3& MH#0.I0D4S93*5G[HV(VILJ%I$*=^M"
K^;1K6+&S6BL&2:,E;?L[A%N-U*4, MD UR*$V@:*8,W%H&[G>XDO?:E-C M*(U!:1Q*$RB:*;LZ:79=@$^YT*082J-0&H/2.)0F4#13*G52[-JG%G_?I D[
MM+5TH,DQE,:@-%[2'&?+M?K#H\%+U_H9D;!;1*N/1+^MFMMTD'G=3K8[[G? M^PW+WJG6FH+&T% :@](XE"90-%-Z=0SM#A#.!8V&H30*I3$HC4-I
D4SI5)' MPZY]]G&KO,_:JT8:$(,I;&2MOT3G6/:"X'36[)PBS@B;'4!J%TAB4QJ$T@:*94JF38]<^ M([F=64$#Y))F_../:0@4VB"#TCB4)E
T\]]XZU38LZ?"^YI5T[R+/=WJ55[8 MI#![-]LJ#$JC4!J#TCB4)E T4XQU..TY /ORH(RE:A- :E<2A-H&BF5.I MV;-/76YE7W96:\5 :DF=
<;&0S(O]%\XIWRR,4V,VZ_1T?'@PY)-DO?;#:R M>%6LO'(?9UD<%B^72LY4DI^@C_C.'O>R!NH%B :_0]02P,$% @ W85G M6<*LY/"< P 8@\ !D
!X;"]W;W)K&ULK9?Q M;Z,V%,?_E2=VVNZD6X"$I&F71&I+;LNIE:JVUVF:]H.!EV =V,PV2?O?SP;* MA8:P1J(_)#;X^[7?
IWZ.WVS'Q7<9(RIX3A,FYU:L5'9AVS*,,25RP#-D^LV: MBY0HW14;6V8"252(TL0>.L[$3@EEUF)6/+L3BQG/54(9W@F0>9H2\7*%"=_- M+==Z?7!/-
[$R#^S%+",;?$#U+;L3NF?7+A%-D4G*&0A(U)8IST.OZM3*UZ3B/<;[^Z?RF" MU\$$1.(U3_ZDD8KGUM2""-@4I9>4W>:Y [E<[XA@6 F&
[Q6,*L'HO0*O$G@%F3*4@H-/%%G,!-^!,*.U MFVD4, NU#I\R\W]_4$*_I5JG%LO;JZ7O+WWPE_>KI\O'U=,2;E:75ZN;U>-? M\-%'16@B/\&O\.W!AX\?/L$'H
P>8YY+PB(YLY5>A?&RPVK&JW+&X9$9+S,Q M -?[#$-GZ+;(K[OE#Y@-8.04#@K]O] !8*4SE/VUL2C>OWQ1+%%:_'S3^[$^:V- M5)]F?
D]F#8JCFN*RWVQ3 .,(HQTQ@JZ)>8H@(22@"94O;1A[+0[%6-I-BG, MS#FY77C3T[M-I&3.9UF,:07MUT-[[@O9_!/V%,L)"2I*]/=6:8YW6IP+H
MT\SOR:R!=%PC'?>:C>,^*?9IYO=DUJ XJ2E..C?F+7FF:9Y"P(564K:!D.C) MCJ3BY" S1H[^:^;/=>>,I\+IR:P!YZR&<]8)YW?!I81,\! QDK 6/ 4J9:[3
M%H&O]0D6J#9,9P>8W/$AILZY3\74DUD#T[3&-.T^W)ZI@C5]) Q4C++#.F3GJ M,D'U\9;I\RT@B4'6AJIT=IT]5L[
\=Z@ZIS_5%0]F350G=>HSM^'BJ0\9ZV; MY_Q@\TP.MD[G)*?RZ,FLP<-U?MQ)G7ZO]U^IQ[DE=L^[O%;W/[_#&I&OG<;
M=SLCOT,1ZA\N77&9LT2W=,"_2) QT>N&&),(@A=] =^BK@Q$^^W;;4N?T?C- M=NE>R*G[I2^W$IN]5\^8ZO.6B UE$A)<:WMG<*9_'459T)4=Q;.BQ
FXT@53 MT8QU$8S"#-#OUYRKUXZIFNJR>O$?4$L#!!0 (-V%9UEX^"L@$PL 'Z1 M 9 >&PO=V]R:W-H965T/&38.BZ ,MCR0B%*DEJ2@!]L>7I&B-
1J+&9'RR^["6 M+,F@&CK@/&S8!QUP&39L"D_NON_ASUWS((MB_#Z,DNW)*L>76K5C3H0]>CR3Q@E57;OBJR\-RK'%==WXLU'*C[\&M"/=W\E
M])^?WOWK/^05N$L=RO+;7\]3P[\2UZ]%.VZLQC[Z3ZPOB6F.OSC;\(=U]F-W:\\YXG\I 9-LL*@J9D-O-?1S- MR(?
Y7&91LFAY=F^-6K76>)VOPYF\&I2KA5QF7^7@^B]_LD?6W]I"@L0")$;1 M&$-
B'(D)$*8ES]LGSZMU]TSR;N(PSTDZ)W=%.OM"_OMK>3]Y5\A5_K^VX'G(MX"&Q (E1),:0&$=B H1IP?/WP?.-B[R[>B5,WN7Y1CZ\+-?;T4R26YF1^HZV
M![F]OME#8@$2HTB,[;!1C55; U^OR[7=U\- (:<3($P+U&@?J)$Q4-4[O_GN MG=^V>>??EB(CTC=%2"Q 8A2),23&D9@ 85K@QOO
C9&KSC$R>$@L0&(4B3$D MQI&8 &%:\";[X$V,2[I_;%;WY8JR3-YN2[:Z-4M7JS0A>1W%61C'Y6+P_OM^
M24BB>CW;EDOC7'USB<0")$9WF'^P)G1LUZK^TU>(##DK1V("A&F9F^XS-S5F
M;K\S)=T4>1$F#^66Z4MR+Q=1DI0WR8MW29/&7]I"9L3[A@R)!=.37-B^Y5CN MV-9S09&S,B3&D9@ 85K(;$OMU+.Z;!7DFRR3U3Z1QW25CQRO-
\VM(L]<[M6T@M:#0M6R/;IXUG8[&QU%#SLN@&H=J J7I45.M@6VN#5IV>9#?R9V<;;*HB,IEG/PV M6X;)0I)PD4FYDDE1WO\^_!:M-
JO6_$&+!:@60#4*U1A4XU!-H#0]HZI?L*$% M@PUM&*!:.-4H5&-0C4,U@=+T!*JBP38W#?L5U):4>BL#*IQJ"90FG[K2HH'-!\9R] M>V:Z;]"@6N"
<=A2M08/.RJ :AVH"I>E!4RV%TZFEZ'%\G!GL'2]H30'5*%1C M4(U#-=%HDX-_EJ,+;]J^QG141^%TZBAV=2IYL2YC52^WVA=;T%("J@50C4(U
M!M4X5!.-=I@KZ\(Z\T[,486$8RXDJC-)SN[W,(_MG2-HN0#5*%1C4(U#-8'2 M]+RIV-SX] M+!,Z+8-
J'*H)E*:'374,CG$/[WA!6P:H1AOM,*S>>.R.)D9!1FT"8!J'*H)E*8G3=4%CKDN M^($]:]"&H-
'&!XEP+\;'!VLTDI5&-0C4,U@=+T"SFH@L#M5!!TV[5FMOH& MJ]$.@V5=6-;1@B: 3DJA&H-J'*H)E*8'2Q4"KKD0V.WK>%,&]J-YSF:M=[2@
M;0!4HU"-034.U01*TQ.H6@/70>YMP(/+))G[MA<]/[T(S"[U3YY[N0INV;-D%T&DI5&-0C4,U@=+T0*D"P37N'FX6:6\[KU2A M!0)4"Z
:A6H,JG&H)E":GD!5(+@^=*4*;0B@6@#5*%1C4(U#-8'2] 2J%L'M MV"(85JK0IL]W;=O6].6?6(!=%X*U1A4XU!-H#0]4:HJ<,U5 7T\[?3.=4?
N!/H>A1:&4"U *I1J,:@&H=J J7I"52] M@OM33T,PZ[T3"3T-P3T]#6%W[:SCP\.ATS*HQJ&:0&GZ57M5S>#]I LEF=V^ M,8-J@=?I0DG0.1E4XU!-
H#0]8ZIQ_ 72C){O;,%[1R\KA=*@D[+H!J':@*E MZ?%2=8+W\RZ49*9[)PW:+7BG%TIRW,G4GXZ.DP:M#: :AVH"I>E)4[6!9ZX- MM.W1IZZ0U!HW:*D
U0*H1J$:@VHN7+H==AE8SUQH.2->P8+V M"E"-034.U01*TX.E>@7/?%Y"KVT\]55S3/U?@\'[1R@&H5J#*IQJ"90FIV.
MU3EX4^A6!+1C@&H!5*-0C4$U#M4$2M,_Q4T5$7['"R{]Z^JJS21/7<'TQOQD M^D8.JE&HQJ :AVH"I>F14[V$;^XEJL]L/7MHB7ELWT4<5
N@&H5J#*IQJ"90 MFIXW553XT/,>?&@W =4"J$:A&H-J'*H)E*8G4!48?L?S'G[LT!*SWCN1T/K"
M/SW#PAW[+8>60*=E4(U#-8'2]+"I9L(W[G=^5B]KIGLG#5I3-%]'I$$;"*C& MH9I :7K2#CX"VMQ [-_(D=_)I^HHIFT6%85,R.WF/HYFY,-
\+K,R=:U)PWX< M-/;SH+$?"(W]1&AH*0'5!$K3XZA*"7\$?9\'/2D"J@50C4(U!M4X5!,H34^@ M:C%\-<'"M3STV.E.@S?W&'TO^*- M&>P='6A5 =4H5&.-
IE_;YV0W)H=.*E":GB[50?B=SGOH5KV:K=[!@C804(U" M-0;5N'JZ":J6 ER@)MT%;Y@OI2R"L BO+U7]\S0M'K^I)MBFV9?ZZ5W_'U!+ P04 " #=A6=9
M0'-B1><" "P!P &0 'AL+W=OJ=,XL3?4L M-(5&EGI0+L)V%/7#G'$9Q ._-M;Q0,VMX!+'&LP\SYG^Y2(=!Y!Q"@8EU#(P^"QRA$(Z(W/A=<0;UD0ZX/EZQ?
_#:2]D-]PE IP)TO-#2,R_KE%D6#[1:@G;6Q.8&/C8>36JX=%F<6$V[MG' VGIP?7Y^=?[X\/;N>O(&S+S<77W_;2C=A?&FB^811@+EB!ESL+N*5K&
MA=DCD\>[!W S.87=G3W8@1!,QC0:X!)N)+=FGQ9I?,6%H/2906C)>^=#F%2> MGI2>MI_PM 572MK,P)E,,=W$AZ2ZEMY>23]I;R7\-!>'T&GM>[$-
_HR>@TN" M1TWP#7MP&]0*#^/6K5C]ZWZ3T/Y%MZ.[6NKO;V../6I'N0JL$,34PU2H';LR< MR01=.!*5Y_3>C8*E2U(F,E@E^Y2>K6FWE9-
D^KNDPPD:3S!)B>WZLL%6P_ MS*BEHG8&M#]5RJXF[H"Z2<=_ 5!+ P04 " #=A6=99:&@SY\$ X%@ M&0 'AL+W=O,-(Z)2**6I.(LT(C &IL\F?
#QDB0QH!!..1!*&A'^_@(M1A:VE@\>Z/-!B39YB"?(PG7-W9A1>?AA)RB+$83:RSO'9I>MJ@[3%7Q06HG*--,H38R_Z MYM8?68Z."
+PI'9!U+]7N(0@T)Y4'-]RIU;1IS:L7B^]?TKA%KZ8?H+NO[C\?;/O]%'Y#IN!SU&/O %IU)"A.YG,^ T M>D9'5R)#

<2Q;O8XO4)"X[1!V0C,2<607663NELA^2Z(6 MW@)^&1 A$)NAJ63>"_KGBWJ/;B6$XM\Z[O8^N??D;(6[4W!WC!/^>Q(^ =?@
MR\P6(@&_CCESU$T=Z;KY.L;8[3KJ-[1?JSS&'AOR= N>KI%G6J% ,;<>U*%D M/GH5E,X:@[&7A@R]@J%G9)APY@'X
LTX"U,4$GF@Y\AC8:A6!:%SM(ZKM\G5 M70,S=MT0K%^]8U@GSE3'UF\@B=(D*+!MX3*[W50F4^,*U2]?LLYK?[6((UA M-(0<%)"#W4JH7D9*CR61%
(@$OGI]*GIU"L%.D*W$8J!>Q!)I22.Z\BSCK!3 M(7=:3F\-UAA.0]C3 O;4'"LOYVGUR%=-CPE9NPB>;LZATUI/36-7#4&P4TH$ M9Q_S!F]*6XK:J)W@-WJ]
[=!:0ZC*69%"6%SP5>BV2-B7GR&M22XYIMS6^N9 M9^ZJ*4JI57!SL8+^0Q,.Z%.BVOCH*^&?SARF;.Z^FK%N[OS="\5Y*NW*LI\]4[PA_IDIH!S!3
M[IU67P7$LV/*[$:R.#WI>V)2LC"]G -1E5@W4.]GC,GEC3X\+ Z+Q_\#4$L# M!!0 (-V%9UF5%QV>L0, .(. 9 >&PO=V]R:W-H965T%[?
32A+G#:3DY'(-69)0^?P1N-B.'=_9/WA@ZUB;!^YDE-$US$$_9C.)+;=66;($4L5$2B2LQLZU M?S7UN\:@Z/$7@ZTZN"
<&92'$DVE\6HX=SW@$'")M)"C^;6 *G!LE]..?2M2I MOVD,#^_WZG<%/,(LJ(*IX%_94L=C9^B0):QHSO6#V-Y#!=0S>I'@JO@EVZJO MYY
H5UHDE3%ZD+"T_*>[:B .#/S.&8.@,@A>&W3/&'0J@TX!6GI68-U032?_G]YO9A_BNY_>/QTY]_ MDPMRNXMBFJZ!7*\E (9-DW4$>YS?DW<_O
M1ZY&%\V'W*ARYV/I3G#&G<_TF?B=#R3P@FZ#]?1[UO*2>,,FL]608RPMAA MYC9!6>7:0I5BOG= Y5UZ ^_H\IL)NS5AUTIX1YDD&\IS,#$K&9O
K"IMP4JQ M_@%7;V")5]JFZ5E9IE3%)*//16YIL<^X.GBQX$N0C7A6XU;9XO1.\SEFV?LW6 MM[+5Z\Q,PL5=GBXQU[Y2*6FJ&X&L:FV!WDCL"'Q0@P_>-
@6M6J49;K,8T-51,FXMX;4JMH4&:>FXO^09GCVQ?1 MT!Y!OY3'-A>*E8 M?'O)\CKEZ(+#!R*V*>[M,HY
M2ZVS"]=5T1(3IFHBPY1&YD(F3%-3+ER5260S*TJXV_"\MINP.'6"KNV;R* K
MUIK'*4XDJ'62,/E[@%QL>T[=V75,X\52FPXWZ&9L@2'JNVPBJ>66+K,XP53% M(@6)\Y[3KU\,.V:^G?
UQJW:>P9##KEDD:X_[QS_V#9B>6>*1P*_BV>Z67/>>? #.=LS?54;"^QX&D9OTAP M97]A6\SU'(C62HND$%,$29SF_^RAV(<]0;UY0M H!(W'@M8)@5\
(? N:1V:Q M1DRSH"O%%J2936[FP>Z-51--G)I3#+6DT9AT.@@O^]/QY>WU:#P-7\'X\]W5 ME^_P%C[B?
(XR1@6WE']PP^2*,BIDG'KZ"XE(!ZGA]0@UB[DZ)T5?@U[B;N:M ME:<+&K@+1_#Z[!S.(":CF',Z/=5U-05O0G"C(M!A'FCC1* ^W(A4+Q6,TQG.
M#O4N09?DC1WYH%%I^$EL:E!OOH&&U_"/Q5,M#S&K@>]9>;,B'+\\"_Z^2?\ MAIPI!6(.H1;1"GYR NUER-ZO<@WXBUI1*S"35#+0 >L4Y,
492C#%BK+=H2RR<=V MR7=L4_*5VG8E4[XV0("=*J2-R=Q]^I\@G)AKS]%F40!YB6_ M["UOV+Z]6-R_T_/KF>KT(DX5<)R3U*MU: -=E?
N7E#2TN>VO<'TUWD'U-UPAHCO3Y N7!)C?THB$\LF2L@ -+>S0$C"S[QA#>C5!+!<0C_O'(EA^< T5E3NFKNGAR
M^H:E*B(^60@%@>5A0T;$]Q62K.-[FJD.57@X?D>_<^8O"0SQYR,J/_5L "#WJ,;@%3HR6:.HE[$T=+-EZH_L:98/*I M)^/$8/9I.'V\N1_.'A_ Z/G+Y'$\&
[X\/8_!

3WP<APWNFD&6J9.8B*>E^5Q(Z M51*);D'#^@,@"S5+PD?Z\,_K\%2X*9N3=@BE'4(Q7N-4.8K3S;V<*@X8T4#J MA^.X"T/&<+@B^;FD)
VY9F$FBFA9C5"6=IVMJ@DLUZI.VJI.G4M+IRBQ]M'T MUN8[DTTW9=.M=5WIOD]'F_!,.M#*7(3UGEY;)_6JCZTZ"^M"RS,]\$OPRH-
M"JBK736AY=N5F2>H-1Q5=9N@Y68Z:AQ-=7W*6^)PBITO8 M')CY'*@W.E*_W=/ZU<96GI UH>699C8)VM?6;TW&*6G7)6P8S'P8U!NQJOIM
M%>8ZLHZ-I3[EN90RTP6U1J6Z?ML_P^D2Y@AF[@CJ[9%\UX6G]5N3U4F87L(X MPZU]5N3E4K:=0ECAC)CAO3&K*)^$[3\NZG=.9[M^J3GDLH\&-
:ELH M3N#RK&0UQZPN8970P7>FJE9)]P:/BDZI^ JOSW@NH\PI(;U3>@J=]6*GR(]2 MG**41TW&)R%\"1N%,AN%FM?
^5EBK%ZL++=^NS(NAJM^L](M3\:L5*GQTE1BF{J<:C5,YL%N@=JJ^8+9R@LY\,E2PENW;5D,V^U^["X$ MC>(-A#B5@@;QJ4NP0Y@:()\O*17["
[4GD>Y!#?X'4$L#!!0 (-V%9UE4 MXL(I?0( )L% 9 >&PO=V]R:W-H965TG6#],^F.0@4?V2V8:4?S_;"1G;*!H? MB,^^>UZ*0C;
M@M#I;HB/&8P@6$01C"G%54[!$AU2)[AF0KI\+<""24 M<'@W0TU*JMZ;['.)(U\;W9;=SUJ-DT9C^(K&/MP+K@L%];_QVIL.# MZ4EX%C#%ZA+ZP0?
K:@"J(!+5&=A^=Y=]!]M_#=8"74R,T1RF@IF^4<1}>K&4 MA&_0?,L:5GLXSDO(WFW'-9$Y?+\SD'"KD:D?I^ZIX1^ZTJDN'8,PVJ M4.
[0B]Z^Z5T%G\^X&W3N!N?0&W<*6N H?-0Q#N7%C04$FMEPWO=/M=I,G;AKN=WHS MMNZ)W)1<
<6U*0TN/QI>V8R")M"B&ULM5AM4^HX%/KZ:ZSHS.*FY0W76 &T7NO.RLZH-?)$0Z0 ML6W8)(#^^TU?:$LIT>W@%]J&G.<\3]*<Y)
H7??"V376BBUO+)M M.5F 3V6-+R'0_\RX*G2CV)NRZ4 .HV,?,\FCM.T?)QAY%K\-7RF,! M/ HD5[Y/Q<'S3M;"U'1BQ^4*% W:OLZ1S&(-
Z7CX*_62G<%/F0R 9#Y" M6=?JXZL!]8<&T8S?##8R=X]"*:^ M_R:@5NHS-,S?;I%_1.*UF%7/?'MS=H\'#_ M>#L<]Y_N'H:H/[O!+_W1J#]\&J,+-
%9\\H8>EN':2_2P4E+18,J".3J] 469 M)_TK.?Q#3H].4,GR$9R005(Q +T'# ESW,#3PN^DMI<#YZ$S_?,\T+#;-?CFA@!QI"L(=]NHI9%J:1BU_!0T4!(ICL!?
>OP#H'3O&GM"2-TIR# Z MJBBCF8$?=8 M:+OZ46!1@= M5!6097QL3+'FB)O8[D@@M7J]*.$[LCC.TC@VYW%CW$UL"Q*:Q=QM=E%50I:] ML3E]?
S'X)B@8O29**:19-K!D[-+,LO-V)eR<:/FM(KTOB-)XRQ+ MX]; B\ C"+]:]NA?[46U$/_-FY='X2$DZ68OO2/DXR_G8G/0SZ9.< M= 7"1Z"\#,/DNA?
M&CH34(QSQ]FI%2.GV755:5D]0OX'991M\0DE>Q+;=6*A;&9256E625"S)7(#\I$ M;A.3WL_\<(&5X!7>SV(R-
'NMJBHK3HBY.$FS#4VR321(!P]JH[-4\;E19[TD MG=?W=N^H%8R=Z_'Y(.91ZU/]+++$*5-S>2D?3]FH_:BH6OJ_QU2!NDF8P<<_V
MG@I=_4ODP4Q#.K66KEI$W :-'Q1?1IW$5ZX4]Z/;!= IB'"'_G_&N=H^A [2 M9G3O/U!+ P04 " #=A6=9HEW?8/D" O!P &0 'AL+W=OM"(4M=DLC\.
AZOF \]Z*A6YNI:"BW\N,YSA3H MK1!,'<:8R?W(<WLQ"W.^6AN[X$?#@JUP@>9[,5,T\RN4E O,-9!?P@^->GXS!.GF2#I^0?_JO).7)Z;Q2F://#7KD3?
P(,4EVV9F+O?7>/1S8?$2F6GW"_MC;.!! MLM5&BF,R*1 \+__9\[$.)PGAQ1L)X3$A=+I+(J=RP@R+ADKN0=EH0K,#9]5E
MDSB>VTU9&$5?.>69:'$=SZ?GXW@QG<#5_>UL>K>('V[N[R"^F\!C/)_'=P\+ M.(=*9P]3B'>H:+<@UK2/A:VLAK,)&L8S_9$"'VC+SL=4IW3H&Q)H:?
SD*&9< MB@G?$-.!6YF;M89IGK[.]\E8Y2Y\<3<.&P$76+2@$WR", B[\!Y\T&NF4#= M=ZK"=1QTYRUH"U0:A2LIZ))HYLY9K!3+5T@'U\#3
4[C9NS@EN,]4RG_$:0 M<&-0Z%]UM2KYN_7\]K)>ZH(E./+H-FI4._2B#^_:O>!++@[MNY:I;A![=,K6A MCE HGB#()212"/)&QS'9 U6Y-%
R@S6*2^O!PI;=H5=U&WU.T._5Z/HHE)T MT:AH^ES01:8B[F1&A@-+A0@\ TC5 M-J#>L%V"??Z'/NCTZ_G[%7___[P3N8"S S*E/I:Q-
\/TP&5"&X2]9M"C#3PT MW85!I6_0"#SA.YYBGL*!8U9[[PE ME.9E8@FJ-S+Z U!+ P04 " #=A6=9PXA+L:,# ";#0 &0 'AL+W=O MC
=O*)*8XYR"V:4KX88P)VP\MUWH96,2;2.H!>S3(R :7*)^R.5<] MNT0)XQ2IB!D%CNNAY;NW$]?
3#L;BSQCWHM(&'_Q2@5KFF=JRV7]!'_,\&K8%9$X(0EG^-01D.K9T&(:[)-Y(+M M/V(14$?C!2P1YA?VA:UC0; 5DJ6%LV*0QC3_)\^%$!4'KWW&P2L
M=1OA_10EB1/Q01D_+:?P_MT'> (;06AH1C84A'6R]H!06ZXEV[#4"+C&[AI;S"WB.UZ[A,_G_[JT&.JU2_);! M:YW#TZ)>U8CJO MKU/$K?W*
!S:YTX%P(IDJI=2M5N0A\=R1,P(>NBS2&Z M!D+GK]W(;3O.P-Y5HZ@QZK7[I=$1NTI)KM//([HER#-B&QO^]'1)FMU9FMX(J M;Y,[U0Q1,^I;
!GRF(5U<3>OZ<(!"8<^I'D:<'L0DD-=(IDT GVC-#>E-#>- M-!<*D? @ I7E8(H]6W,S!V=G=_P1L2OO9@7 CL*OE<&W_O!.:QW2:DN!'8D
M5;^4JO_]..S_)A/J:FMB#K$?]E(C M%I(3760UG>-FT*_=G4NA'4M0J87<'WR6"P*7DNM":,=R>:]R>=|_G@N,ZH'N M]GHG!]K&R'69CR^14F M?I;
<$[Z)J8 $UPK2N;Y1EXSG+X&\(UEFBND5DZHT-\U(O9Z0:P,UOV9,OG3T M N5[;/0?4$L#!!0 (-V%9UG'5S!$?0($L& 9 >&PO=V]R:W-H M965TS,-J3]]
[MV0D0EJ/;0E\0?]QS?<^)[$U5"/JL,0).7(N=]X&1: ME]>NJU89%%1=B!(X[]R%+*C&J=RXJ11 4PLJCT,3;@%\,*G4P)D;)4HAG,YFD \$ T U// /P&X^O(&@
@15:9V9EC;FF<21% M1:2)1C8SL-Y8-*IAW'S%A9:XRQ"GX\5=,K_I#)/%S9B,'NYG-]-%\5@[,'36H-BM*7:U>N>]0(>4*HC)F
KU0F:",DG+U//7 M+78E-PHR^7<;SZY-GC;%0DMB#9Z]FF?/&)7WJ^P1!.'S.A](N7J]>DN I5!/ M"Q7[T//0]X.>AY^^^[P+QSCBOG LB37@G-1P3HQP;I
%91&07"3X?8#Y,>9I M2H4D.4+3Q [;4)6R)SNHNJ\8&0?>EY$EL0:CTYK1J9%1JU)SSC@OFPLB378^-[V7=+[F+17Z9KRGGGH?
3G94FN"VGGI]HV@IC0%'42* M1T]8/D6 Q4],<%FJ[1)M!>6_ =5[&U+FT?=F94FMR2K8L@K^QSY!;C'"F 0R M6@@
+$35JRVDE9YQI'V3FE6UT)9:D_*VQO ['[11^%;K#:MJH2VU)M1MR>$; MW\"'FQA5(#*=#5\ M**["."G!;5?CFLN(N20&S(D9<
M3E^*9=WFY*59&]:O;:DVLRIH:TAFURV!85OKBCTBL2WWYVM%;=4#" 5'DXV MRX2K2JW8-&M"WO'I:T(?44WXVW+"-]<3;R.'8(RS]I?*S6"Y7:;CAN
M@[&$X^X<^&4@%OK@5)*(KY@JS_IJN_7A[$@?2;K;[N7)[AT5BX1)DL(<3?&I M8IR+\K"T;"B>Z^/#1ZX4S_3E$B@69T4'_'_.N=HTB@'J(^OA=U!+ P04
M" #=A6=9^TS>XD\$ #F&0 &0 'AL+W=OSGE\GI-SPM/CP8ZR)[XF1(#G)$[YT%H+L;FU;1ZL28+Y
M#=V05#Y94I9@(2_9RN8;1G"8.R6QC1S'MQ,W([W==?V!O]YD>6WFPX_0KJP8%KZ+@F:1PI\KCL/8+ M$MZ;2!Q;:4CX%0E?2T+6/P3SCP^M/:UU/;?:#
($U6'8KEMVK:,^NR809 FLD MK%1]NP=U2Q4W]M&7;?0^#YL+^M^%7__0KW9%P.#%IN3#*!3_YH[K[4F
M.MF:>M!S2\T46I/IGFZ!5]&>91BFDF8(K9DT5"<-7:1%RV7VJ[<'.]V#$F^Q M@JB/3A5YK9N@5F48;-1RH==X'%OI>-1R!NKUC"S5-4YE_"
<;5NM_=NT90FNR MK94/I*ZC8;4*[.RD&4)K)JU66E OM8PUK']4PLCK] \+_3WT%JP%%]3*$Y-] MW7T3W?
=02["62U"OE]1_H:=;7^M[=A4;0FLRK845[%]'ZVL%WME),X36G%74 M4@[]I9RIUB^7V>\%M^LY![V@#^;_DJW5'-(*'X.M7R[T&MWWT&&HUF%(K\-D
MJ2>RRA>"!D^M)+3NYQ:R*;0FV5JNH>N8*B6O2A2\V[4,LHJXW(L5D;$7MO8IX0MLHW$C@(:)*8J!< MW:TV*\;YB/[@_@3>3HLMAQJFV
'YBMDJ2CF(R5)"..C==&1,K-A6*"T$W^5S^ MD0I!D_QT37!(F#*0SY>4BI<+M4"UM3/Z#U!+ P04 "_#=A6=9:61G)-@' M "_"@ &0
'AL+W=OYD*B.G=D&VG_VPDIT!2U5;XD?MQS?,[- M37(<'6\8?1 H@T6-.J!A:J93%A6V+.(47$ M]ARG9^K5*I%^QH4. 5
M+$#^+F9R:)S%Q'0TP$7\RV(J],=)6[AE[T).?R=!R MM"(@$$M-@=5M Q,@1#.I'?\J4JL^4P/WQSOV'\:\,G./!4P8^9LE,AU:?0LE ML,1K(N=L>P65H:
[FBQD1YHJV96S0L5"'\%I+E%5@IR#-:WO%CE8@]@.)I!G@5 MP#L&O':"7P%\8[149FQ=8HFC 6=;Q'6T8M,#DQN#5FXRJA_C0G*UFRFC+)4B<$?
%5[8@45HDGB2YKT/H26R \>]VG&OA9KK MM6FW);(#NT%M-_A8S04O:\X)@NY1S;V,"ETG;*ZY?BVI?U+2-:QP_{2VF'-, M9>-G\23!>]/?
$MF'U!#V&K90;6&=ELB.[#K.L_2^=C]5:A]DNIWW6/RJTI MJ-_*C=[!U>^U^9%D>@*F'VI+'^%]6K=1HU,W'T/M;ME>D1GFG*WNP&\U5&
M!2*P5)3.>: 4\;+=*2>2%:9CN&=2]1]FF*H6$;@.4/M+QN1NH@^HF\[H/U!+ M P04 " #=A6=9_AQEW"D& !7+P &0
'AL+W=O4WFX1%1,A3]MCE.T;).AL4A5WH>?UN1(*X,QEGGWUFDW&R
M%V$0T\\,\'T4$?;]/0V3Y\N.W_GQP5WPN!7I!]W)>$<>Z8**A]UG)L^Z!I@.RB"\!?>:E8Y!.99DD3^G);'W9\=*,:$A7(H4@
M\M^!3FD8ID@RCZ\Y:*>X9CJP?/P#_2:;O)S,DG Z3<)_@[787G:&;"F&[(/ MQ5WR_#?-)]1+\59)R+._X#F/]3I@M>\$*4!/JX9 /,! M\-0!*!^
LHD>,\NF=4T$F8Q9\@Q8&BW1TH.L-MEH.9L@3I=Q(9C\-I#GC.1F M-K^:3V=7'\%A6;]6W-%?S:[*'8?9C/;F;3J_D]F'Z:3^47=U?WLT_S
M!7@+;DC P!<2[BE(UP+L2!^!.\)#SAX?4T%"4+^1L8^+*[!ZU=OP"L0 MQ.!^F^PYB==\W!4R_32)[BI/]?TQ55B3ZH+N+@#R_@#0@]@P?&H?
L\^KAO> ME44K*@>+RL$,#SFLG&G2QZM@\U72N_@=WY$5O>S(VY13=]"=R>^^7WO3U,) M'(%!4%%09 -?7)+V)-<]65(Y7VT%("GG A$0(UK?
<3J9UCIL^8P\;T!ZJ%Q M]U">4#6LUQ]@OXC2,L5%IMB::<%64V+6H4W7PQ&8-LM>,*P3MN2R((S"M M(/VB('WKLM\$,8E7 0D!X9P*#B)*^)[1-2 ";-

(GVB%]HIE]< 3NE=G[(X@' M+]AJ"AN,1IZ9KH,B[\%I= 7_@=LDIM_E#T!ZJX'-ON9!:L5KNF2.P+2I#XNI M#UOA\-
!E01R!:049%0496;DP)7P+Y.\G6*4'].L^D)REL3#28%2A8V\XPB\X M6PWJ^Q"/S)3U/:4KO)-).TW8+F%$4+!*HHBR[!]1@988BOP?A"QX;PJ
W@G5$5JK&M\N: M,I$?+A87X$-RH"R6KS("R!<=^8-2D[85MO&*.4+3BZ $DX_:H;%3=>4*32^* MTE>^5:TTI7&O^C2&@Y<*PA#ECT:#&A(KY>/:I8^-
Q0E.J@N:2MPXQ5SA*:7 M00DI?] .C9T*+%=H>E&4Q/*M@J4IC8=5@J)^_Z6J.(3! :P1PKY2/!Y=_IA5 M19P(RC-5M$SJK
4K;N,5O!J=)RA:8712DM:!4M#6F<@VE/ MX_ZP]*:6SZD:AKPA@F8>PY)W9%= 91Y?I2^C;Y=D]23?1'^2M5NSZ!QN$53"
M"J)V6.Q4:+E"TXNBA!:T6U,-6>Q43N5HVC.[CVJHKE02M*ND,M4_T@,.-@6^< MBE.;R16:/FDF7K/] HW7[AQ^%%)R"[73\T-.I95NZ/J1'=+NY[3
M+>)3!SFWMA[7%C17:7M@A_/&K+#'/5#XOQ=1+9>!?PA>)!G8S!9K(1XJN=I.7<&UE!R+#0EH&8OSTF MR)@E,C+^.7)Z_9$6>#I^9+]UN9M<-
D1A(MB?M-35W+ORH,0M:9E>B<-'/.8S MM7R%8,K]PN$8._*@:)46]1%L%-24=__DV]&'$X#A&08$1T!P#I@\ PB/@-.E MVBES:=T03>*9% >0-
MJPV8'SQJ%--I3;*N9:FEUJ<#J^3;-%EJ2+3Y!F^7KU MPR&X@3S]DZ6V:++(U))^SQ&RL%NOT%.<%TI>,]++)_B?9-[;T#P:,_R>)PQ^82PM%!*-@.J
G^7EX^(*< ML*]'Z/C"Y^K1VW[>(5&MQ!+,I[_"HI62\ATLB:+J AZXV"B4 M>[)A""EO6FUC!"\,FMC;<@$)847+W 3^6@G&P-R" Y'EWT,UZ#1.AC7:QG*M
M&E+@W#.=PQZ,7OS[;^-HI,>0@?\3V1,[)IV=DY?8XR5AA!<(1+N/-)=#7S]Z>Y#,2,@$[FB<1I+W'ZHL23^[.UQ=_;X@_IZVBF M)V>/IV?
R!D(FP^JB7EWT*P8B+X>D13_.:1N(":(SK_1.R<)WS;'UIGI;N)?A.T[U+=T2:;T !PZVA'%V^,V[)KM=W$RT: MURXW0IOFZX:5>1Y1V@"SOQ5"/T[L ?
V#&_\'4$L#!!0 (-V%9UFPZAA, MUP, *$+ 9 >&PO=V]R:W-H965T7?=^R$+-RQW%V%^@7\ M,L_,..9R0QV0FY4 J#)2Y9R-702K?-;UU51
AE5#9$#QYN5D!G5N)5K5^42 M:&Q!6>JV/*_K9I1Q9S2P9P]R-!"%3AF'!TE4D654[N\@%;NATW0.!X]LG6AS MX(X&.5U#"/HI?Y"XC&+3,?
HBD2K[2W:5K.>0J%!:9!48/<@8+__I2Q6'"P&T M*D#K*T"S_0; KP"^)5IZ9FE-J*:C@10[(HTT:C,+&QN+1C:,FU<,M<1;AC@] MFL[FXWDP&_])9O-P\?
AT_VF^",EX/B'A[/-\-IT%X_F'!%_F 5X\CA>S+_.0 M?"0A6W.V8A'EF@2"1\"UI.9=%'D_ 4U9JCZ@V%,X(>_??2#O"-.DD8A"41ZK
M@:O10WR*=Y%Q3;MUH'W7NJ@PA+Q!?.^& MM+Q6^XP_P67X'P5_"W[BCE^_@F_U^5=\A7-1+*VTSULQ#>%6Y32"H8,5KT!N
MP1G]^DNSZ_UV+@174G82D'8=D/8E[.3G"*2J;@C.N"CS!FLV% M8OIL5ETTZ#&\"DSW+*]T0+$IWF
MOU@=>VIN%5.:Y))AFV3IW@I0E=S87P+/!=O2U%K!XD"K6U"ZM(I%@Y@-UM,R
M!22Z1!\@*B33#%@"^K5#],PL>S0OM6*R!C;:_#@_TR$H4U@FN28'?[^%S0 ME.D]69U09KHP1!ID;+D8'?BQL*1U(@%(5I8BF%(D6$@:LB7(NAPL
A=^1?#P M/B2A6R#P$@$8H-%',^.2L6(?$YT C)/8,B. [ZZ*Z B_W%O0%.$2?9U4Q&8U M-! R%^4S-,BYC/X/Z?#=C.[4&=VYF-
'W;S[DN<0M=76M+O,AWHZ:7L_O^ -W M>TSH6[%.M]=NUE(GGG9K3[L7/;VC?,/XVK[C:S6$& \6@<)XQ_A9DF\X?E'U MSW:@*RD[B4*OCD+O?
VG)O6L&Y$K*3@+2KP/2OV("I[_)S';3][RO\O>BQ9_E MXQY-01G(M1T.L1^:'E,.1/5I/7^.[=CEOHJ7PRMR79M>FL(*H5ZCAX4FRX&P
MW&B1VYEJ*31.:';9X P-T@C@_4H(?=@8__54/OH74$L#!!0 (-V%9UE* MV]&PO=V]R:W-H965TBU+"HQMI92KNYL6V1+6A)QRU:T4I_,
M&2^)5*M\88L5IV16A\K=ATGM$N25]9D5+_WR"GM8'KP]FF0CZP(HO^4PNQU9DH1F=DW4A/['M.]H<4*!Y&2M$_8]VNVV# MP$+96DA6-F&U!V5>
[?Z2U^9$' 6P?R'@-@'WVH#7!+QK WX3*\-!$T@>!OP M+@3")E#+M'6M'T0JVK3JL3G%?ZRH*KC[-54Y.ID_W MT^2?
I^3CORCYK%ZGZ)>82I(7XE=T@\22<"I&ME0CZ>WMK*'>[ZCN!>I'MKE% MSN WY#JN?R;^8([_GZ,L93<_P#^;;?=[>;
MMI6;5I#;"G)KG'\!E[QF2U(M*'KD]"9=5S,Z0U\(YZ229\48:;I.W8D5R>C8 M4H5(4+ZAUN3GGW#H_'Y.$R0LAH0ED+ 4"-;QZ[5^O9KN7;I8U\^"?
EW32J)D MHU__^TMM@=Y+6HK_SPGV(5#PF)(6 ()2X%@'<%^*]@W?H'W7U9$7RG/"-[<^P+O+;9& M4E]KD+ 8$I9 PE(@6,=MV+H-
88MM'"D8$A9#PA)(6 H$ZP@>M((' ,76R.AK M%1(60*2P4GEOO$' R^,_&[M3H%&[1B+6F.1T9BNM/-=I=WNY4F&5FNN?O<* MVMR'
(#9'&2M+=2^J;HFREW-6C>/TM0H)BR%A"20LC4XN$>P.7>P$07N)=*P. M6ZM#H]630OL=];V1,0[05RNDC8V,,X-^'VN9$UTWL+!6TK@=(2
M4%H*1>M:/[26L \\XX+VF4!I,2@M :6E4+2NYT-+"IM[4E?.N,%I'0W>[Q]2[%&POD&X3"MSM6SH@[?B2!$YN5*1L0![./OZ>%_KZ0^#N)Y].3EH/Y]>[
M\3,+G)/0*WIU@.A%JX4+ XB)QX>)[]/&I+O;TJOAIT:KX9YBY)Z'O&:BM.2@ MZ>R9#2+<;7DGLS$52PSK,AGVLT*NJR4B+F"4:B,=@A
M+C#LEU1KIN2-Z=C!-O@""NKV_;(T#J>*+MN=*[(FV)M),BY4RE23IDU6H6%? ML SL*#Z=P5T790B@UD5N&BFGTT)2ZV'%J!M&=L*$N(/'^U>VI;W(-
O;,[HAL MFL90W70RK@/ZFVI.>U/\V\E6ZOF-)]L1OXH6MZSA5Z5 MTR+#/7>.T/._7>M6Y_A^FUX^9$;7)QF:
(%2T=U5TW'MAF8ALE:7T#816[LY4.A^'8=YZ7J2'!FO)SH@AV%?.&/<$XDB08-K7HK]$X1E8GAH]_ M?!["G)(J2Q(\ YG<011@"3R..8-[
X9$D7T/[KR/PM5[*ES_]W+X#%!+ P04 M_" #=A6=9EXJ[', 3 @ "P %]R96QS+RYR96QSG9*Y;L,P#$!_ MQ=">, ?0(8@S9?$6!/D!5J(/V!
(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+ MJ1C[$%)I6M6X 4BV)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D M5XA-/E_G;@
M2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/ M['X 4$L#!!0 (-V%9UGQ)^6I^00 &HG / >&PO=V]R:V)O;VLN
M>&ULQ9I;DZ(X%(#_2LJ7[7UP52Y]JW&J4&(WNXHNH+/SM$5#;%.#P4IB]\S\ M^@W8UH1N/+4OT2<%
(GZ<0+Z3$SZ]EOS;4UE^0]^W!1/#SD;*W7VO)[(-V:;B MCW)'F#JR+ODVE6J3/_?$CI,T%QM"Y+;H6?W^=6^;4M;Y_.EXK@7OZ1NE))FD M)5,
[JQTK2E[%K^/5)GJA@C[1@LH?PT[]O2 =M*6,;NE/D@\[_0X2F_+UL>3T M9\ED6L09+XMBV!D<#JP(ES3[L#NN()/T2=1[9/H4I0IDV+GNJQ.N*1>R;E&?
M/U6,+T0U/FSM93FAA23<3R5YX.5^1]ES=1IU%3WM,NHX'#\/0;SG_R>,Y7I- M,^*7V7Y+F#S$D9.B
F1B0W>B@UBZ)0UN#G+)TGU.)+P390%S161!FD!D-8%(?^U M-$@;@+0Q"6EKD X Z5P2TM%@70#2O22DJT%> Y#79B%#+UE&&,TG:+[D9<$
M\S!&7NBC>#F;>9$&>0- WIB%G 9_+P,_2+YJ.+< SJU9G"!)0@#?(.@+PS"_G6G>$#FF(OQK$^3O>A@;IONB_'.(PQ\AXB
MC,L8ZF2@0@P[!,]&V/>QKWHQ"E8J=BN,IH$W"J;-.V\.*61@V"'QHQ?AQ_E4 M,<;_(:R>BR8;9(Z!8774;-V1NMM\-)[/%JJ?
ZP&E'D^^>#HFY(Z!87DHM%GP M]OA69.-Y6#TG.!P'S<<$%%R5?41)Y*I;C>G36"2%Q# R; M(PA5(#%*O'^:48,\,3 LBA G:#J/8Z0&/U3?
CCH9I(R!86=,@M!3-Y@W5<:(MDVCYZ_:+@XCF(UJ"@XA%?O!F<+TH9E6!N+] =Z$6A!>/US MEA'D4Y$5I=CS1GH/&<0R;)"
"9H3CA*>YFJZACS.4_9,JE\)G1&<@Q@6")CP M-28A%N02R[!+P!RKB0FYQ#+LDO=9%KI2,_B"B-]U0,@CEF&/M.4+K9"02BS#
M*@$3AV9G0W:QSFZ7UDA"FK$NJ9EF)"'-6(8U P]">I'!AJ1C&Y^KO,T[T95/ M9$J+1D?;D&ILTZH!Q\=&!'";V(9M V/JA1H;K'E=U#9ZJ<:&;&.?VS9=Y E!
MI$ IR]%X:JARHJF>K=F0=6S#UFF+9I[3]EU:(#TEMR'K MV(:MTX(YV4N5]1Z"JF-"YK$-F^=C7:=]T(2T8QO6#ECA05=Z;1O2CF-8.ZTY M6Q.9""
M',,*@C'U],B!%.085A",>:UC0A9R3-?80,P;??$2LI![#@N=Q+S5,2$+N>>P MT$G,.QT3LI!KV$*GZ_EUFJ1C0A9R#5NHI<3115\(?
=Y4Z]CZ$HX+6<@U;*%6 M3(])VLUL6]$$WP!P+'"%X&],;B$7LI!KV$(P9N-M"LA"KF$+P9BZA5S(0]YI M"[U?0FF=![F0@=S:0+WCNUTY65-
&\E"=7JC]65ID"SZJC\-RM.-6:T;K?5&, MU;XYFY9I?GQ5[/B:V^?_ %!+ P04 " #=A6=9678!^/4! X(P &@ M 'AL+U]R96QS+W=OZ)0A&51G ;-
JJRQY>V_^F2-??>4]VW9=<=QN^O'MV<=A?QR7S;:4_E]*XVJ;#^UXU?7Y>+JR[H9#6T[+89/Z=O7:;G+2^7R1AI\S MFON[GS-
GSY]|_I^)W7]H6^6';O5VR,?RR^#TW@VOXS;GTLR>VV&3R[))'_O+ MZ3&=#W)UFMS,'E^6S?#X(DV]':00I/6##(*L?I!#D-
BOJK01Z*^JM!'HKZJT$>BOJK01Z*^JM!'H;ZFT$>AOJ;01Z&^IM!'K;9+,$ M0&]#O8U ;T.]C4!O0[V-0&]#O8U ;T.]C4!O0[V-0&]'O9U ;T>]G4!O1[V=
M0&\'O9U ;Y]L=A/H[:BW$^CMJ+<3Z.VHMO/H[:BW$^CMJ+<3Z!VH=Q#H':AW M$.@=J'<0Z!VH=Q#H':AW$.@=DX^5!'H'ZAT$>@?
J'01Z!^H=!'H'ZAU_J?=8 M/O=YO/1\K_$[]U]274[WYLOCS\OODXCSXHQS@A]E[K\ 4$L#!!0 (-V% M9UD7R,P;VP$ -$B 3 6T-O;G1E;G1?5'EP97-
=+GAM;,W:74^#,!0& MX+^R<&M&UZ_Y$>>->]M>^ .+HS#9M4T7%ED5H[M@+!05M2;DUE&71I;6MR:F1[]BSA1KLR(F9K,Y*VP7 MJ8O3V-?
(KBYO:&DV39S<[M+K4-MND7EJ0C;YWD_LLQ:9<;ZI"Q/3.-MVY9>4 MZ5M"GE8. MW7W6_*^+FGR8'R\,VV:Q?8-"_&EH9"/
ME_BF1[MG"=3AHHHMDV^+WHRGAS3#M/^RH_.\J,!::9#]ZZ MD$[,T^%Q[T?2KYZZ5(A\K,<_\2,QE3[Z^Z@_[9+*7V:G[7VV?CV<1V##[?@]
M_GS&'_4/[$.]"%!^E @?6B0/N8@?9R"]$&TL&UL4$L! A0#% @ W85G639I MF('A!0 A\ !2@ ("!#@@ 'AL+W=O&]MM$" !R"0 & @(&J% >&PO=V]R:W-
H965T M&UL4$L! A0#% @ W85G698(D8:G! 5A$!@ M ("!L1< 'AL+W=O=SE@< " Y" 8 " @8X< !X;"]W;W)K M&PO=V]R:W-H965T&UL4$L! M A0#% @
W85G62]JMJ1X"0 >Q< !@ ("!#2P 'AL M+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ W85G63QV MC$T;! _@H !D ("!94$ 'AL+W=O&PO=V]R:W-
H965T_&UL4$L! A0#% @ W85G608\)$L+#0 KR@ !D M ("!!%$ 'AL+W=O&PO M=V]R:W-H965T&UL4$L! A0#% @ W85G66/*XZ4!!)@D !D ("! M>&L
'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% M @ W85G6>KWOFX4"@ YB$!D ("!BG@ 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @
W85G60!ZCZM M @ B@8 !D ("!=8@ 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ W85G6>S&PO=V]R:W-H965T&UL M4$L! A0#% @
W85G64_=DQ:% P JPD !D ("![:D M 'AL+W=O&PO=V]R:W-H965TR !X;"]W;W)K&UL4$L! A0#% @ MW85G64PU%_>1!0 +R, !D ("!!;4
'AL+W=O&PO=V]R:W-H965T] !X;"]W M;W)K&UL4$L! A0#% @ W85G6>8P7V8+! M0Q(!D ("!E<$ 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @
W85G625>)%\W @ _00 !D M ("!_\L 'AL+W=O&PO=V]R:W-H M965T&UL4$L! M A0#% @ W85G6<*LY/"< P 8@\ !D ("!L-@ 'AL M+W=O/@K(!,+ M
!^D0 &0 @(&#W >&PO=V]R:W-H965T&UL4$L! A0#% @ W85G M666AH,^?! .!8 !D ("!Z^H 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @
W85G659[:ST\! CQH M !D ("!W/8 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ W85G6:)=WV#Y @ +P< !D M ("!'@,! 'AL+W=O&PO=V]R:W-H965T
M&UL4$L! A0# M% @ W85G61=)Q41%! I1$!D ("!W P! 'AL+W=O M&PO=V]R:W-H965T$5 M 0!X;"]W;W)K&UL4$L! A0#% @ W85G66ED M9R38 @
@ H !D ("!9QH! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ W85G6;#J&$S7 P H0L !D M ("!$2&PO M=V]R:W-H965T7!E&UL4$L%!@ !# $, 3!(
"T] 0 $! end XML 70 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p ;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent) {a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 71 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-

align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 73 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3 html 151 244 1 false 58 0 false 5 false false R1.htm 995200090 - Document - Document And Entity Information Sheet http://www.rezolutebio.com/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 995200100 - Statement - Unaudited Condensed Consolidated Balance Sheets Sheet http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets Unaudited Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 995200105 - Statement - Unaudited Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedBalanceSheetsParenthetical Unaudited Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 995200200 - Statement - Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss Sheet http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss Statements 4 false false R5.htm 995200300 - Statement - Unaudited Condensed Consolidated Statements of Shareholders' Equity Sheet http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedStatementsOfShareholdersEquity Unaudited Condensed Consolidated Statements of Shareholders' Equity Statements 5 false false R6.htm 995200400 - Statement - Unaudited Condensed Consolidated Statements of Cash Flows Sheet http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows Unaudited Condensed Consolidated Statements of Cash Flows Statements 6 false false R7.htm 995210101 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://www.rezolutebio.com/role/DisclosureNatureOfOperationsAndSummaryOfSignificantAccountingPolicies NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 7 false false R8.htm 995210201 - Disclosure - LIQUIDITY Sheet http://www.rezolutebio.com/role/DisclosureLiquidity LIQUIDITY Notes 8 false false R9.htm 995210301 - Disclosure - INVESTMENTS IN MARKETABLE DEBT SECURITIES Sheet http://www.rezolutebio.com/role/DisclosureInvestmentsInMarketableDebtSecurities INVESTMENTS IN MARKETABLE DEBT SECURITIES Notes 9 false false R10.htm 995210401 - Disclosure - OPERATING LEASES Sheet http://www.rezolutebio.com/role/DisclosureOperatingLeases OPERATING LEASES Notes 10 false false R11.htm 995210501 - Disclosure - LICENSE AGREEMENTS Sheet http://www.rezolutebio.com/role/DisclosureLicenseAgreements LICENSE AGREEMENTS Notes 11 false false R12.htm 995210601 - Disclosure - EMBEDDED DERIVATIVE LIABILITY Sheet http://www.rezolutebio.com/role/DisclosureEmbeddedDerivativeLiability EMBEDDED DERIVATIVE LIABILITY Notes 12 false false R13.htm 995210701 - Disclosure - SHAREHOLDERS' EQUITY Sheet http://www.rezolutebio.com/role/DisclosureShareholdersEquity SHAREHOLDERS' EQUITY Notes 13 false false R14.htm 995210801 - Disclosure - SHARE-BASED COMPENSATION AND WARRANTS Sheet http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrants SHARE-BASED COMPENSATION AND WARRANTS Notes 14 false false R15.htm 995210901 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://www.rezolutebio.com/role/DisclosureCommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES Notes 15 false false R16.htm 995211001 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://www.rezolutebio.com/role/DisclosureRelatedPartyTransactions RELATED PARTY TRANSACTIONS Notes 16 false false R17.htm 995211101 - Disclosure - INCOME TAXES Sheet http://www.rezolutebio.com/role/DisclosureIncomeTaxes INCOME TAXES Notes 17 false false R18.htm 995211201 - Disclosure - NET LOSS PER SHARE Sheet http://www.rezolutebio.com/role/DisclosureNetLossPerShare NET LOSS PER SHARE Notes 18 false false R19.htm 995211301 - Disclosure - FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS Sheet http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrations FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS Notes 19 false false R20.htm 995211401 - Disclosure - SUBSEQUENT EVENTS Sheet http://www.rezolutebio.com/role/DisclosureSubsequentEvents SUBSEQUENT EVENTS Notes 20 false false R21.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 21 false false R22.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 22 false false R23.htm 99920102 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://www.rezolutebio.com/role/DisclosureNatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 23 false false R24.htm 99930303 - Disclosure - INVESTMENTS IN MARKETABLE DEBT SECURITIES (Tables) Sheet http://www.rezolutebio.com/role/DisclosureInvestmentsInMarketableDebtSecuritiesTables INVESTMENTS IN MARKETABLE DEBT SECURITIES (Tables) Tables http://www.rezolutebio.com/role/DisclosureInvestmentsInMarketableDebtSecurities 24 false false R25.htm 99930403 - Disclosure - OPERATING LEASES (Tables) Sheet http://www.rezolutebio.com/role/DisclosureOperatingLeasesTables OPERATING LEASES (Tables) Tables http://www.rezolutebio.com/role/DisclosureOperatingLeases 25 false false R26.htm 99930703 - Disclosure - SHAREHOLDERS' EQUITY (Tables) Sheet http://www.rezolutebio.com/role/DisclosureShareholdersEquityTables SHAREHOLDERS' EQUITY (Tables) Tables http://www.rezolutebio.com/role/DisclosureShareholdersEquity 26 false false R27.htm 99930803 - Disclosure - SHARE-BASED COMPENSATION AND WARRANTS (Tables) Sheet http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsTables SHARE-BASED COMPENSATION AND WARRANTS (Tables) Tables http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrants 27 false false R28.htm 99931203 - Disclosure - NET LOSS PER SHARE (Tables) Sheet http://www.rezolutebio.com/role/DisclosureNetLossPerShareTables NET LOSS PER SHARE (Tables) Tables http://www.rezolutebio.com/role/DisclosureNetLossPerShare 28 false false R29.htm 99931303 - Disclosure - FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS (Tables) Sheet http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsTables FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS (Tables) Tables http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrations 29 false false R30.htm 99940101 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) Sheet http://www.rezolutebio.com/role/DisclosureNatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetails NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) Details http://www.rezolutebio.com/role/DisclosureNatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies 30 false false R31.htm 99940201 - Disclosure - LIQUIDITY (Details) Sheet http://www.rezolutebio.com/role/DisclosureLiquidityDetails LIQUIDITY (Details) Details http://www.rezolutebio.com/role/DisclosureLiquidity 31 false false R32.htm 99940301 - Disclosure - INVESTMENTS IN MARKETABLE DEBT SECURITIES - Investments in Marketable Securities (Details) Sheet http://www.rezolutebio.com/role/DisclosureInvestmentsInMarketableDebtSecuritiesInvestmentsInMarketableSecuritiesDetails INVESTMENTS IN MARKETABLE DEBT SECURITIES - Investments in Marketable Securities (Details) Details 32 false false R33.htm 99940302 - Disclosure - INVESTMENTS IN MARKETABLE DEBT SECURITIES - Additional Information (Details) Sheet http://www.rezolutebio.com/role/DisclosureInvestmentsInMarketableDebtSecuritiesAdditionalInformationDetails INVESTMENTS IN MARKETABLE DEBT SECURITIES - Additional Information (Details) Details 33 false false R34.htm 99940303 - Disclosure - INVESTMENTS IN MARKETABLE DEBT SECURITIES - Cash and Cash Equivalents and Marketable Securities Held (Details) Sheet http://www.rezolutebio.com/role/DisclosureInvestmentsInMarketableDebtSecuritiesCashAndCashEquivalentsAndMarketableSecuritiesHeldDetails INVESTMENTS IN MARKETABLE DEBT SECURITIES - Cash and Cash Equivalents and Marketable Securities Held (Details) Details 34 false false R35.htm 99940401 - Disclosure - OPERATING LEASES - Assets and Operating Lease Liabilities (Details) Sheet http://www.rezolutebio.com/role/DisclosureOperatingLeasesAssetsAndOperatingLeaseLiabilitiesDetails OPERATING LEASES - Assets and Operating Lease Liabilities (Details) Details 35 false false R36.htm 99940402 - Disclosure - OPERATING LEASES - Operating Lease Expense (Details) Sheet http://www.rezolutebio.com/role/DisclosureOperatingLeasesOperatingLeaseExpenseDetails OPERATING LEASES - Operating Lease Expense (Details) Details 36 false false R37.htm 99940403 - Disclosure - OPERATING LEASES - Additional Information (Details) Sheet http://www.rezolutebio.com/role/DisclosureOperatingLeasesAdditionalInformationDetails OPERATING LEASES - Additional Information (Details) Details 37 false false R38.htm 99940404 - Disclosure - OPERATING LEASES - Future Operating Lease Payments (Details) Sheet http://www.rezolutebio.com/role/DisclosureOperatingLeasesFutureOperatingLeasePaymentsDetails OPERATING LEASES - Future Operating Lease Payments (Details) Details 38 false false R39.htm 99940501 - Disclosure - LICENSE AGREEMENTS (Details) Sheet http://www.rezolutebio.com/role/DisclosureLicenseAgreementsDetails LICENSE AGREEMENTS (Details) Details http://www.rezolutebio.com/role/DisclosureLicenseAgreements 39 false false R40.htm 99940601 - Disclosure - EMBEDDED DERIVATIVE LIABILITY (Details) Sheet http://www.rezolutebio.com/role/DisclosureEmbeddedDerivativeLiabilityDetails EMBEDDED DERIVATIVE LIABILITY (Details) Details http://www.rezolutebio.com/role/DisclosureEmbeddedDerivativeLiability 40 false false R41.htm 99940701 - Disclosure - SHAREHOLDERS' EQUITY - Pre-Funded Warrants (Details) Sheet http://www.rezolutebio.com/role/DisclosureShareholdersEquityPreFundedWarrantsDetails SHAREHOLDERS' EQUITY - Pre-Funded Warrants (Details) Details 41 false false R42.htm 99940702 - Disclosure - SHAREHOLDERS' EQUITY - 2024 Private Placement (Details) Sheet http://www.rezolutebio.com/role/DisclosureShareholdersEquity2024PrivatePlacementDetails SHAREHOLDERS' EQUITY - 2024 Private Placement (Details) Details 42 false false R43.htm 99940703 - Disclosure - SHAREHOLDERS' EQUITY - 2024 Underwritten Offering (Details) Sheet http://www.rezolutebio.com/role/DisclosureShareholdersEquity2024UnderwrittenOfferingDetails SHAREHOLDERS' EQUITY - 2024 Underwritten Offering (Details) Details 43 false false R44.htm 99940704 - Disclosure - SHAREHOLDERS' EQUITY - Exchange Agreement (Details) Sheet http://www.rezolutebio.com/role/DisclosureShareholdersEquityExchangeAgreementDetails SHAREHOLDERS' EQUITY - Exchange Agreement (Details) Details 44 false false R45.htm 99940705 - Disclosure - SHAREHOLDERS' EQUITY - Jefferies Open Market Sales Agreement (Details) Sheet http://www.rezolutebio.com/role/DisclosureShareholdersEquityJefferiesOpenMarketSalesAgreementDetails SHAREHOLDERS' EQUITY - Jefferies Open Market Sales Agreement (Details) Details 45 false false R46.htm 99940801 - Disclosure - SHARE-BASED COMPENSATION AND WARRANTS - Stock Option Plans (Details) Sheet http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionPlansDetails SHARE-BASED COMPENSATION AND WARRANTS - Stock Option Plans (Details) Details 46 false false R47.htm 99940802 - Disclosure - SHARE-BASED COMPENSATION AND

WARRANTS - 2022 Employee Stock Purchase Plan (Details) Sheet http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrants2022EmployeeStockPurchasePlanDetails SHARE-BASED COMPENSATION AND WARRANTS - 2022 Employee Stock Purchase Plan (Details) Details 47 false false R48.htm 99940803 - Disclosure - SHARE-BASED COMPENSATION AND WARRANTS - Stock Options Outstanding (Details) Sheet http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionsOutstandingDetails SHARE-BASED COMPENSATION AND WARRANTS - Stock Options Outstanding (Details) Details 48 false false R49.htm 99940804 - Disclosure - SHARE-BASED COMPENSATION AND WARRANTS - Weighted Average Assumptions (Details) Sheet http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsWeightedAverageAssumptionsDetails SHARE-BASED COMPENSATION AND WARRANTS - Weighted Average Assumptions (Details) Details 49 false false R50.htm 99940805 - Disclosure - SHARE-BASED COMPENSATION AND WARRANTS - Share Based Compensation Expense (Details) Sheet http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsShareBasedCompensationExpenseDetails SHARE-BASED COMPENSATION AND WARRANTS - Share Based Compensation Expense (Details) Details 50 false false R51.htm 99940806 - Disclosure - SHARE-BASED COMPENSATION AND WARRANTS - Pre-Funded Warrants (Details) Sheet http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsPreFundedWarrantsDetails SHARE-BASED COMPENSATION AND WARRANTS - Pre-Funded Warrants (Details) Details 51 false false R52.htm 99940807 - Disclosure - SHARE-BASED COMPENSATION AND WARRANTS - Summary of Legacy Warrants (Details) Sheet http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsSummaryOfLegacyWarrantsDetails SHARE-BASED COMPENSATION AND WARRANTS - Summary of Legacy Warrants (Details) Details 52 false false R53.htm 99941001 - Disclosure - RELATED PARTY TRANSACTIONS (Details) Sheet http://www.rezolutebio.com/role/DisclosureRelatedPartyTransactionsDetails RELATED PARTY TRANSACTIONS (Details) Details http://www.rezolutebio.com/role/DisclosureRelatedPartyTransactions 53 false false R54.htm 99941201 - Disclosure - NET LOSS PER SHARE - Weighted Average Number of Shares Outstanding (Details) Sheet http://www.rezolutebio.com/role/DisclosureNetLossPerShareWeightedAverageNumberOfSharesOutstandingDetails NET LOSS PER SHARE - Weighted Average Number of Shares Outstanding (Details) Details 54 false false R55.htm 99941202 - Disclosure - NET LOSS PER SHARE - Anti-dilutive (Details) Sheet http://www.rezolutebio.com/role/DisclosureNetLossPerShareAntiDilutiveDetails NET LOSS PER SHARE - Anti-dilutive (Details) Details 55 false false R56.htm 99941301 - Disclosure - FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS - Fair Value on a Recurring Basis (Details) Sheet http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsFairValueOnRecurringBasisDetails FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS - Fair Value on a Recurring Basis (Details) Details 56 false false R57.htm 99941302 - Disclosure - FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS - Summary of Changes in the Fair Value (Details) Sheet http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsSummaryOfChangesInFairValueDetails FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS - Summary of Changes in the Fair Value (Details) Details 57 false false R58.htm 99941303 - Disclosure - FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS - Significant Concentrations (Details) Sheet http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsSignificantConcentrationsDetails FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS - Significant Concentrations (Details) Details 58 false false R59.htm 99941401 - Disclosure - SUBSEQUENT EVENTS (Details) Sheet http://www.rezolutebio.com/role/DisclosureSubsequentEventsDetails SUBSEQUENT EVENTS (Details) Details http://www.rezolutebio.com/role/DisclosureSubsequentEvents 59 false false All Reports Book All Reports rzlt-20240930.xsd rzlt-20240930_cal.xml rzlt-20240930_def.xml rzlt-20240930_lab.xml rzlt-20240930_pre.xml rzlt-20240930x10q.htm http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 http://xbrl.sec.gov/ecd/2024 true true JSON 76 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "rzlt-20240930x10q.htm": { "nsprefix": "rzlt", "nsuri": "http://www.rezolutebio.com/20240930", "dts": { "schema": { "local": ["rzlt-20240930.xsd"], "remote": ["http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/2023/calculation-1.1.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"] }, "calculationLink": { "local": ["rzlt-20240930_cal.xml"] }, "definitionLink": { "local": ["rzlt-20240930_def.xml"] }, "labelLink": { "local": ["rzlt-20240930_lab.xml"] }, "presentationLink": { "local": ["rzlt-20240930_pre.xml"] }, "inline": { "local": ["rzlt-20240930x10q.htm"] } }, "keyStandard": 201, "keyCustom": 43, "axisStandard": 21, "axisCustom": 1, "memberStandard": 24, "memberCustom": 32, "hidden": { "total": 9, "http://fasb.org/us-gaap/2024": 4, "http://xbrl.sec.gov/dei/2024": 5 }, "contextCount": 151, "entityCount": 1, "segmentCount": 58, "elementCount": 517, "unitCount": 5, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 442, "http://xbrl.sec.gov/dei/2024": 29, "http://xbrl.sec.gov/ecd/2024": 4 }, "report": { "R1": { "role": "http://www.rezolutebio.com/role/DocumentDocumentAndEntityInformation", "longName": "995200090 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_HjkltemRHkyQOxOvfPP7xw", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_HjkltemRHkyQOxOvfPP7xw", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets", "longName": "995200100 - Statement - Unaudited Condensed Consolidated Balance Sheets", "shortName": "Unaudited Condensed Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "As_Of_9_30_2024_vyT1CCJAUkqoANp6FVvKtw", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "Unit_Standard_USD_YiPJqncFB0CvtWuzjbs6-w", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_vyT1CCJAUkqoANp6FVvKtw", "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent", "unitRef": "Unit_Standard_USD_YiPJqncFB0CvtWuzjbs6-w", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "unique": true } }, "R3": { "role": "http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedBalanceSheetsParenthetical", "longName": "995200105 - Statement - Unaudited Condensed Consolidated Balance Sheets (Parenthetical)", "shortName": "Unaudited Condensed Consolidated Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "As_Of_9_30_2024_vyT1CCJAUkqoANp6FVvKtw", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "Unit_Divide_USD_shares_PWSs94aLm0a0XGM_nLuFGA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_vyT1CCJAUkqoANp6FVvKtw", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "Unit_Divide_USD_shares_PWSs94aLm0a0XGM_nLuFGA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss", "longName": "995200200 - Statement - Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss", "shortName": "Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_HjkltemRHkyQOxOvfPP7xw", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "Unit_Standard_USD_YiPJqncFB0CvtWuzjbs6-w", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_HjkltemRHkyQOxOvfPP7xw", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "Unit_Standard_USD_YiPJqncFB0CvtWuzjbs6-w", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "first": true, "unique": true } }, "R5": { "role": "http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedStatementsOfShareholdersEquity", "longName": "995200300 - Statement - Unaudited Condensed Consolidated Statements of Shareholders' Equity", "shortName": "Unaudited Condensed Consolidated Statements of Shareholders' Equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_TIoIsVHEP0qa3-wbrJn1MA", "name": "us-gaap:StockholdersEquity", "unitRef": "Unit_Standard_USD_YiPJqncFB0CvtWuzjbs6-w", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_aV0ThbTgn0ylRpYFtJexzA", "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "unitRef": "Unit_Standard_USD_YiPJqncFB0CvtWuzjbs6-w", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "unique": true } }, "R6": { "role":

{"http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows", "longName": "995200400 - Statement - Unaudited Condensed Consolidated Statements of Cash Flows", "shortName": "Unaudited Condensed Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_HjkltemRHkyQOxOvfPP7xw", "name": "us-gaap:ProfitLoss", "unitRef": "Unit_Standard_USD_YiPJqncFB0CvtWuzjbs6-w", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_HjkltemRHkyQOxOvfPP7xw", "name": "us-gaap:ProfitLoss", "unitRef": "Unit_Standard_USD_YiPJqncFB0CvtWuzjbs6-w", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "first": true, "unique": true } }, "R7": { "role": "http://www.rezolutebio.com/role/DisclosureNatureOfOperationsAndSummaryOfSignificantAccountingPolicies", "longName": "995210101 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "shortName": "NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_HjkltemRHkyQOxOvfPP7xw", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_HjkltemRHkyQOxOvfPP7xw", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.rezolutebio.com/role/DisclosureLiquidity", "longName": "995210201 - Disclosure - LIQUIDITY", "shortName": "LIQUIDITY", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_HjkltemRHkyQOxOvfPP7xw", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_HjkltemRHkyQOxOvfPP7xw", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.rezolutebio.com/role/DisclosureInvestmentsInMarketableDebtSecurities", "longName": "995210301 - Disclosure - INVESTMENTS IN MARKETABLE DEBT SECURITIES", "shortName": "INVESTMENTS IN MARKETABLE DEBT SECURITIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_HjkltemRHkyQOxOvfPP7xw", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_HjkltemRHkyQOxOvfPP7xw", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.rezolutebio.com/role/DisclosureOperatingLeases", "longName": "995210401 - Disclosure - OPERATING LEASES", "shortName": "OPERATING LEASES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_HjkltemRHkyQOxOvfPP7xw", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_HjkltemRHkyQOxOvfPP7xw", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.rezolutebio.com/role/DisclosureLicenseAgreements", "longName": "995210501 - Disclosure - LICENSE AGREEMENTS", "shortName": "LICENSE AGREEMENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_HjkltemRHkyQOxOvfPP7xw", "name": "rzlt:LicenseAgreementsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_HjkltemRHkyQOxOvfPP7xw", "name": "rzlt:LicenseAgreementsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.rezolutebio.com/role/DisclosureEmbeddedDerivativeLiability", "longName": "995210601 - Disclosure - EMBEDDED DERIVATIVE LIABILITY", "shortName": "EMBEDDED DERIVATIVE LIABILITY", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_HjkltemRHkyQOxOvfPP7xw", "name": "us-gaap:DiscussionOfHybridInstrumentsAndEmbeddedDerivativesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_HjkltemRHkyQOxOvfPP7xw", "name": "us-gaap:DiscussionOfHybridInstrumentsAndEmbeddedDerivativesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.rezolutebio.com/role/DisclosureShareholdersEquity", "longName": "995210701 - Disclosure - SHAREHOLDERS' EQUITY", "shortName": "SHAREHOLDERS' EQUITY", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_HjkltemRHkyQOxOvfPP7xw", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_HjkltemRHkyQOxOvfPP7xw", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrants", "longName": "995210801 - Disclosure - SHARE-BASED COMPENSATION AND WARRANTS", "shortName": "SHARE-BASED COMPENSATION AND WARRANTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_HjkltemRHkyQOxOvfPP7xw", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_HjkltemRHkyQOxOvfPP7xw", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.rezolutebio.com/role/DisclosureCommitmentsAndContingencies", "longName": "995210901 - Disclosure - COMMITMENTS AND CONTINGENCIES", "shortName": "COMMITMENTS AND CONTINGENCIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_HjkltemRHkyQOxOvfPP7xw", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_HjkltemRHkyQOxOvfPP7xw", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.rezolutebio.com/role/DisclosureRelatedPartyTransactions", "longName": "995211001 - Disclosure - RELATED PARTY TRANSACTIONS", "shortName": "RELATED PARTY TRANSACTIONS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_HjkltemRHkyQOxOvfPP7xw", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_HjkltemRHkyQOxOvfPP7xw", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.rezolutebio.com/role/DisclosureIncomeTaxes", "longName": "995211101 - Disclosure - INCOME TAXES", "shortName": "INCOME TAXES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_HjkltemRHkyQOxOvfPP7xw", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_HjkltemRHkyQOxOvfPP7xw", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.rezolutebio.com/role/DisclosureNetLossPerShare", "longName": "995211201 - Disclosure - NET LOSS PER SHARE", "shortName": "NET LOSS PER SHARE", "isDefault": "false", "groupType": "disclosure", "subGroupType": "",

"menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_HjkltemRHkyQOxOvfPP7xw", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_HjkltemRHkyQOxOvfPP7xw", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrations", "longName": "995211301 - Disclosure - FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS", "shortName": "FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_HjkltemRHkyQOxOvfPP7xw", "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_HjkltemRHkyQOxOvfPP7xw", "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.rezolutebio.com/role/DisclosureSubsequentEvents", "longName": "995211401 - Disclosure - SUBSEQUENT EVENTS", "shortName": "SUBSEQUENT EVENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_HjkltemRHkyQOxOvfPP7xw", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_HjkltemRHkyQOxOvfPP7xw", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "first": true, "unique": true } }, "R21": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_HjkltemRHkyQOxOvfPP7xw", "name": "us-gaap:NetIncomeLoss", "unitRef": "Unit_Standard_USD_YiPJqncFB0CvtWuzjbs6-w", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "first": true }, "uniqueAnchor": null }, "R22": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_HjkltemRHkyQOxOvfPP7xw", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_HjkltemRHkyQOxOvfPP7xw", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.rezolutebio.com/role/DisclosureNatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies", "longName": "99920102 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "shortName": "NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "23", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_HjkltemRHkyQOxOvfPP7xw", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_HjkltemRHkyQOxOvfPP7xw", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.rezolutebio.com/role/DisclosureInvestmentsInMarketableDebtSecuritiesTables", "longName": "99930303 - Disclosure - INVESTMENTS IN MARKETABLE DEBT SECURITIES (Tables)", "shortName": "INVESTMENTS IN MARKETABLE DEBT SECURITIES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_HjkltemRHkyQOxOvfPP7xw", "name": "us-gaap:MarketableSecuritiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_HjkltemRHkyQOxOvfPP7xw", "name": "us-gaap:MarketableSecuritiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.rezolutebio.com/role/DisclosureOperatingLeasesTables", "longName": "99930403 - Disclosure - OPERATING LEASES (Tables)", "shortName": "OPERATING LEASES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_HjkltemRHkyQOxOvfPP7xw", "name": "rzlt:LesseeOperatingLeaseRightOfUseAssetsAndOperatingLeaseLiabilities", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_HjkltemRHkyQOxOvfPP7xw", "name": "rzlt:LesseeOperatingLeaseRightOfUseAssetsAndOperatingLeaseLiabilities", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.rezolutebio.com/role/DisclosureShareholdersEquityTables", "longName": "99930703 - Disclosure - SHAREHOLDERS' EQUITY (Tables)", "shortName": "SHAREHOLDERS' EQUITY (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_rzlt_PreFundedWarrantsMember_k0BZrjfuc0SJJrpIU0i73g", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_rzlt_PreFundedWarrantsMember_k0BZrjfuc0SJJrpIU0i73g", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsTables", "longName": "99930803 - Disclosure - SHARE-BASED COMPENSATION AND WARRANTS (Tables)", "shortName": "SHARE-BASED COMPENSATION AND WARRANTS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_HjkltemRHkyQOxOvfPP7xw", "name": "rzlt:ShareBasedPaymentArrangementOptionSharesAuthorizedOutstandingAndAvailableForFutureGrants", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_HjkltemRHkyQOxOvfPP7xw", "name": "rzlt:ShareBasedPaymentArrangementOptionSharesAuthorizedOutstandingAndAvailableForFutureGrants", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.rezolutebio.com/role/DisclosureNetLossPerShareTables", "longName": "99931203 - Disclosure - NET LOSS PER SHARE (Tables)", "shortName": "NET LOSS PER SHARE (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_HjkltemRHkyQOxOvfPP7xw", "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "us-gaap:EarningsPerShareTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_HjkltemRHkyQOxOvfPP7xw", "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "us-gaap:EarningsPerShareTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsTables", "longName": "99931303 - Disclosure - FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS (Tables)", "shortName": "FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_HjkltemRHkyQOxOvfPP7xw", "name": "us-

gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_HjkltemRHkyQOxOvfPP7xw", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.rezolutebio.com/role/DisclosureNatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetails", "longName": "99940101 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)", "shortName": "NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_HjkltemRHkyQOxOvfPP7xw", "name": "rzlt:NumberOfWhollyOwnedSubsidiaries", "unitRef": "Unit_Standard_subsidiary_8BUUUBsBvUyiChulRRb63A", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:ConsolidationPolicyTextBlock", "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_HjkltemRHkyQOxOvfPP7xw", "name": "rzlt:NumberOfWhollyOwnedSubsidiaries", "unitRef": "Unit_Standard_subsidiary_8BUUUBsBvUyiChulRRb63A", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:ConsolidationPolicyTextBlock", "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.rezolutebio.com/role/DisclosureLiquidityDetails", "longName": "99940201 - Disclosure - LIQUIDITY (Details)", "shortName": "LIQUIDITY (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "As_Of_6_30_2024_rjIkKWLsbUGI-1Y_doTOtA", "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "unitRef": "Unit_Standard_USD_YiPJqncFB0CvtWuzjbs6-w", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "first": true }, "uniqueAnchor": null }, "R32": { "role": "http://www.rezolutebio.com/role/DisclosureInvestmentsInMarketableDebtSecuritiesInvestmentsInMarketableSecuritiesDetails", "longName": "99940301 - Disclosure - INVESTMENTS IN MARKETABLE DEBT SECURITIES - Investments in Marketable Securities (Details)", "shortName": "INVESTMENTS IN MARKETABLE DEBT SECURITIES - Investments in Marketable Securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "As_Of_9_30_2024_vyT1CCJAUkqoANp6FVvKtw", "name": "us-gaap:MarketableSecuritiesCurrent", "unitRef": "Unit_Standard_USD_YiPJqncFB0CvtWuzjbs6-w", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "first": true }, "uniqueAnchor": null }, "R33": { "role": "http://www.rezolutebio.com/role/DisclosureInvestmentsInMarketableDebtSecuritiesAdditionalInformationDetails", "longName": "99940302 - Disclosure - INVESTMENTS IN MARKETABLE DEBT SECURITIES - Additional Information (Details)", "shortName": "INVESTMENTS IN MARKETABLE DEBT SECURITIES - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "As_Of_9_30_2024_vyT1CCJAUkqoANp6FVvKtw", "name": "us-gaap:DebtSecuritiesAvailableForSaleTerm", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_vyT1CCJAUkqoANp6FVvKtw", "name": "us-gaap:DebtSecuritiesAvailableForSaleTerm", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.rezolutebio.com/role/DisclosureInvestmentsInMarketableDebtSecuritiesCashAndCashEquivalentsAndMarketableSecuritiesHeldDetails", "longName": "99940303 - Disclosure - INVESTMENTS IN MARKETABLE DEBT SECURITIES - Cash and Cash Equivalents and Marketable Securities Held (Details)", "shortName": "INVESTMENTS IN MARKETABLE DEBT SECURITIES - Cash and Cash Equivalents and Marketable Securities Held (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "As_Of_9_30_2024_vyT1CCJAUkqoANp6FVvKtw", "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss", "unitRef": "Unit_Standard_USD_YiPJqncFB0CvtWuzjbs6-w", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "ix:continuation", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_vyT1CCJAUkqoANp6FVvKtw", "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss", "unitRef": "Unit_Standard_USD_YiPJqncFB0CvtWuzjbs6-w", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "ix:continuation", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.rezolutebio.com/role/DisclosureOperatingLeasesAssetsAndOperatingLeaseLiabilitiesDetails", "longName": "99940401 - Disclosure - OPERATING LEASES - Assets and Operating Lease Liabilities (Details)", "shortName": "OPERATING LEASES - Assets and Operating Lease Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "As_Of_9_30_2024_vyT1CCJAUkqoANp6FVvKtw", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "Unit_Standard_USD_YiPJqncFB0CvtWuzjbs6-w", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "first": true }, "uniqueAnchor": null }, "R36": { "role": "http://www.rezolutebio.com/role/DisclosureOperatingLeasesOperatingLeaseExpenseDetails", "longName": "99940402 - Disclosure - OPERATING LEASES - Operating Lease Expense (Details)", "shortName": "OPERATING LEASES - Operating Lease Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_HjkltemRHkyQOxOvfPP7xw", "name": "us-gaap:OperatingLeaseExpense", "unitRef": "Unit_Standard_USD_YiPJqncFB0CvtWuzjbs6-w", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_HjkltemRHkyQOxOvfPP7xw", "name": "us-gaap:OperatingLeaseExpense", "unitRef": "Unit_Standard_USD_YiPJqncFB0CvtWuzjbs6-w", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.rezolutebio.com/role/DisclosureOperatingLeasesAdditionalInformationDetails", "longName": "99940403 - Disclosure - OPERATING LEASES - Additional Information (Details)", "shortName": "OPERATING LEASES - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "As_Of_9_30_2024_vyT1CCJAUkqoANp6FVvKtw", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_vyT1CCJAUkqoANp6FVvKtw", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.rezolutebio.com/role/DisclosureOperatingLeasesFutureOperatingLeasePaymentsDetails", "longName": "99940404 - Disclosure - OPERATING LEASES - Future Operating Lease Payments (Details)", "shortName": "OPERATING LEASES - Future Operating Lease Payments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "As_Of_9_30_2024_vyT1CCJAUkqoANp6FVvKtw", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "Unit_Standard_USD_YiPJqncFB0CvtWuzjbs6-w", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "ix:continuation", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_vyT1CCJAUkqoANp6FVvKtw", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "Unit_Standard_USD_YiPJqncFB0CvtWuzjbs6-w", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "ix:continuation", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.rezolutebio.com/role/DisclosureLicenseAgreementsDetails", "longName": "99940501 - Disclosure - LICENSE AGREEMENTS (Details)", "shortName": "LICENSE AGREEMENTS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "As_Of_9_30_2024_srt_CounterpartyNameAxis_rzlt_XomaUsLlcMember_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_rzlt_ScenarioOneMember_us-gaap_TypeOfArrangementAxis_rzlt_XomaLicenseAgreementMember_BFdkPLLTAESHunh4LICsxw", "name": "rzlt:MaximumAmountOfMilestoneEvents", "unitRef": "Unit_Standard_USD_YiPJqncFB0CvtWuzjbs6-w", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "rzlt:LicenseAgreementsTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-

20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_srt_CounterpartyNameAxis_rzlt_XomaUsLlcMember_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_rzlt_ScenarioOne_us-gaap_TypeOfArrangementAxis_rzlt_XomaLicenseAgreementMember_BFdkPLLTAESHunh4LICsxw", "name": "rzlt:MaximumAmountOfMilestoneEvents", "unitRef": "Unit_Standard_USD_YiPJqncFB0CvtWuzjbs6-w", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "rzlt:LicenseAgreementsTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.rezolutebio.com/role/DisclosureEmbeddedDerivativeLiabilityDetails", "longName": "99940601 - Disclosure - EMBEDDED DERIVATIVE LIABILITY (Details)", "shortName": "EMBEDDED DERIVATIVE LIABILITY (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "As_Of_9_30_2024_vyT1CCJAUkqoANp6FVvKtw", "name": "us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability", "unitRef": "Unit_Standard_USD_YiPJqncFB0CvtWuzjbs6-w", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_4_14_2021_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember_aWQnKmQe0UOKQM2qzawTug", "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "unitRef": "Unit_Standard_USD_YiPJqncFB0CvtWuzjbs6-w", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:DiscussionOfHybridInstrumentsAndEmbeddedDerivativesTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "unique": true } }, "R41": { "role": "http://www.rezolutebio.com/role/DisclosureShareholdersEquityPreFundedWarrantsDetails", "longName": "99940701 - Disclosure - SHAREHOLDERS' EQUITY - Pre-Funded Warrants (Details)", "shortName": "SHAREHOLDERS' EQUITY - Pre-Funded Warrants (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "As_Of_6_24_2024_us-gaap_SubsidiarySaleOfStockAxis_rzlt_UnderwrittenPublicOfferingMember_UZ-_QLgxuEG23SfLoE00SA", "name": "us-gaap:SharesIssuedPricePerShare", "unitRef": "Unit_Divide_USD_shares_PWSs94aLm0a0XGM_nLuFGA", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_us-gaap_ClassOfWarrantOrRightAxis_rzlt_PreFundedWarrantsMember_x0bYF_V3pUSa7s8uRjhgHQ", "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "unitRef": "Unit_Standard_shares_FxYZVnXBsUiOuLvQLB_TBQ", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "unique": true } }, "R42": { "role": "http://www.rezolutebio.com/role/DisclosureShareholdersEquity2024PrivatePlacementDetails", "longName": "99940702 - Disclosure - SHAREHOLDERS' EQUITY - 2024 Private Placement (Details)", "shortName": "SHAREHOLDERS' EQUITY - 2024 Private Placement (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_7_31_2024_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_muzGP5rfTEakEefRItfpIg", "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "unitRef": "Unit_Standard_shares_FxYZVnXBsUiOuLvQLB_TBQ", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_jrlaBZRjv0OdLG3GDUuHfg", "name": "us-gaap:SharesIssuedPricePerShare", "unitRef": "Unit_Divide_USD_shares_PWSs94aLm0a0XGM_nLuFGA", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "unique": true } }, "R43": { "role": "http://www.rezolutebio.com/role/DisclosureShareholdersEquity2024UnderwrittenOfferingDetails", "longName": "99940703 - Disclosure - SHAREHOLDERS' EQUITY - 2024 Underwritten Offering (Details)", "shortName": "SHAREHOLDERS' EQUITY - 2024 Underwritten Offering (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "Duration_6_24_2024_To_6_24_2024_us-gaap_SubsidiarySaleOfStockAxis_rzlt_UnderwrittenPublicOfferingMember_QFPZ_nmdg02Lz54wn1v-EQ", "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "unitRef": "Unit_Standard_shares_FxYZVnXBsUiOuLvQLB_TBQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_6_24_2024_To_6_24_2024_us-gaap_SubsidiarySaleOfStockAxis_rzlt_UnderwrittenPublicOfferingMember_QFPZ_nmdg02Lz54wn1v-EQ", "name": "us-gaap:ProceedsFromIssuanceOfCommonStock", "unitRef": "Unit_Standard_USD_YiPJqncFB0CvtWuzjbs6-w", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "unique": true } }, "R44": { "role": "http://www.rezolutebio.com/role/DisclosureShareholdersEquityExchangeAgreementDetails", "longName": "99940704 - Disclosure - SHAREHOLDERS' EQUITY - Exchange Agreement (Details)", "shortName": "SHAREHOLDERS' EQUITY - Exchange Agreement (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "Duration_3_8_2024_To_3_8_2024_rzlt_AgreementAxis_rzlt_SecuritiesExchangeAgreementMember_oCOlBLFyt0Smp3OuzsWPew", "name": "us-gaap:TreasuryStockSharesAcquired", "unitRef": "Unit_Standard_shares_FxYZVnXBsUiOuLvQLB_TBQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_3_8_2024_To_3_8_2024_rzlt_AgreementAxis_rzlt_SecuritiesExchangeAgreementMember_oCOlBLFyt0Smp3OuzsWPew", "name": "us-gaap:TreasuryStockSharesAcquired", "unitRef": "Unit_Standard_shares_FxYZVnXBsUiOuLvQLB_TBQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.rezolutebio.com/role/DisclosureShareholdersEquityJefferiesOpenMarketSalesAgreementDetails", "longName": "99940705 - Disclosure - SHAREHOLDERS' EQUITY - Jefferies Open Market Sales Agreement (Details)", "shortName": "SHAREHOLDERS' EQUITY - Jefferies Open Market Sales Agreement (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "Duration_11_14_2023_To_11_14_2023_us-gaap_SubsidiarySaleOfStockAxis_rzlt_AtMarketOfferingMember_Ai9GVFudrUyCDQjDs0EhOw", "name": "rzlt:SaleOfStockMaximumAmountAgreedToSellAsPerOpenMarketSalesAgreement", "unitRef": "Unit_Standard_USD_YiPJqncFB0CvtWuzjbs6-w", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_11_14_2023_To_11_14_2023_us-gaap_SubsidiarySaleOfStockAxis_rzlt_AtMarketOfferingMember_Ai9GVFudrUyCDQjDs0EhOw", "name": "rzlt:SaleOfStockMaximumAmountAgreedToSellAsPerOpenMarketSalesAgreement", "unitRef": "Unit_Standard_USD_YiPJqncFB0CvtWuzjbs6-w", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionPlansDetails", "longName": "99940801 - Disclosure - SHARE-BASED COMPENSATION AND WARRANTS - Stock Option Plans (Details)", "shortName": "SHARE-BASED COMPENSATION AND WARRANTS - Stock Option Plans (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "As_Of_9_30_2024_vyT1CCJAUkqoANp6FVvKtw", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "unitRef": "Unit_Standard_shares_FxYZVnXBsUiOuLvQLB_TBQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "rzlt:ShareBasedPaymentArrangementOptionSharesAuthorizedOutstandingAndAvailableForFutureGrants", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_vyT1CCJAUkqoANp6FVvKtw", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "unitRef": "Unit_Standard_shares_FxYZVnXBsUiOuLvQLB_TBQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "rzlt:ShareBasedPaymentArrangementOptionSharesAuthorizedOutstandingAndAvailableForFutureGrants", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrants2022EmployeeStockPurchasePlanDetails", "longName": "99940802 - Disclosure - SHARE-BASED COMPENSATION AND WARRANTS - 2022 Employee Stock Purchase Plan (Details)", "shortName": "SHARE-BASED COMPENSATION AND WARRANTS - 2022 Employee Stock Purchase Plan (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "As_Of_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_BF7WHpCJm063v5M5K91rew", "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "unitRef": "Unit_Standard_shares_FxYZVnXBsUiOuLvQLB_TBQ", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_BF7WHpCJm063v5M5K91rew", "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "unitRef": "Unit_Standard_shares_FxYZVnXBsUiOuLvQLB_TBQ", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionsOutstandingDetails", "longName": "99940803 - Disclosure - SHARE-BASED COMPENSATION AND WARRANTS - Stock Options Outstanding (Details)", "shortName": "SHARE-BASED COMPENSATION AND WARRANTS - Stock Options Outstanding (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType":

"details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "As_Of_6_30_2024_rjIkKWLsbUGI-1Y_doTOtA", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Unit_Standard_shares_FxYZVnXBsUiOuLvQLB_TBQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_HjkltemRHkyQOxOvfPP7xw", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "unitRef": "Unit_Standard_shares_FxYZVnXBsUiOuLvQLB_TBQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "unique": true } }, "R49": { "role": "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsWeightedAverageAssumptionsDetails", "longName": "99940804 - Disclosure - SHARE-BASED COMPENSATION AND WARRANTS - Weighted Average Assumptions (Details)", "shortName": "SHARE-BASED COMPENSATION AND WARRANTS - Weighted Average Assumptions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "As_Of_9_30_2024_us-gaap_AwardTypeAxis_rzlt_StockOptionVestingTimeBasedMember_G_TcWc22nk6K4gZ4N9S5bw", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue", "unitRef": "Unit_Divide_USD_shares_PWSs94aLm0a0XGM_nLuFGA", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_us-gaap_AwardTypeAxis_rzlt_StockOptionVestingTimeBasedMember_G_TcWc22nk6K4gZ4N9S5bw", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue", "unitRef": "Unit_Divide_USD_shares_PWSs94aLm0a0XGM_nLuFGA", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "first": true, "unique": true } }, "R50": { "role": "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsShareBasedCompensationExpenseDetails", "longName": "99940805 - Disclosure - SHARE-BASED COMPENSATION AND WARRANTS - Share Based Compensation Expense (Details)", "shortName": "SHARE-BASED COMPENSATION AND WARRANTS - Share Based Compensation Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_HjkltemRHkyQOxOvfPP7xw", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "Unit_Standard_USD_YiPJqncFB0CvtWuzjbs6-w", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_HjkltemRHkyQOxOvfPP7xw", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "Unit_Standard_USD_YiPJqncFB0CvtWuzjbs6-w", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "first": true, "unique": true } }, "R51": { "role": "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsPreFundedWarrantsDetails", "longName": "99940806 - Disclosure - SHARE-BASED COMPENSATION AND WARRANTS - Pre-Funded Warrants (Details)", "shortName": "SHARE-BASED COMPENSATION AND WARRANTS - Pre-Funded Warrants (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "As_Of_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_rzlt_PreFundedWarrantsMember_CGR8ctzs9EG8bPKp2rdqGw", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "Unit_Standard_shares_FxYZVnXBsUiOuLvQLB_TBQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "first": true }, "uniqueAnchor": null }, "R52": { "role": "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsSummaryOfLegacyWarrantsDetails", "longName": "99940807 - Disclosure - SHARE-BASED COMPENSATION AND WARRANTS - Summary of Legacy Warrants (Details)", "shortName": "SHARE-BASED COMPENSATION AND WARRANTS - Summary of Legacy Warrants (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "As_Of_6_30_2024_us-gaap_ClassOfWarrantOrRightAxis_rzlt_LegacyWarrantsMember_pLO9Y0CZAkWfMvZodFHP9A", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "Unit_Standard_shares_FxYZVnXBsUiOuLvQLB_TBQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_us-gaap_ClassOfWarrantOrRightAxis_rzlt_LegacyWarrantsMember_pLO9Y0CZAkWfMvZodFHP9A", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "Unit_Standard_shares_FxYZVnXBsUiOuLvQLB_TBQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "first": true, "unique": true } }, "R53": { "role": "http://www.rezolutebio.com/role/DisclosureRelatedPartyTransactionsDetails", "longName": "99941001 - Disclosure - RELATED PARTY TRANSACTIONS (Details)", "shortName": "RELATED PARTY TRANSACTIONS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "Duration_6_24_2024_To_6_24_2024_us-gaap_SubsidiarySaleOfStockAxis_rzlt_UnderwrittenPublicOfferingMember_QFPZ_nmdg02Lz54wn1v-EQ", "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "unitRef": "Unit_Standard_shares_FxYZVnXBsUiOuLvQLB_TBQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_6_24_2024_To_6_24_2024_srt_CounterpartyNameAxis_rzlt_HandokInc.Member_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_us-gaap_SubsidiarySaleOfStockAxis_rzlt_UnderwrittenPublicOfferingMember_NNtWAxthzUi08x-ZvLWakA", "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "unitRef": "Unit_Standard_shares_FxYZVnXBsUiOuLvQLB_TBQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "unique": true } }, "R54": { "role": "http://www.rezolutebio.com/role/DisclosureNetLossPerShareWeightedAverageNumberOfSharesOutstandingDetails", "longName": "99941201 - Disclosure - NET LOSS PER SHARE - Weighted Average Number of Shares Outstanding (Details)", "shortName": "NET LOSS PER SHARE - Weighted Average Number of Shares Outstanding (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_HjkltemRHkyQOxOvfPP7xw", "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic", "unitRef": "Unit_Standard_shares_FxYZVnXBsUiOuLvQLB_TBQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_rzlt_PreFundedWarrants2021Member_oitg_0JumkmFlf03_QMy6Q", "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic", "unitRef": "Unit_Standard_shares_FxYZVnXBsUiOuLvQLB_TBQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "ix:continuation", "us-gaap:EarningsPerShareTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "unique": true } }, "R55": { "role": "http://www.rezolutebio.com/role/DisclosureNetLossPerShareAntiDilutiveDetails", "longName": "99941202 - Disclosure - NET LOSS PER SHARE - Anti-dilutive (Details)", "shortName": "NET LOSS PER SHARE - Anti-dilutive (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_HjkltemRHkyQOxOvfPP7xw", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Unit_Standard_shares_FxYZVnXBsUiOuLvQLB_TBQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_HjkltemRHkyQOxOvfPP7xw", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Unit_Standard_shares_FxYZVnXBsUiOuLvQLB_TBQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "first": true, "unique": true } }, "R56": { "role": "http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsFairValueOnRecurringBasisDetails", "longName": "99941301 - Disclosure - FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS - Fair Value on a Recurring Basis (Details)", "shortName": "FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS - Fair Value on a Recurring Basis (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "As_Of_9_30_2024_vyT1CCJAUkqoANp6FVvKtw", "name": "us-gaap:MarketableSecurities", "unitRef": "Unit_Standard_USD_YiPJqncFB0CvtWuzjbs6-w", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:MarketableSecuritiesTextBlock", "us-

gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_V50YEUThnUW8hZWMwHYrig", "name": "us-gaap:AssetsFairValueDisclosure", "unitRef": "Unit_Standard_USD_YiPJqncFB0CvtWuzjbs6-w", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "unique": true } }, "R57": { "role": "http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsSummaryOfChangesInFairValueDetails", "longName": "99941302 - Disclosure - FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS - Summary of Changes in the Fair Value (Details)", "shortName": "FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS - Summary of Changes in the Fair Value (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "As_Of_6_30_2024_rjIkKWLsbUGI-1Y_doTOtA", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "unitRef": "Unit_Standard_USD_YiPJqncFB0CvtWuzjbs6-w", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_rjIkKWLsbUGI-1Y_doTOtA", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "unitRef": "Unit_Standard_USD_YiPJqncFB0CvtWuzjbs6-w", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "first": true, "unique": true } }, "R58": { "role": "http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsSignificantConcentrationsDetails", "longName": "99941303 - Disclosure - FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS - Significant Concentrations (Details)", "shortName": "FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS - Significant Concentrations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_HjkltemRHkyQOxOvfPP7xw", "name": "us-gaap:ConcentrationRiskCreditRiskUninsuredDeposits", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_HjkltemRHkyQOxOvfPP7xw", "name": "us-gaap:ConcentrationRiskCreditRiskUninsuredDeposits", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "first": true, "unique": true } }, "R59": { "role": "http://www.rezolutebio.com/role/DisclosureSubsequentEventsDetails", "longName": "99941401 - Disclosure - SUBSEQUENT EVENTS (Details)", "shortName": "SUBSEQUENT EVENTS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "As_Of_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_rzlt_ExchangePreFundedWarrantsMember_sYa3ruFGk0OAS8DAD3uh2A", "name": "rzlt:ClassOfWarrantOrRightExercised", "unitRef": "Unit_Standard_shares_FxYZVnXBsUiOuLvQLB_TBQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_10_31_2024_us-gaap_ClassOfWarrantOrRightAxis_rzlt_ExchangePreFundedWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_aUlXnvK7H0WC2WEOSee11Q", "name": "rzlt:ClassOfWarrantOrRightExercised", "unitRef": "Unit_Standard_shares_FxYZVnXBsUiOuLvQLB_TBQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:SubsequentEventsTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240930x10q.htm", "unique": true } } }, "tag": { "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "presentation": ["http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Accounts Payable, Current", "verboseLabel": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r44", "r637"] }, "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments", "crdr": "credit", "presentation": ["http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Accretion (Amortization) of Discounts and Premiums, Investments", "negatedLabel": "Accretion of discounts and amortization of premiums on marketable debt securities, net", "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": ["r68"] }, "rzlt_AccruedClinicalCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rezolutebio.com/20240930", "localname": "AccruedClinicalCurrent", "crdr": "credit", "presentation": ["http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "documentation": "Amount of accrued for clinical liabilities.", "label": "Accrued Clinical, Current", "terseLabel": "Accrued clinical and other" } } }, "auth_ref": [] }, "us-gaap_AccruedLiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrentAbstract", "presentation": ["http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Accrued Liabilities, Current [Abstract]", "terseLabel": "Accrued liabilities:" } } }, "auth_ref": [] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "presentation": ["http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive income (loss)", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": ["r12", "r13", "r61", "r113", "r462", "r482", "r483"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": ["http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedStatementsOfShareholdersEquity"], "lang": { "en-us": { "role": { "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Loss", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r1", "r6", "r13", "r356", "r359", "r406", "r478", "r479", "r751", "r752", "r753", "r758", "r759", "r760", "r762"] }, "rzlt_ActivesitePharmaceuticalsIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rezolutebio.com/20240930", "localname": "ActivesitePharmaceuticalsIncMember", "presentation": ["http://www.rezolutebio.com/role/DisclosureLicenseAgreementsDetails"], "lang": { "en-us": { "role": { "documentation": "Represent the information pertaining to ActiveSite Pharmaceuticals, Inc.", "label": "ActiveSite Pharmaceuticals, Inc" } } }, "auth_ref": [] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "auth_ref": ["r688"] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapital", "crdr": "credit", "presentation": ["http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Additional Paid in Capital", "verboseLabel": "Additional paid-in capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": ["r56", "r637", "r852"] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": ["http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedStatementsOfShareholdersEquity"], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": ["r496", "r758", "r759", "r760", "r762", "r814", "r853"] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "auth_ref": ["r701"] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation:" } } }, "auth_ref": ["r701"] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": ["r701"] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": {

"en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": ["r701"] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": ["http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedStatementsOfShareholdersEquity"], "lang": { "en-us": { "role": { "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "verboseLabel": "Share-based compensation", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": ["r33", "r34", "r289"] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "crdr": "debit", "presentation": ["http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedStatementsOfShareholdersEquity"], "lang": { "en-us": { "role": { "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs", "negatedLabel": "Payment of commissions and other offering costs", "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration." } } }, "auth_ref": ["r7", "r79"] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table" } } }, "auth_ref": ["r734"] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r660", "r670", "r680", "r712"] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": ["r663", "r673", "r683", "r715"] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Pension Adjustments Service Cost [Member]", "terseLabel": "Aggregate Pension Adjustments Service Cost" } } }, "auth_ref": ["r735"] }, "rzlt_AgreementAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.rezolutebio.com/20240930", "localname": "AgreementAxis", "presentation": ["http://www.rezolutebio.com/role/DisclosureShareholdersEquityExchangeAgreementDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityPreFundedWarrantsDetails"], "lang": { "en-us": { "role": { "documentation": "Information of agreement.", "label": "Agreement [Axis]" } } }, "auth_ref": [] }, "rzlt_AgreementDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.rezolutebio.com/20240930", "localname": "AgreementDomain", "presentation": ["http://www.rezolutebio.com/role/DisclosureShareholdersEquityExchangeAgreementDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityPreFundedWarrantsDetails"], "lang": { "en-us": { "role": { "documentation": "Information of agreement.", "label": "Agreement [Domain]" } } }, "auth_ref": [] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "auth_ref": ["r701"] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "auth_ref": ["r708"] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "auth_ref": ["r664", "r674", "r684", "r708", "r716", "r720", "r728"] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } }, "auth_ref": ["r726"] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": ["http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsShareBasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expense", "verboseLabel": "Compensation cost", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": ["r318", "r323"] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": ["http://www.rezolutebio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": ["http://www.rezolutebio.com/role/DisclosureNetLossPerShareAntiDilutiveDetails"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Total", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": ["r162"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": ["http://www.rezolutebio.com/role/DisclosureNetLossPerShareAntiDilutiveDetails"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": ["r18"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": ["http://www.rezolutebio.com/role/DisclosureNetLossPerShareAntiDilutiveDetails", "http://www.rezolutebio.com/role/DisclosureNetLossPerShareWeightedAverageNumberOfSharesOutstandingDetails"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "NET LOSS PER SHARE", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": ["http://www.rezolutebio.com/role/DisclosureNetLossPerShareAntiDilutiveDetails"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": ["r18"] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": ["http://www.rezolutebio.com/role/DisclosureLicenseAgreementsDetails", "http://www.rezolutebio.com/role/DisclosureLiquidityDetails"], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": ["r347"] }, "us-gaap_AssetBackedSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetBackedSecuritiesMember", "presentation": ["http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsFairValueOnRecurringBasisDetails"], "lang": { "en-us": { "role": { "label": "Asset-Backed Securities [Member]", "terseLabel": "Asset-backed securities", "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans." } } }, "auth_ref": ["r616", "r638", "r770", "r771", "r772"] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "presentation": ["http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Assets", "totalLabel": "Total assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r88", "r95", "r109", "r131", "r166", "r170", "r171", "r172", "r209", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r349", "r353", "r385", "r457", "r534", "r605", "r606", "r637", "r651", "r782", "r783", "r838"] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": ["http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "auth_ref": [] }, "us-gaap_AssetsAndLiabilitiesLesseeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAndLiabilitiesLesseeAbstract", "presentation": ["http://www.rezolutebio.com/role/DisclosureOperatingLeasesAssetsAndOperatingLeaseLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Assets and Liabilities, Lessee [Abstract]", "terseLabel": "Carrying value of right-of-use assets and operating lease liabilities" } } }, "auth_ref": [] },

{"us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "presentation": ["http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Assets, Current", "totalLabel": "Total current assets", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": ["r106", "r114", "r131", "r209", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r349", "r353", "r385", "r637", "r782", "r783", "r838"] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": ["http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "presentation": ["http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsFairValueOnRecurringBasisDetails"], "lang": { "en-us": { "role": { "label": "Assets, Fair Value Disclosure", "terseLabel": "Financial assets measured at fair value", "documentation": "Fair value portion of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r367", "r368", "r625"] }, "us-gaap_AssetsNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsNoncurrentAbstract", "presentation": ["http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Assets, Noncurrent [Abstract]", "terseLabel": "Long-term assets:" } } }, "auth_ref": [] }, "rzlt_AtMarketOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rezolutebio.com/20240930", "localname": "AtMarketOfferingMember", "presentation": ["http://www.rezolutebio.com/role/DisclosureShareholdersEquityJefferiesOpenMarketSalesAgreementDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to at the market offering.", "label": "At the Market Offering [Member]", "terseLabel": "At the Market Offering" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "crdr": "credit", "presentation": ["http://www.rezolutebio.com/role/DisclosureInvestmentsInMarketableDebtSecuritiesCashAndCashEquivalentsAndMarketableSecuritiesHeldDetails"], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Gross Unrealized Gains", "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r180"] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "crdr": "debit", "presentation": ["http://www.rezolutebio.com/role/DisclosureInvestmentsInMarketableDebtSecuritiesCashAndCashEquivalentsAndMarketableSecuritiesHeldDetails"], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax", "negatedLabel": "Gross Unrealized Losses", "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r181"] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "auth_ref": ["r723"] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } }, "auth_ref": ["r724"] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } }, "auth_ref": ["r719"] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "auth_ref": ["r719"] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } }, "auth_ref": ["r719"] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } }, "auth_ref": ["r719"] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "auth_ref": ["r719"] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "auth_ref": ["r719"] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": ["http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrants2022EmployeeStockPurchasePlanDetails", "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsWeightedAverageAssumptionsDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": ["r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317"] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "auth_ref": ["r722"] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r721"] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "auth_ref": ["r720"] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": ["r720"] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": ["http://www.rezolutebio.com/role/DisclosureNatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Basis of Accounting, Policy [Policy Text Block]", "verboseLabel": "Basis of Presentation", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": ["http://www.rezolutebio.com/role/DisclosureLiquidityDetails", "http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, at Carrying Value", "verboseLabel": "Cash and cash equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": ["r16", "r108", "r596"] }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsFairValueDisclosure", "crdr": "debit", "presentation": ["http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsFairValueOnRecurringBasisDetails"], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash and cash equivalents", "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r816", "r817"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": ["http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents at end of period", "periodStartLabel": "Cash and cash equivalents at beginning of period", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand

deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r16", "r66", "r128"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "presentation": ["http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net decrease in cash and cash equivalents", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r0", "r66"] }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "presentation": ["http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]", "terseLabel": "NON-CASH INVESTING AND FINANCING ACTIVITIES:" } } }, "auth_ref": [] }, "rzlt_ChangeInFairValueOfWarrantDerivativeLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rezolutebio.com/20240930", "localname": "ChangeInFairValueOfWarrantDerivativeLiability", "crdr": "credit", "presentation": ["http://www.rezolutebio.com/role/DisclosureShareholdersEquityExchangeAgreementDetails"], "lang": { "en-us": { "role": { "documentation": "The amount of change in fair value of warrant derivative liability.", "label": "Change in Fair Value of Warrant Derivative Liability", "terseLabel": "Change in fair value of derivative liability" } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "auth_ref": ["r699"] }, "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]", "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year" } } }, "auth_ref": ["r696"] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]", "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested" } } }, "auth_ref": ["r694"] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": ["http://www.rezolutebio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "rzlt_ClassBPreFundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rezolutebio.com/20240930", "localname": "ClassBPreFundedWarrantsMember", "presentation": ["http://www.rezolutebio.com/role/DisclosureShareholdersEquityPreFundedWarrantsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information relating to Class B pre-funded warrants.", "label": "Class B pre-funded warrants", "terseLabel": "Class B Pre-Funded Warrants" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": ["http://www.rezolutebio.com/role/DisclosureNetLossPerShareWeightedAverageNumberOfSharesOutstandingDetails"], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": ["r102", "r110", "r111", "r112", "r131", "r156", "r157", "r159", "r161", "r168", "r169", "r209", "r233", "r235", "r236", "r237", "r240", "r241", "r260", "r261", "r264", "r267", "r274", "r385", "r486", "r487", "r488", "r489", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r522", "r543", "r565", "r586", "r587", "r588", "r589", "r590", "r738", "r755", "r763"] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockLineItems", "presentation": ["http://www.rezolutebio.com/role/DisclosureShareholdersEquity2024PrivatePlacementDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquity2024UnderwrittenOfferingDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityJefferiesOpenMarketSalesAgreementDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityPreFundedWarrantsDetails"], "lang": { "en-us": { "role": { "label": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r110", "r111", "r112", "r168", "r260", "r261", "r262", "r264", "r267", "r272", "r274", "r486", "r487", "r488", "r489", "r615", "r738", "r755"] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightAxis", "presentation": ["http://www.rezolutebio.com/role/DisclosureNetLossPerShareWeightedAverageNumberOfSharesOutstandingDetails", "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsPreFundedWarrantsDetails", "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsSummaryOfLegacyWarrantsDetails", "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsTables", "http://www.rezolutebio.com/role/DisclosureShareholdersEquity2024UnderwrittenOfferingDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityExchangeAgreementDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityPreFundedWarrantsDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityTables", "http://www.rezolutebio.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": ["r30"] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightDomain", "presentation": ["http://www.rezolutebio.com/role/DisclosureNetLossPerShareWeightedAverageNumberOfSharesOutstandingDetails", "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsPreFundedWarrantsDetails", "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsSummaryOfLegacyWarrantsDetails", "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsTables", "http://www.rezolutebio.com/role/DisclosureShareholdersEquity2024UnderwrittenOfferingDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityExchangeAgreementDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityPreFundedWarrantsDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityTables", "http://www.rezolutebio.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Domain]", "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": ["http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsSummaryOfLegacyWarrantsDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityExchangeAgreementDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityPreFundedWarrantsDetails"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "periodEndLabel": "Warrants Outstanding, Ending Price (in dollars per share)", "periodStartLabel": "Warrants Outstanding, Beginning Price (in dollars per share)", "terseLabel": "Warrant price (per share)", "verboseLabel": "Warrants exercise price", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": ["r275"] }, "rzlt_ClassOfWarrantOrRightExercised": { "xbrltype": "sharesItemType", "nsuri": "http://www.rezolutebio.com/20240930", "localname": "ClassOfWarrantOrRightExercised", "presentation": ["http://www.rezolutebio.com/role/DisclosureShareholdersEquityJefferiesOpenMarketSalesAgreementDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityPreFundedWarrantsDetails", "http://www.rezolutebio.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights exercised.", "label": "Class of Warrant or Right, Exercised", "negatedLabel": "Shares of common stock issued", "terseLabel": "Warrants exercised" } } }, "auth_ref": [] }, "rzlt_ClassOfWarrantOrRightExpirationExercisePriceOfWarrantsOrRights": { "xbrltype": "perShareItemType", "nsuri": "http://www.rezolutebio.com/20240930", "localname": "ClassOfWarrantOrRightExpirationExercisePriceOfWarrantsOrRights", "presentation": ["http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsSummaryOfLegacyWarrantsDetails"], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights expired.", "label": "Class of Warrant or Right, Expiration, Exercise Price of Warrants or Rights", "terseLabel": "Warrant expirations, Price (in dollars per share)" } } }, "auth_ref": [] },

"rzlt_ClassOfWarrantOrRightExpirations": { "xbrltype": "sharesItemType", "nsuri": "http://www.rezolutebio.com/20240930", "localname": "ClassOfWarrantOrRightExpirations", "presentation": [
"http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsSummaryOfLegacyWarrantsDetails"], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights expired.", "label": "Class of Warrant or Right, Expirations", "negatedLabel": "Warrant expirations (In shares)" } } }, "auth_ref": [] }, "rzlt_ClassOfWarrantOrRightIssued": { "xbrltype": "sharesItemType", "nsuri": "http://www.rezolutebio.com/20240930", "localname": "ClassOfWarrantOrRightIssued", "presentation": [
"http://www.rezolutebio.com/role/DisclosureLiquidityDetails",
"http://www.rezolutebio.com/role/DisclosureShareholdersEquityPreFundedWarrantsDetails"], "lang": { "en-us": { "role": { "documentation": "The number of warrants issued.", "label": "Class of Warrant or Right, Issued", "terseLabel": "Warrants issued" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightLineItems", "presentation": ["http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsTables",
"http://www.rezolutebio.com/role/DisclosureShareholdersEquityTables"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Line Items]", "terseLabel": "Class of warrant or right", "verboseLabel": "SHARE-BASED COMPENSATION AND WARRANTS", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": [
"http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsSummaryOfLegacyWarrantsDetails",
"http://www.rezolutebio.com/role/DisclosureShareholdersEquity2024UnderwrittenOfferingDetails",
"http://www.rezolutebio.com/role/DisclosureShareholdersEquityExchangeAgreementDetails",
"http://www.rezolutebio.com/role/DisclosureShareholdersEquityPreFundedWarrantsDetails",
"http://www.rezolutebio.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "netLabel": "Warrants to purchase shares of common stock", "terseLabel": "Pre-funded warrants to purchase shares of common stock", "verboseLabel": "Number of shares of common stock called by warrants issued", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": ["r275"] }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": [
"http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsPreFundedWarrantsDetails",
"http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsSummaryOfLegacyWarrantsDetails",
"http://www.rezolutebio.com/role/DisclosureShareholdersEquityPreFundedWarrantsDetails"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Outstanding", "periodEndLabel": "Warrants outstanding, ending (In shares)", "periodStartLabel": "Warrants outstanding, beginning (In shares)", "terseLabel": "Warrants outstanding (In shares)", "documentation": "Number of warrants or rights outstanding." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightTable", "presentation": ["http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsTables",
"http://www.rezolutebio.com/role/DisclosureShareholdersEquityTables"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Table]", "documentation": "Disclosure of information about warrant or right issued that give holder right to purchase security from issuer at specific price within certain time frame." } } }, "auth_ref": ["r30"] }, "rzlt_ClassOfWarrantOrRightWarrantsSurrendered": { "xbrltype": "sharesItemType", "nsuri": "http://www.rezolutebio.com/20240930", "localname": "ClassOfWarrantOrRightWarrantsSurrendered", "presentation": [
"http://www.rezolutebio.com/role/DisclosureShareholdersEquityPreFundedWarrantsDetails"], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights surrendered.", "label": "Class of Warrant or Right, Warrants Surrendered", "negatedLabel": "Shares surrendered for exercise price" } } }, "auth_ref": [] }, "rzlt_ClassPreFundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rezolutebio.com/20240930", "localname": "ClassPreFundedWarrantsMember", "presentation": [
"http://www.rezolutebio.com/role/DisclosureShareholdersEquityPreFundedWarrantsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information relating to Class A pre-funded warrants.", "label": "Class A Pre-Funded Warrants", "verboseLabel": "Class A pre-funded warrants" } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } }, "auth_ref": ["r700"] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "auth_ref": ["r700"] }, "us-gaap_CollaborativeArrangementMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CollaborativeArrangementMember", "presentation": [
"http://www.rezolutebio.com/role/DisclosureLicenseAgreementsDetails", "http://www.rezolutebio.com/role/DisclosureLiquidityDetails"], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement [Member]", "terseLabel": "Collaborative Arrangement", "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity." } } }, "auth_ref": ["r347"] }, "us-gaap_CommercialPaperMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommercialPaperMember", "presentation": [
"http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsFairValueOnRecurringBasisDetails",
"http://www.rezolutebio.com/role/DisclosureInvestmentsInMarketableDebtSecuritiesCashAndCashEquivalentsAndMarketableSecuritiesHeldDetails"], "lang": { "en-us": { "role": { "label": "Commercial Paper [Member]", "terseLabel": "Corporate commercial paper", "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds." } } }, "auth_ref": ["r74", "r232", "r645", "r646", "r647", "r648"] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "presentation": [
"http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (Notes 5, 9 and 10)", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": ["r52", "r89", "r459", "r521"] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "COMMITMENTS AND CONTINGENCIES." } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [
"http://www.rezolutebio.com/role/DisclosureCommitmentsAndContingencies"], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "COMMITMENTS AND CONTINGENCIES", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": ["r73", "r226", "r227", "r592", "r779", "r781"] }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "presentation": [
"http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrants2022EmployeeStockPurchasePlanDetails"], "lang": { "en-us": { "role": { "label": "Common Stock, Capital Shares Reserved for Future Issuance", "verboseLabel": "Shares reserved for purchase", "documentation": "Aggregate number of common shares reserved for future issuance." } } }, "auth_ref": ["r55"] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": [
"http://www.rezolutebio.com/role/DisclosureNetLossPerShareWeightedAverageNumberOfSharesOutstandingDetails",
"http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedStatementsOfShareholdersEquity"], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "terseLabel": "Common Stock", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": ["r641", "r642", "r643", "r645", "r646", "r647", "r648", "r758", "r759", "r762", "r814", "r851", "r853"] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [
"http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Common Stock, Par or Stated Value Per Share", "verboseLabel": "Common stock, par value (in dollars per share)", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": ["r55"] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": [
"http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r55", "r522"] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": [
"http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares

represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": ["r55"] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": ["http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": ["r7", "r55", "r522", "r540", "r853", "r854"] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "presentation": ["http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Common Stock, Value, Issued", "verboseLabel": "Common stock, $0.001 par value; 100,000 shares authorized; issued and outstanding 55,394 and 53,246 shares as of September 30, 2024 and as of June 30, 2024, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r55", "r461", "r637"] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": ["r705"] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": ["r704"] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": ["r706"] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": ["r703"] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "presentation": ["http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive loss", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r14", "r118", "r120", "r124", "r452", "r471", "r472"] }, "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTaxAbstract", "presentation": ["http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]", "terseLabel": "Other comprehensive income (loss):" } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskCreditRiskUninsuredDeposits": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskCreditRiskUninsuredDeposits", "presentation": ["http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsSignificantConcentrationsDetails"], "lang": { "en-us": { "role": { "label": "Concentration Risk, Credit Risk, Uninsured Deposits", "terseLabel": "Concentration risk, credit risk, uninsured deposits", "documentation": "Description of credit risk that arises from having significant balances in excess of the Federal Deposit Insurance Corporation or other insurance limits on deposits in financial institutions." } } }, "auth_ref": ["r39", "r87"] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConsolidationPolicyTextBlock", "presentation": ["http://www.rezolutebio.com/role/DisclosureNatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Consolidation, Policy [Policy Text Block]", "verboseLabel": "Consolidation", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": ["r35", "r600"] }, "us-gaap_CorporateDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CorporateDebtSecuritiesMember", "presentation": ["http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsFairValueOnRecurringBasisDetails", "http://www.rezolutebio.com/role/DisclosureInvestmentsInMarketableDebtSecuritiesCashAndCashEquivalentsAndMarketableSecuritiesHeldDetails"], "lang": { "en-us": { "role": { "label": "Corporate Debt Securities [Member]", "terseLabel": "Corporate notes and bonds", "verboseLabel": "Corporate notes and bonds", "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment." } } }, "auth_ref": ["r616", "r618", "r625", "r638", "r640", "r850"] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CounterpartyNameAxis", "presentation": ["http://www.rezolutebio.com/role/DisclosureLicenseAgreementsDetails", "http://www.rezolutebio.com/role/DisclosureLiquidityDetails", "http://www.rezolutebio.com/role/DisclosureRelatedPartyTransactionsDetails"], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]" } } }, "auth_ref": ["r135", "r136", "r245", "r262", "r413", "r434", "r456", "r597", "r599"] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Document And Entity Information [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": ["http://www.rezolutebio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "rzlt_DebtInstrumentExitFee": { "xbrltype": "percentItemType", "nsuri": "http://www.rezolutebio.com/20240930", "localname": "DebtInstrumentExitFee", "presentation": ["http://www.rezolutebio.com/role/DisclosureEmbeddedDerivativeLiabilityDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the exit fee on the funded principal balance.", "label": "Debt Instrument, Exit Fee", "terseLabel": "Exit fee on the funded principal balance" } } }, "auth_ref": [] }, "rzlt_DebtInstrumentExitFeeAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rezolutebio.com/20240930", "localname": "DebtInstrumentExitFeeAmount", "crdr": "debit", "presentation": ["http://www.rezolutebio.com/role/DisclosureEmbeddedDerivativeLiabilityDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of expenses associated with exit fees on the funded principal balance.", "label": "Debt Instrument, Exit Fee Amount", "terseLabel": "Exit fee amount" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentLineItems", "presentation": ["http://www.rezolutebio.com/role/DisclosureEmbeddedDerivativeLiabilityDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r137", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r610", "r611", "r612", "r613", "r614", "r635", "r756", "r832", "r833"] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTable", "presentation": ["http://www.rezolutebio.com/role/DisclosureEmbeddedDerivativeLiabilityDetails"], "lang": { "en-us": { "role": { "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "Disclosure of information about long-term debt instrument or arrangement." } } }, "auth_ref": ["r11", "r25", "r28", "r42", "r77", "r78", "r137", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r610", "r611", "r612", "r613", "r614", "r635", "r756", "r832", "r833"] }, "us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent", "crdr": "debit", "presentation": ["http://www.rezolutebio.com/role/DisclosureInvestmentsInMarketableDebtSecuritiesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Accrued Interest, after Allowance for Credit Loss, Current", "terseLabel": "Interest receivable", "documentation": "Amount, after allowance for credit loss, of accrued interest on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current." } } }, "auth_ref": ["r183", "r217", "r218"] }, "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterestCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterestCurrent", "crdr": "credit", "presentation": ["http://www.rezolutebio.com/role/DisclosureInvestmentsInMarketableDebtSecuritiesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Amortized Cost, Allowance for Credit Loss, Excluding Accrued Interest, Current", "terseLabel": "Allowance for credit losses related to investments in marketable debt securities", "documentation": "Amount excluding accrued interest, of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current." } } }, "auth_ref": ["r217"] }, "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":

"DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss", "crdr": "debit", "presentation": ["http://www.rezolutebio.com/role/DisclosureInvestmentsInMarketableDebtSecuritiesCashAndCashEquivalentsAndMarketableSecuritiesHeldDetails"], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, before Allowance for Credit Loss", "totalLabel": "Amortized Cost", "documentation": "Amortized cost excluding accrued interest, before allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r217"] }, "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleExcludingAccruedInterest", "crdr": "debit", "presentation": ["http://www.rezolutebio.com/role/DisclosureInvestmentsInMarketableDebtSecuritiesCashAndCashEquivalentsAndMarketableSecuritiesHeldDetails"], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Excluding Accrued Interest", "terseLabel": "Fair Value", "documentation": "Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r778"] }, "us-gaap_DebtSecuritiesAvailableForSaleRealizedGain": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleRealizedGain", "crdr": "credit", "presentation": ["http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Realized Gain", "negatedLabel": "Realized gain from investments", "documentation": "Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r207"] }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleTable", "presentation": ["http://www.rezolutebio.com/role/DisclosureInvestmentsInMarketableDebtSecuritiesCashAndCashEquivalentsAndMarketableSecuritiesHeldDetails"], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale [Table]", "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r176", "r177", "r178", "r179", "r180", "r181", "r182", "r184", "r185", "r186", "r187", "r188"] }, "us-gaap_DebtSecuritiesAvailableForSaleTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleTerm", "presentation": ["http://www.rezolutebio.com/role/DisclosureInvestmentsInMarketableDebtSecuritiesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Term", "terseLabel": "Debt securities, available-for-sale, term", "documentation": "Period between issuance and maturity of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r818", "r819", "r820"] }, "rzlt_DebtSecuritiesAvailableForSaleWeightedAverageTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.rezolutebio.com/20240930", "localname": "DebtSecuritiesAvailableForSaleWeightedAverageTerm", "presentation": ["http://www.rezolutebio.com/role/DisclosureInvestmentsInMarketableDebtSecuritiesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Weighted average period of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Debt Securities, Available-for-Sale, Weighted Average Term", "terseLabel": "Debt securities, available-for-sale, weighted average term" } } }, "auth_ref": [] }, "us-gaap_DepositsAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepositsAssetsNoncurrent", "crdr": "debit", "presentation": ["http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Deposits Assets, Noncurrent", "terseLabel": "Deposits and other", "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer." } } }, "auth_ref": ["r748"] }, "us-gaap_DepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationAndAmortization", "crdr": "debit", "presentation": ["http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Depreciation, Depletion and Amortization, Nonproduction", "terseLabel": "Depreciation expense", "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production." } } }, "auth_ref": ["r4", "r22"] }, "us-gaap_DerivativeContractTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeContractTypeDomain", "presentation": ["http://www.rezolutebio.com/role/DisclosureEmbeddedDerivativeLiabilityDetails"], "lang": { "en-us": { "role": { "label": "Derivative Contract [Domain]", "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": ["r511", "r513", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r535", "r536", "r537", "r538", "r553", "r554", "r555", "r556", "r559", "r560", "r561", "r562", "r580", "r581", "r582", "r583", "r641", "r643", "r821", "r822", "r823", "r824", "r825", "r826", "r828", "r829"] }, "us-gaap_DerivativeInstrumentRiskAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentRiskAxis", "presentation": ["http://www.rezolutebio.com/role/DisclosureEmbeddedDerivativeLiabilityDetails"], "lang": { "en-us": { "role": { "label": "Derivative Instrument [Axis]", "documentation": "Information by type of derivative contract." } } }, "auth_ref": ["r36", "r37", "r38", "r85", "r511", "r513", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r535", "r536", "r537", "r538", "r553", "r554", "r555", "r556", "r559", "r560", "r561", "r562", "r580", "r581", "r582", "r583", "r599", "r641", "r643", "r821", "r822", "r823", "r824", "r825", "r826", "r828", "r829"] }, "rzlt_DevelopmentAndLicenseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rezolutebio.com/20240930", "localname": "DevelopmentAndLicenseAgreementMember", "presentation": ["http://www.rezolutebio.com/role/DisclosureLicenseAgreementsDetails"], "lang": { "en-us": { "role": { "documentation": "Development And License Agreement [Member]", "label": "Development And License Agreement [Member]", "terseLabel": "Development And License Agreement" } } }, "auth_ref": [] }, "rzlt_DevelopmentAndLicenseAgreementRoyaltiesPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.rezolutebio.com/20240930", "localname": "DevelopmentAndLicenseAgreementRoyaltiesPercentage", "presentation": ["http://www.rezolutebio.com/role/DisclosureLicenseAgreementsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the percentage of royalties.", "label": "Development and License Agreement, Royalties Percentage", "terseLabel": "Royalties percentage" } } }, "auth_ref": [] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": ["http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrants"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Text Block]", "terseLabel": "SHARE-BASED COMPENSATION AND WARRANTS", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": ["r287", "r291", "r319", "r320", "r322", "r620"] }, "us-gaap_DiscussionOfHybridInstrumentsAndEmbeddedDerivativesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DiscussionOfHybridInstrumentsAndEmbeddedDerivativesTextBlock", "presentation": ["http://www.rezolutebio.com/role/DisclosureEmbeddedDerivativeLiability"], "lang": { "en-us": { "role": { "label": "Discussion of Hybrid Instruments and Embedded Derivatives [Text Block]", "terseLabel": "EMBEDDED DERIVATIVE LIABILITY", "documentation": "The entire disclosure for hybrid instruments and embedded derivatives, including discussion of the process used in evaluating whether a hybrid instrument in the form of a share constitutes a debt or equity security, and on what basis an embedded derivative was deemed to be separable or inseparable from the host instrument." } } }, "auth_ref": ["r86"] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": ["http://www.rezolutebio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": ["http://www.rezolutebio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": ["http://www.rezolutebio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": ["http://www.rezolutebio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": ["r655"] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": ["http://www.rezolutebio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": ["r687"] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": ["http://www.rezolutebio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri":

"http://xbrl.sec.gov/ecd/2024", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]", "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year" } } }, "auth_ref": ["r698"] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "label": "NET LOSS PER SHARE" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": [
"http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic", "terseLabel": "Net loss per common share - basic (in dollars per share)", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": ["r125", "r143", "r144", "r145", "r146", "r147", "r148", "r154", "r156", "r159", "r160", "r161", "r165", "r343", "r346", "r364", "r365", "r453", "r473", "r602"] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": [
"http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Diluted", "terseLabel": "Net loss per common share - diluted (in dollars per share)", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": ["r125", "r143", "r144", "r145", "r146", "r147", "r148", "r156", "r159", "r160", "r161", "r165", "r343", "r346", "r364", "r365", "r453", "r473", "r602"] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": [
"http://www.rezolutebio.com/role/DisclosureNetLossPerShare"], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Text Block]", "terseLabel": "NET LOSS PER SHARE", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": ["r153", "r162", "r163", "r164"] }, "us-gaap_EmbeddedDerivativeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmbeddedDerivativeAbstract", "lang": { "en-us": { "role": { "label": "EMBEDDED DERIVATIVE LIABILITY" } } }, "auth_ref": [] }, "us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability", "crdr": "credit", "presentation": [
"http://www.rezolutebio.com/role/DisclosureEmbeddedDerivativeLiabilityDetails",
"http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Embedded Derivative, Fair Value of Embedded Derivative Liability", "terseLabel": "Embedded derivative liability", "documentation": "Fair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as a liability." } } }, "auth_ref": ["r84", "r818", "r819", "r820"] }, "us-gaap_EmbeddedDerivativeFinancialInstrumentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmbeddedDerivativeFinancialInstrumentsMember", "presentation": [
"http://www.rezolutebio.com/role/DisclosureEmbeddedDerivativeLiabilityDetails"], "lang": { "en-us": { "role": { "label": "Embedded Derivative Financial Instruments [Member]", "terseLabel": "Embedded derivative", "verboseLabel": "Embedded Derivative Financial Instruments", "documentation": "Derivative instrument embedded in host contract." } } }, "auth_ref": [] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "presentation": ["http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Employee-related Liabilities, Current", "terseLabel": "Compensation and benefits", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r47"] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [
"http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsShareBasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Expected to be recognized over a remaining weighted average period", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r321"] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "crdr": "debit", "presentation": ["http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsShareBasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "verboseLabel": "Unrecognized share-based compensation expense", "documentation": "Amount of cost to be recognized for option under share-based payment arrangement." } } }, "auth_ref": ["r812"] }, "us-gaap_EmployeeStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockMember", "presentation": [
"http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrants2022EmployeeStockPurchasePlanDetails"], "lang": { "en-us": { "role": { "label": "Employee Stock [Member]", "terseLabel": "Employee Stock Purchase Plan", "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock." } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": ["http://www.rezolutebio.com/role/DisclosureNetLossPerShareAntiDilutiveDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] },
"dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": ["http://www.rezolutebio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": ["http://www.rezolutebio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] },
"dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": ["http://www.rezolutebio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] },
"dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": ["http://www.rezolutebio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] },
"dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": ["http://www.rezolutebio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": ["r653"] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [
"http://www.rezolutebio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [
"http://www.rezolutebio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [
"http://www.rezolutebio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": ["r653"] },
"dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": ["http://www.rezolutebio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence

number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": ["http://www.rezolutebio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": ["r653"] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": ["http://www.rezolutebio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": ["http://www.rezolutebio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": ["r737"] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": ["http://www.rezolutebio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": ["r653"] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": ["http://www.rezolutebio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": ["r653"] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": ["http://www.rezolutebio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": ["r653"] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": ["http://www.rezolutebio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": ["r653"] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Footnote [Text Block]", "terseLabel": "Equity Awards Adjustments, Footnote" } } }, "auth_ref": ["r692"] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]", "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table" } } }, "auth_ref": ["r733"] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments [Member]", "terseLabel": "Equity Awards Adjustments" } } }, "auth_ref": ["r733"] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table" } } }, "auth_ref": ["r733"] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": ["http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedStatementsOfShareholdersEquity"], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": ["r7", "r104", "r121", "r122", "r123", "r138", "r139", "r140", "r142", "r147", "r149", "r151", "r167", "r210", "r211", "r222", "r276", "r334", "r335", "r340", "r341", "r342", "r344", "r345", "r346", "r355", "r356", "r357", "r358", "r359", "r360", "r363", "r386", "r387", "r388", "r389", "r390", "r391", "r393", "r395", "r406", "r469", "r478", "r479", "r480", "r496", "r565"] }, "us-gaap_EquitySecuritiesByIndustryAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesByIndustryAxis", "presentation": ["http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsSignificantConcentrationsDetails"], "lang": { "en-us": { "role": { "label": "Industry Sector [Axis]", "documentation": "Information by industry sector, examples include but are not limited to, commercial, industrial, agricultural, financial services, technology, healthcare and real estate." } } }, "auth_ref": ["r508", "r509", "r510", "r574", "r576", "r579", "r585", "r608", "r625", "r626", "r628", "r643"] }, "us-gaap_EquitySecuritiesIndustryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesIndustryMember", "presentation": ["http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsSignificantConcentrationsDetails"], "lang": { "en-us": { "role": { "label": "Industry Sector [Domain]", "documentation": "Industry sector consisting of government, private and corporate entities engaged in business activities, including but not limited to, commercial, industrial, agricultural, financial services, technology, healthcare and real estate." } } }, "auth_ref": ["r508", "r509", "r510", "r574", "r576", "r579", "r585", "r625", "r626", "r628", "r643"] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": ["r702"] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis" } } }, "auth_ref": ["r660", "r670", "r680", "r712"] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery" } } }, "auth_ref": ["r657", "r667", "r677", "r709"] }, "rzlt_ExchangePreFundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rezolutebio.com/20240930", "localname": "ExchangePreFundedWarrantsMember", "presentation": ["http://www.rezolutebio.com/role/DisclosureNetLossPerShareWeightedAverageNumberOfSharesOutstandingDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityExchangeAgreementDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityPreFundedWarrantsDetails", "http://www.rezolutebio.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information relating to exchange pre-funded warrants.", "label": "Exchange Pre Funded Warrants [Member]", "terseLabel": "Exchange Pre-Funded Warrants", "verboseLabel": "Exchange PFWs" } } }, "auth_ref": [] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category:" } } }, "auth_ref": ["r708"] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": ["http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsFairValueOnRecurringBasisDetails"], "lang": { "en-us": { "role": { "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r367", "r368", "r379", "r625"] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": ["http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsFairValueOnRecurringBasisDetails"], "lang": { "en-us": { "role": { "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": ["r367", "r368", "r379", "r625"] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "presentation": ["http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsTables"], "lang": { "en-us": { "role": { "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of financial assets measured at fair value on a recurring basis", "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level

2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": ["r816", "r817"] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": ["http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsFairValueOnRecurringBasisDetails"], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": ["r250", "r278", "r279", "r280", "r281", "r282", "r283", "r366", "r368", "r369", "r370", "r371", "r378", "r379", "r381", "r421", "r422", "r423", "r611", "r612", "r616", "r617", "r618", "r625", "r628"] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": ["http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsFairValueOnRecurringBasisDetails"], "lang": { "en-us": { "role": { "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": ["r367", "r368", "r369", "r371", "r625", "r819", "r830"] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS" } } }, "auth_ref": [] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": ["http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsFairValueOnRecurringBasisDetails"], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": ["r250", "r278", "r283", "r368", "r379", "r421", "r616", "r617", "r618", "r625"] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": ["http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsFairValueOnRecurringBasisDetails"], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": ["r250", "r278", "r283", "r368", "r369", "r379", "r422", "r611", "r612", "r616", "r617", "r618", "r625"] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "presentation": ["http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsSummaryOfChangesInFairValueDetails"], "lang": { "en-us": { "role": { "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "presentation": ["http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsSignificantConcentrationsDetails"], "lang": { "en-us": { "role": { "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "terseLabel": "FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r372", "r373", "r374", "r375", "r376", "r377"] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "presentation": ["http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsSignificantConcentrationsDetails"], "lang": { "en-us": { "role": { "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "documentation": "Disclosure of information about financial instrument liability measured at fair value on recurring basis using unobservable input." } } }, "auth_ref": ["r372", "r373", "r374", "r375", "r376", "r377", "r380"] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "presentation": ["http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsTables"], "lang": { "en-us": { "role": { "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Schedule of changes in the fair value of the company's derivative liabilities, fair value, level 3 inputs", "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability." } } }, "auth_ref": ["r372", "r377", "r380"] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementFrequencyDomain", "presentation": ["http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsFairValueOnRecurringBasisDetails"], "lang": { "en-us": { "role": { "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": ["r367", "r368", "r369", "r371", "r625", "r819", "r830"] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "crdr": "credit", "presentation": ["http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsSummaryOfChangesInFairValueDetails"], "lang": { "en-us": { "role": { "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings", "verboseLabel": "Changes in fair value", "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3)." } } }, "auth_ref": ["r373", "r380"] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "crdr": "credit", "presentation": ["http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsSummaryOfChangesInFairValueDetails"], "lang": { "en-us": { "role": { "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "periodEndLabel": "Balance at the end", "periodStartLabel": "Balance at the beginning", "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": ["r372", "r380"] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": ["http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsFairValueOnRecurringBasisDetails"], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": ["r250", "r278", "r279", "r280", "r281", "r282", "r283", "r366", "r368", "r369", "r370", "r371", "r378", "r379", "r381", "r421", "r422", "r423", "r611", "r612", "r616", "r617", "r618", "r625", "r628"] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsRecurringMember", "presentation": ["http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsFairValueOnRecurringBasisDetails"], "lang": { "en-us": { "role": { "label": "Fair Value, Recurring [Member]", "terseLabel": "Recurring", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": ["r625", "r816", "r817", "r818", "r819", "r820", "r830"] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentAxis", "presentation": ["http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsFairValueOnRecurringBasisDetails", "http://www.rezolutebio.com/role/DisclosureInvestmentsInMarketableDebtSecuritiesCashAndCashEquivalentsAndMarketableSecuritiesHeldDetails"], "lang": { "en-us": { "role": { "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": ["r176", "r177", "r178", "r179", "r180", "r181", "r182", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r212", "r213", "r214", "r215", "r216", "r219", "r220", "r221", "r258", "r272", "r361", "r382", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r470", "r609", "r625", "r626", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r638", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r773", "r774", "r775", "r776", "r815", "r818", "r819", "r820", "r827", "r830"] }, "us-gaap_FinancialInstrumentsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentsDisclosureTextBlock", "presentation": ["http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrations"], "lang": { "en-us": { "role": { "label": "Financial Instruments Disclosure [Text Block]", "terseLabel": "FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS", "documentation": "The

entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures." } } }, "auth_ref": [] }, "us-gaap_FinancialServicesSectorMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialServicesSectorMember", "presentation": [
"http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsSignificantConcentrationsDetails"], "lang": { "en-us": { "role": { "label": "Financial Services Sector [Member]", "terseLabel": "Banking and Financial Services Industries", "documentation": "Sector of the economy consisting of companies engaged in financial services." } } }, "auth_ref": ["r625", "r643", "r855", "r856", "r857", "r858"] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": ["r664", "r674", "r684", "r716"] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": ["r664", "r674", "r684", "r716"] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": ["r664", "r674", "r684", "r716"] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": ["r664", "r674", "r684", "r716"] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r664", "r674", "r684", "r716"] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]", "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year" } } }, "auth_ref": ["r697"] }, "us-gaap_GainLossOnDerivativeInstrumentsNetPretax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnDerivativeInstrumentsNetPretax", "crdr": "credit", "presentation": [
"http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows",
"http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Gain (Loss) on Derivative Instruments, Net, Pretax", "negatedLabel": "Loss from change in fair value of embedded derivative liability", "terseLabel": "Loss from change in fair value of embedded derivative liability", "documentation": "Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects." } } }, "auth_ref": ["r36"] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "presentation": [
"http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "General and Administrative Expense", "terseLabel": "General and administrative", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": ["r63", "r545"] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": [
"http://www.rezolutebio.com/role/DisclosureOperatingLeasesOperatingLeaseExpenseDetails",
"http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsShareBasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label": "General and Administrative Expense [Member]", "terseLabel": "General and Administrative Expense", "verboseLabel": "General and administrative", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": ["r63"] }, "rzlt_HandokInc.Member": { "xbrltype": "domainItemType", "nsuri": "http://www.rezolutebio.com/20240930", "localname": "HandokInc.Member", "presentation": ["http://www.rezolutebio.com/role/DisclosureRelatedPartyTransactionsDetails"], "lang": { "en-us": { "role": { "documentation": "Handok, Inc. [Member]", "label": "Handok, Inc. [Member]", "terseLabel": "Handok, Inc." } } }, "auth_ref": [] }, "rzlt_HandokLicenseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rezolutebio.com/20240930", "localname": "HandokLicenseAgreementMember", "presentation": ["http://www.rezolutebio.com/role/DisclosureRelatedPartyTransactionsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Handok License agreement", "label": "Handok License Agreement [Member]", "terseLabel": "Handok License Agreement" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": [
"http://www.rezolutebio.com/role/DisclosureOperatingLeasesOperatingLeaseExpenseDetails",
"http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsShareBasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": ["r223", "r224", "r225", "r373", "r377", "r380", "r475", "r477", "r550", "r595", "r627", "r849"] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": ["http://www.rezolutebio.com/role/DisclosureOperatingLeasesOperatingLeaseExpenseDetails", "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsShareBasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Domain]", "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": ["r224", "r225", "r373", "r377", "r380", "r475", "r477", "r550", "r595", "r627", "r849"] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "label": "INCOME TAXES" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureTextBlock", "presentation": ["http://www.rezolutebio.com/role/DisclosureIncomeTaxes"], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Text Block]", "terseLabel": "INCOME TAXES", "documentation": "The entire disclosure for income tax." } } }, "auth_ref": ["r132", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r336", "r337", "r338", "r339", "r491", "r622"] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "presentation": [
"http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Decrease in accounts payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": ["r3"] }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccruedLiabilities", "crdr": "debit", "presentation": ["http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accrued Liabilities", "terseLabel": "Increase in accrued liabilities", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid." } } }, "auth_ref": ["r3"] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [
"http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "verboseLabel": "Changes in operating assets and liabilities:" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "presentation": [
"http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Increase in prepaid expenses, deposits, and other assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": ["r3"] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel": "Individual:" } } }, "auth_ref": ["r664", "r674", "r684", "r708", "r716", "r720", "r728"] },

"rzlt_InducementGrantMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rezolutebio.com/20240930", "localname": "InducementGrantMember", "presentation": [
"http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionPlansDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to the inducement grant.", "label": "Inducement Grant" } } }, "auth_ref": [] },
"ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]", "terseLabel": "Insider Trading Arrangements:" } } }, "auth_ref": ["r726"] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]", "terseLabel": "Insider Trading Policies and Procedures:" } } }, "auth_ref": ["r656", "r732"] },
"ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": ["r656", "r732"] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": ["r656", "r732"] }, "us-gaap_InterestAndOtherIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestAndOtherIncome", "crdr": "credit", "presentation": [
"http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Interest and Other Income", "verboseLabel": "Interest and other income, net", "documentation": "The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [] }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "presentation": ["http://www.rezolutebio.com/role/DisclosureInvestmentsInMarketableDebtSecurities"], "lang": { "en-us": { "role": { "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "terseLabel": "INVESTMENTS IN MARKETABLE DEBT SECURITIES", "documentation": "The entire disclosure for investments in certain debt and equity securities." } } }, "auth_ref": ["r93", "r103", "r174", "r175", "r383", "r384", "r847"] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCostTableTextBlock", "presentation": [
"http://www.rezolutebio.com/role/DisclosureOperatingLeasesTables"], "lang": { "en-us": { "role": { "label": "Lease, Cost [Table Text Block]", "terseLabel": "Schedule of operating lease expense", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": ["r835"] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "label": "OPERATING LEASES" } } }, "auth_ref": [] },
"rzlt_LegacyWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rezolutebio.com/20240930", "localname": "LegacyWarrantsMember", "presentation": ["http://www.rezolutebio.com/role/DisclosureNetLossPerShareAntiDilutiveDetails",
"http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsSummaryOfLegacyWarrantsDetails",
"http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsTables"], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to legacy warrants.", "label": "Legacy Warrants [Member]", "terseLabel": "Legacy warrants" } } }, "auth_ref": [] }, "us-gaap_LesseeLeaseDescriptionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeaseDescriptionLineItems", "presentation": ["http://www.rezolutebio.com/role/DisclosureOperatingLeasesOperatingLeaseExpenseDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Lease, Description [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r399", "r405"] }, "us-gaap_LesseeLeaseDescriptionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeaseDescriptionTable", "presentation": [
"http://www.rezolutebio.com/role/DisclosureOperatingLeasesOperatingLeaseExpenseDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Lease, Description [Table]", "documentation": "Disclosure of information about lessee's leases." } } }, "auth_ref": ["r399", "r405"] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [
"http://www.rezolutebio.com/role/DisclosureOperatingLeasesTables"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "verboseLabel": "Schedule of future payments under operating lease agreements", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": ["r836"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "presentation": [
"http://www.rezolutebio.com/role/DisclosureOperatingLeasesFutureOperatingLeasePaymentsDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total lease payments", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": ["r403"] }, "rzlt_LesseeOperatingLeaseLiabilityPaymentsDueAfterTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rezolutebio.com/20240930", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterTwo", "crdr": "credit", "presentation": [
"http://www.rezolutebio.com/role/DisclosureOperatingLeasesFutureOperatingLeasePaymentsDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, Payments Due after Two", "terseLabel": "Thereafter" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "presentation": [
"http://www.rezolutebio.com/role/DisclosureOperatingLeasesFutureOperatingLeasePaymentsDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2026", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r403"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "presentation": [
"http://www.rezolutebio.com/role/DisclosureOperatingLeasesFutureOperatingLeasePaymentsDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2027", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r403"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "presentation": [
"http://www.rezolutebio.com/role/DisclosureOperatingLeasesFutureOperatingLeasePaymentsDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "terseLabel": "Remainder of fiscal year 2025", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." } } }, "auth_ref": ["r836"] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": ["http://www.rezolutebio.com/role/DisclosureOperatingLeasesFutureOperatingLeasePaymentsDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less imputed interest", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": ["r403"] }, "rzlt_LesseeOperatingLeaseRightOfUseAssetsAndOperatingLeaseLiabilities": { "xbrltype": "textBlockItemType", "nsuri": "http://www.rezolutebio.com/20240930", "localname": "LesseeOperatingLeaseRightOfUseAssetsAndOperatingLeaseLiabilities", "presentation": [
"http://www.rezolutebio.com/role/DisclosureOperatingLeasesTables"], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of carrying value of ROU assets and operating lease liabilities.", "label": "Lessee, Operating Lease, Right Of Use Assets And Operating Lease Liabilities", "terseLabel": "Schedule of carrying value of right-of-use assets and operating lease liabilities" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeasesTextBlock", "presentation": ["http://www.rezolutebio.com/role/DisclosureOperatingLeases"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "OPERATING LEASES", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": ["r394"] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit",

{"presentation": ["http://www.rezolutebio.com/role/DisclosureLiquidityDetails",
"http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities", "totalLabel": "Total liabilities", "verboseLabel": "Total liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": ["r11", "r46", "r47", "r48", "r50", "r51", "r52", "r53", "r131", "r209", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r350", "r353", "r354", "r385", "r520", "r603", "r651", "r782", "r838", "r839"] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "presentation": [
"http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities and Equity", "totalLabel": "Total liabilities and shareholders' equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": ["r60", "r90", "r464", "r637", "r757", "r777", "r831"] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [
"http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and Shareholders' Equity" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "presentation": [
"http://www.rezolutebio.com/role/DisclosureLiquidityDetails",
"http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities, Current", "terseLabel": "Current liabilities", "totalLabel": "Total current liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": ["r48", "r107", "r131", "r209", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r350", "r353", "r354", "r385", "r637", "r782", "r838", "r839"] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": ["http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesNoncurrentAbstract", "presentation": ["http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities, Noncurrent [Abstract]", "terseLabel": "Long-term liabilities:" } } }, "auth_ref": [] }, "us-gaap_LicenseAgreementTermsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LicenseAgreementTermsMember", "presentation": ["http://www.rezolutebio.com/role/DisclosureLicenseAgreementsDetails",
"http://www.rezolutebio.com/role/DisclosureLiquidityDetails"], "lang": { "en-us": { "role": { "label": "License Agreement Terms [Member]", "terseLabel": "License agreement", "documentation": "Terms of the license agreements under research and development arrangements accounted for as a contract to perform research and development for others." } } }, "auth_ref": [] }, "rzlt_LicenseAgreementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.rezolutebio.com/20240930", "localname": "LicenseAgreementsAbstract", "lang": { "en-us": { "role": { "documentation": "n/a", "label": "LICENSE AGREEMENTS" } } }, "auth_ref": [] }, "rzlt_LicenseAgreementsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.rezolutebio.com/20240930", "localname": "LicenseAgreementsTextBlock", "presentation": [
"http://www.rezolutebio.com/role/DisclosureLicenseAgreements"], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about License agreements.", "label": "LICENSE AGREEMENTS [Text block]", "terseLabel": "LICENSE AGREEMENTS" } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": [
"http://www.rezolutebio.com/role/DisclosureEmbeddedDerivativeLiabilityDetails"], "lang": { "en-us": { "role": { "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Maximum borrowing capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": ["r45", "r49"] }, "rzlt_LiquidityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.rezolutebio.com/20240930", "localname": "LiquidityAbstract", "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "LIQUIDITY" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [
"http://www.rezolutebio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_MarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecurities", "crdr": "debit", "presentation": [
"http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsFairValueOnRecurringBasisDetails",
"http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsSignificantConcentrationsDetails",
"http://www.rezolutebio.com/role/DisclosureInvestmentsInMarketableDebtSecuritiesInvestmentsInMarketableSecuritiesDetails"], "lang": { "en-us": { "role": { "label": "Marketable Securities", "terseLabel": "Marketable debt securities", "totalLabel": "Total investments", "documentation": "Amount of investment in marketable security." } } }, "auth_ref": ["r91", "r749"] }, "us-gaap_MarketableSecuritiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesAbstract", "lang": { "en-us": { "role": { "label": "INVESTMENTS IN MARKETABLE DEBT SECURITIES" } } }, "auth_ref": [] }, "us-gaap_MarketableSecuritiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesCurrent", "crdr": "debit", "presentation": [
"http://www.rezolutebio.com/role/DisclosureInvestmentsInMarketableDebtSecuritiesAdditionalInformationDetails",
"http://www.rezolutebio.com/role/DisclosureInvestmentsInMarketableDebtSecuritiesInvestmentsInMarketableSecuritiesDetails",
"http://www.rezolutebio.com/role/DisclosureLiquidityDetails",
"http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Marketable Securities, Current", "terseLabel": "Investments in marketable debt securities", "verboseLabel": "Short-term investments", "documentation": "Amount of investment in marketable security, classified as current." } } }, "auth_ref": ["r749"] }, "us-gaap_MarketableSecuritiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesNoncurrent", "crdr": "debit", "presentation": ["http://www.rezolutebio.com/role/DisclosureInvestmentsInMarketableDebtSecuritiesAdditionalInformationDetails",
"http://www.rezolutebio.com/role/DisclosureInvestmentsInMarketableDebtSecuritiesInvestmentsInMarketableSecuritiesDetails",
"http://www.rezolutebio.com/role/DisclosureLiquidityDetails",
"http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Marketable Securities, Noncurrent", "terseLabel": "Investments in marketable debt securities", "verboseLabel": "Long-term investments", "documentation": "Amount of investment in marketable security, classified as noncurrent." } } }, "auth_ref": ["r749"] }, "us-gaap_MarketableSecuritiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesTextBlock", "presentation": [
"http://www.rezolutebio.com/role/DisclosureInvestmentsInMarketableDebtSecuritiesTables"], "lang": { "en-us": { "role": { "label": "Marketable Securities [Table Text Block]", "terseLabel": "Schedule of investments in marketable debt securities", "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets." } } }, "auth_ref": [] }, "rzlt_MaximumAmountOfMilestoneEvents": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rezolutebio.com/20240930", "localname": "MaximumAmountOfMilestoneEvents", "crdr": "credit", "presentation": [
"http://www.rezolutebio.com/role/DisclosureLicenseAgreementsDetails"], "lang": { "en-us": { "role": { "documentation": "The maximum amount of milestone event which need to occur for making specific range of milestone payment.", "label": "Maximum Amount of Milestone Events", "terseLabel": "Maximum amount of milestone events" } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": [
"http://www.rezolutebio.com/role/DisclosureLicenseAgreementsDetails",
"http://www.rezolutebio.com/role/DisclosureShareholdersEquityExchangeAgreementDetails",
"http://www.rezolutebio.com/role/DisclosureShareholdersEquityPreFundedWarrantsDetails"], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "auth_ref": ["r228", "r229", "r230", "r231", "r285", "r324", "r371", "r450", "r474", "r476", "r484", "r512", "r513", "r573", "r575", "r577", "r578", "r584", "r593", "r594", "r607", "r615", "r619", "r628", "r629", "r633", "r634", "r639", "r784", "r840", "r841", "r842", "r843", "r844", "r845"] }, "rzlt_MaximumNumberOfAdditionalSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://www.rezolutebio.com/20240930", "localname": "MaximumNumberOfAdditionalSharesIssued", "presentation": [
"http://www.rezolutebio.com/role/DisclosureShareholdersEquity2024UnderwrittenOfferingDetails"], "lang": { "en-us": { "role": { "documentation": "Represent the maximum number of additional shares offered.", "label": "Maximum Number Of Additional Shares Issued", "terseLabel": "Maximum number of additional shares issued" } } }, "auth_ref": [] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure:" } } }, "auth_ref": ["r700"] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } }, "auth_ref": ["r700"] }, "rzlt_MilestoneClosingPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rezolutebio.com/20240930", "localname": "MilestoneClosingPayment", "crdr": "debit", "presentation": ["http://www.rezolutebio.com/role/DisclosureLicenseAgreementsDetails",
"http://www.rezolutebio.com/role/DisclosureLiquidityDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of milestone payment made during the period.", "label": "Milestone Closing Payment", "terseLabel": "Milestone closing payment" } } }, "auth_ref": [] },
"ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label":

"MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": ["r719"] }, "us-gaap_MoneyMarketFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MoneyMarketFundsMember", "presentation": ["http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsFairValueOnRecurringBasisDetails"], "lang": { "en-us": { "role": { "label": "Money Market Funds [Member]", "terseLabel": "Money Market Mutual Fund", "verboseLabel": "Money market funds", "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities." } } }, "auth_ref": ["r785"] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, "auth_ref": ["r727"] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "auth_ref": ["r701"] }, "us-gaap_NatureOfOperations": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NatureOfOperations", "presentation": ["http://www.rezolutebio.com/role/DisclosureNatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Nature of Operations [Text Block]", "verboseLabel": "Nature of Operations", "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward." } } }, "auth_ref": ["r96", "r101"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "presentation": ["http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net Cash Provided by Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": ["r127"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": ["http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "verboseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "presentation": ["http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Total Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": ["r127"] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": ["http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "verboseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "presentation": ["http://www.rezolutebio.com/role/DisclosureLiquidityDetails", "http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net Cash Used in Operating Activities", "verboseLabel": "Net cash used in operating activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": ["r66", "r67", "r68"] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "presentation": ["http://www.rezolutebio.com/role/DisclosureLiquidityDetails", "http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss", "http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedStatementsOfShareholdersEquity", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "totalLabel": "Net loss", "verboseLabel": "Net loss", "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": ["r62", "r68", "r92", "r105", "r117", "r119", "r123", "r131", "r141", "r143", "r144", "r145", "r146", "r147", "r150", "r151", "r158", "r209", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r343", "r346", "r365", "r385", "r468", "r542", "r563", "r564", "r649", "r782"] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": ["http://www.rezolutebio.com/role/DisclosureNatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "verboseLabel": "Recent Accounting Pronouncements Not Yet Adopted", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "rzlt_NonCashLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rezolutebio.com/20240930", "localname": "NonCashLeaseExpense", "crdr": "debit", "presentation": ["http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "Amount representing the non cash lease expense.", "label": "Non Cash Lease Expense", "terseLabel": "Non-cash lease expense" } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "auth_ref": ["r700"] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "auth_ref": ["r664", "r674", "r684", "r708", "r716"] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": ["r691"] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": ["r690"] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "auth_ref": ["r708"] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": ["r727"] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": ["r727"] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "presentation": ["http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense)", "totalLabel": "Total non-operating income, net", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": ["r64"] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": ["http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "verboseLabel": "Non-operating income (expense):" } } }, "auth_ref": [] }, "rzlt_NumberOfWhollyOwnedSubsidiaries": { "xbrltype": "integerItemType", "nsuri": "http://www.rezolutebio.com/20240930", "localname": "NumberOfWhollyOwnedSubsidiaries", "presentation": ["http://www.rezolutebio.com/role/DisclosureNatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role":

{ "documentation": "Represents the number of wholly owned subsidiaries.", "label": "Number of Wholly Owned Subsidiaries", "terseLabel": "Number of wholly owned subsidiaries" } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "presentation": ["http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Operating Expenses", "totalLabel": "Total operating expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": ["http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "presentation": ["http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Operating Income (Loss)", "totalLabel": "Operating loss", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": ["r94", "r604", "r764", "r765", "r766", "r767", "r768"] }, "us-gaap_OperatingLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseExpense", "crdr": "debit", "presentation": ["http://www.rezolutebio.com/role/DisclosureOperatingLeasesOperatingLeaseExpenseDetails"], "lang": { "en-us": { "role": { "label": "Operating Lease, Expense", "terseLabel": "Operating lease expense", "documentation": "Amount of operating lease expense. Excludes sublease income." } } }, "auth_ref": ["r834"] }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "presentation": ["http://www.rezolutebio.com/role/DisclosureOperatingLeasesFutureOperatingLeasePaymentsDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]", "terseLabel": "Future lease payments related to operating lease agreements" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "presentation": ["http://www.rezolutebio.com/role/DisclosureOperatingLeasesAssetsAndOperatingLeaseLiabilitiesDetails", "http://www.rezolutebio.com/role/DisclosureOperatingLeasesFutureOperatingLeasePaymentsDetails"], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability", "totalLabel": "Total", "verboseLabel": "Present value of operating lease liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": ["r397"] }, "us-gaap_OperatingLeaseLiabilityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityAbstract", "presentation": ["http://www.rezolutebio.com/role/DisclosureOperatingLeasesAssetsAndOperatingLeaseLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability [Abstract]", "terseLabel": "Operating lease liabilities:" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "presentation": ["http://www.rezolutebio.com/role/DisclosureOperatingLeasesAssetsAndOperatingLeaseLiabilitiesDetails", "http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Current", "terseLabel": "Current", "verboseLabel": "Current portion of operating lease liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": ["r397"] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "presentation": ["http://www.rezolutebio.com/role/DisclosureOperatingLeasesAssetsAndOperatingLeaseLiabilitiesDetails", "http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Long-term", "verboseLabel": "Operating lease liabilities, net of current portion", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": ["r397"] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": ["http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Operating Lease, Payments", "terseLabel": "Cash paid for amounts included in the measurement of operating lease liabilities", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": ["r398", "r400"] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "presentation": ["http://www.rezolutebio.com/role/DisclosureOperatingLeasesAssetsAndOperatingLeaseLiabilitiesDetails", "http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Operating Lease, Right-of-Use Asset", "verboseLabel": "Right-of-use assets", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": ["r396"] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": ["http://www.rezolutebio.com/role/DisclosureOperatingLeasesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted average discount rate for operating lease liabilities", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": ["r402", "r636"] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": ["http://www.rezolutebio.com/role/DisclosureOperatingLeasesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted average remaining lease term under operating leases", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r401", "r636"] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "presentation": ["http://www.rezolutebio.com/role/DisclosureNatureOfOperationsAndSummaryOfSignificantAccountingPolicies"], "lang": { "en-us": { "role": { "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]", "verboseLabel": "NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles." } } }, "auth_ref": ["r69", "r70", "r71", "r83"] }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "crdr": "credit", "presentation": ["http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss", "http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedStatementsOfShareholdersEquity"], "lang": { "en-us": { "role": { "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax", "terseLabel": "Net unrealized gain (loss) on marketable debt securities", "verboseLabel": "Net change in accumulated other comprehensive loss", "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale." } } }, "auth_ref": ["r115", "r116", "r208"] }, "rzlt_OtherOfferingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rezolutebio.com/20240930", "localname": "OtherOfferingCosts", "crdr": "credit", "presentation": ["http://www.rezolutebio.com/role/DisclosureShareholdersEquity2024UnderwrittenOfferingDetails"], "lang": { "en-us": { "role": { "documentation": "Related to other offering costs", "label": "Other Offering Costs", "verboseLabel": "Other offering costs" } } }, "auth_ref": [] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "auth_ref": ["r700"] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r662", "r672", "r682", "r714"] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } } }, "auth_ref": ["r665", "r675", "r685", "r717"] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r665", "r675", "r685", "r717"] },

"ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": ["r689"] }, "rzlt_PayablesForOfferingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rezolutebio.com/20240930", "localname": "PayablesForOfferingCosts", "crdr": "credit", "presentation": ["http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "The amount of payables accrued for offering costs in the period.", "label": "Payables for offering costs", "terseLabel": "Payables for offering costs" } } }, "auth_ref": [] }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForRepurchaseOfCommonStock", "crdr": "credit", "presentation": ["http://www.rezolutebio.com/role/DisclosureShareholdersEquityExchangeAgreementDetails", "http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Payments for Repurchase of Common Stock", "negatedLabel": "Net cash payment pursuant to Exchange Agreement", "terseLabel": "Cash payment to exchanging shareholders", "documentation": "The cash outflow to reacquire common stock during the period." } } }, "auth_ref": ["r65"] }, "us-gaap_PaymentsOfStockIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfStockIssuanceCosts", "crdr": "credit", "presentation": ["http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Payments of Stock Issuance Costs", "negatedLabel": "Payment of offering costs", "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security." } } }, "auth_ref": ["r15"] }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireMarketableSecurities", "crdr": "credit", "presentation": ["http://www.rezolutebio.com/role/DisclosureInvestmentsInMarketableDebtSecuritiesAdditionalInformationDetails", "http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Payments to Acquire Marketable Securities", "negatedLabel": "Purchase of marketable debt securities", "terseLabel": "Investment in marketable securities", "documentation": "Amount of cash outflow for purchase of marketable security." } } }, "auth_ref": ["r769"] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote" } } }, "auth_ref": ["r699"] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": ["r699"] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": ["r691"] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "auth_ref": ["r708"] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "auth_ref": ["r701"] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "auth_ref": ["r690"] }, "rzlt_PercentageOfEntitySSharesHeldByInvestors": { "xbrltype": "percentItemType", "nsuri": "http://www.rezolutebio.com/20240930", "localname": "PercentageOfEntitySSharesHeldByInvestors", "presentation": ["http://www.rezolutebio.com/role/DisclosureEmbeddedDerivativeLiabilityDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the percentage of entity's shares held by investors.", "label": "Percentage Of Entity's Shares Held By Investors", "terseLabel": "Percentage of entity's shares held by investors" } } }, "auth_ref": [] }, "rzlt_PercentageOfTreasuryStockAcquiredOfSharesOutstanding": { "xbrltype": "percentItemType", "nsuri": "http://www.rezolutebio.com/20240930", "localname": "PercentageOfTreasuryStockAcquiredOfSharesOutstanding", "presentation": ["http://www.rezolutebio.com/role/DisclosureShareholdersEquityExchangeAgreementDetails"], "lang": { "en-us": { "role": { "documentation": "The percentage of stock acquired to the total of outstanding shares.", "label": "Percentage of Treasury Stock Acquired, of Shares Outstanding", "terseLabel": "Outstanding shares percentage" } } }, "auth_ref": [] }, "rzlt_PharmaceuticalLicenseAgreementMilestonePayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rezolutebio.com/20240930", "localname": "PharmaceuticalLicenseAgreementMilestonePayment", "crdr": "debit", "presentation": ["http://www.rezolutebio.com/role/DisclosureRelatedPartyTransactionsDetails"], "lang": { "en-us": { "role": { "documentation": "The amount of milestone payments to be incurred for the approval of license.", "label": "Pharmaceutical License Agreement, Milestone Payment", "terseLabel": "Milestone payments" } } }, "auth_ref": [] }, "rzlt_PharmaceuticalLicenseAgreementMilestonePaymentEarned": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rezolutebio.com/20240930", "localname": "PharmaceuticalLicenseAgreementMilestonePaymentEarned", "crdr": "credit", "presentation": ["http://www.rezolutebio.com/role/DisclosureRelatedPartyTransactionsDetails"], "lang": { "en-us": { "role": { "documentation": "The amount of milestone payments earned by the entity.", "label": "Pharmaceutical License Agreement Milestone Payment Earned", "terseLabel": "Milestone payments earned" } } }, "auth_ref": [] }, "rzlt_PharmaceuticalLicenseAgreementTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.rezolutebio.com/20240930", "localname": "PharmaceuticalLicenseAgreementTerm", "presentation": ["http://www.rezolutebio.com/role/DisclosureRelatedPartyTransactionsDetails"], "lang": { "en-us": { "role": { "documentation": "Term of pharmaceutical license agreement in years.", "label": "Pharmaceutical License Agreement, Term", "terseLabel": "License term (in years)" } } }, "auth_ref": [] }, "rzlt_PharmaceuticalLicenseAgreementTransferPrice": { "xbrltype": "percentItemType", "nsuri": "http://www.rezolutebio.com/20240930", "localname": "PharmaceuticalLicenseAgreementTransferPrice", "presentation": ["http://www.rezolutebio.com/role/DisclosureRelatedPartyTransactionsDetails"], "lang": { "en-us": { "role": { "documentation": "The percentage of transfer price on sale of products.", "label": "Pharmaceutical License Agreement, Transfer Price", "terseLabel": "Transfer price (in percent)" } } }, "auth_ref": [] }, "rzlt_Phase1ClinicalTrialRz402Member": { "xbrltype": "domainItemType", "nsuri": "http://www.rezolutebio.com/20240930", "localname": "Phase1ClinicalTrialRz402Member", "presentation": ["http://www.rezolutebio.com/role/DisclosureLicenseAgreementsDetails"], "lang": { "en-us": { "role": { "documentation": "N/A.", "label": "Phase 1 Clinical Trial RZ402" } } }, "auth_ref": [] }, "rzlt_Phase2ClinicalTrialRz358Member": { "xbrltype": "domainItemType", "nsuri": "http://www.rezolutebio.com/20240930", "localname": "Phase2ClinicalTrialRz358Member", "presentation": ["http://www.rezolutebio.com/role/DisclosureLicenseAgreementsDetails"], "lang": { "en-us": { "role": { "documentation": "N/A.", "label": "Phase 2 Clinical Trial RZ358 (ersodetug)" } } }, "auth_ref": [] }, "rzlt_Phase2ClinicalTrialRz402Member": { "xbrltype": "domainItemType", "nsuri": "http://www.rezolutebio.com/20240930", "localname": "Phase2ClinicalTrialRz402Member", "presentation": ["http://www.rezolutebio.com/role/DisclosureLicenseAgreementsDetails"], "lang": { "en-us": { "role": { "documentation": "N/A.", "label": "Phase 2 Clinical Trial RZ402" } } }, "auth_ref": [] }, "rzlt_Phase3ClinicalTrialRz358Member": { "xbrltype": "domainItemType", "nsuri": "http://www.rezolutebio.com/20240930", "localname": "Phase3ClinicalTrialRz358Member", "presentation": ["http://www.rezolutebio.com/role/DisclosureLicenseAgreementsDetails", "http://www.rezolutebio.com/role/DisclosureLiquidityDetails"], "lang": { "en-us": { "role": { "documentation": "Phase 3 Clinical Trial Rz 358 [Member].", "label": "Phase 3 Clinical Trial RZ 358 (ersodetug)" } } }, "auth_ref": [] }, "rzlt_Phase3ClinicalTrialRz402Member": { "xbrltype": "domainItemType", "nsuri": "http://www.rezolutebio.com/20240930", "localname": "Phase3ClinicalTrialRz402Member", "presentation": ["http://www.rezolutebio.com/role/DisclosureLicenseAgreementsDetails"], "lang": { "en-us": { "role": { "documentation": "Phase 3 Clinical Trial Rz 402 [Member].", "label": "Phase 3 Clinical Trial RZ 402" } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": ["http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionPlansDetails"], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": ["r786", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r811"] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": ["http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionPlansDetails"], "lang": { "en-us": { "role": { "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": ["r786", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r811"] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Adjustments Prior Service Cost [Member]", "terseLabel": "Pension Adjustments Prior Service Cost" } } }, "auth_ref": ["r692"] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Adjustments Service Cost [Member]", "terseLabel": "Pension Adjustments Service Cost" } } }, "auth_ref": ["r736"] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote [Text Block]", "terseLabel": "Pension Benefits Adjustments, Footnote" } } }, "auth_ref": ["r691"] }, "rzlt_PreFundedWarrants2021Member": { "xbrltype": "domainItemType", "nsuri": "http://www.rezolutebio.com/20240930", "localname": "PreFundedWarrants2021Member", "presentation": ["http://www.rezolutebio.com/role/DisclosureNetLossPerShareWeightedAverageNumberOfSharesOutstandingDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityPreFundedWarrantsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information relating to pre-funded 2021 warrants.", "label": "Pre Funded Warrants 2021 [Member]", "terseLabel": "2021 Pre-Funded

Warrants", "verboseLabel": "2021 PFWs" } } }, "auth_ref": [] }, "rzlt_PreFundedWarrants2022Member": { "xbrltype": "domainItemType", "nsuri": "http://www.rezolutebio.com/20240930", "localname": "PreFundedWarrants2022Member", "presentation": [
"http://www.rezolutebio.com/role/DisclosureNetLossPerShareWeightedAverageNumberOfSharesOutstandingDetails",
"http://www.rezolutebio.com/role/DisclosureShareholdersEquityPreFundedWarrantsDetails",
"http://www.rezolutebio.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information relating to pre-funded 2022 warrants.", "label": "2022 Pre-Funded Warrants", "terseLabel": "2022 PFWs" } } }, "auth_ref": [] },
"rzlt_PreFundedWarrants2024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.rezolutebio.com/20240930", "localname": "PreFundedWarrants2024Member", "presentation": [
"http://www.rezolutebio.com/role/DisclosureNetLossPerShareWeightedAverageNumberOfSharesOutstandingDetails",
"http://www.rezolutebio.com/role/DisclosureShareholdersEquity2024UnderwrittenOfferingDetails",
"http://www.rezolutebio.com/role/DisclosureShareholdersEquityPreFundedWarrantsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information relating to pre-funded 2024 warrants.", "label": "Pre Funded Warrants 2024", "terseLabel": "Pre Funded Warrants 2024", "verboseLabel": "2024 PFWs" } } }, "auth_ref": [] }, "rzlt_PreFundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rezolutebio.com/20240930", "localname": "PreFundedWarrantsMember", "presentation": [
"http://www.rezolutebio.com/role/DisclosureNetLossPerShareWeightedAverageNumberOfSharesOutstandingDetails",
"http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsPreFundedWarrantsDetails",
"http://www.rezolutebio.com/role/DisclosureShareholdersEquityPreFundedWarrantsDetails",
"http://www.rezolutebio.com/role/DisclosureShareholdersEquityTables"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to pre-funded warrants.", "label": "Pre Funded Warrants [Member]", "terseLabel": "Pre-funded warrants" } } }, "auth_ref": [] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [
"http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in dollars per share)", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": ["r54", "r260"] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": [
"http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r54", "r522"] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": [
"http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares, issued", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": ["r54", "r260"] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "presentation": [
"http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Value, Issued", "verboseLabel": "Preferred stock, $0.001 par value; 400 shares authorized; no shares issued", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r54", "r460", "r637"] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "presentation": ["http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Prepaid Expense and Other Assets, Current", "verboseLabel": "Prepaid expenses and other", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r750"] }, "us-gaap_PrivatePlacementMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrivatePlacementMember", "presentation": [
"http://www.rezolutebio.com/role/DisclosureLiquidityDetails",
"http://www.rezolutebio.com/role/DisclosureShareholdersEquity2024PrivatePlacementDetails",
"http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedStatementsOfShareholdersEquity"], "lang": { "en-us": { "role": { "label": "Private Placement [Member]", "terseLabel": "Private Placement", "verboseLabel": "Private Placement", "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "presentation": [
"http://www.rezolutebio.com/role/DisclosureShareholdersEquity2024UnderwrittenOfferingDetails"], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds from issuance of common stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": ["r2"] },
"rzlt_ProceedsFromIssuanceOfCommonStockNetOfUnderwritingDiscountsAndCommissions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rezolutebio.com/20240930", "localname": "ProceedsFromIssuanceOfCommonStockNetOfUnderwritingDiscountsAndCommissions", "crdr": "debit", "presentation": ["http://www.rezolutebio.com/role/DisclosureShareholdersEquity2024UnderwrittenOfferingDetails"], "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity net of underwriting discounts, commissions and other fees.", "label": "Proceeds From Issuance Of Common Stock, Net Of Underwriting Discounts And Commissions", "terseLabel": "Net cash proceeds" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfDebt", "crdr": "debit", "presentation": [
"http://www.rezolutebio.com/role/DisclosureEmbeddedDerivativeLiabilityDetails"], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance of Debt", "verboseLabel": "Gross proceeds from issuance of debt", "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt." } } }, "auth_ref": ["r754"] }, "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfPrivatePlacement", "crdr": "debit", "presentation": [
"http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance of Private Placement", "terseLabel": "Gross proceeds from issuance of common stock in 2024 Private Placement", "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement." } } }, "auth_ref": ["r2"] }, "us-gaap_ProceedsFromIssuanceOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfWarrants", "crdr": "debit", "presentation": [
"http://www.rezolutebio.com/role/DisclosureShareholdersEquity2024UnderwrittenOfferingDetails"], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance of Warrants", "terseLabel": "Proceeds from warrants issued", "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)." } } }, "auth_ref": ["r2"] }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOrSaleOfEquity", "crdr": "debit", "presentation": [
"http://www.rezolutebio.com/role/DisclosureShareholdersEquity2024UnderwrittenOfferingDetails"], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance or Sale of Equity", "terseLabel": "Gross proceeds from sale of equity", "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity." } } }, "auth_ref": ["r2", "r486"] }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "crdr": "debit", "presentation": [
"http://www.rezolutebio.com/role/DisclosureInvestmentsInMarketableDebtSecuritiesAdditionalInformationDetails",
"http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Proceeds from Sale and Maturity of Marketable Securities", "terseLabel": "Proceeds from maturities of marketable debt securities", "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "presentation": [
"http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from exercise of stock options", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": ["r2", "r10"] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProfitLoss", "crdr": "credit", "presentation": [
"http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net loss", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": ["r105", "r117", "r119", "r126", "r131", "r141", "r147", "r150", "r151", "r209", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r343", "r346", "r348", "r351", "r352", "r365", "r385", "r454", "r467", "r495", "r542", "r563", "r564", "r623", "r624", "r650", "r753", "r782"] }, "us-

gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "presentation": [
"http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": ["r5", "r404", "r455", "r466", "r637"] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": ["r689"] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": ["r689"] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": [
"http://www.rezolutebio.com/role/DisclosureLicenseAgreementsDetails",
"http://www.rezolutebio.com/role/DisclosureShareholdersEquityExchangeAgreementDetails",
"http://www.rezolutebio.com/role/DisclosureShareholdersEquityPreFundedWarrantsDetails"], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "auth_ref": ["r228", "r229", "r230", "r231", "r277", "r285", "r314", "r315", "r316", "r324", "r371", "r424", "r433", "r450", "r474", "r476", "r484", "r512", "r513", "r573", "r575", "r577", "r578", "r584", "r593", "r594", "r607", "r615", "r619", "r628", "r629", "r633", "r634", "r639", "r643", "r780", "r784", "r819", "r841", "r842", "r843", "r844", "r845"] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": [
"http://www.rezolutebio.com/role/DisclosureLicenseAgreementsDetails",
"http://www.rezolutebio.com/role/DisclosureShareholdersEquityExchangeAgreementDetails",
"http://www.rezolutebio.com/role/DisclosureShareholdersEquityPreFundedWarrantsDetails"], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "auth_ref": ["r228", "r229", "r230", "r231", "r277", "r285", "r314", "r315", "r316", "r324", "r371", "r424", "r433", "r450", "r474", "r476", "r484", "r512", "r513", "r573", "r575", "r577", "r578", "r584", "r593", "r594", "r607", "r615", "r619", "r628", "r629", "r633", "r634", "r639", "r643", "r780", "r784", "r819", "r841", "r842", "r843", "r844", "r845"] }, "rzlt_ReceivableFromExerciseOfStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rezolutebio.com/20240930", "localname": "ReceivableFromExerciseOfStockOptions", "crdr": "debit", "presentation": ["http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "Amount of receivable from exercise of stock options in non-cash investing or financing transactions.", "label": "Receivable From Exercise of Stock Options", "terseLabel": "Receivable from exercise of stock options" } } }, "auth_ref": [] },
"ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure" } } }, "auth_ref": ["r657", "r667", "r677", "r709"] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyDomain", "presentation": ["http://www.rezolutebio.com/role/DisclosureRelatedPartyTransactionsDetails"], "lang": { "en-us": { "role": { "label": "Related and Nonrelated Parties [Domain]", "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": ["r173", "r284", "r410", "r411", "r458", "r465", "r515", "r516", "r517", "r518", "r519", "r539", "r541", "r572"] }, "us-gaap_RelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyMember", "presentation": ["http://www.rezolutebio.com/role/DisclosureRelatedPartyTransactionsDetails"], "lang": { "en-us": { "role": { "label": "Related Party [Member]", "terseLabel": "Related Party", "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family." } } }, "auth_ref": ["r133", "r134", "r410", "r411", "r412", "r413", "r458", "r465", "r515", "r516", "r517", "r518", "r519", "r539", "r541", "r572"] }, "us-gaap_RelatedPartyTransactionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionAxis", "presentation": ["http://www.rezolutebio.com/role/DisclosureRelatedPartyTransactionsDetails"], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Axis]", "documentation": "Information by type of related party transaction." } } }, "auth_ref": ["r410", "r411", "r837"] }, "us-gaap_RelatedPartyTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionDomain", "presentation": ["http://www.rezolutebio.com/role/DisclosureRelatedPartyTransactionsDetails"], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Domain]", "documentation": "Transaction between related party." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionLineItems", "presentation": ["http://www.rezolutebio.com/role/DisclosureRelatedPartyTransactionsDetails"], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r173", "r546", "r547", "r550"] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "RELATED PARTY TRANSACTIONS" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [
"http://www.rezolutebio.com/role/DisclosureRelatedPartyTransactionsDetails"], "lang": { "en-us": { "role": { "label": "Related and Nonrelated Parties [Axis]", "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": ["r173", "r284", "r410", "r411", "r458", "r465", "r515", "r516", "r517", "r518", "r519", "r539", "r541", "r572", "r837"] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": ["http://www.rezolutebio.com/role/DisclosureRelatedPartyTransactions"], "lang": { "en-us": { "role": { "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "RELATED PARTY TRANSACTIONS", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": ["r407", "r408", "r409", "r411", "r414", "r492", "r493", "r494", "r548", "r549", "r550", "r569", "r571"] },
"srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": ["http://www.rezolutebio.com/role/DisclosureLicenseAgreementsDetails",
"http://www.rezolutebio.com/role/DisclosureLiquidityDetails", "http://www.rezolutebio.com/role/DisclosureRelatedPartyTransactionsDetails"], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]" } } }, "auth_ref": ["r135", "r136", "r245", "r262", "r413", "r434", "r456", "r598", "r599"] }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis", "presentation": ["http://www.rezolutebio.com/role/DisclosureLicenseAgreementsDetails",
"http://www.rezolutebio.com/role/DisclosureLiquidityDetails"], "lang": { "en-us": { "role": { "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]", "documentation": "Information by form of arrangement related to research and development." } } }, "auth_ref": ["r326", "r813"] }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems", "presentation": [
"http://www.rezolutebio.com/role/DisclosureLicenseAgreementsDetails"], "lang": { "en-us": { "role": { "label": "Research and Development Arrangement, Contract to Perform for Others [Line Items]", "terseLabel": "License Agreements", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r326", "r813"] }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain", "presentation": ["http://www.rezolutebio.com/role/DisclosureLicenseAgreementsDetails", "http://www.rezolutebio.com/role/DisclosureLiquidityDetails"], "lang": { "en-us": { "role": { "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]", "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others." } } }, "auth_ref": ["r326", "r813"] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "presentation": [
"http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Research and Development Expense", "verboseLabel": "Research and development", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": ["r325", "r595", "r605", "r846"] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [
"http://www.rezolutebio.com/role/DisclosureOperatingLeasesOperatingLeaseExpenseDetails",

"http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsShareBasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label": "Research and Development Expense [Member]", "terseLabel": "Research and Development Expense", "verboseLabel": "Research and development", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date:" } } }, "auth_ref": ["r658", "r668", "r678", "r710"] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } }, "auth_ref": ["r659", "r669", "r679", "r711"] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "auth_ref": ["r666", "r676", "r686", "r718"] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "presentation": ["http://www.rezolutebio.com/role/DisclosureLiquidityDetails", "http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r57", "r79", "r463", "r481", "r483", "r490", "r523", "r637"] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": ["http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedStatementsOfShareholdersEquity"], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r104", "r138", "r139", "r140", "r142", "r147", "r149", "r151", "r210", "r211", "r222", "r334", "r335", "r340", "r341", "r342", "r344", "r345", "r346", "r355", "r357", "r358", "r360", "r363", "r393", "r395", "r478", "r480", "r496", "r853"] }, "rzlt_RisksAndUncertaintiesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.rezolutebio.com/20240930", "localname": "RisksAndUncertaintiesPolicyTextBlock", "presentation": ["http://www.rezolutebio.com/role/DisclosureNatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the risks and uncertainties during the reporting period.", "label": "Risks and Uncertainties [Policy Text Block]", "verboseLabel": "Risks and Uncertainties" } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": ["r727"] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": ["r727"] }, "rzlt_SaleOfStockAdditionalSharesOptionPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://www.rezolutebio.com/20240930", "localname": "SaleOfStockAdditionalSharesOptionPricePerShare", "presentation": ["http://www.rezolutebio.com/role/DisclosureShareholdersEquity2024UnderwrittenOfferingDetails"], "lang": { "en-us": { "role": { "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the additional shares option of a stock transaction.", "label": "Sale of stock, Additional Shares Option, price per share" } } }, "auth_ref": [] }, "rzlt_SaleOfStockCommissionAgreedToPayAsPercentageOnGrossSalesPrice": { "xbrltype": "percentItemType", "nsuri": "http://www.rezolutebio.com/20240930", "localname": "SaleOfStockCommissionAgreedToPayAsPercentageOnGrossSalesPrice", "presentation": ["http://www.rezolutebio.com/role/DisclosureShareholdersEquityJefferiesOpenMarketSalesAgreementDetails"], "lang": { "en-us": { "role": { "documentation": "Percentage of commission agreed to pay as a percentage on gross sales price.", "label": "Sale of Stock, Commission Agreed to Pay as a Percentage on Gross Sales Price", "terseLabel": "Percentage of commission agreed" } } }, "auth_ref": [] }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockConsiderationReceivedOnTransaction", "crdr": "debit", "presentation": ["http://www.rezolutebio.com/role/DisclosureLiquidityDetails", "http://www.rezolutebio.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquity2024PrivatePlacementDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquity2024UnderwrittenOfferingDetails"], "lang": { "en-us": { "role": { "label": "Sale of Stock, Consideration Received on Transaction", "terseLabel": "Sale of stock received on transaction", "documentation": "Cash received on stock transaction after deduction of issuance costs." } } }, "auth_ref": [] }, "rzlt_SaleOfStockMaximumAmountAgreedToSellAsPerOpenMarketSalesAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rezolutebio.com/20240930", "localname": "SaleOfStockMaximumAmountAgreedToSellAsPerOpenMarketSalesAgreement", "crdr": "credit", "presentation": ["http://www.rezolutebio.com/role/DisclosureShareholdersEquityJefferiesOpenMarketSalesAgreementDetails"], "lang": { "en-us": { "role": { "documentation": "Maximum amount agreed to sell as per open market sales agreement.", "label": "Sale of Stock, Maximum Amount Agreed to Sell as Per Open Market Sales Agreement", "terseLabel": "Amount agreed to sell as per open market sales agreement" } } }, "auth_ref": [] }, "rzlt_SaleOfStockMaximumAmountRemainingForSaleAsPerOpenMarketSalesAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rezolutebio.com/20240930", "localname": "SaleOfStockMaximumAmountRemainingForSaleAsPerOpenMarketSalesAgreement", "crdr": "credit", "presentation": ["http://www.rezolutebio.com/role/DisclosureShareholdersEquityJefferiesOpenMarketSalesAgreementDetails"], "lang": { "en-us": { "role": { "documentation": "Maximum amount remaining for sale as per open market sales agreement.", "label": "Sale of Stock, Maximum Amount Remaining for Sale as Per Open Market Sales Agreement", "terseLabel": "Sales agreement amounts" } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": ["http://www.rezolutebio.com/role/DisclosureLiquidityDetails", "http://www.rezolutebio.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquity2024PrivatePlacementDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquity2024UnderwrittenOfferingDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityJefferiesOpenMarketSalesAgreementDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityPreFundedWarrantsDetails", "http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedStatementsOfShareholdersEquity"], "lang": { "en-us": { "role": { "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "presentation": ["http://www.rezolutebio.com/role/DisclosureShareholdersEquityJefferiesOpenMarketSalesAgreementDetails"], "lang": { "en-us": { "role": { "label": "Sale of Stock, Number of Shares Issued in Transaction", "terseLabel": "Common stock to sales agreement", "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction." } } }, "auth_ref": [] }, "rzlt_ScenarioAfterClinicalAndRegulatoryMilestonesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rezolutebio.com/20240930", "localname": "ScenarioAfterClinicalAndRegulatoryMilestonesMember", "presentation": ["http://www.rezolutebio.com/role/DisclosureLicenseAgreementsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to after the clinical and regulatory milestones.", "label": "Scenario, After Clinical and Regulatory Milestones [Member]", "terseLabel": "After Clinical and Regulatory Milestones" } } }, "auth_ref": [] }, "us-gaap_ScenarioPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScenarioPlanMember", "presentation": ["http://www.rezolutebio.com/role/DisclosureLicenseAgreementsDetails", "http://www.rezolutebio.com/role/DisclosureLiquidityDetails"], "lang": { "en-us": { "role": { "label": "Scenario, Plan [Member]", "terseLabel": "Scenario, Plan", "verboseLabel": "Plan", "documentation": "The scenario under which facts represent plans as distinct from actual." } } }, "auth_ref": [] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioUnspecifiedDomain", "presentation": ["http://www.rezolutebio.com/role/DisclosureLicenseAgreementsDetails", "http://www.rezolutebio.com/role/DisclosureLiquidityDetails"], "lang": { "en-us": { "role": { "label": "Scenario [Domain]" } } }, "auth_ref": ["r152", "r286", "r739", "r761"] }, "rzlt_ScenarioUponClinicalAndRegulatoryMilestonesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rezolutebio.com/20240930", "localname": "ScenarioUponClinicalAndRegulatoryMilestonesMember", "presentation": ["http://www.rezolutebio.com/role/DisclosureLicenseAgreementsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to upon the clinical and regulatory milestones.", "label": "Scenario, Upon Clinical and Regulatory Milestones [Member]", "terseLabel": "Upon Clinical and Regulatory Milestones" } } }, "auth_ref": [] }, "rzlt_ScenarioUponDosingOfLastPatientMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rezolutebio.com/20240930", "localname": "ScenarioUponDosingOfLastPatientMember", "presentation": ["http://www.rezolutebio.com/role/DisclosureLicenseAgreementsDetails", "http://www.rezolutebio.com/role/DisclosureLiquidityDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to dosing of the last patient milestones.", "label": "Scenario, Upon Dosing Of The Last Patient [Member]", "terseLabel": "Scenario, Upon Dosing Of The Last Patient" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",

"presentation": ["http://www.rezolutebio.com/role/DisclosureNetLossPerShareAntiDilutiveDetails",
"http://www.rezolutebio.com/role/DisclosureNetLossPerShareWeightedAverageNumberOfSharesOutstandingDetails"], "lang": { "en-us": { "role": {
"label": "Antidilutive Security, Excluded EPS Calculation [Table]", "documentation": "Disclosure of information about security that could
potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS." } } }, "auth_ref": ["r18"] }, "us-
gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
"presentation": ["http://www.rezolutebio.com/role/DisclosureNetLossPerShareTables"], "lang": { "en-us": { "role": { "label": "Schedule of
Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of potential common stock
equivalents were excluded from the computation of diluted net loss per share", "documentation": "Tabular disclosure of securities (including those
issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included
in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by
antidilutive securities." } } }, "auth_ref": ["r18"] }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "presentation": [
"http://www.rezolutebio.com/role/DisclosureInvestmentsInMarketableDebtSecuritiesCashAndCashEquivalentsAndMarketableSecuritiesHeldDetails"
], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale [Line Items]", "terseLabel": "INVESTMENTS IN MARKETABLE DEBT
SECURITIES", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable
information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r176", "r177", "r178", "r179", "r180",
"r181", "r182", "r184", "r185", "r186", "r187", "r188"] }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "presentation": [
"http://www.rezolutebio.com/role/DisclosureInvestmentsInMarketableDebtSecuritiesTables"], "lang": { "en-us": { "role": { "label": "Schedule of
Available-for-Sale Securities Reconciliation [Table Text Block]", "terseLabel": "Summary of unrealized gains and losses that result in differences
between the amortized cost basis and fair value of the Company's marketable debt securities", "documentation": "Tabular disclosure of the
reconciliation of available-for-sale securities from cost basis to fair value." } } }, "auth_ref": [] }, "us-
gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": [
"http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsTables"], "lang": { "en-us": { "role": { "label": "Share-Based
Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Schedule of share-based compensation expense",
"documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to
statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in
financial statement." } } }, "auth_ref": ["r32"] }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
"presentation": ["http://www.rezolutebio.com/role/DisclosureRelatedPartyTransactionsDetails"], "lang": { "en-us": { "role": { "label": "Related
Party Transaction [Table]", "documentation": "Disclosure of information about related party transaction." } } }, "auth_ref": ["r40", "r41", "r546",
"r547", "r550"] }, "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable",
"presentation": ["http://www.rezolutebio.com/role/DisclosureLicenseAgreementsDetails"], "lang": { "en-us": { "role": { "label": "Research and
Development, Contract to Perform for Others [Table]", "documentation": "Disclosure of information about research and development arrangement
accounted for as contract to perform research and development for others. Includes, but is not limited to, royalty arrangement, purchase provision,
license agreement, and commitment to provide additional funding." } } }, "auth_ref": ["r326", "r813"] }, "us-
gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
"presentation": ["http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrants2022EmployeeStockPurchasePlanDetails",
"http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsPreFundedWarrantsDetails",
"http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsShareBasedCompensationExpenseDetails",
"http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionPlansDetails",
"http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsSummaryOfLegacyWarrantsDetails",
"http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsWeightedAverageAssumptionsDetails"], "lang": { "en-us": {
"role": { "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of
information about share-based payment arrangement." } } }, "auth_ref": ["r288", "r290", "r292", "r293", "r294", "r295", "r296", "r297", "r298",
"r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317"]
}, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [
"http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsTables"], "lang": { "en-us": { "role": { "label": "Share-Based
Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Schedule of the stock option plans", "documentation": "Tabular
disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures,
and weighted-average grant date fair value." } } }, "auth_ref": ["r8", "r9", "r80"] }, "us-
gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
"presentation": ["http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsTables"], "lang": { "en-us": { "role": { "label":
"Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Schedule of the fair value of
stock options", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock
options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c)
expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": ["r82"] }, "us-
gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfStockByClassTable", "presentation": ["http://www.rezolutebio.com/role/DisclosureShareholdersEquity2024PrivatePlacementDetails",
"http://www.rezolutebio.com/role/DisclosureShareholdersEquity2024UnderwrittenOfferingDetails",
"http://www.rezolutebio.com/role/DisclosureShareholdersEquityJefferiesOpenMarketSalesAgreementDetails",
"http://www.rezolutebio.com/role/DisclosureShareholdersEquityPreFundedWarrantsDetails"], "lang": { "en-us": { "role": { "label": "Stock, Class of
Stock [Table]", "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and
preferred stocks." } } }, "auth_ref": ["r23", "r24", "r25", "r26", "r27", "r28", "r75", "r77", "r78", "r79", "r110", "r111", "r112", "r168", "r260",
"r261", "r262", "r264", "r267", "r272", "r274", "r486", "r487", "r488", "r489", "r615", "r738", "r755"] }, "us-
gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "presentation": [
"http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsTables",
"http://www.rezolutebio.com/role/DisclosureShareholdersEquityTables"], "lang": { "en-us": { "role": { "label": "Schedule of Stockholders' Equity
Note, Warrants or Rights [Table Text Block]", "terseLabel": "Schedule of warrant activity", "documentation": "Tabular disclosure of warrants or
rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from
the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return
potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are
exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical
option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of
securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the
warrant or right is exercisable." } } }, "auth_ref": ["r30"] }, "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
"presentation": ["http://www.rezolutebio.com/role/DisclosureNetLossPerShareTables"], "lang": { "en-us": { "role": { "label": "Schedule of
Weighted Average Number of Shares [Table Text Block]", "terseLabel": "Schedule of weighted average shares outstanding", "documentation":
"Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per
share (or unit)." } } }, "auth_ref": ["r17"] }, "rzlt_SecuritiesExchangeAgreementMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.rezolutebio.com/20240930", "localname": "SecuritiesExchangeAgreementMember", "presentation": [
"http://www.rezolutebio.com/role/DisclosureShareholdersEquityExchangeAgreementDetails",
"http://www.rezolutebio.com/role/DisclosureShareholdersEquityPreFundedWarrantsDetails"], "lang": { "en-us": { "role": { "documentation":
"Represents information pertaining to securities exchange agreement.", "label": "Securities Exchange Agreement [Member]", "terseLabel":
"Securities exchange agreement" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [
"http://www.rezolutebio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security",
"documentation": "Title of a 12(b) registered security." } } }, "auth_ref": ["r652"] }, "dei_SecurityExchangeName": { "xbrltype":
"edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [

"http://www.rezolutebio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": ["r654"] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "presentation": ["http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Noncash Expense", "verboseLabel": "Share-based compensation expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": ["r3"] }, "us-gaap_ShareBasedCompensationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationAbstract", "lang": { "en-us": { "role": { "label": "SHARE-BASED COMPENSATION AND WARRANTS" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": ["http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsWeightedAverageAssumptionsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "verboseLabel": "Dividend yield", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": ["r315"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": ["http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsWeightedAverageAssumptionsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "verboseLabel": "Expected volatility", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": ["r314"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": ["http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsWeightedAverageAssumptionsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "verboseLabel": "Risk free interest rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": ["r316"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": ["http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrants2022EmployeeStockPurchasePlanDetails", "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsPreFundedWarrantsDetails", "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsShareBasedCompensationExpenseDetails", "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionPlansDetails", "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsSummaryOfLegacyWarrantsDetails", "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsWeightedAverageAssumptionsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r288", "r290", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": ["http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionPlansDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized", "terseLabel": "Number of shares authorized", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": ["r621"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": ["http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionPlansDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "terseLabel": "Number of shares available", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": ["r31"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "presentation": ["http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionsOutstandingDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]", "verboseLabel": "Weighted Average Remaining Contractual Life" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "crdr": "debit", "presentation": ["http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionsOutstandingDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value", "terseLabel": "Total intrinsic value of exercised", "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares." } } }, "auth_ref": ["r310"] }, "rzlt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rezolutebio.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodFairValue", "crdr": "credit", "presentation": ["http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionsOutstandingDetails"], "lang": { "en-us": { "role": { "documentation": "Fair value of options granted. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grant in Period, Fair Value", "terseLabel": "Fair value of options granted" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": ["http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionsOutstandingDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "netLabel": "Grants to employees", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": ["r299"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": ["http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionsOutstandingDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average grant date fair value, granted", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": ["r309"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": ["http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionsOutstandingDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "verboseLabel": "Intrinsic value of outstanding options", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": ["r31"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",

"presentation": ["http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionPlansDetails",
"http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionsOutstandingDetails"], "lang": { "en-us": { "role": {
"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel":
"Outstanding, ending", "periodStartLabel": "Outstanding, beginning", "terseLabel": "Number of shares outstanding", "documentation": "Number of
options outstanding, including both vested and non-vested options." } } }, "auth_ref": ["r295", "r296"] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation": [
"http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionsOutstandingDetails"], "lang": { "en-us": { "role": {
"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "verboseLabel": "Number
of Options", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } },
"auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice":
{ "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [
"http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionsOutstandingDetails"], "lang": { "en-us": { "role": {
"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
"periodEndLabel": "Outstanding, ending", "periodStartLabel": "Outstanding, beginning", "documentation": "Weighted average price at which
grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": ["r295", "r296"] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
"presentation": ["http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionsOutstandingDetails"], "lang": {
"en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average
Exercise Price [Abstract]", "verboseLabel": "Weighted Average Exercise Price" } } }, "auth_ref": [] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [
"http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrants2022EmployeeStockPurchasePlanDetails",
"http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsWeightedAverageAssumptionsDetails",
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types",
"documentation": "Award under share-based payment arrangement." } } }, "auth_ref": ["r292", "r293", "r294", "r295", "r296", "r297", "r298",
"r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317"]
}, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
"xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [
"http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionsOutstandingDetails"], "lang": { "en-us": { "role": {
"label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise
Price", "terseLabel": "Exercises", "documentation": "Weighted average price at which option holders acquired shares when converting their stock
options into shares." } } }, "auth_ref": ["r300"] }, "us-
gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
"xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation":
["http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionsOutstandingDetails"], "lang": { "en-us": { "role":
{ "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise
Price", "verboseLabel": "Forfeited", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with
respect to stock options that were terminated." } } }, "auth_ref": ["r301"] }, "us-
gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype":
"perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [
"http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionsOutstandingDetails"], "lang": { "en-us": { "role": {
"label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
"verboseLabel": "Granted", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by
exercise of options." } } }, "auth_ref": ["r299"] },
"rzlt_ShareBasedPaymentArrangementOptionSharesAuthorizedOutstandingAndAvailableForFutureGrants": { "xbrltype": "textBlockItemType",
"nsuri": "http://www.rezolutebio.com/20240930", "localname":
"ShareBasedPaymentArrangementOptionSharesAuthorizedOutstandingAndAvailableForFutureGrants", "presentation": [
"http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsTables"], "lang": { "en-us": { "role": { "documentation": "The
tabular disclosure of the number of shares authorized, outstanding, and available for future grants under stock option.", "label": "Share-based
Payment Arrangement, Option, Shares Authorized, Outstanding, and Available for Future Grants", "terseLabel": "Schedule of the number of shares
authorized, outstanding, and available for future grants under stock option" } } }, "auth_ref": [] }, "us-
gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [
"http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsWeightedAverageAssumptionsDetails"], "lang": { "en-us": {
"role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
"verboseLabel": "Expected term (years)", "documentation": "Expected term of award under share-based payment arrangement, in
'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [
"r313"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": {
"xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [
"http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsWeightedAverageAssumptionsDetails"], "lang": { "en-us": {
"role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price",
"verboseLabel": "Market price of common stock on grant date", "documentation": "Weighted average grant-date fair value of non-vested options
outstanding." } } }, "auth_ref": [] }, "us-
gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
"xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
"presentation": ["http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionsOutstandingDetails"], "lang": {
"en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average
Remaining Contractual Term", "terseLabel": "Remaining contractual term (years)", "documentation": "Weighted average remaining contractual
term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five
months, and thirteen days." } } }, "auth_ref": ["r81"] }, "us-
gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemaining
{ "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingCont
"presentation": ["http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionsOutstandingDetails"], "lang": {
"en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest,
Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Vested (years)", "documentation": "Weighted average remaining
contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents
reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not
been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } },
"auth_ref": ["r311"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "crdr": "credit", "presentation": [
"http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionsOutstandingDetails"], "lang": { "en-us": { "role": {
"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value", "verboseLabel":
"Aggregate intrinsic value of vested stock options", "documentation": "Fair value of options vested. Excludes equity instruments other than
options, for example, but not limited to, share units, stock appreciation rights, restricted stock." } } }, "auth_ref": ["r310"] }, "us-
gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": { "xbrltype": "sharesItemType", "nsuri":

"http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares", "presentation": ["http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionsOutstandingDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares", "terseLabel": "Vested, ending", "documentation": "Number of options vested." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue", "presentation": ["http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionsOutstandingDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value", "terseLabel": "Vested, ending", "documentation": "Weighted average grant-date fair value of options vested." } } }, "auth_ref": [] }, "us-gaap_SharesIssuedPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesIssuedPricePerShare", "presentation": ["http://www.rezolutebio.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquity2024PrivatePlacementDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquity2024UnderwrittenOfferingDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityPreFundedWarrantsDetails"], "lang": { "en-us": { "role": { "label": "Shares Issued, Price Per Share", "terseLabel": "Shares issue price", "verboseLabel": "Issuance price (in dollars per share)", "documentation": "Per share or per unit amount of equity securities issued." } } }, "auth_ref": [] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesOutstanding", "presentation": ["http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedStatementsOfShareholdersEquity"], "lang": { "en-us": { "role": { "label": "Shares, Outstanding", "periodEndLabel": "Balance ending (in shares)", "periodStartLabel": "Balance beginning (in shares)", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": ["http://www.rezolutebio.com/role/DisclosureNatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Significant Accounting Policies", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": ["r69", "r129"] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": ["http://www.rezolutebio.com/role/DisclosureNetLossPerShareWeightedAverageNumberOfSharesOutstandingDetails"], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": ["r102", "r110", "r111", "r112", "r131", "r156", "r157", "r159", "r161", "r168", "r169", "r209", "r233", "r235", "r236", "r237", "r240", "r241", "r260", "r261", "r264", "r267", "r274", "r385", "r486", "r487", "r488", "r489", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r522", "r543", "r565", "r586", "r587", "r588", "r589", "r590", "r738", "r755", "r763"] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": ["http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedStatementsOfShareholdersEquity"], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": ["r7", "r55", "r58", "r59", "r104", "r121", "r122", "r123", "r138", "r139", "r140", "r142", "r147", "r149", "r151", "r167", "r210", "r211", "r222", "r276", "r334", "r335", "r340", "r341", "r342", "r344", "r345", "r346", "r355", "r356", "r357", "r358", "r359", "r360", "r363", "r386", "r387", "r388", "r389", "r390", "r391", "r393", "r395", "r406", "r469", "r478", "r479", "r480", "r496", "r565"] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": ["http://www.rezolutebio.com/role/DisclosureLiquidityDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityExchangeAgreementDetails", "http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedStatementsOfShareholdersEquity"], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r138", "r139", "r140", "r167", "r395", "r451", "r485", "r507", "r514", "r515", "r516", "r517", "r518", "r519", "r522", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r535", "r536", "r537", "r538", "r539", "r541", "r544", "r545", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r565", "r644"] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Unaudited Condensed Consolidated Statements of Cash Flows" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Unaudited Condensed Consolidated Balance Sheets" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Unaudited Condensed Consolidated Statements of Shareholders' Equity" } } }, "auth_ref": [] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementScenarioAxis", "presentation": ["http://www.rezolutebio.com/role/DisclosureLicenseAgreementsDetails", "http://www.rezolutebio.com/role/DisclosureLiquidityDetails"], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "auth_ref": ["r152", "r286", "r739", "r740", "r761"] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": ["http://www.rezolutebio.com/role/DisclosureLiquidityDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityExchangeAgreementDetails", "http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedStatementsOfShareholdersEquity"], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": ["r138", "r139", "r140", "r167", "r173", "r395", "r451", "r485", "r507", "r514", "r515", "r516", "r517", "r518", "r519", "r522", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r535", "r536", "r537", "r538", "r539", "r541", "r544", "r545", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r565", "r644"] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "auth_ref": ["r661", "r671", "r681", "r713"] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "presentation": ["http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrants2022EmployeeStockPurchasePlanDetails"], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "terseLabel": "Shares purchases", "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan." } } }, "auth_ref": ["r7", "r54", "r55", "r79"] }, "rzlt_StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants": { "xbrltype": "sharesItemType", "nsuri": "http://www.rezolutebio.com/20240930", "localname": "StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants", "presentation": ["http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedStatementsOfShareholdersEquity"], "lang": { "en-us": { "role": { "documentation": "Number of shares issued upon exercise of pre-funded warrants.", "label": "Stock Issued During Period, Shares, Exercise of Pre-funded Warrants", "verboseLabel": "Cashless exercise of pre-funded warrants (in shares)" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": ["http://www.rezolutebio.com/role/DisclosureLiquidityDetails", "http://www.rezolutebio.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquity2024PrivatePlacementDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquity2024UnderwrittenOfferingDetails", "http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedStatementsOfShareholdersEquity"], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, New Issues", "presentationGuidance": "Number of shares issued", "terseLabel": "Gross proceeds from issuance of common stock for cash (in shares)", "verboseLabel": "Number of shares issued", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": ["r7", "r54", "r55", "r79", "r486", "r565", "r587"] }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationForfeited", "presentation": ["http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionsOutstandingDetails"], "lang": { "en-us": { "role": { "label": "Shares Issued, Shares, Share-Based Payment Arrangement, Forfeited", "negatedLabel": "Forfeited", "documentation": "Number of shares (or other type of equity) forfeited during the period." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": ["http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionsOutstandingDetails", "http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedStatementsOfShareholdersEquity"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "negatedLabel": "Exercises", "verboseLabel": "Issuance of common stock upon exercise of stock options (in shares)", "documentation": "Number of share options (or share

```
units) exercised during the current period." } } }, "auth_ref": [ "r7", "r54", "r55", "r79", "r300" ] },
"rzlt_StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.rezolutebio.com/20240930", "localname": "StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants", "crdr": "credit",
"presentation": [ "http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedStatementsOfShareholdersEquity" ], "lang": { "en-
us": { "role": { "documentation": "Value of stock issued upon exercise of pre-funded warrants", "label": "Stock Issued During Period, Value,
Exercise of Pre-funded Warrants", "verboseLabel": "Cashless exercise of pre-funded warrants" } } }, "auth_ref": [] }, "us-
gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [
"http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedStatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": {
"label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Gross proceeds from issuance of common stock for cash",
"documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a
secondary public offering." } } }, "auth_ref": [ "r7", "r54", "r55", "r79", "r496", "r565", "r587", "r650" ] }, "us-
gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": [
"http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedStatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": {
"label": "Stock Issued During Period, Value, Stock Options Exercised", "verboseLabel": "Issuance of common stock upon exercise of stock options",
"documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": [ "r7", "r55", "r58", "r59", "r79" ] },
"rzlt_StockOptionVestingTimeBasedMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rezolutebio.com/20240930", "localname":
"StockOptionVestingTimeBasedMember", "presentation": [
"http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsWeightedAverageAssumptionsDetails" ], "lang": { "en-us": {
"role": { "documentation": "Represents information pertaining to stock options time based vesting.", "label": "Time-Based" } } }, "auth_ref": [] },
"us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity",
"crdr": "credit", "presentation": [ "http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets",
"http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedStatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": {
"label": "Equity, Attributable to Parent", "periodEndLabel": "Balance ending", "periodStartLabel": "Balance beginning", "totalLabel": "Total
shareholders' equity", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to
noncontrolling interest." } } }, "auth_ref": [ "r55", "r58", "r59", "r72", "r524", "r540", "r566", "r567", "r637", "r651", "r757", "r777", "r831", "r853" ]
}, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StockholdersEquityAbstract", "presentation": [ "http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets" ],
"lang": { "en-us": { "role": { "label": "Equity, Attributable to Parent [Abstract]", "terseLabel": "Shareholders' equity:" } } }, "auth_ref": [] }, "us-
gaap_StockholdersEquityNoteAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StockholdersEquityNoteAbstract", "lang": { "en-us": { "role": { "label": "SHAREHOLDERS' EQUITY" } } }, "auth_ref": [] }, "us-
gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareholdersEquity" ], "lang": { "en-
us": { "role": { "label": "Equity [Text Block]", "verboseLabel": "SHAREHOLDERS' EQUITY", "documentation": "The entire disclosure for equity." } }
}, "auth_ref": [ "r76", "r130", "r259", "r261", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r273", "r276", "r362", "r568",
"r570", "r591" ] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SubsequentEventLineItems", "presentation": [ "http://www.rezolutebio.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role":
{ "label": "Subsequent Event [Line Items]", "documentation": "Detail information of subsequent event by type. User is expected to use existing line
items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member
elements pertaining to a subsequent event." } } }, "auth_ref": [ "r392", "r416" ] }, "us-gaap_SubsequentEventMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventMember", "presentation": [
"http://www.rezolutebio.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Member]",
"terseLabel": "Subsequent Event", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements
are issued or available to be issued." } } }, "auth_ref": [ "r392", "r416" ] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTable", "presentation": [
"http://www.rezolutebio.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Table]",
"documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and
date when financial statements were issued." } } }, "auth_ref": [ "r392", "r416" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeAxis", "presentation": [
"http://www.rezolutebio.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]",
"documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be
issued." } } }, "auth_ref": [ "r392", "r416" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://www.rezolutebio.com/role/DisclosureSubsequentEventsDetails"
], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but
before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r392", "r416" ] }, "us-gaap_SubsequentEventsAbstract": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": {
"label": "SUBSEQUENT EVENTS" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsTextBlock", "presentation": [
"http://www.rezolutebio.com/role/DisclosureSubsequentEvents" ], "lang": { "en-us": { "role": { "label": "Subsequent Events [Text Block]",
"terseLabel": "SUBSEQUENT EVENTS", "documentation": "The entire disclosure for significant events or transactions that occurred after the
balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.
Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange
rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r415", "r417" ] }, "us-
gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SubsidiarySaleOfStockAxis", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLiquidityDetails",
"http://www.rezolutebio.com/role/DisclosureRelatedPartyTransactionsDetails",
"http://www.rezolutebio.com/role/DisclosureShareholdersEquity2024PrivatePlacementDetails",
"http://www.rezolutebio.com/role/DisclosureShareholdersEquity2024UnderwrittenOfferingDetails",
"http://www.rezolutebio.com/role/DisclosureShareholdersEquityJefferiesOpenMarketSalesAgreementDetails",
"http://www.rezolutebio.com/role/DisclosureShareholdersEquityPreFundedWarrantsDetails",
"http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedStatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": {
"label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "us-
gaap_SubstantialDoubtAboutGoingConcernTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SubstantialDoubtAboutGoingConcernTextBlock", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLiquidity" ], "lang": { "en-us": {
"role": { "label": "Substantial Doubt about Going Concern [Text Block]", "terseLabel": "LIQUIDITY", "documentation": "The entire disclosure when
substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that
raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or
events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events
that raise substantial doubt about the ability to continue as a going concern." } } }, "auth_ref": [ "r43" ] }, "us-
gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SupplementalCashFlowInformationAbstract", "presentation": [
"http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label":
"SUPPLEMENTAL FINANCIAL INFORMATION", "verboseLabel": "SUPPLEMENTARY CASH FLOW INFORMATION:" } } }, "auth_ref": [] },
"ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Tabular List
[Table Text Block]", "terseLabel": "Tabular List, Table" } } }, "auth_ref": [ "r707" ] }, "ecd_TotalShareholderRtnAmt": { "xbrltype":
"monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total
Shareholder Return Amount" } } }, "auth_ref": [ "r699" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]",
"terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": [ "r706" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement:" } } }, "auth_ref": [ "r726" ] },
"ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable",
"presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by
Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "auth_ref": [ "r728" ] }, "dei_TradingSymbol": { "xbrltype":
"tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [
```

"http://www.rezolutebio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": ["http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsFairValueOnRecurringBasisDetails", "http://www.rezolutebio.com/role/DisclosureInvestmentsInMarketableDebtSecuritiesCashAndCashEquivalentsAndMarketableSecuritiesHeldDetails"], "lang": { "en-us": { "role": { "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": ["r176", "r177", "r178", "r179", "r180", "r181", "r182", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r258", "r272", "r361", "r382", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r470", "r625", "r626", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r638", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r773", "r774", "r775", "r776", "r815", "r818", "r819", "r820", "r827", "r830"] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } }, "auth_ref": ["r729"] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "auth_ref": ["r730"] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Expiration Date", "terseLabel": "Expiration Date" } } }, "auth_ref": ["r730"] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r728"] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } }, "auth_ref": ["r728"] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate Available" } } }, "auth_ref": ["r731"] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" } } }, "auth_ref": ["r729"] }, "us-gaap_TreasuryStockSharesAcquired": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockSharesAcquired", "presentation": ["http://www.rezolutebio.com/role/DisclosureShareholdersEquityExchangeAgreementDetails"], "lang": { "en-us": { "role": { "label": "Treasury Stock, Shares, Acquired", "terseLabel": "Purchased shares of common stock", "documentation": "Number of shares that have been repurchased during the period and are being held in treasury." } } }, "auth_ref": ["r7", "r55", "r79"] }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockValueAcquiredCostMethod", "crdr": "debit", "presentation": ["http://www.rezolutebio.com/role/DisclosureShareholdersEquityExchangeAgreementDetails"], "lang": { "en-us": { "role": { "label": "Treasury Stock, Value, Acquired, Cost Method", "terseLabel": "Fair value of shares", "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method." } } }, "auth_ref": ["r7", "r29", "r79"] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfArrangementAxis", "presentation": ["http://www.rezolutebio.com/role/DisclosureLicenseAgreementsDetails", "http://www.rezolutebio.com/role/DisclosureLiquidityDetails"], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": ["r347"] }, "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "USGovernmentAgenciesDebtSecuritiesMember", "presentation": ["http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsFairValueOnRecurringBasisDetails", "http://www.rezolutebio.com/role/DisclosureInvestmentsInMarketableDebtSecuritiesCashAndCashEquivalentsAndMarketableSecuritiesHeldDetails"], "lang": { "en-us": { "role": { "label": "US Government Agencies Debt Securities [Member]", "terseLabel": "U.S. Government agencies", "verboseLabel": "Obligations of U.S. government agencies", "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB)." } } }, "auth_ref": ["r601", "r616", "r848"] }, "us-gaap_USTreasurySecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "USTreasurySecuritiesMember", "presentation": ["http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsFairValueOnRecurringBasisDetails", "http://www.rezolutebio.com/role/DisclosureInvestmentsInMarketableDebtSecuritiesCashAndCashEquivalentsAndMarketableSecuritiesHeldDetails"], "lang": { "en-us": { "role": { "label": "US Treasury Securities [Member]", "terseLabel": "U.S. Government treasuries", "verboseLabel": "U.S. Treasury obligations", "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)." } } }, "auth_ref": ["r601", "r616", "r618", "r625", "r848"] }, "rzlt_UnderwritersOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rezolutebio.com/20240930", "localname": "UnderwritersOptionMember", "presentation": ["http://www.rezolutebio.com/role/DisclosureShareholdersEquity2024UnderwrittenOfferingDetails"], "lang": { "en-us": { "role": { "documentation": "Underwriters Option.", "label": "Underwriters Option [Member]", "terseLabel": "Underwriters Option" } } }, "auth_ref": [] }, "rzlt_UnderwritingDiscountsAndCommissions": { "xbrltype": "percentItemType", "nsuri": "http://www.rezolutebio.com/20240930", "localname": "UnderwritingDiscountsAndCommissions", "presentation": ["http://www.rezolutebio.com/role/DisclosureShareholdersEquity2024UnderwrittenOfferingDetails"], "lang": { "en-us": { "role": { "documentation": "The percentage of underwriting discounts and commissions.", "label": "Underwriting Discounts and Commissions", "terseLabel": "Underwriting discounts and commissions (In percentage)" } } }, "auth_ref": [] }, "rzlt_UnderwritingDiscountsAndCommissionsExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rezolutebio.com/20240930", "localname": "UnderwritingDiscountsAndCommissionsExpense", "crdr": "debit", "presentation": ["http://www.rezolutebio.com/role/DisclosureShareholdersEquity2024UnderwrittenOfferingDetails"], "lang": { "en-us": { "role": { "documentation": "The costs for underwriter discounts, commissions and other fees.", "label": "Underwriting Discounts And Commissions Expense", "terseLabel": "Underwriting discounts and commissions expense" } } }, "auth_ref": [] }, "rzlt_UnderwrittenPublicOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rezolutebio.com/20240930", "localname": "UnderwrittenPublicOfferingMember", "presentation": ["http://www.rezolutebio.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquity2024UnderwrittenOfferingDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityPreFundedWarrantsDetails", "http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedStatementsOfShareholdersEquity"], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to underwritten Public Offering.", "label": "Underwritten Public Offering [Member]", "terseLabel": "Underwritten Public Offering", "verboseLabel": "Underwritten Public Offering" } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent", "terseLabel": "Underlying Security Market Price Change" } } }, "auth_ref": ["r725"] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": ["http://www.rezolutebio.com/role/DisclosureNatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Use of Estimates, Policy [Policy Text Block]", "verboseLabel": "Use of Estimates", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": ["r19", "r20", "r21", "r97", "r98", "r99", "r100"] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]", "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year" } } }, "auth_ref": ["r695"] }, "rzlt_WarrantDerivativeLiabilityNonCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rezolutebio.com/20240930", "localname": "WarrantDerivativeLiabilityNonCurrent", "crdr": "credit", "presentation": ["http://www.rezolutebio.com/role/DisclosureShareholdersEquityExchangeAgreementDetails", "http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "documentation": "Fair value as of the balance sheet date of the warrants derivative classified as a liability.", "label": "Warrant Derivative Liability, Non-Current",

"terseLabel": "Warrant derivative liability" } } }, "auth_ref": [] }, "us-gaap_WarrantsAndRightsOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantsAndRightsOutstanding", "crdr": "credit", "presentation": ["http://www.rezolutebio.com/role/DisclosureShareholdersEquityExchangeAgreementDetails"], "lang": { "en-us": { "role": { "label": "Warrants and Rights Outstanding", "verboseLabel": "Estimated fair value of warrants", "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price." } } }, "auth_ref": ["r818", "r819", "r820"] }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantsAndRightsOutstandingTerm", "presentation": ["http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsSummaryOfLegacyWarrantsDetails"], "lang": { "en-us": { "role": { "label": "Warrants and Rights Outstanding, Term", "terseLabel": "Weighted average remaining contractual term", "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r818", "r819", "r820"] }, "rzlt_WarrantsExercisableOwnershipBlockerPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.rezolutebio.com/20240930", "localname": "WarrantsExercisableOwnershipBlockerPercentage", "presentation": ["http://www.rezolutebio.com/role/DisclosureShareholdersEquityExchangeAgreementDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityPreFundedWarrantsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the designated ownership percentage by holder not exceeding the specified percentage for exercise of warrants.", "label": "Warrants Exercisable, Ownership Blocker Percentage", "terseLabel": "Warrants exercisable, ownership blocker percentage" } } }, "auth_ref": [] }, "rzlt_WarrantsExercisedGrantedOrExpired": { "xbrltype": "sharesItemType", "nsuri": "http://www.rezolutebio.com/20240930", "localname": "WarrantsExercisedGrantedOrExpired", "presentation": ["http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsSummaryOfLegacyWarrantsDetails"], "lang": { "en-us": { "role": { "documentation": "Number of warrants exercised, granted or expired.", "label": "Warrants Exercised, Granted Or Expired", "terseLabel": "Warrants granted, exercised or expired" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": ["http://www.rezolutebio.com/role/DisclosureNetLossPerShareWeightedAverageNumberOfSharesOutstandingDetails", "http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted average number of common shares outstanding - diluted (in shares)", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": ["r155", "r161"] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": ["http://www.rezolutebio.com/role/DisclosureNetLossPerShareWeightedAverageNumberOfSharesOutstandingDetails", "http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted average number of common shares outstanding - basic (in shares)", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": ["r154", "r161"] }, "rzlt_XomaCorporationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rezolutebio.com/20240930", "localname": "XomaCorporationMember", "presentation": ["http://www.rezolutebio.com/role/DisclosureLicenseAgreementsDetails", "http://www.rezolutebio.com/role/DisclosureLiquidityDetails"], "lang": { "en-us": { "role": { "documentation": "XOMA Corporation [Member]", "label": "XOMA Corporation [Member]", "terseLabel": "XOMA Corporation" } } }, "auth_ref": [] }, "rzlt_XomaLicenseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rezolutebio.com/20240930", "localname": "XomaLicenseAgreementMember", "presentation": ["http://www.rezolutebio.com/role/DisclosureLicenseAgreementsDetails", "http://www.rezolutebio.com/role/DisclosureLiquidityDetails"], "lang": { "en-us": { "role": { "documentation": "Xoma License Agreement [Member]", "label": "Xoma License Agreement [Member]", "terseLabel": "Xoma License Agreement" } } }, "auth_ref": [] }, "rzlt_XomaUsLlcMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rezolutebio.com/20240930", "localname": "XomaUsLlcMember", "presentation": ["http://www.rezolutebio.com/role/DisclosureLicenseAgreementsDetails", "http://www.rezolutebio.com/role/DisclosureLiquidityDetails"], "lang": { "en-us": { "role": { "documentation": "XOMA (US) LLC [Member]", "label": "XOMA (US) LLC [Member]", "terseLabel": "XOMA (US) LLC" } } }, "auth_ref": [] }, "rzlt_Year2015PlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rezolutebio.com/20240930", "localname": "Year2015PlanMember", "presentation": ["http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionPlansDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to 2015 plan.", "label": "2015 Plan" } } }, "auth_ref": [] }, "rzlt_Year2016PlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rezolutebio.com/20240930", "localname": "Year2016PlanMember", "presentation": ["http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionPlansDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to 2016 plan.", "label": "2016 Plan" } } }, "auth_ref": [] }, "rzlt_Year2019PlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rezolutebio.com/20240930", "localname": "Year2019PlanMember", "presentation": ["http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionPlansDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to year 2019 plan.", "label": "2019 Plan" } } }, "auth_ref": [] }, "rzlt_Year2021PlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rezolutebio.com/20240930", "localname": "Year2021PlanMember", "presentation": ["http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionPlansDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to year 2021 plan.", "label": "2021 Plan" } } }, "auth_ref": [] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]", "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested" } } }, "auth_ref": ["r693"] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "40", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205-40/tableOfContent" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" },

"r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "250", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/250/tableOfContent" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/275/tableOfContent" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481573/470-10-45-12A" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/810/tableOfContent" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "15", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/815-15/tableOfContent" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/942-320/tableOfContent" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/275/tableOfContent" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1403", "Paragraph": "b", "Publisher": "SEC" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r117": { "role":

{"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260",

"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/320/tableOfContent" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-10" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2A" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14" }, "r215": { "role":

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16" }, r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5" }, r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1" }, r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-3A" }, r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7" }, r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9" }, r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB",

"URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification",

"Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/740/tableOfContent" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section":

"65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/842-20/tableOfContent" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/850/tableOfContent" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",

"Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/855/tableOfContent" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r459": { "role":

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r505": { "role":

{"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, r506: { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, r507: { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, r508: { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, r509: { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2" }, r510: { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, r511: { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, r512: { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, r513: { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, r514: { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, r515: { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, r516: { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, r517: { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, r518: { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, r519: { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, r520: { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, r521: { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, r522: { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, r523: { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, r524: { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, r525: { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, r526: { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, r527: { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, r528: { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, r529: { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, r530: { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, r531: { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, r532: { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, r533: { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, r534: { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, r535: { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, r536: { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, r537: { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, r538: { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, r539: { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, r540: { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, r541: { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, r542: { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, r543: { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3" }, r544: { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, r545: { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, r546: { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, r547: { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, r548: { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, r549: { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946",

"SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B" }, r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1" }, r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954",

"SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, r596": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, r597": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16" }, r598": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21" }, r599": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, r600": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, r601": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, r602": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, r603": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, r604": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, r605": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, r606": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, r607": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, r608": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479294/326-20-55-12" }, r609": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8" }, r610": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, r611": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, r612": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, r613": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, r614": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F" }, r615": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, r616": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, r617": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, r618": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, r619": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, r620": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, r621": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, r622": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, r623": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, r624": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, r625": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, r626": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "101", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101" }, r627": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, r628": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, r629": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, r630": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, r631": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, r632": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, r633": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, r634": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, r635": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, r636": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, r637": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, r638": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4" }, r639": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, r640": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-17" }, r641": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50",

"Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r642": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r643": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r644": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r645": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r646": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r647": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r648": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r649": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r650": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r651": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r652": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r653": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r654": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r655": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r656": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r657": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r658": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r659": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r660": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r661": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r662": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r663": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r664": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r665": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r666": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r667": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r668": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r669": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r670": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r671": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r672": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r673": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r674": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r675": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r676": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r677": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r678": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r679": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r680": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r681": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r682": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r683": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r684": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r685": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r686": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r687": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r688": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r689": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r690": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r691": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r692": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r693": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r694": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r695": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r696": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r697": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r698": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r699": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r700": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r701": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r702": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r703": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r704": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r705": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r706": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r707": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":

"Regulation S-K", "Number": "229", "Section": "402", "Subsection": "y", "Paragraph": "6" }, "r708": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "y", "Paragraph": "6", "Subparagraph": "i" }, "r709": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r710": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r711": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r712": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r713": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r714": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r715": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r716": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r717": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r718": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r719": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r720": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r721": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r722": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r723": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r724": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r725": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r726": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r727": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r728": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r729": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r730": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r731": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r732": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r733": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "y", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r734": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "y", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r735": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "y", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r736": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "y", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r737": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r738": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r739": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10" }, "r740": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3" }, "r741": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r742": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(1)", "Publisher": "SEC" }, "r743": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(2)", "Publisher": "SEC" }, "r744": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(3)", "Publisher": "SEC" }, "r745": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r746": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r747": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r748": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r749": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r750": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r751": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r752": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r753": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r754": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r755": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r756": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r757": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r758": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r759": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r760": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r761": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r762": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r763": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55" }, "r764": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher":

"FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r765": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r766": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r767": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r768": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r769": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11" }, "r770": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r771": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r772": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r773": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r774": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r775": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r776": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r777": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r778": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1" }, "r779": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r780": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r781": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r782": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r783": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r784": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r785": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r786": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r787": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r788": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r789": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r790": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r791": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r792": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r793": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r794": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r795": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r796": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r797": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r798": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r799": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r800": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r801": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r802": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r803": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r804": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r805": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r806": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r807": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r808": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r809": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r810": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r811": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification",

"Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r812": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r813": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1" }, "r814": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r815": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r816": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r817": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r818": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r819": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r820": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r821": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r822": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r823": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r824": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r825": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r826": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r827": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r828": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r829": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r830": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r831": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r832": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r833": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r834": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4" }, "r835": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r836": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r837": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r838": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r839": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r840": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r841": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r842": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r843": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r844": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r845": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r846": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r847": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "940", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/940-320/tableOfContent" }, "r848": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2" }, "r849": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r850": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-1" }, "r851": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r852": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r853": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r854": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r855": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r856": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r857": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r858": { "role":

"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" } } } ZIP 77 0001558370-24-014893-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001558370-24-014893-xbrl.zip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{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}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|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{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}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`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{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

M04)>1(%^H. /D->A@H*B)$8UYY>756@%-Y68L5!IQ=60@B6I,&',2&C/PT%*K"0!7*S%CA,LW:TUZ<9?2"TXSN M/E(41&A;2>?*
CQPRE)1EP+]!>MKOG.,E.R*1MB6BEF+"&?Y/@G1?XB\\[NELC M7FV5/>.D%C,HY+?"A',$+003'8(%&HACL.:KH74Y)LI1V>+#D-%!R IN4?UE
MQ!PU94+&%-NA#9M-?.[,!LVX,8/?D-EMQ$9> >/,"ZUW7ZH;$90(6M?V7B[H M[371F1:Y!ADXM#:K16@J=A,64,=5S"C5O4)P+?5@+*$=/
MP=)#KZ806PT.YP-,(HC6KX(%L7L],\TRAQP<-5='8%OO*H@C&YK5#M,6<[*3 M)?92?!L\/6>KS0/9K%%Q%"(
<."LP4H8T22T""!V8<%10Z=*',209HBAG<2; M$X+(+09\S>@B5RG&GF8Y'-A%W20Q$2-[NR%L9O/(IX<%.[J072MM18\"F4TS
MBU)/HZGA@?)GH8D226.,D,.B;G@$HTL*6.;B7$MZ2$3$P97PD0:82;..&CW MD?#0!"7N #!3T*U>9SG,<^L3^J$EE:X;T MESTZG *W%5%4<5M<$"-
HQUQSGUFAEPZ>N$=G4F@#B\G-]X;39P93A 5 MP(#ADI;]6O@DA80)IS2L-,.K'!CET.ZAP;4^V6,_]9)@@0=J"W9" M'9B%'@G*0FRXDFD9Q4-N+QM|I7-
G]5AL=V'\AO$M#ME;JPV)%#-@@0=G1]9" MB79D1 *Q(TNNF@T"1AQ@.'$C*63*?2)9XT,;22RQ7=H1]F$>LURY9DHD[CLO/
M%%)"HB=V+8=HG1ER*V=HERMT)$?8(C?H7$+0/A$(?OFS7]]B-Q%T[0N)S?@ M.&&P=H7E6@1H,[:ORQ8MVL4Z\TY"E06F[N1M% NUL=34
L^YL%9??&I$(RDU"]>0M\$/\=)\.+1 MMPI$"30I*CL\H(15&Z"*])4-$EPRRYZ[AJ9=>$&"7FA[".2E5*VR9XP>\YY8 M*>V)A7SVW"7_RRL?
*45^.19:AUZ:!IL ^Y2$5RKK&U0RK,=TY*BHPCWVPC"<. MI,H&D$_X?.7G@CXA>L2^C_U**]J:K'');M/\8RFR,NG?E1SD>5* .*:@?.W6C
M!73ZU(=9R:$4QQ"L>(:8HV,DJ2^3@%2&#GY>-/\5 M=$_HEOXNA6.W)UI?*.! ,S3/LB1XW/,. UF,;CRW4L*M!:O?C, , M!3@=?$/(8+*_Y-
<^=.U.I9"@O==4C!_T6CL$@^]M)N=#UF>,0Q;/-S'@&5]F MZ1[[X)%3%T%2+LC_^_[K]^_H)V7YZ?^)_KN_7N4\K>IO'WV""?!G|C_GRB* MB]\&>]$G"
[WR1{BT[8 ;8+!!EHSEP\A*A $+IYI,2*,.ZC4SMPRBG0A*4_CP M_OWLO=PS;W_XCOWZ^V]G'[_[6XG+TKYW1$?P]A$GZ-OW M,T2UFH'R/_[O?
83+W\\0P=IA]G9Q")Q F/L^>P3""V^\P%]&9]XN(!LQQ=PK MH0&O8N@%]%W D(/"7+O0\=*LUBRA$06GS:%R!'!S["P(;>YY0@19&P29ZI;2 M?
KMGU>YL02FM7">A(XY28]/+.:!UO\66!#^XS MM2$!=;NI/8^R8NF"2MYFMT8'<4+H'27U%>LB0GT^H0=_^VE@Z5F%,%K7[ ]R
MZ4,J/:P9W^+,"R+L+[PD(DMV*K!^CC?!.E"E(6P0X8S57BS1/LU8("9IRU:S M%U2.B L]$Y4S1Q9K8'3V%QG\419? [I6B[/.B_C5NI.+F?G2*ZN4XYN7)W?
ML0D/.[S&NR07E_Q$]!%(W.OO$HT)IQ?KJ62O*A MSIQ?2UOAF(\3%6A.G'1K16K3C0GZ3%S#E&7W)7?.S-O(TCB49A*Y9T:E\Y[W M=%U0.HLZD
//J];8E3ZDRB!@GTP56&B>,!5 Z#<&ICXBFU8/+DD(NB0_JHH5 M9(_Z$.#;:E.E%"P>G' ADXW*"ABL, *4C]-(L'C*F%L^BR5?H,3=F1J=12E M1G;ED-
(DGOK<4H7IP%&6C7SZ2;!1W&",(6\G)/0X%T$P9O?#B)I?N93'O:@ M=T&$_#@.O21%9$O %W#@5%5=5BB8.B\/H:PFJ(GDBN6IQ0%%;W"&& Y8F9\EL
M81P/58A.655KJ7)K;IR3NF<^_("ZQ2P4*&Z9351,D\EP:&?,163'VE2FJ"SH M9":6TM1,9.9:$4W+*,*TXE2FS;QG04:=$%.RWBG7J,#&-;UJ|GI)N51A'2"
ME);QG!;#"1NSB>0TX- V91GMU&W)M0"NLSQNAFX-<;1QFQ+:(?-01VP*4#?, M0AO=R$QBFAK0]O9@(TC=%AP+T;@8JZK8U%;R&HI#%B$116L6
KP;MM%@R-) M!#$7K,1:I+JIQ!8236(OO&"MS*H;+I8IH>&LQ"" :" *4!#;T/+2T*&'R-O[M
=V$G,61CZ.4_Y3&8>"SO4E)B!7&YWUZ"$!^65.L+*3%B8YT[UI\IIVL2>BE MUSH-O /=NE1"2+MT'0+#=N>2CFM!@&HDM;(D:2(EN,P;RM@%?
8"GBK]+91? M8<&;RR<+$0,.B2!S?QM$ 35V>N5+,S!&+#B3L11(:!H#"HC96/'4T+;$MHNJ4X&658#E1F'E'5 !5W++;.1Y+-^.&#.6(6E>W-MKTQRBI
.J':3<:ER5V"PZGW(AT;!:[?X7-'R%OR'X+OEZSB*ZXSG1FK8-5O@ MP6F^M5"B'1B10*S"DJN&CHEXI9GD]%]-ML&VV#ST$/"DDK"XT)HO&5\!;[N7
M$8G]<)J1R([=XN6"*9-U,_7K24P8)E/-4L]+0G@*8!=\?CB"|[>`M[F+PB][<$EC#=.*]M!=$=!%<157;UF5$;)]UL;8WV&\2G"D;,]BC ^ZN6XI8
MVV9;XL+LMULQU]RA$O0*$-Q)+8;%HBPI@LSQ F-9'8_<%$C_,0>P1Q/8HJ* MJ'*@]3/Y/>VP@#95E_EX@W"GCL03Y2'<%!XV &X;KS@9\+8*=-T*
<+L$ML!; MP+;R\(1')(ED'5B_B=4;,QX',(&(&.VIO0BP&B*;M:0)AM-#<>9/C$PV=9L
M"&;G1LCZ.4_Y3&8>"SO4E)B!7&YWUZ"$!^65.L+*3%B8YT[UI\IIVL2>BE MUSH-O /=NE1"2+MT'0+#=N>2CFM!@&HDM;(D:2(EN,P;RM@%?
8"GBK]+91? M8<&;RR<+$0,.B2!S?QM$ 35V>N5+,S!&+#B3L11(:!H#"HC96/'4T+;$MHNJ4X&658#E1F'E'5 !5W++;.1Y+-^.&#.6(6E>W-MKTQRBI
.J':3<:ER5V"PZGW(AT;!:[?X7-'R%OR'X+OEZSB*ZXSG1FK8-5O@ MP6F^M5"B'1B10*S"DJN&CHEXI9GD]%]-ML&VV#ST$/"DDK"XT)HO&5\!;[N7
M$8G]<)J1R([=XN6"*9-U,_7K24P8)E/-4L]+0G@*8!=\?CB"|[>`M[F+PB][<$EC#=.*]M!=$=!%<157;UF5$;)]UL;8WV&\2G"D;,]BC ^ZN6XI8
MVV9;XL+LMULQU]RA$O0*$-Q)+8;%HBPI@LSQ F-9'8_<%$C_,0>P1Q/8HJ* MJ'*@]3/Y/>VP@#95E_EX@W"GCL03Y2'<%!XV &X;KS@9\+8*=-T*
<+L$ML!; MP+;R\(1')(ED'5B_B=4;,QX',(&(&.VIO0BP&B*;M:0)AM-#<>9/C$PV=9L
M"&;G1LCZ.4_Y3&8>"SO4E)B!7&YWUZ"$!^65.L+*3%B8YT[UI\IIVL2>BE MUSH-O /=NE1"2+MT'0+#=N>2CFM!@&HDM;(D:2(EN,P;RM@%?
8"GBK]+91? M8<&;RR<+$0,.B2!S?QM$ 35V>N5+,S!&+#B3L11(:!H#"HC96/'4T+;$MHNJ4X&658#E1F'E'5 !5W++;.1Y+-^.&#.6(6E>W-MKTQRBI
.J':3<:ER5V"PZGW(AT;!:[?X7-'R%OR'X+OEZSB*ZXSG1FK8-5O@ MP6F^M5"B'1B10*S"DJN&CHEXI9GD]%]-ML&VV#ST$/"DDK"XT)HO&5\!;[N7
M$8G]<)J1R([=XN6"*9-U,_7K24P8)E/-4L]+0G@*8!=\?CB"|[>`M[F+PB][<$EC#=.*]M!=$=!%<157;UF5$;)]UL;8WV&\2G"D;,]BC ^ZN6XI8
MVV9;XL+LMULQU]RA$O0*$-Q)+8;%HBPI@LSQ F-9'8_<%$C_,0>P1Q/8HJ* MJ'*@]3/Y/>VP@#95E_EX@W"GCL03Y2'<%!XV &X;KS@9\+8*=-T*
<+L$ML!; MP+;R\(1')(ED'5B_B=4;,QX',(&(&.VIO0BP&B*;M:0)AM-#<>9/C$PV=9L
M"&;G\61CZ.4_Y3&8>"SO4E)B!7&YWUZ"$!^65.L+*3%B8YT[UI\IIVL2>BE MUSH-O /=NE1"2+MT'0+#=N>2CFM!@&HDM;(D:2(EN,P;RM@%?
8"GBK]+91? M8<&;RR<+$0,.B2!S?QM$ 35V>N5+,S!&+#B3L11(:!H#"HC96/'4T+;$MHNJ4X&658#E1F'E'5 !5W++;.1Y+-^.&#.6(6E>W-MKTQRBI
.J':3<:ER5V"PZGW(AT;!:[?X7-'R%OR'X+OEZSB*ZXSG1FK8-5O@ MP6F^M5"B'1B10*S"DJN&CHEXI9GD]%]-ML&VV#ST$/"DDK"XT)HO&5\!;[N7
M$8G]<)J1R([=XN6"*9-U,_7K24P8)E/-4L]+0G@*8!=\?CB"|[>`M[F+PB][<$EC#=.*]M!=$=!%<157;UF5$;)]UL;8WV&\2G"D;,]BC ^ZN6XI8
MVV9;XL+LMULQU]RA$O0*$-Q)+8;%HBPI@LSQ F-9'8_<%$C_,0>P1Q/8HJ* MJ'*@]3/Y/>VP@#95E_EX@W"GCL03Y2'<%!XV &X;KS@9\+8*=-T*
<+L$ML!; MP+;R\(1')(ED'5B_B=4;,QX',(&(&.VIO0BP&B*;M:0)AM-#<>9/C$PV=9L
M"&;G1LCZ.4_Y3&8>"SO4E)B!7&YWUZ"$!^65.L+*3%B8YT[UI\IIVL2>BE MUSH-O /=NE1"2+MT'0+#=N>2CFM!@&HDM;(D:2(EN,P;RM@%?
8"GBK]+91? M8<&;RR<+$0,.B2!S?QM$ 35V>N5+,S!&+#B3L11(:!H#"HC96/'4T+;$MHNJ4X&658#E1F'E'5 !5W++;.1Y+-^.&#.6(6E>W-MKTQRBI
.J':3<:ER5V"PZGW(AT;!:[?X7-'R%OR'X+OEZSB*ZXSG1FK8-5O@ MP6F^M5"B'1B10*S"DJN&CHEXI9GD]%]-ML&VV#ST$/"DDK"XT)HO&5\!;[N7
M$8G]<)J1R([=XN6"*9-U,_7K24P8)E/-4L]+0G@*8!=\?CB"|[>`M[F+PB][<$EC#=.*]M!=$=!%<157;UF5$;)]UL;8WV&\2G"D;,]BC ^ZN6XI8
MVV9;XL+LMULQU]RA$O0*$-Q)+8;%HBPI@LSQ F-9'8_<%$C_,0>P1Q/8HJ* MJ'*@]3/Y/>VP@#95E_EX@W"GCL03Y2'<%!XV &X;KS@9\+8*=-T*
<+L$ML!; MP+;R\(1')(ED'5B_B=4;,QX',(&(&.VIO0BP&B*;M:0)AM-#<>9/C$PV=9L
M"&;G\61CZ.4_Y3&8>"SO4E)B!7&YWUZ"$!^65.L+*3%B8YT[UI\IIVL2>BE MUSH-O /=NE1"2+MT'0+#=N>2CFM!@&HDM;(D:2(EN,P;RM@%?
8"GBK]+91? M8<&;RR<+$0,.B2!S?QM$ 35V>N5+,S!&+#B3L11(:!H#"HC96/'4T+;$MHNJ4X&658#E1F'E'5 !5W++;.1Y+-^.&#.6(6E>W-MKTQRBI
.J':3<:ER5V"PZGW(AT;!:[?X7-'R%OR'X+OEZSB*ZXSG1FK8-5O@ MP6F^M5"B'1B10*S"DJN&CHEXI9GD]%]-ML&VV#ST$/"DDK"XT)HO&5\!;[N7
M$8G]<)J1R([=XN6"*9-U,_7K24P8)E/-4L]+0G@*8!=\?CB"|[>`M[F+PB][<$EC#=.*]M!=$=!%<157;UF5$;)]UL;8WV&\2G"D;,]BC ^ZN6XI8
MVV9;XL+LMULQU]RA$O0*$-Q)+8;%HBPI@LSQ F-9'8_<%$C_,0>P1Q/8HJ* MJ'*@]3/Y/>VP@#95E_EX@W"GCL03Y2'<%!XV &X;KS@9\+8*=-T*
<+L$ML!; MP+;R\(1')(ED'5B_B=4;,QX',(&(&.VIO0BP&B*;M:0)AM-#<>9/C$PV=9L
M"&;G1LC

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{J23Y8HD

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|K2A)1$Q4;1OUP MHM"TI[.]-!SI#4<>L*WAP%-4:WPX$&V8UHB#,F^U:-,*[7+5II\)"4-0VRH& MH4US>/=4NP/*(>7:[N|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|21G)]\ MT&/WA#JI)G*+LWJ3(LH&ROEP);H1JK9^";+GQIRF=8G2VX/D(9^J-T:K1878 M &,Y8.]C3)ZI^[_W0,Y4"0XDB=:6Q1L.KV0\BXO^4,*";@ MDQ=$EW&:+B-^$7D9%3>/!_X"'<8_/F??>9*6 !:#WY4BT)'Z:9<*&:(M47Z^0@5']&64@B?P0BWHV3]|)O\B(3:9$U=2\O3\+7NK"G1.WY:1OT^S1'?1 MVH0$Y[KLQ!'|C1X#Q$G8L-30K0*$5H(1-7'BXM.A(6/VO)"$Y({RB471Z=< M=0PGE$O&DEFYW+B@5)QYWA'?':QQRKG37\?0XP &73;"U (E'0), <&/F2'-N M72"5.N9&&6L7H4Z]Z/>BG$XB8&Y-X*6M9U0KHRSA,4Z0_GZ68#_(Z$\/)(QA M6;_V)=*^:R:AIVFYOR=:%=]V)%N\T$>$=.]42$$!&^UK6*_U MV)? P;375S+2T*,*%#%8-RHZ#@4@0^E>9U!!NZ,R!P+HM"8'=4)Q:KR8=8?" M.[&!D\BA{5*A@7=*A]3=)Y3 KNB1MJN$0I.=QBD"^3 U8T% !4 !R M>FQT+3(P,C0P.3,P7W!R92YX;6SM?5MSX[B2YOM$[' 0UC[,S$-U^R)7E4[, MF0E9EJLU8TLZDMQ]>E\]. JRN4V1;EY, *P'7RW@N?!QGUY.9S!/? \R[8'UYZU M?0*#P?G93U]^.OMI=#7X^/$_HS&N#1_V<9U!--C%3^?I+R;)<*[SM\'Y^<^? M?[XXNQ@.SB_^=CG\V_!R,+Y/&]!#N>VLVI:VY?SQ-_2?1_C% 232\?_VP[?^ M_N$Y"%[^]O//W[]__^GI/4^N]P3[GYW__,_[N!7$GXW__,_[N!7$/;&1\OQ \,QP87WR\//_IA[_]$$^^1 M8OP/*3'H!U7DG(]&KH^CWZ9- 2RUK1H:_M0CMCPSZSW\9#&)&>ZX-5F WB#{[MM^#P-O[^P;?V+S8:-/K9LP=V?__@_64''Y&\SD:79XCN_W.3X"G]<^QLITY@ M!8>9LW.]? <3U#P,T_L-JEIN4!_YR{3 CY;{D^GN?T9M?J8;[F<>,U\'$+#H M&P^.,$6XM"-Z)ZVR!XT=_|5W;VB)$7QLV8M;Z&8# 9Z"DV?#2*%L;'NSP# ++ M-&S!9!;^U?7-QV;^8K=X 5X$*|^B;,+N7SSP##M8K^#.]06(FN7;LGBR?H:R M>7;M+=Q1IG^&<.&)Y4/5|V31/C'\YUO;_2Y8|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{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|\ETI:A>1T4+;7U_DM.* 'AFRQ?5C;N'|..VEN$=UH8-DA,4Z5R :Z^V7)G. M!$PDJQNK*7LF.99AP$"J$N<)S(,1#PZ$#+?FQA[^=>,9CF^8B!CB]E[? M42NQ:0Z1"\@[;K#/ZUU@MX;*BF2%NY_LBT<3K#R? 3^8PH"*/T]ZN(K0*HA+|&1# M.J/Z77/P/2H-?CN@Z*L96AJ3+/3YLN)FU3LQ"NJ(7@*G15%3U.04 .*A@T: M1D:/M_\O|..WO38NYIHEPS'T7U2%>>+Z 0YG;894%'T-=1=W3K1U88]B #K@ M"5VHJ*W4HL4=_6X1D>E/?P#/M'QLR'[S.'J!C0_YG+*:U,JO)JI\#A C#*0H MQGA A7%K9<:@7GG^5'L!8M2C$46& [E$J<@2*%8!G9=*P!IXKY8)8J;N@.D^ M.=$HI*?F1'J647R+W+!Y8ZPN2KDB7\6*W],!MB$*2D\?.B[9A MFZ'T@!AW#G#*RN*J)=DP%.\+?$!4.Y92*. (.!CJ<-6.2EMNQEGGO7Z# KG]H M&Z5PB5-;HUJP;EG2I>\ ]B>-4RXB3NK%Z[F>W3#V7?Z4|/'*)(POEZ9.V9/6 MZPQ&W]. BKP4!'SNF4D@4"Z_=&+XS[>V^YWE-8-AV[12]-%!_%6IR:1'XMER M2$O=OEV=R]'V<)-#DUEZ[JL%I75]>("8Y.HI@(M\T!*Z0DV M054:"SS(5R+VE$,0LKNS H+5>&J@%_@X"[,,DAJZA5X)#^59$==%!R?)E"@U-M?EL08>.!Z@EM0Z=4DH8CS0'52NNM U!JHD3X.D;GKL.8N =@.NGNDHQKMG; MP ,3]0)2'&4KE[%I0IPC >Y=+[#^BH2)*@?YIANB!$%G"Q?"W@KW_LQY!XVM-%@;P-H GC4-IA$A!JJ#<@; &=O6K&LG6V62QC4$7]\+6BQ,D+ ;Z2R M@]UNP&.0N;-X-2P;I9-6X=5C:*3X{(]\P=:L9&UNC0.A *+M?W>*KQHV"#T MX22% <,2%D!++>+3L:*M@@5*AZQM&$PTGA";L28O'H,1 6M_1*0DN81982[!P M*DE>^9J74M?"L8^&P[4P82"EH"? H6IB5?"$W/3(NAHU#F@]A_AE:'K@WO#] M@*R"TW$;=V=,TS?'O>'9<'195-7]Z"U6$%1<)S=FB6##7<[^"!EL K#U;R'W MD9\&'F#NC0"QX;#8L2"- =9PWACHN[-'QI51JCK?>+-\6XEKR1%;5#&;,ZF+X6FPG=^8^!J MSA,-'OI4DL*P=+4I2)U>6-08N6$X-I32FW]*MC;VBL_6_!JR1=.,):A4\LTC M=J#_1SFIKX:-UMX*GH,]RT3I>O 78V>;_T&F99S+7KY5,^T0)3=.?T SPWD" M*[BTIKL=P!XBNYU$7K3GP]$7B:6+VQY %6 =K]!NN1Z15HP4@>MWF!(YP4D7 MEZLPOV.ODN.]=M()8 6G^.]BAKZ45YY>7NR(HX:=6QMW9G!* A#R9ED2]HLDS7%6>-6); M11 @5)(GP+ S1+WK) PD5L $T%I#*560HZ<:DMF;LRIXT/3+<^9"C0JO74"E M,7,Z"<416[?]Q+$Y"D6"5"<;,:09\G@=[O>&=X"\L)X<:V>9AA,D60FHOJ-K M6V;&,UM;P.K\#/[? X./@]%7XC_EX\[":#A:W@\5RNAIO9HOY>C">WPS6#_?W MX]7OZ#?KV=?Y[`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|KE M:? +H%G>QRQQFB'<'}1W5E#63V"K$WHQLE<[L2\|ZA8'"&M"L/ZM7-U93M,U$ M4Y8Q \VD?\0@7O:NI@E1NJB85&*IV.-L*CL7)U^0K%NCI@F^;EC4TS MW(&BQ^L[JBUDLKRJ;FP;T2LT&:E8,+0:R.Q|,'-,=#0]OXCT&M'C;DV>-8.AZ/AEQX#H9XT#5_<@D1/#/]YZ;FOUA9LKP\//MC.G.-S4DFEJG*:.M!OL VJ&E#=-V''7]N2HT 00\,.%OV!:IB\0AL,79% I6G> ?(DRK!+#W0/1]-4+ M0LU)YN0LQJ%'G0>F)Z&'V(_!#*&'7DAA)913)2#U\3%W'9,9{J=.^J.DAE;" M\:6_0,&_/5S10B\(U!&6R/NSKO(F[Q?EAMI*GV)W^*)1'8W(T3?S_1 >VD-4 MK2$NW!A7T9J#[]&O\&XLFLYZ0:4%S0E\1EKID(R_&.7NPR-=G NU B;P7E$A MD(P#N?X6I'Z,/&NOAJ-/O893:I)3?]J9.EH)6?DS7DI5U^.$YGI@H!&5 MJ;@5*N:$$?>]90,_FTA6ET:L!/4_T\WX^FXZ MN)E>;P;KZ>1A-=N@*

*D>P[6E"_\L9G*8T,.U):AVD*B;5E#HTK?<$J+'<-9 MA7D<37#$A^Y.7O+J&%BQI|C?N&/SS]#R N8:/KJ_J#&M'**Y5$)-&0+;VR:.M7HB";N&4X3EZO(-_HF<N;7W^?A M:%C,A%%-30T;^#RQE/:^IDS%4XJ$RA*8UDJ"H*E(R^!@H;KW@(C"!N%,H|?% MHO?;HWHK54]NHE*,?O6OB,4K>'Y"2>BQ *8,-^'LZ3U&)^Y^#SQ$\-)X 5Y- MNE90>UE_=5^ YT8\ D[\.&)VGR!BB;;[.[PX\$M(M\)$4S&V\Z"3 S7*<=6(0T)N%J5L>_&+08!!91'[O..I*9.$7$5**2GZ M#+8A2B4J'!:,;+BK*TK%,H:2D.-W5&S/"'P'1,1 K#PZT:6S$UZ]P MYXKYMS%^8*#.9>PW VAQW-(PF+$IL]#2%@7;W-COL&W-K;9'HE$.6P<\H<\K M ESRMH7;J1K9$KC!\LS^,AQ=2'S!79Z)P,0>3F>ER@G"J]?^A1H/4]%(2.?7JHPE5>KC%,)23 M(TW)G93$0!,)4^.,$1+C0)-3/*F&F-HNLMM_;0TX-{4)).4J!APTR;P\H)'B(MJ81Q)?>BRUP=&T5J-BXEA:/(\F7^O:62;1-JJD1$>3>4&^*9G M13D17$3>N1Q/AJ.+HM$23<@$9O+ZY:5IMZ'/,8/I9QJ"'**/()'@8[4)/105 M.YM(RZ!@I5A74!"#KXE|E 0&JUBI@4&@6:47 U>0XY!;*+_K\KP"VWU!1"2[M)C'XBZ)GGR1.D%=9YDUIU^5-P;_ @6:6#68Z'=-+!> 0UNJ/IJBYSF MU.L2LER]%=_5Q '61%(2+^V-CB94<*)/,.C\KA(Y51(VO8(#&11UKD42/1V M4C%/UL4WER*;PW+2>=5=MWJU,IOX$^34P\S+K5#*;P70OIG^$E7T.Z=;Y?7# M**H B@*I6]X-"=7Q)KS "K1HW=)5N@M;^'9M!<5]Y4 MRHU#ZM7V[@:4D/%SN.%LO@/[%=R[3O!,=GZP#_<.R ;\$1JH(2<^D)8_:(EN MOKLM49B,\@X^>K;PBOZHQ%PQ?ZG-\P:TQ$851,M0:C2& /D#BQY1.DEW45%TM M=9;N&,/"#UYUS(DQ:@K!Z(*9)GX3L)W^,&'3\1[!JPG6<&.] X^5.6T+H]=D MEQ:C3_L;2JLQEEC(YU23')?O\|EC!^>=9:(;O_&3!TS-^95.O+K&4NL85NMPB>H4%%"J+E|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}4]"^@.JKB!D^_BJELKB8 &LJJXHF,@ M6&5)9S=B5':.<5N8T_325?F/2%2ZE71-TFY"YMHSH4"]}0 M/9$SB:YL!5*2]+(]<&3!B^NDWA>H&5?@"3UXYGJ'>\L&?N ZF,>/FPV29],E M9-.7?B*!(_E*6 LU*(DR+EO#A'X4/7'2DGX\"=)"U,F-ZT M+Z@ZZ@D'=I(%Y#9W%+X.Z7$+.4 06:%FA$L+-&:'VW1NGCC:ZM5N|! ML*,Z&G$]7^.I6%V@V2!O&DY\N"6TFENZ/755<60*+]1A>*QX(K MS+5'/U5KCTSOKZU9++A-24'"9U MD& BWX#'8.; "811U >A_$A%2R6U0+5L8MG+56|OYTZL>-$[LKR_R!$5I*Z M*'EZ6F%6P8"15(WP<-P5ZW(U25T4Q0.C5$G H*2Y]\ HZ\];RS$Z/(*8%XIU_G5,*T514GS[8:>2MEI>1S2MAVPV$W@ M1*W@UC"C0T%R(K]V/<_];CE/$^,%_@9;RI)EB#P3KX:CH0)O\[(O R7UN2K MY_9JC:JEYYH ;/U;R.>9[X=0M4(>(3YC,(3OH"%B& (D5\FJH&.=HGB_3'W!% M (Q/JZ*A1}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l:5)/ X_5 M)8O'*OO-0?1!{;Q6Y\67\GKOM5)$)U#PO877BJ^QH9W72A4,,(JSL==*&SB\ M>ZT(XA7OM=(]WUD5L;?U:#4G71''5AT"X*:YB*9&(? E"VQS9\'^CH<3'@)L+ M"B=L&FJURC#B7'U6-B+XV09LJ;>CREN^]PJD& 3"*4@"/0]:@8(*HFEM)0) M4BIL*SD:K47<+K'4@4*W/8 "EIEETGIW3V6*B"A%S&7>RS.>B/+L*^AM44O ML2EP;2'D1DL+Q#!1JMZ-%JZZ3\:l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

*LQ1C^^OW/W[9B;_"?OW^O__6ZZAKRXI^_965*6/9"@__Y-0)F7]%# MMC%^8,BQ_1=ZZ6_T\TX;6;'&&E@\Z(8.<0-E_H![@Z;WIR++4'?_1 U*2!F: MBN0-=V[7,!A3CNF208R(E(@Y)38,,28RI/K7/R1B99B,T1SU]^^= 5YTO$G'--%@TXHE -T-@ +A*

M]E!JQ,4P'FWU2W$01P.5W<%JH+|9G]1*MN;)&BN0H:IEVU1DR#P*,Y'#X^L! MS8('AI@V@82'0SBZX@U00'^(=:2<9&#*HE!/B6VE\CC1I72"3$[MEK,<=BTN MA,8TMQYT14/*PW00"K)8 M/UU^3MQF3N8PI^9;!:LK9'(AJBW*1J-LQS\ZIPZ[3!FE82RA+D*6D16869K2 M9E\SL_?

RJ8+6>V2"0KEN&Y+:!)H#=^9B*K/ETIX.!+4\)=6G--=*]V-5?_+G MK;G0Z4&V/P"P)P T(J-MS9O=G#N7W[O+E-L/8BRT_OD;6P,/EKO0HZ$1KG7P M@-?0__RRE-%8PZN^^]W M:NP\19:&VCW=[_=[_O1,AS3_>2:60^KZ;OC M?4.OK.:+B8S4"X)C4@.65>ZYTX[/%6O3 B/6T-WOBW#4A:8(%+L_+SD1G6]%

M2T\IC:K8(3'^:ST*Z"ZDZT^*C#_W%&@2+@7@7@,XF.%&:]B;(B,A,C-_)Y_V]!.WFH: M%C"166F7S9K2']@N$C >1208:0=91?*J@84?7@'"B"?R@P,3G?-

&"^@&X8+9QP7S*HJA9LC;B MEV1.H$NQL+TL*-S].T"XBN+@CD=''A=OHH M#A'[>03[J7W3]M$AE'\4F<4*I)U2M-Q40\-AO*4^*B6]Y=LU,<#$V372:

[OY MTYB:9<5.V7ZR!9(;M-*//5VPVEW_8NHT;7>Z\1V@^6-HYK;0S)U/PR&,A'+P M.0J%C-

2>U40Q.34M_Z+1CYC@3L<$]Y4:+CX#IMQ8C.$.#OC16#,6$&[KM-'3 MJ!4?2P562(*2E-J-Z7)WX5L0[,SKF?%[)G93FN#E1N'[%K(:M(&B0YD'IJ[H M?

6O0%>5P^&JF 3%P1E&XZI9=+&2'2]?^^TO'%:/]P!-W.R$ TS(M*U^E10"X&(#>9JHM&6XWD165>D*^= MS=^DTWW!]9-U^E*D[8K= MQWI-)-

CE\ZJ2+U&QZ[0;URG\XY@F"#,1?E\/A;*C4MD M,JY=O61_@T[W"[=/UNEUJO05TTIDSBOY9CV?8[1D$01VNJ]0P)U7I^<;/6%F

M/8EY7HF&K5ZHKT23Y+4;<%^MTR]AN9U9IX_3BSEC.'%R,DGT.?*L,({5R_9 MWZ/3?<'MDW6ZW.D#NS 9I'F8B(WX6*YN=0;7+N ^T.F7L-

,_OS%,Z]4HR+3R M91((4AY6GK*]=/W:Y?RB297^BZB]YNJPS5>3L#/)"?5EO5^WK;DY\/"^J. ^X MZ@>?^C57Y[I"I3+]R%!-

+A(6G8A2X>7BVMWIK^*]3ZSJUUQMY(R59H,N&BNS!^Q=Y1=#*(3V?2MN?_DDN?'\<187)G_A9_ M+RE3-'M^F3H7K(5.2*P6^G.'S]!,O5

-+9UA:\!/+CG+UKE)I MCWT;@O,G-OR@-YC=K(A49QI]4'234>N)4:Y6CP\-I7AQMEZ0KM2N@<$-R"=OG$R^>1P MV*G6XS/5Z2Q[?

&@X;G/@&N3I:B!\TWZ=3YTPH<$HA<@,3$F:9++>5>FT*I[D MU8'?XW^,'W=2GI;A84NB=).'72M/J[QML0W?[@%<([!OW2_P@Q'?;\R>C.CP

M,20HD:=6;4"7"['4-42VKPC%-V0W>SN(SI*86.#C&6CB+X"[)DH=FE-%@A9Z MPC;6F+-RA8.S[E+;@=E=F_U\/MU-95;BF(<<;W8

MP9"AZJQ14UM/E/RD0,VDK6M8RX-0QK7X@9/"^1?,^=]N*'N=:,%?%Q9< MJJ[J$[L8HP.C(_!P?8;>8^[H7$P7V&FSEA >O M-\1GPC.SP(V3ZD1,MV?

%5+I>R/C6(//WO:&OS#8Y/Q*$DIZU::,GJQEKJA2Z M#7'.&;Y=5*\)"9?5";N%<9]9/!:,!83;%W ETI%6=IQ\')$<,PT7P_D894+? M MKG=1JDLU5*&JYN3-

2("./LT(CZ=DG^"&_?VIBX/=Y2*]!68T(GT@HEIVJK M;\YK%2G)Q"]?-N4M=$V]?VU6?

T,ECAD43Y5(%,EFV2V5D3S$U5:O..T8B'7)%7V.")*4[>2KX]1H3F;JI79.G)>? MH'^K.?HO@D2'R/#6W56?Y2U%KIA+G<,5[=*S>H=,B

L^OYS+D_2CV,JU;XJY MEW5%J1!%7H*YY*>L!3&GY3E+)!D5SLO+*'PZ&RA(KY%MQ0^ODV?GD\G+VOLDSEPF'J(1SX4&F0$Y)AUV:O87X?$R;OKA

MTOO=R5]V9_4,)V.H%W;CMZ4B%0T=+HK 5*&-]>U:[939]&+R!&(DR5EL5K>9 MZN.$\6ULY!R'8MY;7#XRF*M)B=]/@NO8J_%1?:@#PE0Q6T^Y%M?

AU0F7YV9E MH5&;)GR[A@?X_5K\7N3DI=_7%R,Z[,XC99,2,HEX1I^-PY#RKR<:K"]7)I\W MFC=^0)B>4F&VTFX^EE-J,Q?BM090,_TY M0X:JT^;

QU7>_'B&]L*V[]F.NF9#$TL+A;DY68Z;V=(@;XR2<_\:K?X_5_J] M?#]^_-,<@=QT'DD,>/JQD&.F=I9E0](LVS85WV8# M_5_<7&?

EO/!H:1IB*:&H(#ML""0?GF;2-ZWO?N*Z[OL*D1=?U]6B(\^;LJ21 MDTRV5T[%2\.2<-/VZT]/> XR\7-)+(MSO4O5XG.P^FJPJ G-7L% M72"="9-

IL,N4TAO[UF.Y*"]_).'5=VADMM'(^$17Q033L_JL>$249;Y)3JB,OY]_;3&].5?D#C M@94[ITO&" DF>@F>6\&0W*=V=%7T-6A [A7$T&.ST&6/@=_#F;=

MGB;&A4S.RI?#HTFB,O$MOH[,^EEKG3#MFUY=/X&8#-2A"31$N;@\4G3%LDVW M\-TN9JJ]"#OJM$&/S/1&LKC4:^EBR+N?0,ET[&>^UB

MVB!!N%F.@TJH-_)OBH'O]8P?5J9/(.8T/6/P(V?1)7M I8MZ,=Y6-:K,^#9Z M<05ZQL>HV=#-NP8:FXF&CL."NS6Q95G!G>','D7.Z4DP5FR@K?

"FF1CT&WT MD0>GU<;MM/T(YTO?XN7HC+<*41^;\DTCY84=X_I(\;X)X2:KS?UJQ\]P*U=M M&JUP89FV6'-_P_A3T4P5T;.Z,6^T@=+1)&T,1#

[G52);+%)8=DL22.]I;O= M(]=[VB'?RJ-ZDWX?WR1"I'[8$/[7/_CC#N4_O_WD@X)7_K'D&#&ZD9O-W]\N M-

F]5STN0SCS2*DP*0KFCM2,&)=OIC.\LPY\I/E18"_'E&*%E)7JB&&TW_;@8 MK4OI4,QG:]=,@F'UYGTG0O$+2VBKQXSL,Y?+E..<1S4K_7

M(6$#ENN+VC#3A[Y3?E?AR_DANO@II.#S/(:^?1E).2GWI-F@NN0S\T01BO-Y M9EJ_=D__U31_)"*.U\:,V]X!ZQ<5,>.U

MFMS8HIGLM5FX6EF5<>I_[5%F\4 MI=P_R=M$ T6)%+N)"VY]^B0@E%BFF79D4U@D4]5ARB+Y0=EW,1F? H()452(M8D\!Q(NFG_6^7I?

X/K56+C2MG6R>5-I^C-4B8H2D$]'D7&.KT[9_+V$^N4SM MBVE>SF \3TGL-Y0^CBDE#0>U-\<(8XL2&,%GWF:!+AMJ3I?N7[@Q-:@AD,D5

M_$@#F<\6D#8[3%M/%A0)[ZD<YI(; M$ZFP5W/6%<;UAQL01J.]B(J3UFQ&@E*ADWD$A:F3\IU;$ BCOX21Q!)&A4\1 MQA=-_;=G8R3+6J*07MAD?

31FRL[2:E7\=TOG!4)TU[CCL '!L]F+4/!Q&_C0 M?1'5=*4CZB.Y3]*%99B=Z=0TQ%^_+?P%5S\A,BV5?P8+1+:,7BQ[9CP9*UJ1 M[%A":"KFQ(5<7#8O?

[{K:I))CAL[3\8("%9!D[9VPC=!O#I:) $;QI9:7GTC MC T]95@(B>5> 5AV!8U@GZFS+VTPCOVP^K*B M ?V+%1%+OBQ0YJ+&TS 3R[?

2\U*\]1;%7E95BME((;2I MY9C_CKY]E8$36!CGD&#V= EFSRO!]):#2(MTU/OP:0OC4D)-7]Q8X*>U+]7#

MA,+7&\W08[LW*FNS:]N9N:2Q<#&)/\C;&UZ]F1!)GQ[CH$/T.>.'E+BZ_A.G M4&SN O7'ZOT2#.=:O3./36HV[(\&2H5Y^'6<"0:Y+7M]?A_]3[(OIM;O;'X

MGBC!;M/G:R//(<&KY=O=DT4?UK>"^G;]BZ^?B=4[;&72;=E,E0M-;0!-R@L MZ6L3*MYPB!)S@08[HZ8QW$D MV?3?9K"2U5]4

MY#S[LQ\3Z1/V;S_K8%6K8:VV,&A2K8OS:+2?M-C*T[7)[Z5W4[]>K2GL@VN MS?#]BM"&GP"[I1MZD#TI7/ 2W9_U#=G5"4EJ@\84ZF'J5I%

[OA"QIECJSCK" MHWG+,I2?&^^Y1G%M%X)65<^/JI 4ROEJD9XLP:SA^&YE6(/DV/RW:UF?3H + MV2D4WO2E+G^LJI/US%0RT3&'/4HU8

MJ50KPKE0#EE)F&IP5M.Z6EQ\8VFKFZD0=R9@50NUQ+Q2YA-"P_QXEB&Y,*^'Y>&2 M!W M6X^G@N/85"^YFQX^?3<]?-

[]M,\C(W$(&DNVE9;GR,/D1TQ_3'?ZR8@ZN-I% M\.A<;PH;AZ[C?0,,>^]D,145;'T0J_ 395IZ;-;CM%._6@Q<^D:52P1JSV/P M[F4N.0P-

&A71'JE.I9<4$B;+9,#5ZOZ;OUK,DVN*0DCXE.^-+9;]D0\;08<0FT*4\RMZ/JKL,4^B!/WRP~MW@:,Z:0S*EF.UZ.I>

(IQ!O[+OO5A?.1R/'Y]Y_@GC!PFRRT46; Z0CE'RF78 M3X\$_VW^7]),^31OSWR/^//- V[4PC?7$'2B9)*?9Y0P&5*G;)NR6*TD^\YR

M"**S>_VQ[8L(WO#'MIN>+\XR732H9/(Q+J@3(UX;<^GF-&]?W$;PB9XVASDU MWRI872&3"U%M438:9=L/Y9DNH<@VGGC8FSR=F3*E-

B.)JM(CE4FRU4M'+U\9 M]2-.7_B,6GQ_0"H[5#4;CFI9=5$MS\O37J42N7RFNU_C-XZN>%03T!\X_U&7 M@2F+%KX"VA+3\W:GJ3\E+$$I.X5IM90&XGG]68$@>68\)_5&-UGUN]9_[;^ MC%_TQDN%>DIL*Y7'B2ZE$V1R:K>G4GBGB]^[HS^=$6/4K5B3$J;52;:*?+Y;))>T5$F$I4.\QT]\@O/6

MYKR1&$T(@I"P$E-AH20'CE:K=;FMBT;7G;N+^?-CQI_]6YD,(,(9CBE!R_LX M@$!VY1)1YY^_T7\(RUYH2+Q'8!Z;*;(]>*!(\G_^&@-9O51^2(,]^R%\'XT^

M?V5BTV+]G6&YMXF@UVAN0M-?OU[T:O85/60;XX?(/3VV_T),"@V@VP,=O8^B M;[9>BIX=KY_L(7D-]#_<]Z_N'] #$S8^\^O?S7*2?31&@-

]YXWNWP^Z88Z MYO4Z\T:[^NK7/PW0U2!A] A\I!'G:_W]&_>"2 K0_\=[2"MI$)@/7<,>K ;F M435$D??/@UV1]?G+77:\HK/WHP0TZ0_<@OB_!.T^^>

<+#NPPTB7.+A^]KPYT MO^8*<+$K1E@I+#$P*G;I2$1DV3"RLF0HB707,I3<[;$1V/WE$>+3?,30P H[M!#2EKS]($.> ;C$6#ZN[\Y(5H[J&)],?A5*NP:>

(>B/>X.M__^YZO/GV8=7Y MI%#+-7)\G8B74@3_E,S&2QF>2):+Q5R]GBN7OFZLKFQ$GV7CV+A;P!H@T-B& M?D>D[I/W"&UA-G:^L;HP?![A-

W/<,]QTN5;\WW]1'/F7.T2D^'1#=Q91U2QN0CQHUJL Q:I MBI6C^N^;-T6Z8S_&E="'>%\>ZK'H,VR"A1@X="QD RY>*J6(I745#AN/#0)&148EZ^-

]_16F2^6NC<\\V],/CE!5KK($%LLPU M18>AKF9(JC=31<>6KON,IR_#K/?X+M[P<7=@_^>7@AY!IC-BAJ%U@:89=M>8

M_[H,'*L,,IRAJ2UJ<&R8]A8RHV(LH3Q."E"=/$K])J\.QJ8Z>X7,-1WKL&] M0L@1]<4(H>BE?CF^:*Y@|[__BD58[J_]X/,8^0X,"_%:@Z\5VD2-KY1K#:(B

MU.I"O-0@&F4"J=<&TJ$$Q1#E&D&%_Y#_),IHI'EB2W-N]&Z\60#_TS%&/;, MJNQ4V+^:X'?+P<<7C*/ZV#)>P")R1J6A.>>$1#'HH@]2GI+::!YD?

$H)=3J0 MP6*!;"FH7TAJ*NZ@>,_^3W)(9*&BLVO:;0]4QI%(/\V1AV"WZ>3H%ZG:L>]$[MAKPC\+@NIXO/N? ,Y!=)QE4J6O*F>

<_7I+:C:KU*CYY2^M=ZT-RA;*\Z>:8P(S\3]_"\)V_"M M*8^OI%0LO-M!I!7D>2,\(RWZL&_-.*N \V[($K_2>^.V<9](=U/U:OU1"*4S MD1HH-#-

,ZWW&/8FK=\6X*'-AB_RP<'R954&= (>+\[$&^XJ%I<.05U,0E9_<5CK=.NOU[:M[GG3D:&DN&-+"09FF$^_(MT__?J5[R6/> M M-Q/_]>IG3Z-;AJ9@6-

3X3KD@-/@[(E=*WG^?A8"&\|@<_!Y)-8'+A;-KB:1]0"!S;V(TBNM_LAO!L<_W656^41U=;WB@$;+J'IU>8L(WQ[@LV>L^%

M_V>;'ZL0HKN:A>_9U9KF_O4B_+CU,@.]H*<9LS67UI]#,Q.,'[HF!&IHABCR M9E!Y\SOH(KEQ;"14QGC+.+Q4+/DP#*G38>A%AU?_M>63&$#?1P+R?

Q_Y,?Z9 M@ $7BL!OV\3:Z3V::*4WUS&2\9QPUT]BO02?SJFO,7:/>ZD6+L(R-HTIMEG. M'MKPS)^U1L?'PW3OU#K7C?4+0+D!YKE5@HGD]K?MGB$0

MV\S(7(+RPE'A*%]*#2=C.9+KXU>^"\1T),0@DS :.QRG^Z3ZPDK[6_EYBA/@ MZ@K", D#%^LEAHZI6++BWIV*O0)E6Z^XSV^ M?D_PH[%F+!

X=L62*!GW?[Z0D]^N^^-3R\377FLW0C-,F!0Y4I9%%H1[R&OM MR2(=D<-<6"8!1 MKD1_SER1QF38VYCMNXP(#]"!?7

C"+HS+L@DM:_5/0=$AM17F33%IJ$PB/4'@ MYKGEPJQE%G7I=:=;#<8LP3-0'!G+*4=]$RD2.^1U1=Q1D'X5)'KG=U^T MG[$B3Q+]638;QDS?

HI%DQRI"1C9;PJC8&<759'S>'+UO6Z,&Y9EAR 3N_Q(4 M^0[?>44RUQ(NFQ7T,F3U;F\A#)9+M53L+(LD3(1F@[Z*CZUWY<=D$22@^:F

M*^=PF[]A"7A+ ^KD >:="T>@0?<#O6(@J=(ZRG@G-M3I%60RPUFM:41E[SV,3:1)E##0"SJ'DX% O^AHY4-'Z MK^]\53+_U2)^%;A D=@B?

LNG]DW68;O20^YX%;\'Y%:SKC5! MAR/J(Q,EYVH]DTB!16D2-]/OL28N2!,N_#D[]X)#^_/B!G3!0}JF,C#TUPE! MX0XS+D;EY9.:C$;SVH#CU47E=:;?

MQ"&)KD0&\95A7R2;OK'T')R^9!L$:N&&]"GZC^Z?V!+#.99Q MR7[P?2"8B=%RF TS8C1$I1[U,N@[4@)Y>;%11F2 M7#T16^9S=*HSZXODZ_!N-

^X,FX-H9":46QVEUDLE1\"*HY;TRY:Q13];U/LY MBE\,0[5HWQQP27Z&6K(O6Y]ZW"XO1TR!Y[)]53/:\S(LS9 .7K?\PI2HG<.0 M6X;?JLWK%

(JC;HAGOZZ>8,A[+OI1I_)L1N;.!+T3MZ\E?SNE/K0ZEKL-UH9B M>R=<(9 &A(0KBYQ@?*^I,5!L&$*XE7">.DYM69/T_@AYW/SF,3[985^:1#M3

M/900_8[Y>@Y8^!.)*5_E8C1,X"ZHWOF"/T[R,=_F:B1VNVQER7O2VQ=9^BZ MT@I7=7X(M+HAI]%OGI? 3[18CNBV]WC3YXLVG$6S7=

(]6%D=*XKNN@IT$SFK MY?/SQK07$@4Z,\F6M5Q\BABSU3[L8;O ._F V.A>0GM'(#$BID!S(/"?)4D MA0^"$&YEC(V9\.ZH\4DZ^]*.K0.\QN-

8ZA<8EH8@7FMO%XNY2>BVS#K37K MNH;=BQ,\+5AC!U#MIH1D\;'3-.%C:9BKO@'6$K!D,#D$UV-/$DDP5FR@$45@ MJM#>OY?

_]8E.7WG"\>U:#R_/.!XC:$Z7<+3< %M%3-.39 TU;!1FPPS]Q%.SN(R^_"U<-4,) 3(ST>I#!PKHGUHAXQ9H3SR-OE74X MT-%.4_\]EI>?"Z2<3-

2CT&A\P+2QT!N)"=00[DW#O61:6Q 0K:L+ M(H<7+.!>"$JD@ V\T(O[,%S'!OAP)[#6K)D>'7.$=]8C:.#]5"#^ .3,O(7 M03/T .]%/5 L'.<ZY*/V-

4GM*P/P$6=PZ_HO0#P@-/0\)($E(%A'? M$5@Q.DV\5NW]ED D#^W]P1HA(49O,=?*&]%JA.:_\-8[U!];R_!@^T3?-&;V M8/W[/5JOH3LX&?

84W3T2YZ958).')O\Z-$3W9^JO=;-7#5:_WZT;'!S@NB,\ MS%7; T-=MU1T5]>LK!"Z&Z+7FP_;]L;]M5?D.E=$_[SA^N?LD#!Y44_RA)A=

M83\V=V*5I^N<5UKF/:DRWT^,^,7)\)Z4LJ^EQUZA/#E8[2I38F@_=Q8PT M:][OUAGKH6;V5O)%5#2;G 7J0=\18F+@_?

$9<=VU1/24UNH2R:ZDWH_&Y8$ M)WXK+,*)G2L;4*RL=]JI*GS-XN ZW;1+?GK_R$A3V F$W6X[!EY*\R&,X M,I5_/)4@X%\1Q;)=LDT_'__

MVJX&UP62BI9T1Y=?G$78NG9F?>..R\ ^#'G%Q /&:&@0)N!A;6RD:/1>WIS M;N\YAPPS&.PX7C?X\?PGGMO77R-$4_?\67Q6[83(L2QPG]B#;$UDIQHI

CC)BM =C-"-+#,G! MW1,'+H/.<@61.\?]!X".G:1YOFUJ#\^_9V/G^[=RSG,XPQU-"&EIM [N+W)[

M:KI=C+T/\DG_'UJ/^'[#U<2^+]HP[$*\Q6T'FR.FGTD.7Q%R>=EZ.%?D@1A MK_?%R9H;%5V)UQJY=*X4+R5S\0*RYLJU8AQ?52#&N"C-[$]C?5-

_XUZ)'!$B M-CT36UV_4N:G)WYZ"'I-/;]D@KK2]_ESXY^_UO!+#<0D&CO2;>Y[7"CX+.U^&$ M6/]_Y5YLPT;0@2,K-

I21%8=F:;E_N.H8;ZDF@(;X#NL#^#\;'HG-MT3V_T3 MJQ<0Z W0MMQ$(PHG';G>_^M;I=QLI$='AUOW3'T.A=\+.>]J]<\Q7#WK":-7

M'D,O&&J)=)BD(M$+@>GYG1@]SV]U48.#']"8BA/YB;TWOT;6BR+<"YDPMZ&_2N4& M3Y7B#:&E]/E"E]S?>]ZO)2J"\5BO-8N!<NY3"G],925#!N-V3:(-

^%V"5O_ M>P$2OFH-],K+HXOQ4CSC>7>I7#TIN>K(YR@KPOM>JY>3G\0)*Z[1]\31:"# MOLOY30VKE&))CG=1(58D<1UH"TMQ-=

(S8#"BO/0(W*8&+4=[;8O=G/:AHM>C M?G:AA)C-5'&ZB6*[^QN(9^BCMQ]$&:X9EF-^_DK,/:'] A<56Z\@-N__^2M= MP[%7QXZ)FF*IUZUSZ,@-

*1W$2Q;O\IB&9B$>5DQ#@C+FFDAQ49K]H%GM0H2] M)8]N_!X[OOF-,7G(1'$BJ\YX.\@T62$X3ZU@Y3;^"1N MYQ?>1/I1Z

ED_YJYYQ_9QZLN58!]H+E+K7NDWQ+9*!VF/[..4_>$VRFQU>O- MB3QJS;8^%<=6=1I(MF%:N+@JQWXP8N4Q/'[OFNG$JLM

@Y;1\V+0ST<&/A":_K[=!/H_[\I_["97RL*]=[9U'P";98F.6B ML4^P/GQ/N)T26[T&0N\GH>?X^0!Y0#:2:ZR$6B9.Q# ;]/70531T0"]FTN_2\UQ(^^%/RZAK%]

M$O'H2;7UX4_\JDL')\,CD]>T_')L$0S4CF*LU^V)O0C+@7 ORE!,Y)N//.(3A2M>)^,"WLN*U]K$YH0%4>,S\5HJ M5\H0Z7*MA?X,%+X"(ZX 7'4 +N:K+0BQ

MS#2^<07?G$909*BZ*;SM79)&3+S&!#R4>O@';KPJ(NKUMZH9^J=;S0 HND58 MSUF.2)IP(1:O#(#EC,9NYM_= >=C]#58?

1J;QM"KD6+A,B]8;KP:J2;1A9H" M>Q8!W)R2GH-M#5Q(&7?NUB4&Z+/[":XPL-9C0_.: 5,..8:AKDJTK,:TKG&*_M*

[PHNCOY$00Z;K2]'U(QE2FN4K(5^BR@?_I>M>4:Q)[O<[WU&/*)XY]V/6OO M3D T'C0!]+=AC@VOK%UW@2D"38@/2K@O1PSRR'A'&*LB*"Y3M_-$42/;,+'U M1/2 A%IZ$U_?=(=K$+NCO%L3!KU61G]JQGCT3*@97%']SB,JOL/7)'!*#[!:
M%TUWIJ!9H*]&8$$8$IHZL2+/BNJ8TH?)>D\T!M""VT,'XS%2;;@7L+HNT;U, M6
,2M+8N3D3C0:S%A7HT9>2F,]K&FHT73%^]7P/AU;A-.$:417\2AH,K_P#+ MT%VU/G3D_LC]OK=-F"[F9?H75-
@*H9CN5PR3"]@C@O6]?'TH8E_VI("KVRP M";<+Y*NZ,?/&[.C>WZ9BJ8A:#D*,B<5K$XGWX+)^E@JX?P6#?%Q!>$;+A,=Q<5W!PAW$9O1L/9 CPN
MRN25UG8?M^Y61$5P-7#!);?@^+/8/\Y977D%>9??@V1EAWM:>Z)RLMO$?RA M!*Q7WR.1>56-
>8"9\?);1$7]U7>>]MNNTNSQUILAPIJ%Y$)#DK324_=$3L>% M5]!4'0W?9^D1?*5U/""N-H5J;M=B..5'->#-SS6&)IFS+"']<%#]9\SQG9.
M_&]9@:X)O7V6OJ?,X=YE'AN?7\ M#EX2%'WET_]OOV)<)/;?2[_YA>-[L!K3ATR/M\U95XMX#A>&BM'%*@A73,)W M#QCF NMXTY@"S;O"
S>73:>/]8'L)J%;?VTJ2;WVI -_71\;=N!&%;(MG + MUVN*>VG&MAGC*D:LJY#"7AEKFV8V7K6LM;V""W6M#]NLUDK'MM#RM%ZW=QK\ M%>
SP.>88C!IZY946M;*N=>\ W-@BVQ:P!T7,/>'D7NSB65[KP MN;MG^SU 8H#$=VO*U25O^&?L\N!0_!U&)?*\L&6,E-^V#G6;62NMN*M,1_C6
M'AM?;3\&B[65N+K@QJT.0+:DA!\F0-^$GAT9(#9 [%';<1.^P:[NENN][7_@ M=IJ"D"9C*W/MEFYKU/U6*)X=;HG#(IX^UOL!(--
'@7D*F0C0ZPNW3"H%@=[GX$@#:F6ZD31<&M:&?45R76X=?XLPN-7,+1.-%"CN?CP Z&42 M=&S/?$6^D =^60%]W4#LE5:Q&GP'&SXXM\>7\F(
/D(R&0#9=T#>TH>;P-L> MJ&(DN5LA.$ANK)?P.T(R0EMV ?Z,8--=;?*IL%_%G(!IXEK:7JSO,";W[^*Y M*G"S?_A5UCF"[@6\DT#IV%U?
F^LPT<+RM@>.5.,;) MO@*]GN<1=!>(I@ 'RG'\;+M8; M0G>K6VW=4OHO2MSC26_*M..:U8H7T?]CU6.=3V[VE=Q$X_5&%!4[?_GHMZ\= MW-
@:;JP5J7P,%82%]\?@/5AM!=J]T+L;W_9"[G#3=K-5)&]V8@Z"]XZPC)$; MX$#J#1O^)GS>AH*:!6?NN%_N.3W;6%^XX5)<+9A>V'I-/7?["=%&&>&AN1<
MZ C0B%#(0]E8@1XU5ZOXBE#NN6,+^2IHU-KB#@G,84*MI;CO %SQ'4+YGB@? MZMAE\Q28BP,[(\B;PEMPJXV^T1C9NBZK\/R.
[93A[<(C>FBUD;IF^X9=+E,G M^-!]3]E@0L'B:2,O#:T%[CX+OO05.*YA;"Z>N[W'GKHC=88 A4)&IJ>5Z_-
MO:T2JS5WIP:XB,=;"YBY,_033OD&RL@S?;K:>F\4W|0Q=I\[3@+<<+4UO+5G M*2FFY(QPW7@)JPBKQAAJQ,,N0D9WYBH@^82Z\
M\]W;U7(O2((7$]ZZRPJ-8G4UT?W65)^'=R$#]LV\MZ-%UFMP:6B.C1;ZG"[=
M;\]M>X1^1WW9\U'\,R7CWUFR=C/=+V(*=QI/_LAA.\]P<+D>:V/W(*O:NY"' M "-\#9GUYYF'_VDK9YT5"N2(+ ,@ABE:$EF M!L
'(,KE/1HR$$N$B9WY+DA MB75Z^E@*E^(I%8!!F5E:VFPH5?'M6R];1N/-^]-*<1DU4U8363)&CYKY/FH9 M?
MFR5IM/8H,)]R30HV6;G#E@6"O/1/IUGX5IPNP[<@P($V M.4TV&Q,#MWS5 MYWB>I9J/S=2CFJ0-&->:F:S3[HN,^&I&Q1'-
E,KD,L376:.34C/.4T/HB^SK MEBQ=-^)QK3(Q;35&P,YH;=:<3'\NJ6=9>+9;%8HJO5$?$1GG^KSSK"/[X]Z MV3(S,1B![3YV>+K;J5/E5%[E[2IJ^7I&
(1C6^Y%NC&]E2MRBV],2\45BH5(:ETYBK""/VZ:2[>PD$/#V<'3(M53MJA1Z4R5"NVZYV(K7"DD8#V,/24J7#9?I*@U5#W* 5#?=4LLBCIGMX6@@'
M>Q6.D:,D+4WBX\]PU=6K5=ST5,K:B7*M!9,E& M@)WS(R/AM!^7.@W4=];H48T9FMO8T;:"F>QB;[XK5E*:6LBK(J7:7
MUK*SF!H7F3UT;:;E.64F.$JMYY5Q%:LBLP^ND:+=K*650HJ2-6H8M](#2((A,P>N@)C2*5IANFJCM**PIY.AK,L M&NL>NF98.VZ/9T]5M=
[+"VVNK3=*+!K 'KKJ18Z'N90A", IYP40-GJC=E5D M]T ;=*?\LFH[,CERPN0X)G#S.1)NU/25;(7C![JFPXR8ET"%[6!5+R<1\XC9=
MRY:_KE%Z>6G2>F"K%U*KO:23#AE&6-=A/WRF<,NGV^K?0'WB_)VUJ;/^',+[M1@]>> #GZ;[IF6]MI6V:@J[EFMM?
X:0CYS5\R@V%'[GK[Z2CG@=WW>ZCD8 O M?N0+R?5\\2%?R'N&"ACC0\8$BLRG? G$Q8=LB=U3=,"7B_'E]-HFAQCTIL7\
M17'2PY0Z:S6;CZKU+T'L?"PM\GP^K=[=Z6BV2/O#9/D/[_H7Q^E!'4?^0)2 MO!.0QXBSR1OR:,*0=P>(<|70^(0XG $0Y#U]5(?[#A
XA^TH%MY9$LK_.G+_ MKJT/JH?Y6*C\I6_]?&OW.XGG7?-Y*[K7+S#QM/!-P^0FU/+A*;]4NKOY:9^J MT!>WK.WZ=:?WQV>R^;4GR5YG@0VP_(_-
]",.UO6J9^/!6\ ME>LZ)<"?#MS^>7C7>;NWL^/S;FX-'WRR; HT[SQ*8&I>I1_UW]?C&1V3,.8^ M_')FQ_*')\B3)O +:-+.+IBU_ Y+%SJ3*S;",?
E$6AGA+;2N5QHDOI!)F< MVBUG.>Q:7&CVRROS.?>>BEMBN2?&1(84<2Q&G"X:5#+Y&!?4B1$OC;ET8!SXYE?_U#D'1NA__Z]2XC +[Q2O_ N"X
1JJD(OO5J&79NPMB[-"]R$1)9ZER^6PXRK64TC@Q0Z-#EE"80TY+],R6T'>:/143CH$B M[U::=4OT!*[89XR:,\[N\!E-5A:.?U)>;M#
<64DR[PDR<@+=FW^]?)+#ZBX\ MR8:I,/W4X$,U>6;D9G7]L=(7(VZ,YBY&AH,0S3E-G$ MO+9W JUP0>/G8U]! M&X^[4@V,6;(..]UPI+?D0]49T@HQ<-
[26IHH/0HQ,!'Y?'JV?!1KJ6E$F(E1UY:AR#OJJ.\6R/3M MQ7#.)M)!:.8BULF;WHE13DXGLZJMPB3-9+3XT[2QQ!*-[1 Z>L>%F1N)QGR?
MU/Y$5^R[4UMN]HC NU+/ K3_B-R06STS\#58OW)WVGM%P=#[(7PUQ*T?(PA< MZ2")PF>$"<3$K]YID&'@B[7R9V4=_BS
!Z[>;4>FOC1YL&3HTL%0E9-52_&I M.!GR4,ZDHK,:WRW1M4?+FC:,QZE0 M;X>Y1!]L9'NM.)9H[M<_-'?^R+-OS%//-DE!M]+F)5("?3/3P&OW@ZGB,X?
D M^JVM>AZ^VM'M1Q5R15K=+ZR)"$IVLG%9^A!HXJOVW$S *-,L&<>1"5^8%3B
M^@V>=RB!^C(;S^="PSA9ERFMR3G]P7SFWKG%O:T$KB_J4L/,#AF]$+[U^\RY M?3]+=+_OG+NK+T?H7,N9GBLKH_7^P4(+.C*6;DG6-
#507L43W[(E^NSS-_D ME5IKE(?Q>E]8N#?XN=9')'S!4Y<_35*_.6IRYER\'R&G%[,-WBNGBU*4#H]S M3))OQ>IA"!_%LMB(8SGU#
(0H>>O1D(II()K9"S<:@LM+C?&NS1VA0SOPARX>_M%OGN0T+??&[@NZ?O"V5XP9.3GFA7-*#;<5WFU])=VJL+Q>&$R9$=IZ#2$;'1
M2=@\>G\57R6,=WHN>& R4 \'PB7?+1[?>P3ANV?O"^5PP0.4[U(.^2E3FK8S
M^3JI5$4[F6;2[2;7Q\H!&TKDK1Q7V#DE&410SEPO@D$R+!L.3@/R@PH[8R'. M;Y^G+Y35A4](IE%+QE!(IR("[/#.@(3%E&&-
C3%22UXM3IJY8RDVB+1+WP^UQ/KKXTXN_AJL/"PIP MB:RLJE#6!\"$ _12:%K_)G#KB,YX&'MG7;!A? ;#]Z44=RP^+2Q(B MLFT18[!P#_'-
N"5>BG!O8-^VDXE)&%$JE(F7PFSV2J MF4Q5I&)X=Y.^HR+';B\+I/.:/+3@HD&?[$R>*IN32JJ88IM?)*MBV,
(@NV3X9C42E4%6G*\Y*YH$+=S7C)086Z:_2I/R+4F8:H&=6B M^$36JREZP$R;,VO8QT+M'2QEH@-L+-039RU=N^KQ/_AFVTY"SE:
<9F0'V8ZM>'K5SL3B6?UR1]XZA MCQ5?N*9PB[=QL$YK&QNFRT*C1QCKNCV$A@OW;.\I!+[:9PP;'U>0^#XK)R@L
M\66E\M;.WN*P]DO5V>%"+T19H=XIT:ETO9VR>;3]W%IYX6AP?OMRY[=_ND+8 M=]CIA^J#+RK)=X(^X/C$2*GO0XR0/>^TVF)+QRA*Z^@!90V'N_"5[?
6A[U2? MD5XG_P=.WTV'?6X\N^+Z39N3(M54'G999I/E6)?I-TR>I&[M6.R"I7]]!N@@F'/[>2/7;Z"<)-5-2I.;SBC*D L&L&,FTPQ;>A5+-8>O0>/(
M8ZG8UQ2BV2.YWUF#QC=$")/F;C=OQ@]4^)%H#])KACK5^YL>Z\H&'H_9$-S M%!QC^#F.=I!?
X1_"!&+B5[\U2$+PQ8+YG3OUYTR),ZXY"0K&'QKN0PG]%1CK$;Z(AWQ+IUC8Q=,(_QI MTAH4=+LZ6?WJ'>ZCLAJE)XUF%%%(4,1,H5P"H7K(FF%9=
<\W<-S-7SS'C[H0 MR:>,J&XJ4T2_Z;-]L0@\BXL[X-^=]>(S,@5WU'W3@4]/"Z0V2B -%+,)- >6 M>Z]_W"C7/2JU57LJ6G0[G^:3O+14XA%)YUK(_(EB\X>-
'KNB*E R/^\".Q^% M-[Z;3+Y0,1<\?GHV%9,=UHJ+3K^9AH-"^)@UQCXX*CYE<)=>LA=56)LQ7GT;U9$R(B[1;-#)V%XM< MT!#Z;7+M ZA_9>9A(-5?
DX:X1ZJM>:N:K+8K;;X^*#RFI$Z\X(A5+-4X7D3= M19ACYZ2N/&#T?0(>>'=!#D>0PQ&(29##$>1P7)T;[[TB:8Q&BCV"^ X'7$$* MFS1H %"7\(5T?
Y0,&_T3OB-B[]\4^6?@#009'-^>P7%@AOQVKWG&[KW?)_O9-G/ G?@7 7.E=\1&CA7 M@7/U_C3HB@E[T#0AGH(AJ7?$?Q_?MDPI4T6&
[J:EA1<82ZRTZE:,!841"V>W5.RI^]XKNJ7G[4Y3?TI8@E)V"M-J(2$V M$M4O36C9)9M+(RONV /#1"(DO]P-
=\G5#W%Q*M=0!BIMM6?)>CJ985K]MU#S M\;E?;-O_ W-7[$[.XMAY2U5D(\:IBRR9J51__<.2^PZ-O 2*-W4";-[A2\"$ M+"AAPLT,4[:@?@K52<^Z[#B
M0%LV1H)#I=B\M8@EM#)2KKIQ.E(4M_L@7"'34;V?5WMRA_%8ZD+*/.1Q_2'K M_B.:RFRYM*<#02U/2?4IS;72_5CUY;.?
&K3W$7>$R(B4@.9]LZJVMOKJUS\$ M1B%%/Z,P"'">? CQQ]6-/$$BZ?0@VQ\ V!. 4GDTVM:\V,J?=*/TJ!?B"F"'K&ZZJ2A MRJ&JUK188_8S'- MFIWD@=5
*MZPDE6%I\O+<;\;ZHW;.7_Z$^>=N#EOCWNS MQ#1%.A2O]LCT4]NAD3]!D>0=^5'WTW,PO.L-'=O"5,(EAZX?1>7GV>RE9J$9 MFB7"O?
R$!X.:F,TL>#"2WE0[US#S(RYI7G68]#BJ1_A6>#2@E6:ER,20[(3# M=TQLWR&&EPC".+E^03M"(64Y6+0L=AQ7\T(3A/-E.09Z-Z%=WA*(N;PHQ3*A
M1T=5Z&0<9F2FYRA((,+,'FH,)7S^5SM?\9&?YD,%>[17>*#M*Q8%U_K<G;ELNO6)4/R>72C@L@$QX\\H#CPC9P MFHI 5;%],1RCP];/,8BX]B$6?
A_8D5PU(W,C/Z(L.YU<#"D;L8%=RJ M'FRHW/2&RI49)[<+=Z3-C MY@P+.C)<(J_E_,];BZQLV3$R["F28@<^U\5#*M]=N.^;0R[?/7T_*,>+&3\U M: -
%AS((3!U1SMJ2\)0GX,?T(:]DX?;+AW&^>_9^4!@7LZ8^IS"*=&;9ZYCL0*V;3W9^3"UGH6$5 M*PQD0#%T[(YE7^<0?
=J*^AZX[Y1AM[:J";BIQY&_5C4%B, 9_(RY]!,T75"6 M_0LL(7='?26AO"N9>_17(QJ1BE*C1;J9I\>%&6I.M="D+S)N=7:*8I#^VI=L M'0CXAXV;GR#?
07WVR]LM)XGWHYF.MAPRPZK*F.;I%WGEW8.6UW["::9OLB2KA%$(R.(.G:,1: DOB+HE[&T(,(8<&0%[]PAZ*#Q6]Y?KH_A;NCU M%!WHDH*#5?
C,L7OEP/T9)W68W*>]35F9OK^+_K^6M(@,+'R&/RURS<&OVIM M7I#_*4+:%=Y]6&H M:T*@AD /O?V MZ+52E2$-]NP'[ZGU5ZZ66W]G6&[>WX,)-?
<*3MSW3J\N4VQC_$!3]]R%>/)B M\6&>.? W(8F5I/_:I23^TI-O%TMHHU1:E)-:Z2"XVL 3;T#P*2I>*(63G M/H]V1<;G+W?)_XJNWH]
(UTI_X!;$_R5H]\D_7U!\AW'4UJ]W>J'WU8'NUVP! MKBX7 :!Z7(2ZO^US68G6\9FUW MYY4KMG71XH1^K,&EH3DVO//B-
#E=0MJLZ_'+FUQ]H^>,7GD,38#I88ETF*0B M7S>IM^8A;!1W6 8B),1FP(BO+Z*]HA!6[$((PUXNP,4#O M/(%LJ,B6DRD[?"M
I1G_.B4)J4XGV1>=URD1P52L)3N\S#?OBI7%4C;#T] M0RVYERWE?A&2QE8NR/;;M M#*MB^'7+EE"2>G%U:9$M?CH A7Y?BXAQ,?QZG)%!@AV&'CL+
9B97&DTXQ2V MB?M\-4Y+B9; /WMOVJ2HTJT-?W]^!='GG/?9.T[9!U!1>Y]G1Z#B/"M.7PB$
M%!$$97#Z]6]F@D.55G5UMV:HW!%W[RHKA5RYUKIR3;F2R\ZW;4Z=RZUU>626 M'5Z!YO/)VYOQ27]|H24!+S70<
M7F0X%W%IA%5<$BCHS=%RF%+ZWV)#Y9"*O#LG$I("& MTF>&ZKE(J2M8#0TTFD,^(9\'LK 2J#,<'74WY)H:9@U^4TVS?:Z]*L.B)I"SDTM3:V$5;$U.-
GD9N!GH9K6OJ5%2* M8H8E*H,]PJUVT2T :FB52K=3MGER@RNLQ?.I! ;'KM3=2 M/?<:&JBZ.+?!C]T/Q["*S#K?4$5FC.392:]-R%-#Y-1 =ZS=6_VG41Y(?
S*B M3G^G/LSW'QE)1\\WX3/'NKG:8?[N]P@*/OSP[&W4T/.GI]O>+PRK\21C0,_[[T>>UA_%]NAO].ID!$A(T)&?/9\4LB(+V)$ZCOYX3&2D!$A M-
#T7(T)H"@@C0FBZ+"-^M2#G9^[#EU!]'"+]DH3RSW X($&W^R;R3UD+G6[T MX?_[%O_VNRL0_4['O_0LZ2_'@SL3"P"B"O\PL0G.D(%,[$._H4+?
C:P_!9&! M4>@_U0W_LL+O>[QZ.;HH^;(KJ@ZU_@X4XOABOPM?0GEK]?Y=;:9_5YLI\GLL M>=_:C(K/7FON/;'_4\(<\MGC<_02"'W34E[X3+]4PE
(L)ZCP@K[$A<\>Z)[M:]HN#,2W)B= 9S$>G&XO!A6L[HAOT/EAI/]"5W:'PAIX80VZ&[.O7/::/1$M M8 /1DB:XCE &2Z";,_FW7W._?&[:?YS]2-
"'R=0ONRXS]7.^F1=K[I7 M2 B4=]JG8QZ=#BQ,-=T!LU9!VS3KZ_IRW&@DUG_2'LJ# -:0LP< X#QK^5Q_ M%[?,*KQ=F'-
B9C52XFQ^8Q960ER(H9.!+XGX50X&AAH9:F1P-#)ZK)%18;Z8 MJW]5'-I\9"D4A8UX=N_5LC)@\,@ [#X:O#Y)EJ]+9CX>1WZ4DYP N?
JW#M(%U;NZ]:H$ M">ZO:X#Y\ 71GGT%7N\#?CFSHBFN8.=X.AV5J!K;6K=4=+P%FF"Q%RKYT;GK M$#D>$CDNV*@J!(0;VW^_
0BH=M;=P<#+@*I>QBF&4-DH6 "W Z$OB[+7/ M=Q>RHI+S0^\J\R2O&H+>'@F+,2^HZ+4-#G7\,8RM4Y2^RK#ZCRI5RCJX[5+G#
MN=GBNFRNJD:FR\+YH6A;_"7UL-$TW[XZ5,SHN)/(@SB.800MK#]XI/J#BU\J M<2.CZG
[UT>72JRUGB2[M7E%*T=23BG>K31L7A&2']A7E[B#)M3UAX#L9U7A M+S*F/J?"]H1.K%ZHZ"!ZC#)+"R)*>=64(7?MZO^X%;8&YP/J9E&Y!"6VMWW
MZX>G_KY> /F]S,Y,-Q5J(L67."&DB&@[!ALQ M%E6+6(JZB\Q0!TW9-1<1X9/7N+RH?U!;YO08P@)#')^/:RI><",3UY4#81; M=2.[AZ2B83N6B^^U]
&G80%'7'\40XZVJ[%Q8[K,<6)D29KE5K$^UG 3?&35 MQ:^8 WIP^0]!(2!+REMO@ ()#+Y1J[:BY=X==QS.DMN8*=R+ (!9.A=(8L4
MC&#=J_)GXTRNZ;'"=6&]SE.<6PF0SW[K=0F23W]=4[!F&N;KXH'WC[94$IMJ MAL^O4QR3[8T=8,\+G7P376;D!?
*8CVYK#T'C(4$C/.SV./&]7\&"?'V387). MP> RI>(H7EPW&]T*Q@(F.ZG>!\UA'GL**IYN[30].=Q#K'^X_4P:!Z'-
'*H#5CRVH+W$Z;L^.O76#@L#'R&1H>/X+(YC*+^A_-ZS_-YAX ,^$^2=2 M0]MG-K? !!@V*@_>G5A&,9 +'E>^-:EA%"1TCY[2/0H%/Q3\4/"OOY??[!00
M2EBXA@7@U+9)A11-?S=FS - GY- XXXT@$A@Y%#V$!R+=51[[53;NAAA)7_ M3UOY_V %H-C]R!QI'UXDE-^C6<'4T0(?S@NT]_#%6E D#
7.&/[:@"MIRA) MZ^,./C;P-GA:=TDP*K'B4JN/6Q-E.'5JVY8B4+@U;Y2YXC'P!]>9$#A"X/CZ MGG-?!QRK(]!OM-
+;-1G)L5&GG'N@"UC,.VI&C]6Z=VR)&YMIL13#)C6J,>PZ0ZLJ8%:B47\Y*4]?G M^\(.+Z$^A_I\Y:C+;^ISW)K7XNM8ODTN9L6-
7))=)X9"KRF_;C46/XVB/$BS MEC",$@@;[?GH#KW)Q_F0\$/!?\I!3_H891_#@>%B;E70SN#]IP]$2UPIW?\
MA!&4L'8_V+?[H;B&XOITXGK/_J]7H)H6;57"UPK)JNXQ[MVY#NZW0D?*!0 M9@!)_:/H9E9=JC+ L4UL)MM"H]>V4S&Q,B-%LI°"D;%S>79"ZG#6
MAO(;=/F]PS@;?&8/H"4 ,B'"R8H*(*"=,@(6NOOQ."5E$Z;KV*B\"$TG=*]" MNN\RKW[]&S\>G(VA^#X7W7R7X
MTC#L&OVTS:MUM[)L5M)")]V\Y4&CY"#;L(]3$.5=KU@V.PB^*^_MK>"O]3OBD*PMBQH8SDN=0HR93JB50,=_GN6ZV\7Q0[@G:_1KRX-"N4SJ)1%E
M?A[,#7'T?G'TTH[)K8D+&#Q>]US3G\(CI\3:TWZV:/)M6LB,^$X]7S:Q_O\T MMW6WB_,+\/C!\B!XC%,O,3+U*_"(O8+_P3T- P-I%U<[^"4".6Z\GUID 0I10

MNV;1V,#%)@S3@<^'+(!.!Z'"+RB6J!-ST7)0 -"9 !M @1-=644A0BA$,KI2 M$_^$6U.)Z..Q:HB&I,(O0B;"C17=P/[]@D2]O[9XX H+& 1&7?[T63A97>[^MA?_L'B?I0+00PD[\=^X!%+W;WSQ(\K^N I.O^84._NV=0X]R^NW4_\_QW \N M>D0R==/ZL4/Z(Z(FWDK1&/05$!E90-0BXAB^]X>HK\2-[1.93'ZG8[M=Y,=^ MMT#+0,2_)Y/_11Q^1(MQLI(S<1TY6B]_B_'.+'K?VGV$=X?=9Z:M(E7]80$=M(M02H&>_>BIFBF/.?]#4=^9*/'GCG4!4C%/G],%M_&0\?OE[^DW7U M_@B!5OH+C2#^FZ#Q-_]^L^*O&$<=60O^"[V/WGG\M=CRFP@KXOU$'%*',O) MI!"EF8002R9%812G1D(J#N(IF1R-R3AR2A_KH_)WD6]!}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
<0W!\D5BX:>TI7OM%O->F/L<.V--@(K9E2!\OBQ MIX0-6G;5RA>3,W[3;4U3W5&Q/.3AX]H=6<^O5*:)QYY,P5TOI$BMU8J1&<:>1:8)T+5:*SSV M!9RT{)3&BRDG$;+T?5\,A3@'@.?2Y].5\G"!J"III(T%'GK" MAZWM.%&WOUAK>7:]5@8Q-=49L6CH"1^;FC+9"0T|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|GO/K U;&H8"?- ^|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{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|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|/F??E&J307%5C)(NW^TFFMNL M3$)_+HGM&_HC;RZ$@A *POA.P"VC7T "IK=L%J-R8L+5;3LRFRGQU+:!6@*F'RJNPTH2- 01%\TQ(:NV!"7/L0G(0D*YUFCS2X/L[NM)LUMY(:ORT5C"6P'^X3G^OP"(^8NDOR:9-H;UG'S[*HD-M'$O_V;C)X"85B>$^I] M&/2Y6=#GM_7^W1"0FF]U06Y:IK4,+W.)GEW4I.U*P'VC4HGHH|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|-M,IS(Z;VVR;/)0EP1*-P0,Q%]H:/A2990U1_*S[[SP/GO:KK"4\GMFA\(7+LE M2@M=B8W3RR;2=_9?3IU*GA8T/,XA%]\(LDPX"=F_]@VNM]

<?V04!68U[M9. M"F#2+GAX>W|%$@]7F;H#FAS$&=2'BC7DJH*#.M&7)!UV[0SQYM;+=(^U%]7XGH)N#$GBT&K.E5&6B;_:0]R MK=Z@9#<1W"#
[,/D23WUT(^8]<0^4]W:,1U1]^I;=R4JQ&A#_.47N_Y->.WF MKUCM^FOX$OBS A?/(48(!\M.O9.L=E>AS]7;#9K%]G6C$HP"' ;T>S($FN% MP4]@<;?
06.HE=]9C>#]M%:HM;N,L!)HW# T\5&PZ_ZP(>A[X.W (NCK$D1/]XKW:]W20LA;IFT3 M\U=V@FK;KFA(Y$Z0S-G,-'QS034(!&-$PU*7H@.
(A@YY&\I7[\9%")B@W|R) M?'55C9C>G"@"C7MG.B\D M^=&EP0%7I:!OY5M,_:8(V=7,\AE\W% A9]@5O)@L.P8$SZ&]= M#A*P9;K+4PTG"W?
G572[DV?U,0X=[.R&#(*$,Z9"<;-H+?M,HJ-%LDY?5SLZ M.UVM!!KW>(R?"1S<=8/'H.^;006:H*_;HYQON.O(PR_UHSZNU\^I!H2HL$H_
MK,IP"K]&AXM*O%.6NU?B#\MRE7A4&I;5:ES+;ZAQ*T8I]<58$>@$-C=>XO<< MF0A1(*S-?^)PQ*T$/0Q2A"4*02]1",#&H2]DG <_&7G>Y=
[E.TEW$%6XM341# 2W1 =QX#'3GHW/N@KVB*I1H ME,D99P^4JJWGV2DKT+@G9#SUDJ*O>3G3DRG2DX+'LV"=<^S!P<[R@OX33DZ
M29)TQ,QVXK-"5LHU<78PW_Y-O*02C]QDTGM%YCW[BA =8@3@]PR4D##'Q!RO
M?.B!/7R2\TLS%L$C_\9)#-86ZF.!V1MNUK2HE7L5>\3GBQ%](,AFI^[<"'S/ M0&A$HUE]+G:Z7-UVM)1-?+YEK1OY?N>L,-7-NO61*G&@&;'ZN71*7\44-
'O&NUXW M>OD>1;>L5/W0Y +P\\L;6T^)B]] (I!0#9=U#]"!CXG]6UA1(W,RX/O08,)]&2GR M)9:@P]*/$?
^L.SCV6$@*N3[='T4J4LQOMOC37U8CJT7@^#X35Q]GI-3)2K% M94 WG;#R&]<>LP@&H-&3?"'CB;08YCZ#U/_885,J":AFMP__6P6G)/X0/
M%1^=*VGSC4;%]W*U#ML:$/LNC42QEJNWJFRG6*^%;1GO.0'^T&T9;[77A4)\ MQT(<,!E^X':+.'_]%U49NR9P!PA'7]_6A#7BG-
N!3'@/XBBWGR9CZI()\!W+\@#Z/.(,3 MFNC"]7)9P)(&9 M%T+[!O0S0$]J#<40L?GV'15Q$*!^[F$EN4#6Y9A M&NM!N[W4=RI=01]J:RYWKI<<8-
3+'"@G^5YLN@+I@> RNB)$<2,Y*GEZ&"U$ MA! 1'C]C]W"W1GX:$$BS+G3:VIM[GEH%NZ,&*(QT^#L6YKW2# MRC-
]YR/4.00P:WJ7P61K]SL_=HJ6,ZVZKV;O74H2]VX6^1:8)BT56B.'F5M1')[1#;0^U_7Z< MVL]OW/_C("6ZPIRFKNVHX\WQ,KR1.^\O^Z9>-
!SQ25&\^&0E@,Z^O)YK9P(M49+,&7S M!KG.ANG YXL6_-C AV442]2)N6CA$C%G_]"YX!]B*T-)D1$PPOG, MWD^X6YF(/AY[MPG!+]H._#GF+]?
D*CWE_M7UU96[;DN;A >@G]^;4ZZ:H#(MQ(NH_T14W\[R0 [Y>7GX'UE=[OZ%_^R>)>E M) "3_YY+6M1].R=^I+_=16=
M?"U2=&R'/WN%C+V=^O\YGOL!4"*2]9O6CUW7ER.B_!6F,<(H(#*R@*A%O#%\ M]P]17XD:VR@92#BWY)_R(./Z+%.%G)F;B.'*V7CV<1
M'8R='!ZW=A]A_NX^,VT5;:,_+*!#PV)T+-?/14SQ3'G/VCJ.S+$9_!7GRHJ M]CUV)2Z]V1*B!Y[\KTA,+&3*_$>GGCDKF>AGJ!+01M'_.4X<^1]!V,!.! 2$
M#+*,\+T&OI"*7P5>F"]$IY])=;7 UM1=!]OX$<^B(7W?9]0"-M4: F!OFHY) M\'NHS>RA-G,,M;D]U+;W4'M(UOT<++!T1^#^?I 97[P/[Y6BQ-Y]_X(C0GI
M+S2"'^&^"QM_\ XTFO%(HZLAD\%_H???.XW?*<6(K5Z 2T6B"^>8)G/=9K=]A M]!K;X5MT:*MV?=RPX$YJ.-Y'K@WW$MO. ENR5&S7LX;,PFW9-5"M
M5@-^65*!W8$S3.O0]O=_ 9'02YME1M&O5+,%+DVEOXK<[@F.]X%O3&_I [[8CY;:LHZVE2Z
M4HT7TZ/L*%]QVCU.N>9">Y"M.A"!%]L;>DP$0O(#&==!Q5-3^>U<]B!-('PF M_D)'%)L.T.0 <] Q;1__Q-J-!$)2 ^0&?%@48!82&#%=IR^-R";\!U")UMR
M$5Y"GQ\UTU?'T.$Q"U#J+,YNOX2-8AW'70JS_9/Z$&P4F47>NG$2G4FQ&0S M-Q5](X&9*A*2B!\VVJ"/4?S;=]$%]-JS[P0RHH]F2"7^L8FY!=UY:T-(:!#$
M1D*T;>#B$Y&16:6Q,_Z7^30#+-F7@N KQ%X#) M.3X.NEP'$Z<^B(7W?9]0"-M4: F!OFHY) M\'NHS>RA-G,,M;D]U+;W4'M(UOT<++!T1^#^?I 97[P/[Y6BQ-Y]_X(C0GI
=!;1^F+;BI F(HH=P&]OO14!:PG"%P1K2+8I MNUZ+"<+Z1UA0F>BY.JB10 9S$3/;_F?5V!R=6SQ-XDW6]#&^_=T&\B1]?6D
M4UK6R#*389:CLEW3TX'$&TP86NSC_8^X%>*<>+!\'SQ;WB5!G9UU98B)"41\! M8$!Y!] W]HY4H2=9,AP-//@0]]Q#: ?,D>):J1-4,*AGL._@[ES.(Z%XI'P
M-VS'X35BL72)>X'/LVQC)_$O^"N6BQZ)M,D"BJM[^.T[ZD2;RQQ:7KPB136\ M_"0<[>DB&@Z5%P*_@] SKKD&@#Z02\$4L07R$3;XR&$-_A=LI<3<)*JB
;=8-'C_P*QJPZW51O/$LF&(^L;7 MZX,_@AP6;,KC,2T MP+'?FUI[/%XK*(H-K$!"'4-=$3Q%;-N)F$98*%E/588 M3,W8-!VT:&A/E'03G;*T"<|
[1O;%T3G+LVO^$6H@)3]\"F(-\HP*7F>[1KX0 M<]>R76C,(#W] QR TS M!%#?"19/_ZH;S"T; C91'*O(P9;&)];!H"_ 63[M8,,$FV,6F$ B/ /A"/?A!
^3V7E^+W!:>UDQ[[+R]IS:-&@!TW,%;0(+$20Z&_*X.3A&B!S3$;<]]CQEV^4^5<>7R$LY!<"Y<3 M'8W]VW]\4-)#>TCD65>LVKQ9M MM&/,1E
W#T"&)P,YM9N0BD50ACL\I[]W4G"8F?1*,<\NMD?E3-P@>_+K.9 P M?B ZD6'M8]=A-VVOZS^2SW?4&:WAL3[';V)3O?+"WI.D.H/IQAUPPSPGUI,U
M%,>,F*$#:(E]8]<6^[_FZ#]]-/YEIM=V2KT-RV-D(RS?-\VDXO^8V:F;AZ MJS5BHNR%4Z[%6NY5SC5B
PGE75<0\]!JODJZ0OF#ZE4?]R8FQ/+ZR@!R>S== M%1SRK:0G,S71LH22Z>C1\GBED9'X?$:[M>2VO&6__>NLS)-L*]RPT8,)$SV9
ML(\>3;R&H9T[3/R55LV_B2(*B$%]K:@S%>\!WJ[]CX%#"]1Y: Q5'](<EE5G[M4\-EC_*_U7<+\!'CAV#T0M5^/&
[!,!=!&\2$!9V/KAOAWE[$_0M#5OT+CPR>F:@!8]NK* M"O[V"V2 3R&6,M&VW=G\:!<3]86*GIF$[1T4'MAWQ,"?_U9"<^\XG>9/7X6$ MH [8<&Y(<]Z?
*5P=9&W@< [4$$C5!"*!:>'0$=J H7Y\/?*T?@FUS73AE["1 MCL:;ED^LBJX_U%5H]7A)7!1N,0V.HG/'3O-AM7QT>B%&KG/6W-$]4"20]
[*CQ9,Y=8QB2M#T,U?8QD8F MB@1-;[A0T&#%C+%W@N99.%">-8 +!N"C1@YA(SL0D^OYW-C.PRN#%P;B%]PP M9&2<84?2,[IVBP2-Z=?
C[0F_<1!Z'Q1&ST%Z-?+3 M;TA3===+)*#PAF>/H'PL09^7_Y/?[[%$(QZ6:(0E&K>O>PA+-!ZE1_"HK_O M^8;81[4*_M[[[K<^W+$]!.#
[^VM6=P_9A7_M,@8:0*Y*NG5RF^$6_%#=M5ZNG M 5]QP7(8_P_!0^L'W>L9C[-&%70L9%-Z.CS9[; M1=7?B/]5SU@=]"=08X
M/%*T=BD>X]^..8=B1R?)OW\015P"XR\:%'=OY=M_,'G(Z4)+_W4_L:!*' M9+1?P.$]U?8#++?AQMO^X0XIHYV[[+Y] A58F.!# FR$&77^62Q)$)/?YC-=X]
M#L5$X%:+7-G#?-"G<#5M8NZ.X#(0R-!'GH8/"&?F8]/;%&\^N(#D,$GD]W_P MWD/HP_-14.$.KBJ2/2?2]\>XS_MVBTSVY^)E\]Y7AL4WSC#RZ,BI^/)
[()]:P'G#%=4F ["H<@(FL-1?@CEX*$2 M&3C/ACP&(@MU'"L.%7_QE>=X?EZVR?9RJ[_PF-AW@L-<$F7OE".:UAQ%BAP< M$=P%\R"!\ML$O3B?
ZZI728;6PI%,>^$Z3,\(+9#A+-NXFYN?\0/RZT @6@<4 M"/*D ;W-6Q:\SGA6\,/CA<,L-7%/V?'3<&\G"=^,(^GB(4)M5!$<S5_G_A
MP8Q?!*=ZE<%$@:J#?P0WT?3!+Q!"8?8$;Z'N\)Q/0%5]+<3M M$,:0SO^5QAQ5VD$X4_^Q PA $$%BMZING(H;^Z%@!W;#Y*LG\G/&NB,X&B
M@R:EVE@/#!]D?,STDL4HN8(#K]+&QP(?;5P;C%T=1SAP3=ZYB1\;K.I4847# M0.'"G7S_5-?]Z.3[^O9:,5#J$(GX/@SMZ:*#]D**_X'=0[#1!9]D^]OFS:2W
MCG'TR*]T]QLYWAH.^2U?F"$54! A%GLUDWM9/V#R[@$1'"*XD2-3WD?9_7(_M?^\\+ AZNX[*#[RD/-+S?8C&3RGHFT,._T.\.%<\=-8(=N=(?/TIO!\;^UK/
MS!VA%42AO:SICAP6V0YY$S>]P"'S4\.7:;2=(537,I\O]\"PE6+TY.),^?SY M<8$]GZ?WY?.58I,O9HN=P:TT@[5/@[&
[&.O+]XS8?3N\WT&+WZB*]KB1B99$M@_MN'ZB;"+*V,Z)'?F>FD,&4"[3,4[YW]>]4KNF+4=<=*A,IL3RVL]D:W,FUUV6 MG=4=^PX0D?
NZ\U8(YJ#6+9_$*MCBV! MRSBJLM9FU>PXKGS[-QJ+?3_MK4) ?NMXK\(@?UH^]!VYKK]2;?3,/[B7((2!
MW"$,X"74KL&1/SIR_RL,J@'',Q$]D)R/>5%.I$NL1>F.5F:C756 B)-,0%Y0 M\>^G'=,/K$ 5EW"Y<"V;ZZ<9#EX"&K[TTJN>9>^A]MTO*K]3HN%[2.D-
#^DN M&OMVU.R>Z(]77.ZN:BNU&MG9X56VUV:JK5YE=(]ZI-KV(#ISCE16&4'(BU<4++KK[] MRR2_Q^]-NJ^^J!>1;HZVTR*6L(:,_L,="&$A]]SR
MEBZ]R3C+!S+?RDZJ I\A9U.IM(R/.*>J(90A/Y#!\%Q0PL)P(IY9*TN.:W?U.)#PT6 M5&ID&LISKF?--*0/EI2N,^U>>MD;\;-2L#XCC],J31P,14@&&KKH1??
1=TLN=&;QG/>3M-4O'8Y0V:*7]_LY M'3(QOK*%W'HP[!K]M,VK=,>R,%;20B?=_(2YE!"B_B\^+X5]J?"F#:?BMVIB MUZJ]'^&3M:>]BC%;F+G;?"-
NC3N9Y"R;Y!?,<%VH9!VVDH3;/Q71KN^M)-Y!S-D,?8#[MR:'0S=X8F%NF!(#|=2Y"@-ES>#LJ%8!&@S=]K^,7D.M&YU K?99+R66OFVP/ M>)W?
#'/#]C,NU.P6-!4^MH-O" $_MU!P., QD6UR7&-Z?X!>.NYSJE7KG7T&AV/9U4 MYKT(4,\2GXHZ6E[CR@]QHD= K M<4S=S?QHG@T(+R":\>.2'13Z
M;FVC\>2;-Z(OU<=';WA-J<^B/8?\;Y?IX:(RR"@B61Z4L[H4K:YHX=<=2ESY M7-T)2T;'Z^/?TG5^LUXL,HUDNB/P8G04MZB5M1K$H"$8_T
YC]31%UYB!?^" M$IVR"SPYEO&;=R4N.N0/'(L9A,^L$G@QB>C;6G.D(_N6%EZ.!]D#JK,[NP%? M>/I$_V6'?7U]##$4\<"*,*[WLJ4-W17)]]1DQ,O,N&
FV9^(^.XDZJ&_RCL2 MBU*=1[FQD9>D50SRYZ9U]]:M!=M4,%.W'SV]G:1U. MZQ_IV+ H&U?]+P_8B/EY[^K-^]@Q!1AL] ?ALZJ86:+YR-
01UMH.8(DN:? M(_#F85D;U)F'@-Z_=^3E%Q(PF2=E_5]2=R2FXB=G6D*S]J#)C3;]+SO29B.6-9I'-F1/0UJ5L29.@PKT*?/ MS/>'?,*,<%,>]+5.LCBIU6N:
D>>/#/9K2C5N="+D#VR/1;MZ6 HY%="5"#? MCNR(Z=%D/-KP7#E7C*4&_<'*(EDX\N3M=CGEUI;%T8CK9=OIF;]H%_HM-/+D
M[3E9C*B:62WP==6T^KU*LUDIKX38Z=N9.IV81?D%2*FE'C2;&AP)$G\XP5[=6]VE*R6CG#.>.\5C?H 7KFR3QC MW)!OI?/S$3^+-2-#LLRI?]$
M=IKN)=#=6>4BVHW(UBFOP*CCQY9]ZI9A:%BECC%A7>;A;GK6G&0L]OATY MW\Y MC1MME\K#,?=D]OIC#$G)*O (=-4-
A)#)33X[I;,HR.C'E'..S@X[=MB\^W48XNQ:MZRXG.QA1BYPE)W6JBPJ25:(2<)<51?EM+T+R-1IZ0)+?K^I8! M.LDQ0Y'JCB/_/WM?VJ2HDB]_?
X*HN^=-\Z)6SJ BMIG;D<@XKXK;E\(!%04 M05GWQW&2KT1&RG@=K\ZC$MK=9 S M5NR4EUE8U1!H[=X-
@O4!T5'[3]0(@7;T@\U2/3)@=9WJO2=&JF6X6W,,Y(<"'UZ. A%(,/P MJ5$@/AW5]TI@GQNPDYLW],#[.P0?_=,Q0V&#IC/!!NA8&)#))[F'ZO
M#YWQ_>YSRI//(#+\\&%B(7C <$\(6#(;] M4T<_K9L]]Q@^"H"K##__O!_GCLRB:"./W'3![WCU]>"67'-2[+"G'21W!7[R6 M$H/#R[F-C'L$H?@O(,"0-
S$$UQ<1.A;*US;W1O?.%]C*#2$>8'4+X0U MT/WT;7B(@_6G_OM@P8>QX&&,XLGFWC;/5N-<9]AQ_.E,>Y4IOXXZ_P7&_#X^_MT?
D]0[P_4C"U'_=]!#TRI:3=F&$R_I+ B=M,\(X_9IS[M]+VOO3T?.2GQ4]\"#9?(CH\9+>]EKTG6@[PVX3&SV4:W%V1)C' M)K*F".3*B?
+']=H_+0@\]MM]:5S)9W7(]P*VK/QI?4/$>YGJG?W M/"_;*B]R5E%2I]6XU)ZG2,%KZ30?1?+]18C;R?>_RST#UA"P!*>1B>XR!+.P
M>6P@DFV;YYB:W"4X?!GBQ1%@"4 M(*G(/72"IU%Y8=(0S(!';U*278F\ET+:4L%A9D./Z" M>/22+Q#I!O]&+SFM=KP2?NY+[?
P53C_/4/+^E_C[,R)N74#K92B_-M-4U] L M7:B$H*QD55G8B@2'\XW&V,(64%GP47YR&_.Z'IR?K:)^I[ON)-C;!ZE)!L' M [-0?
W/PI=,I&F4H.V/]T]BW3Q>I^,1ZGZNVK"UBF&=?L?'EU8 J? VZ+]3/OU<>'T]SE6SC:]]K1VJP1,%7O^#EB6=T W\>G9:F@"_S:6+,+2]EL:I->?5ZC?
_PB(Y<(WD$?9Z3)2D83:APZ=3IA067= MF:]Y 02'\QE0&]\O#A"W35=+IT4T0>'=0!!ZT6$WVZO9K!!+1?NB-%$[&X0II(BH=[[I@PX.OS@
MPIOG@.D87]>R/:O::3,2&D$_$@C^0?V(G3G(>^56]1TT>FX@49%7RP^O&&'3 MZAL+M,MZGWLM>?=6:-@ AO;&9H,U#+)&8-?
P2RK*U%*RFMB8;=F%;5;S*X(V M-Z/1CU^7&B$7- M1I=\U.P>-K)RAORH&S@2_'6Z4'8SV)UV[]CYDM>%TIT-[YJ@L#(7<1AW6+G; M5.5@#-5 4-
'<(G,LRP\<0/4,DR\@]WP]]4=.;3Z M9^R@^D9']L.XE25&[IPA[M%E?9M=M_] BJ7TEW03A M@L5UAL A#% 4>C.3K#$P.
"DYKHA&!LTRD@Q4/X/HNE:TTH-)KB2E\V4!G0:(G8\ M]/[24IX\[A70.JB$=ZO8[1FX,0 5IY&<.ZT&3@:SP7_K<%.>2-@$)INSW9S M-
QYQ[ZR2E.%0AK/)X,1%V5K!N5C.)#L7[<"N #.#R M?' APXE( )?G@PL1<+%GAHX8#E^< "F%C0<^)X1(PL:>$2L#$GA$L 1-[
M3K@$3.PIH1(PL6<$2]#$GA,N!!&.7^QH$P#F87ZQ@$]<[NT-SW*#[N7Y ?N MY::^V^]_V]Y21_2T^?^E:+/1
=WPOR+S/FYC]SK=17[;*\KQ/NBR:^I5A_1]"_I;0^\9D#A3!0"_*$3** MM,,'21GD=87D+O$/@YE_7T1")M_F'NU!XTBL?A]D '+PCR^_G^;"0HH0S. M
D^B 0QZCLA00:FW!9A_NW5$.&IU.C/]Q%74RKOVW?E+4)A=_,FT5LRH(;9 M3#;0S-NY,)>_J^F0S]QHYF^QOMCP<>XQ%7:S#P$VRIVD+E/_YA]>8A;
,+O MYDGG-=,R;%B40]\5<_<]LR.^&]2]_JI=X(L1D@)B66?P3E>C]5%;*VV[]4]W MG_E *=!K13\]&;Q-/E\H=*:1C=02DO9Z8L^XS43LED?:]]'U8./;R(]?>
(E MFC@M#[R6\A%PG3.>O(#K!%SGWESGF\\<<2'1K2R3)>2WW[OMH4WJL)N6L#[# M6[;4=A&?538AELE1T?J 2(A3"X[CI@!OB0=\)> K?QY?<8=:!
[@>X/HU(E[/ MCNY_DAB]K+R_I]^?:SJ]%9DD/F32K*QG%Z81LD/Y5!W(38)$2GF,O$DK>L<1 M]#TYRE<(.+[E"*H.P$;=MI+Z$./"S3 V@CF'&NJK((QD0
+R-?IQ?Z?<>E-_N-7M$O/GVZ/EA0O7S.ZHD':)\% 6N/(F%U]8:BA&K?$]>0]XZ(^8]:?,V%^_M?V=152OWAC(YM-AB91'ML&P_68]N^"AT%L5>R-
OT0G^NI*Z'*;4!+PIXT?/R MHENYD#H4%1]VU$D3[R0E7./K1IB#0XY#_?A%GG9;"]A-P&[^"'9S93=2@.!]
MOM\WGSJ0L(_R+F7*M>0]*2=S;%4MIP]S#BE$K#H0]="[!+3X^(TB,T&6T3-G M&2%O4@"NH9:9M;#:]]VH*DHR^3Y+15Y1$7R"F]S22R;/?
$UF4GK;S(59M"=/L M:!W!0_5E>VQ^I32E;=..9G.]:0Y?4'RW-MLD:[,IG,,7^?&+B+Q0L4OSMH(0 MZQGA:EJ]L]+XK)ZG9X1V"'4C
M;2G(;'OFS+9]B:.FPX%U<,[,0>D()?MBI[&K]4^ZM&2B'RFFO&Q(Y-VE'PV M)&:LA/QR'4^-6;)0RD>65BX:#7TE-^1BLPZ1AI[O3C="PZ:EEEP*0")O6-F-
3S.B:_!)=ZRS [O]L(E'Y'L@N0A(XX 1BSI M-AR=_93-'&_8V.2)+N+Q(FFY:1$,4Z"YZ4*G"W,]TUX6K,]47)L0Y5&>)GF) M3B $/!+;#&T*'_%QE.*
(QU_P6\7FOUH/KA^B>BN(#U?%?6<[-:6BX]]K6X M84]D$]Q7'(L]^L58##0*9B\44N9&+D&$S.4[L9?[NP2?A+N\YV_R>\(;,_MG GKD.^^7&
[AN$^=7WD?(?;O??;&D&@7*)8^_TD280IB OC3&T<=#4=O!*4C MOA39P^0_C8VH$SY]U:5.4L@\-^_+H'L4)W'NK-LW(]^_&I!7@2[63)01&F6 MN4-
4X9HT\Z;V ;F/=ZI+TW<:\A9-Y7YQAA7E-3&\&\/S9%NMP%1J9YN6CG&: M 2OA:;);8 UF,Z_4 @3:OO8+I2' 97"DF<,_ 9^EG&162#L#A% ;.U9NX/>
M^P\/R>($WYTO@:@6_X(KL/_%2/3+OX\HX8"@"])_=E_H?/3*XSWB$)"BP2?C MDAC#!9(722''1RE*Y <1,L;C9(2(2Y%()!$=_'#04?!4$VJ3S]O,N,/AG59T
MDTADQB5]3/,$3QZOC%0+BK#RNUN6FG=BW=5HE5HJ=_R=KQ2;BX2XR238:<, MCR?2G7RKKH?]/'GZ3 E/&+T)+8SP:K35+S#3$;,9T&#ER3/CR\5
::74 BNO MA8J1V0BC8A'.]L"/5/UIT+L)6HXD(U^0VZ PR,N\NY[#C\,G;E0Y9W7;L6AJ7 M*]BM/3Q09+XEJ(O6U,6]*3;%D>)
MQ8B078Z7=@5FU9ZLG*[CLZ'99'DVRZ33*7.8D>M)F#%RLD\N:X66G90UGY(# MN5K)VBHK43">])/0D]M&\TQG9_:"&;&^B4U3V6V(!HKFR=OC

*V%&]=?Q/+X8 M,]TZ01!&8K;B$Z"#+Y%"2XA%*.(&5T+9L M9J4KW"(Y:E56%KY.3\[B]=*H|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`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|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|' 3?--D"$--%69;,=P!M1U\0;#VE5EAH M8B:%,TNK8V\G Y,*K=[1:S;NIA5< 7PS>YNMQ8QABQ6F#QLY*WA/\ OE#L M(_#:OYW1-; EV=E^Q9E92E+5:T%Y+OIW.T.I!0/IOTDE6:$!9EC- Q3+]6*- MZ-@NK6 IQQF0 FFAPDL6AC \!)0AV[ET (A=2K*HFY89OJ*P>9]H?6.<_+LD MYRN&ZK-)SZJGQT=>WI2@OD)!%$WUF33"R= (V%EUIQ#++$_D9OA=^0WJ$M7IC,6]$97NU2&S(G\'04 MQCD(XH5\Q62^E%AY)TE];8!P_1!?+XW6-ILE(\UA26=QO'FG.KV23"8;PUYD MA!>3R;K=Z6=#&XE^4V CL@#LR#3O(VL?3A(?DKDU]THRAC[+NWRC.F00NJ*M MG96SG:XD-:;;7 2WJ6AV%F]IK%F#Z4^Q"X+V!7'.OQ3*

D>;&'!HB!X27!GJ8 M#G\{?^$Q.)[4=+,M_"LM$ZH4R'7C.:3Q%:<9:[=Y.(W_84[)X;8V;239SL$

*MUS*75&O.SU>7_(67F=^11'P,,_P2L+]=KGB6)/+3>FY4G187PW+4RB79{0,C_M]^'DF5QQQ%!/Z?:,0\&7OOUDO/<) *[5+&:\612'G#T1I;&<,*

09IZ_,OKW] MG^7=\E#$8P.-UW!Y4H]D\ENY:V^A&^(2[W:44$\K'\&GR]+>_/4KT("\(WA(M$C:8[L3]_(S=GF..(@_-(/BMH'X:]12M/Y1_17!S?_B

*M(Y@YKWR; Z=*T?:BHQ$$R/^IL*+%' ME=NP4/ EG]!>8HDSDO@5S>]Y9.WM0',^Z;J0\9YED+)59FLF-R '. M&@^?1@CW(G+G&/9^]*

MQDZ^S:LL&>;>O-](0%62^8:8,LP^TRFSQ4$9WY)B+143G]8']QX3!8E,SG<] M:

<44(0J:M"8Q^YO:@2A$^DT5=5[7YLO5@&.8!+E9SK4(':?/^_7_Y05FCJ@* M!4Q1L/30NP^7"W.P#*AA@!B!=/O#Z0F!J@IORGL^_^_I+/%$I16^67$=''Q?,

M43MMZHRVC:%DBM/Z]CVCI/T1%Q2K=HH?C\$2_,)=-,.NYI)FRF='"*!.Z?9[_V_WM7.UGV_^>^O:UO-S-A M'?)=F!<25N6A]=/YE?<1:N'L?7;2;O?'T5-*

*WR>LD$;...@!'P]$;@>DHM!O9 M_^4_ C8V(,7^=ZO*O![']OI0&UT))_X#[,) ! &K8!;'%&P6Q#U'M7$+|\X,"5*

MAY'WAKS55=N27YR^4C!3ZS__'CSE5BNZ)9O.-@'+YC3!EA3(O\%-2U"T=W_+A-VAP^;5#GKO/SPDBU>Z50/V)_X% M5V#_"^01_.7?1Y1P0%

'61?."YV/WFB&?<07G7;@ SXT+J9"A,W;>-;@9S.^ MG1#3#,W#I:0CIL O9(FVWEH=N06?/,T?02A!7:CF>"N7Y%R%Z1UR2"XFC"Z M/0=U$V]GC?*

*BS,V3O-.?S+D\/>YB!*OQ<>9YT"]J'E4Z^2D M5OK] -ZN/2>Y=$N'V14K6'6FJJ9*F8V%-V?S2-7>FIW:[SC26D#HFC;0V.#-*

M.NXS6@2V^YDIXTCS(?.)Z:03-64N% (2FF+IC+RL7ZH^?E!U> 3#QI G79Z5QR8[JQRG8KPK0T MW8C10;+#4-

UY%!@@IR,3D.'N[Q;A0LIK$K_WEPT%Q<"6@FJ_)_#P>?OB[N#!-M/TLI:7@7'FB@M5Z6K;%^GF1JA?XZ-^N0(3RD+"Q!."Y.61C*C[W$7R,9/VMK

MR+#+AN3P-5^@U_-9OL+ZG-##X8_=/.;93 96&J(T$=I%,"W!SR W-4U6TH M@LI4;7 X T@/R4,1Z'L;VI9M^)+?X%I1!$HZ^@LA445>"I J<(JC!UDF.Y2*

*MYP1XAXYBX-F\1WL6X>],J!&YV74":Nj$S84-$B= XERXAC\77VO,_9@9W6C(-MGJ@[IXGW8VO&R$NU>D8NLB3352[EZ*SH\A? M> .:'FN2@=*

(R0VKR;5G3UZO4_?$> ^-G-MW#PW%893JK#6QG5*MF*5]^J!/B7..[>Y=@%V4K6FIJ9*F8V%-V?S2-7>FIW:[SC26D#HFC;0V.#-@*

*Y\GS\;,^[H#&XYRH!&_DJ;*3=-O554YI;TV*]14F+Q#37;-9? M92,'H@7UL@*X;#G%NYYD\K,5U"#+2WL_VR@KL/@^%!1W'YW>767)N\F*KC$P*

*MA4ZSSL:[]4U!7Y?UU1CO++#8UNCH(T>04VGWA4\:Q+_/=Z?H[MP",;#D6X:'9 M;HT5\S*D%4V$C]VJ-*

K<]TAQA.1'8_8__%PE.@G<(9=9Y48'IHNHSW"C*H5 MZ9-Y$@QZ4U[+ '@@I^9N6V>PY"QN4)*$R_6M2;/9D:VHUH5IA>NL?OPBPV MC.-VB97GQK)H]*

<; ADM. M^G"6"\"D^'V/0^>Y%QI5Z]K!3L,7&N2<;&'\[H?$'G]G=CQOB*_,I=1V'8J M6QC,QC*?*9QF1_XH\7&_ AV>>^:*

V3+H^29LX.ZY^O!K@N&#'589I ME+.(;EUJZ4U956D3)D069W=(+#LH'*6;46RV7:BU(XVN6I'B91:>;&12D)=*

M!+_4<\0S/5[U(QIX'/V8LN\P[(YBZAIQ4@ QTPRG6-L%U8>![[P3'&T//E$TW M)70 ,!$PA2._T,LNG.8U\=CM?G<33BX84,X%9X2 VWT#9G;#(P'+[

5RUIEM MV6BWB, DMS'M0+96LBL/Z-V!?3MP+NF(_)R (WR"HD%O$Q(IEXXZ%I;0)P56 MP4,"_1B8+!BJ

*GC*W]VGRKO^,K*"$M'}7,8E5P=RCW3R>1L;"_#N@:$,?BMX MA9P.T+7-JS>Q;]5Z=*>'%;0*S.;33 _=CO.-7Z!O$.$'BBL[N<6F@T&OOL$I M@)*

(UV.D%X)4QUPW4^\P&_S(AE@"E7;41$JUT8XH\^\(<2]^PD]/L:VCL'N_H M#4=RP44T'<9^_1CFJ_R HA\BKWXJS\'#.. ^[RSX.^CIY-^-QW9JP04S7\RAI

M65BV@2X>A0#.F_HK75ES I4?!L]'T>M+|'G4W;]N=4)2@8 GC-53G#4OEZN[0UBDIA>;%34,B418BT@!=(IJQ=

*M:$:VBTWZ"K+S9WN1';3[RY']0JO0Z7/4FK*7FW%)5H;TCU^:?H*AEB,<#ACL MA4KMXSC5":*

*<]L5YFCK[C,E(WE<;3$I&&^#I7]9CO+;7'QV#$[ZN,#>\B ;'| M-1]7'RO"L)>E&TR(V\A9,3XF\Y%ZGWY+?73,WE,R_EXU'410TQ'4=#R^4"*H*

*MZ7A(38TSBS;+>' T%,CGN3QXY6UM%DH-U(KUE*34PNEANC/C(Z3X98Y&LS_2(S8:ZHVQT6A8C98X&*T^>*?,M>S@O2;FI M'3+&,.K:792-.A\]?*

>:DRQ1SZSE?QYFNQ69::FH\R[RI-G4@.NOTI6ASS; M:8R[^:Y=FO2W-!\[L_H=#G.M]K3:6?$Y>O%U*B5';"5)\^TMC99:T?'=9:2 M*K/>IL"IZ=**ITZ?*

*N2JD0GB[IH. X$V%:$C'"%S;89_QXFY68KEQ+;C-B=5BI) M>DIE4VNZ"U>>O+U>H4*AM:I)<0K3Z>?*V:'5(V@^C(M#@,@GNQ!7]+8_2F6G(;O&-*

*)FY7B"B9_'4-*KRVFZN MU&F6$RI-NY.V-LT56'F"4T,JE95+W%*8SM+106$6ZZ\R4[@R?G(R;4P:L0TY M .(IO2:S14HKU^KG<'_CE&!TUM,!+NO5*

*MAJ4OIYI1>.89/*5'4S$4&YE=O%I)K:V$S&S*Z]4Y!)M3_7XHKQ2CK*+'+>(B< M#A@.8'24/Z'!HAV=;,AA;H)OZ%QY+.H#NJ"!LG\.^>'2!Z-*

AJ=H;/BC,V+W2[MXE(]BU/Q4'T2(9N#,5>:<5[GZ:D1#0*N/'E[0Q9U=FEH?59HJO5N3DXV,L/Z M.>Q+*-V2-!]OBFRH0H>F+5RD6OD1;"/MKG245& D*

*=DF?D2_STVF*I ZC=QT M4Z^NJ\MAK19?KXX.,5@(K>JF;3C9XM 6=[M"JU"(H=X$R#)+P1BKEY;- GM*

M:0,_/)X^76>R"T'K]]A9KC/>B'FVELK63VOVSJ]#O)_X@>VD:BHPGM'&;H0]CMEVC!8TC$V.D+C;,0M,=L5 ME/@REFA-*

*HI>"HD)M%9AW&51>DG7[ZKDX1 M&A[YQQ\$_<"@.V>[T"YT-66H;XN.676@I /(ZH<:.OKD0(<^5:%/O0"6X6W, M4\W=67>[47)'D^J<*W&?*

0I'A!/$O_ST>#?;UJ?>^Y^O@F4. T=Y%>G^'X-"[MGXY-#[UX;YK3ONG)NZ7"P$36W3WL: Q"Z%T]'OSN+.643Q>W6.!OJ] H57 M1P;&$[$_+D\(%SP4+

A!-4)IW%F<\S6&PCJ8%P3]0I=7V?DDW.R;UZS]P]O\'&5]HWM+ MRZ9H,A+RW](=OQ&&[/V:UT.0BV9/@"!?"T%\[NZ A5P)0Z+? M"D-*

*V(9"K"%^?!UP49?EP8OC=,87$B1B*1%T-[Y_L@=5BI) M>DIE4VNZ"U>>O+U>H4*AM!)<0K3Z>?*V:'5(V@^C(M#@,@GNQ!7]+8_2F6G(;O&-*

*)FY7B"B9_'4-*KRVFZN MU&F6$RI-NY.V-LT56'F"4T,JE95+W%*8SM+106$6ZZ\R4[@R?G(R;4P:L0TY M .([O

*MWD8_\J@3IJX# M5_)Q?QLX'S!SH!= -#-V>=9#$LDY41=M-O(-\(]W,.@C?!'T%@=URH*HOO!D1*
*M0+=E6]UT]AS#:0/30LR=.J8X1NR^=GMB5_\HLA_&]H!\]P*ZO#G2OGY>+4:M-M/AE6P+*ZCH/"A.Q<6OL@CL-758=-(#HFE'I@I015!5)R.QCOQQ-*
F.UE?]-.+-M'&"4Z@3$&^M"76&Z]5=:YYYO7(QL-MCQ$D$G6)3E"U\DENPK]-A]XLY]I[2-M'F='P+DT-354ZG_[Y99+U-
FNNIK8FSQ5&E6.TR9EHVG6^_I"0QB:>(R<1ESV-MVNJZ!NM-OM"7$/.YX3.XEA /R;>YH&L+KF4V;.S]!S6'G6LPE3NSN="G)R5*
*MA6ZAMM8C.04*L07F0'<=G&.WYX'0A!7R)#T1=9MX"80H6&/4&AK]7P661<#% M-G)$;;?)K^K!G=?5UT.H!YR5L0]96/@QF+DNJ\L,B(4(]22O.*
*(N%7B2AW1YY-MX+AE&J:""BL+_,GF46>;00C(<48%#M""&+[-'>.FYS$:1TU-*V5Y*N!6O!M2-M;EHA/Q+LUD*JJT-(ABA[-LLRAO}HˆJA_5R-(N584#,&-*
I[^,;?[-2>0_%FN-M^VO!USYCS2$!575#U.UK%P#2S/6-76PY/RO\@/^TCP$'U0CPNW&!BT%=A-,*
MEQEPAN@!'KF.K,JC1Z3/E53YC.J0D]"X5>O;FN+4ABD^;3+AK,"^T-/B84G-M+1QF-G*%CG'EM-Q* \)Y>]B@-4\7C94]%T-2IC3?A!NQ_-F2'<13:H2,*
*<16_8@NC&Z$BX4P20]B:WG,I0'XYC=1A/I]Q3-MQ_;D)$1%*Y3HITF>;#MM:&UTX]34'*F/J[0C]RT(W[;XZJKPKK:-5]\%P-_-MR2#OD;-<#:)YA8*
X<'QH]]79.0$ZV+%2ˆY56BY0]89ZC/C@H-%MB8=WLO;H93G34X".H5S(TUUM5=;!)N<,&Q';F+HI98=4A9?AF_ZB_H:0YDP#
*M&0T0[55ZH4W"KY%*ˆD0]/ˆ92ˆ"Q5=6_#]8$H.#K8!M9"]L6]HFNF2JQRJ=87G>,Z1,KI;X>/KZF]/7]A+7$W1V1";$_M!AE]*@T:/5T?=2U4:8/ˆ]2<>I:*
*{4*L5_M5R>495+-FSR'1IJ:R=?2>H2@H<(*@;Y2%ˆIND)@.F^O-M,:]FTEU7[M]X!.%M6710DLU<.Y0SHDW-R_51-FQ(U+Q.(DF.H?:ˆ]/,M);]3*
MJ.PJRXY37]R^2-]E'?E5]N>?)>#K;@CQEV_,8)Q57U-6!'4D)&K<3)Y7"NTF-M2SO-JQ&_8"I^<$5OFK#Y%L_T+1K^BH-ZQC\-%\?1>7X@/"F@LF@M
M,A:$A/8"ZC_T3R/TX[6]-=R91?17T/,\FMU?Q/$TIS=8.WUT[72O93^MU?W-MB;AD>#)93JHJ7ˆ2CI70ˆ7$MEJ&X3%=1-<\Y{CDA=T_GW'T:X.37X4'*
MMPA.ED).(E.8%-;\L-#KV,+(2-7F-F)$!!\<35S1^;MCC;F/X.1UY?[2P2N/'>;%7%VGC3N$KN]) MU".5--
*J9K,K#5,G]!,NM/*NY>ˆ.5[65SGCX.YR0\!&I;H>H-M-,8R0]##701)D.B]ˆˆE/ISA:]CFU/""5>V634H'"$%*%E>'8OX?R$DCG#M;M*
MTCP[5S0,YD]WQO&,0/U%UG)UT""]'6'"2NWJ!&CLZTC7U((?%-MNX1Z4DVA.03H\"0ˆ67U<(VES.).8(JORN$T7/5&=0%-N*BCT=Q,4$VB"K-C*
MN\B4('?!$53"AAB]/96KXT(DZ.PN+K@-?31;5@\/]-\YO@%,=O#Q#WFX\.R-M.ˆ0ZQGKXMW=D7?"5M!$)NBK\PA"_ˆ+:@+865YLXS"'VEFIQˆ;42Z)''
M>/Q?Q.[CCO-'S%F&]@AV<&S8_=7AP6'OVBOG#/983L-UUY%591Z9['IR',,-M[YCR'X$8F\AIˆN]6-?5\R:.;7-*N%D1-J18T+WA=<&19-1:D-(2]N:*
(/ˆ&]2U2R-ME,BXE4D@;FVK\>_EN[ˆ.%EBZ0X<>H"O>NXN':O&,!P-A_@7NH/X7X+&Q-S[-M2!,.%(K:6U1X+W0OO>)@'N'BINR'LLQD9X+>ZW);KC-
*>B7FNELS6<3D/ˆOE?-MO5@$Y"P(GURY>!7&HU6SH6FRC;D*UQ,I_.H1@-P'5EJV1-6P'!,<5D&)QIG,*
MS$XUIXJ<[.7FR_4\I/38*]4U.1'B9ZO#5:HMCDC@&C44_0ˆ1JI;+ˆ5:9JI2:-M!%M)P[\KK7PERU52>:[ID]J-)>A"ZA;R$?98<;/JC>>J-T:PLS)T3%PL2()2
*MX5B65\Y)W(T9W:\)"D#USH!EPY44JLOD?H4+/1GH;\(T5H***]X1J/*B2:AX-M_H-01B9PT<6ME/14+,/X=RPN1M2$&.67X;'@*
*M>V0+KLB,@5LW#TH.=.0L0X=_PG=#"5=:AP!LB@M.-M72N/*I;IHH/*>[F*=;Q$N++E:2-9!!*J3K9J049:.C3U1;,3R8#X[-MG'!,.EH,M:,+?*
*Y@=BMS:G0978EM#5.3A3)E4!-$Y^(ˆA$-AAQBB("MFAPN6B"M$+-M:M>)ˆ2'ˆ(ˆMJMRY_WO$s[-+*CWZ+*-M[&BE:VW:J+N5Q-*
*S*W[M+@]4ˆD1X0!JB.Y#[3V-X.PPˆT;@:;$9F>$2=GH,21]-M=CXR'J\'3N\HG;F%D42?BKC>,S&.;/ZP3+N?0K-/S"D2PPK$CUUHW1T$6FEY-M8?*
5=2[JSP'+\2V_T6X%^VU.LY&K_FZ->N+LO-MW'NJMX?]99+$BA4NIE"T)I-M[J3/YR&?
**T17.V#Q\8B/ZGGV0&VY2MAVE7.2ZE17EW(M*H]01OWY8IX$CG%@-M:1C*IF5C9PY%-J$P68*[_,9FW9-*
*\$Z;.'!D5B/M+_ON+;:L;7.LˆT21TV5(MD<9X+NL5;MW3L7S*4-MP7UI6\!W$Q90]X-4!ˆM/F3A35?R5Q&6EL>U_!N_E940_2>K-*S*+V8*
*M%N09IQD4N\JW1KF9"$$P=KM_Zˆ-U=:!C;4&+URP/'A?;*0(6CVX2(3?W-1-MU-NU+[L#\4AETEVQ4N22I)*
NYL.QKIZHS5Y^GJI,.O[P(P33/V96JVY<2;3-MR&HTKV@VVZ4']K!CKT?G:[6>L7)X838-'H]ˆ!U''7M7W:8Z0QUU4#!-[<+@*
M+-2M,>0A45,AG7W@Z'NHO1!0%-G%,_!X-Q;A_)-W02HW]K'7XF(QEJ%5,=-+-MX8]UCJ-!J,@;U=[]<5G5?J=2;KYJ.@-+EF3!7#6%;5'LW2AX%"M90)-K
]V&-M%S95Z.2;$"">]YU0J=H==VN,U+Y/Q9:@W+W4$Y0/8ORW/C=Z?QRR!](/O<5OV
MN%5VH(#AKTXR]K%&DW]>E5IS.T'2ˆ6133)35;CN%:OT_T'R@3R3L_],0P;7-M0=BVSM@:A"NV8;@SJ9BGC+"B/83KQ7Y7O,IK%3;V?*
*I"_IBL)@9TY=VK#"YEY#5=&)@HB0ILO-B!95UVZ-M_&Q,>%?2[EKU!H'U]&,N#1M-!/(<2%5[;\IGER^=#-?AZM%LGRS*3(]>KNNE*
M9:Oˆ2T_D\8Q$>,N7FT1$W:;G+6'Y4@BT-#3;BB"94876U3&8V;.'4:J?]A\X-M?!]5ˆP^\-V!;0.FˆAJJ6N:*
*(%OMTT7VY=W9F0M0G;&&Y[6LH81N$HH;P\9H7-MU,+[#&XS1'>%JZ[032BJB#<9<-*0KL,%)6ZTYX;%4*A1WKW-1.X*^JGL1MJ0*
*M1P*Q:.K=*5>C)GRENMJ\$JYW)30#X+8&0>Z-"6SW63(4K.TFC1=W@W]M79T5-M88BB8[J1.Q0D=&QAOQO+_EBW$]B->CO<[:+\D!R[B)-(3!2>W#*
[%W2:S(7E-M(7?E-M#Z&+A(:01]L-^V0<<'8N#8A&[8^IKLAMW=.XVWT0;R\#DGBSP;$)OZ*K!M,0#+1M-!/(<2%5[;\IGER^=#-?AZM%LGRS*3(]>KNNE*
M9:Oˆ2T_D\8Q$>,N7FT1$W:;G+6'Y4@BT-#3;BB"94876U3&8V;.'4:J?]A\X-M?!]5ˆP^\-V!;0.FˆAJJ6N:*
*AC2AWDA[=/4\=;T4*2]HL@)4>6RXX4[48G&.X1"GM<\98_Q@H5;-XR-MCB;E#@(]!._#P/>A*;F<$D0160+TH!U!'-8#-95,L2SG6(_>+-N^#M*
M:!,0>C%HCPRZSSK4&]3:!T5%D$0\$)KA;0B9,IH4$FQC@'@(I(?GV1$-'K!M9@\/!7O=Y#>L_I<-@T=L]A]IQ?WB=O?'WU7VPO$3-3Z]W
*'09(E+)O;OIFX-M$=$>.P>0CT,9KC<,WNSN-M>#_7VP/TZ(I>AQX(\1QO92#I-\$(>B-(8LZ,P%6;%V02?NOH&QU&US>9,N]M-M(;*AY7D;ˆCW3#)D@S3!*
(,[Q][EZ09GCG:88O>NWGT@,%_,M^?!AE$F*$[D?I-MQ+#/,%^@AV1\D$@R(),0X$Q=_N6(M;(X'S6K6C)J(-;@\LCOY2I4N=>?P
M710Z#'MXYZ0P#E*J=OFH]F2$.8UK19+C."=D>,[4QEEU&L)+]*2C2Q+K41U-ML.*
GJ!X2>7SG=,JR(4JMQQ2M%Z%,8J=TVR]'SZ]4S/J.9#IE=MDE>H^\5VK-MK6M)="#OY$X^VXF&RDQ%4*HMLU0T]$*1K=7[D=,*
[8XN\4=2;'$Y""1O.4"6[-MFVBQ\,IH\9VE>);A>GJ#(JNK<5.S0CTF71W!1?O).R?10BX*Y'Z-DT$Y1U6>-MUCUMC.X\>6:RENQ&<^%5FXP.
<[UL8^V$3E;+:T$1^O5.:=")@;YZEJNUSKR33(JJ-M,:Z3D)H@TTPJ5-/=R9S0@+7C.:=B#C@AFFTP&O,4CH?
8PM0:2X(K.10D2(ZNWT(,/NI26RX:M6J5+%;-@J1RX6F]XI=D(W]I=JYP+:)4;3:)&M<@FCFVP7UAL[:D-M8$'FH-TTG(&WZZ-J6YM%"MXZO=7;,3DY,[.
[$+/?BI:Z>RN]PQ7X.1,0S4.254RM,\2T9+2$<%?%^T?/$)5U-M,(+LD3HKXZ[-IX]GSN^?\BE=HX]_&COLGQH?P-M/Y(\WZ3C4KT>O[B18RS\&
(\%'6J>W;N^84>G<-YR(=\H1Z9>,7__$E@2-6-M-5_\QI<-Q_S)EP#'_,F7,;?\U#'P5??X/CL&O@S9-^D7=2(^X&J=Y+E-JW@-MR,*
<8[:N"ZY_MN>56:,U(/S)?RH]?>@C>H^"$#PGU,8SU6>%!+PZ+D_XNIA,^_MF^/7FQ;7Z_SQ9'"=/\7H[SFF827R_EO=-^"]XI:[#.!MU4NLH/BZE_4KR/9H
*M67%B.M>)5Y[2*E6S0_V/]YQ[<:M@K]XEWG\Z4^@9=.TL$V6;(MELY&:MT'C0-M"O%HQS*\K?(9T'5'U[2[A7%"WG=1%FTE1"(/5#1VID+N-4KF!J@>H'J*
*ZB?H-M$]Y'G_"GT*=A2:I&K\D\3U<2$7M=DJ-C[/-M:(0]T:]-]6]'UW>@ˆO.41:@>CC[$Z7>A^O<+!]4">4CAEXMLLPOT%P*_%M.]Q*
MSJ_%B^_5PGRI#5C-!!E4?4W;%+!"K57-]++16JH7B@@XKG8F^1FF,MUP^^)Z\[[-WSQ,8]UA$4;TO6T+\+,P*MYR3)=8W*
B"R"T7!+XG[SMP^GD"8YQ^B$;/-4V[\++-9\$-R"_ZLBL%GTTP-M"&(%0:Q;FZ[+ˆ<+#TIA!9K36L-M5@S4XW*S=']IV^VQ/A:\K[#=#U/8-SM\X%B@GV*.,*
(#B+^#U2]QT0-M_SR\W2C20X+^@N7)+0&.6WKU?8=BR-B%D3$KN3W;K3L!!P]8!RV$15*HPR6-M?*
#5DI4"Z%;7:UNV6%JO^@!GEC"%=J8)Y-.)H%;&:1&4P?+RT\->)WV%[GBKUG^W_HTAK_(]&QXX-9DNA=7[MSZ-MEMED2;#)XK@5'BRY:-
G2"CVED\UJMPL?#.1&]I0=9"W%69HJ.3-(+8&V@&M:M'[MQMR?O.URXYPE,DQX?8I'3-N%!A#@P$8&)\))/O>!ONXXI5O-ZT#%M0@U7<
M9_3]0&K#4&HEPT'EO'ZT=M^;+YW]YZK/7@C7ZW?BT:,=-'-=4:JVFJW%S6HG-M/$$576_AJWT-;=[A:#U(/>1H11,/L7-T")8%,!O-[,UA]FC7>#J;RFJ9[%E*
*M:-[/]U=2>=TV;W>L^VDN;;OI-MAW")WC-QJBF\-*9;"]J"XN.5AL95G^$U\[-\-BI)/8=*@FI1XY\)D'\A_&QY-MCDH_>Q6#OZ;\,PM?*
OGEW$XB.=LRL+BE6Q\[8QI:.E<;NS[\O4#[)"=56W&C-M9BM%I9R11^5\]I,_5H'VUZH;L[@Z^;NMA=P2T*B(]Y!Z;F!Z@_C[CXO\@]X*
MQ"&D%KGRHF_J8BXK$&#:'NML=SF05Y_U3WI.*TV_65%Y=]?*/I.JD(_YZW$-MR<>@+J$/ZT52CU$ZX(O_^!)_I(*ZZC[D2Z-O_N1+H"\^J7O[40?*
*@'D.TKX'%-M/<[9540?;>3Y]+)M(_W(0^2*UCK(]%OP24^N?3;C-M1$=1AYM>?Q-U=E/K4^[%+2UO"8P$<44L-MO/59CWD3@>O@*Z_9)QAT*
*S\")X6[(GUTH(\?#\7VL*3SI#,+9UO,.BT/I_[# MGIQJOM1]SLGQQ=2"2QFA'M5_L-CROLJD>U;:+6C/!-MS[+J*B_7M6B^]?$JHM=2V2=ZT.JL8X,*
(F%/QC2OQVF&+('7PZEG(UT+V;(]4HO2YS.0@0!"HUWUEYEY+O:;*I"4K]59%$3I2GY^W2I5Q;-35"Z_=-M$XES-?C.YI_>*
*(/7L0S^-11;.1&I;B4%OVBPK7RUTKQ@YJ7]WK0;QEZB;+XCJED!-DDVH+J_*(,-M!,0SS,*OR@L]R;%&PYGCX<@61+VAK.)$"ROH-M7FR6U)5[BP?U-V-O*
-).%8%/F@J(!,H3]""B3!T/!YM1S!"$FSP2'3&\!<2-ML(&IR0A)B>%V/FZB,();05\A<;=D^-+MQ'3T;!6-5S,LFQ"D.7R3,-&8VV&-M,*
*<*3;XX)F1[.U(+)R+OG@9GI6CNCJ5+]'/#=XGG6-^#XX7D16-%8UD2[4M-MB1Z)UMZXA>E4A1;D*.EY-TMB+--3,,7QZL$;+'RZ@Q7,@>K.<2!8WA-*
$2.H1?.;;S8]>R/98=AFR?;DK#>@2'"&-M],0/M=TD-!$^:"K.$8O0*"\JH/(2.#N0G'L+!L/:X_65ITSOUH.)>-M'!G-@_*-I^X8*"T*\,8-CF6/>#[V#':*
[P(TG82O\#-63\>$F&2&-#C$-DU;=_03$UG-%XHV:B-M89H&]'*Q9#[@!UO.-!T(0,<-\/WP=8Z]$@@BD#P^HW0W)FW8(RVOIY')T]Q#
*M:NV/^B6E]F0+C@6)#^;"Z:,17W3#WJDE!DT3#%;H+(R'-8BFLNT>5[)VH(AO-M1#H-1V*C7\K(#*PVG,&:@<;XPO!?E/,3=V\O'W*
OZU%4@6"B%=+XR+4,(UY<-M(ˆWQV3P>FMDL![?FE8H]BB-EV@&M;-M'[MQMR?O.URXYPE,DQX?8I'3-N%!A#@P$8&)\))/O>!ONXXI5O-ZT#%M0@U7<
*M9_3]0&K#4&HEPT'EO'ZT=Mˆ

Z=;H':!V@5J=\|G%%_;+DX9YA3U-M'0$:&@:,'%-RJDP!>;}Q9SN<4OGLNKPE0M37\6O[GW/.;55[AK2;>_7H];B MR8A/"B%>CCUU&F.Z6DJD1Q_>N]D%QW8]8\|LTU"@YNB%O,US,ZNB<,QR5K'* MJ#)Z^->?,/40H>D?*

L$\38)$O:.+'O>E@SR>0\FOXZ;X2\N^3@$'[)0'CO W/ M:U4[5LR(<3(4KM"J(ZG&N/WQSN]OM.$IS6;(CC:.*=G1F.?3%6ZPI%EHPQ,_MR(8'>!;@V<_9 '?C!?QC\Y'(HLIN.]XT(XP@Z$&,^!'!R& G5]]DNLEF|W?P M>KI61>&:.VA@/61(@X&]\R6\|_*ML%R*+80Y">4@5V\VYF">O|K7,D$SFB?.*

M)"DGFXWF_5*#6 M4.H@/R+QH_V(!H#:/1+U,1'(1+;Q(AXR2");U0^V,;T!4V"E(I;^"@M5[%7 M)UX)EYI,>O4FNU" 6DK78I;O7[3Q74QSW\ MZP\5?HA&?\+YUP'0?$&3(*_B/OWN0.I]O@\9!!LN:<@SCI8+]TM,2]'[Z_34 M6$S(U.#]"9+#_*K6EN)BEMEN]'F4GE*1++O(D"=^D"$/0"T M9^67+$[C*$;-M-GPH*I_^,"Y0PL_/X4,_;4/>L*O_X2,Y[,O_-.=P9>^TU"&O-_HZM7AK68G/AB&E:40:-8-/)$I2O4^1."]1J+0?:Q\LGO]%]B0]7G:I-KJ=*2DCU1VTIM2[,1\A]2?QL]R5 MU !1OTV0Z.:)(Q2-7X%[S!+W%\N]W5KF0(###4(EPT'%.WW9'2*"#1U\-'%? M.D.7\5S:$;++|:VQSG?BXUZGO,AUX6P_[':X+=O?*

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|>/

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`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|.

*[;8AA5#8@16D*BRD$8.ST5"(+7%$N=3(M6%7(L)\UIE]C+LXUJ0(36!09HFG*C2HG("A^F(E)>@W_53VY@;&@HD7*Q5#H MGN&T#NM/A#-X L13)=1N0&GA1(";<1I;[T%12'VW18C>W004&;!<"2S\DP)3 M*R8SNJZA;,9=^%<"-#T_QD[+EV, !0L+=9(^GU,LVR6'W.J)KQN>(U_(\<+A MV1GL()>8C%0>(%# 3^1^7LE)P]T:;W3X!H7E"N/F.G+0KA MP80Q)IK@O1*I@V@+D4Y)1'(Z0I6I,]>)\3_%HGHMFX[L"A@3;C#6:,_MP'_/\+I/"8Z88G$LZ7+)@DB*(.(0'*P8ACOB@_N1_+7GE]5+@SL1U!)#\.M1PH6'! 3#9+X,4H!(;(@|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|(8U71"07LA0#\7Q&;1,"5+3X.)7[DL&[?-6R;KIKB M(A,JKL,@3*-ZFV8IDIHR)B RSA8Q2@$QC7D@C%C<6.84E4W+)!&.^P"@D%N-MRE5QD124ED3&GG-)I*!I,'^5]^#T>E!"8L%1&IRKA'LM,#)D=2[@SI&L,_!_MQ4S2G(/V.MZDMTC!NVBDD)]&VR+2^/K-S'DPS 2F_USHAR'*YTH$0@3?A"A MU65RO(OV)=&PXM]"ST^H/$UTVFJH,0"! *K=@A :1VA'&969SN:"4-5]X45J MIQ0:\, B$/.&!]GR+C1Y*]2WXFW J00']%3$K1*P:[",?'>4!B9^A;B*?J84 M[H7MAHRC@P^O=0),#|\,,)\4$*/KG3D3!,_ 1S%OP

(A.PJ;Y)@V/]M^@2 -B$/K)8S^'?5\!UXFN,D'U^W3OF(.FJC)_ M/7%BB,885P:Z#H]*Y<"APV6@4I:$]?@$ ^']&XZ#7/LY_]BN#S-ODV6L/F7L M,6U+S*/(B8Y+V[7${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|(<]DZE:[&SPO5A\%O"+4HN?@<%TOJD,E'U^U"F]XQ*UDE$%A6 %R)2TDA M4D03DC-YG@81P98THTK/32.&@ 8*9*I34!P225W9"IDR"Q$I)@)$NH71RZB)C@P7@VU?\>>@&24)ZO1& M04&1$5[[REJH(B6@"1))X;"C|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}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|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|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|'#ITD$JQY#NR (*Y0-$7_,- O<$F_46%2H'0A M]H8S"0;@W:/6"BU&O=P!&8:MWL=\++#RXZM!^'!G@C:0;<[=(S"T\.S3R=IY5# MMS:@'!AG%NS2.SGAZ;GMUQ[MU[,V;$E2M";;[T")BT_9Q0N0S"]Z^YU^9[T6M;KOIT;8\:U]K=#DDKJ,A&/B#;F_OX*+=&HX 7"W_XF"O)2X&^_NMT7 X%'N! M/^=.:!^BW^0M:'AI!C!N[0]Z[:^&-+WN3:0?P1A;VW$LA8X MPP#"&";%6/2OWCKRH@]3))2*UVV4O.K]OV-X'7PDQGP-NDDI\0$G;^']IIE MJEL6+.K=VF0#.VP2<9:H,ES/WQPI>Q67-IIL^T!ILL8)@>[CBEM8Z5WDS1P* MD4ACAK0AK871SF0.I#(*EX#+0=R#=A@.NOW!Q?ZH#8@[W-^[&';%Z*+3'8A M^/O!<*\_A[B=SPG8>5&.27;AN0^6;#IZ]9>,3-P62NSZ#0]>XL>[1'ARKNL M7M]GCEU)SK+&R*@MP.V4]!']SS >HSHJR34:[8^&[? B;'7"BUY_KW-Q$+3" MB_WN*!AV0[\+C'_>'WTL1CZF1'Z>ILFY2*(T,X"YZ/1:_>X3\Z/;_=%JBQ[N MT>--6M>W.1*@%_1%1^P#W\=KZ+7\X&*X[W/1B&(MW][!Z*"U-]@;SH=C^A^1L9X8C][%0;\WV#]8*]S[38^VY5G[6F.FQA>P%)(/ MY03>%9")#8^?H<5Q7'*IP<7>1?L"I=C%I_3BX*+;XG_\_-M5#,/ M7SY>CTY/][ASI_7YRC_[/\%^__H&,.2OWSL[M7M,!@#??W3Z.\7)Y=7O_:"?_6G^Z+S M^UZK^#WH_G;XX@=1/8*KZK>"?K_5]2]\L F![8/:M!_LCRY:@U'8]P_Z^ZU!M:X[7#-Y\&4?#J #>WNGUU\QC!DU/;>=1\SZ6&J"?4,%,.6" _C\AUR:U'0LT M,E!S*9@QG''&A2"G>B:5;IDLK]7BE5[*5W0>3GA3BA07\@6P 7^:BU?J#WO[MZ+N17@;T503L#'$<''Y9I*YW@SYQ__S[H=Y3UV1J8U9,RM?W+491+M'GK#E MM8>;,Q/S,>>S[F_)?-;[GYG]F]WM/:'L9E+=7K^YUW\8J^[''XSKVE\UO$VR M4 ^$!%CSCS3^CS%]&1 H:PE+6Y-B@P!QYPF =R>$=6/!*N?J;> X%GF0193W MRG!(1_Q?)7/O.^^O2*=W9?Z/8Z%JJV^2,'(MUVL_T_CX;_ M7Q>WGZS9PMU8^]<)_H(N*I?9S46P"[_._*!X)76QU_;:?_E/F1:O;!T!_^SU M"OF"RGZ/BUU4VUL'W=87\:7;#MO-<3%9%):ZYR%O#6(=(?Q'F!CZ>JJ5&W M)+A0?@M;:5@]D6,.)#I1SV7:>+?5T:E+?C;T$Y'O?OP2BYG*6NJT6IW_F8N<_M/2/R[M3D79.W0]Z=L/-*4Z>']4HN24H^5MCZO9BZC$6UT3? J*^ MJSGJ%N/LW\HXN>.HJ=G;VH'N8;:& MU_):U2#V$R#Q_] EAA[F;6-B]M>I/7O6Q6;[=;%976RVC:WN9-9@-Q@,AH-> M[\(/X/]Z_=[>A3_L]"Y&PT"(3KOC=WTW0_G\Y*KE$VZYFX7D]:9R%Q6_:7?NW%B"RF*H+B3#(%#@,1ETH++X/D'LC:G3."I$!N4@I9IQD<*MPHGO]\\R%[M!\U!?SLRY[YB[?GT0:7G]]"C.\W!EN0K/B>H]_::@\%V@'U9FNBCT?6&<-9'MI)GM.]&M^/BU4U'/WOS[X[O/G]XTO),/1\W)EK6"+AM)UH+ C[T2%N @,=^ M(5YY'T! 4(7Z'A>H;P&>_3A[]4#<67>JN7.,[_/OX=%KP*^CL9]AS?J;V)]LM%0K5/.P/X2&Z=]:,A#4"?I,(^%6/M*1W:8UH-:(]I%V[MX(]TGG8?YA.&_(M-K8S>G3PF-$CVPG*H1O'"^I\A.*\VUH8U;_U/;.A+_5W3IW"N=B>-\@3[.H'CW965H[]YCT:TBQB,?DP M_O21Q#([J4I89$BE].N9F2L M\1'(&I2=9!:03L?_W>^VN_NDTPUZ^T'W@)Q\(GM?QH,WMO79Y6#\Y]70#7OU MY?3C^8 T/-__5V_@^V?C,U>QWVIWR%C13'/#94:%[P\O&J0Q-28/?'\^G[?F MO994$W\\\J(;0P MW AV?.17_UW;4,:+XZ.8SX@V"\'>-5*J)CSSC,R#7CLW?>CI0_6M-C?>G,=F M&G3:[;_W)L."*?AP/;H-?N/J/RWS7!H/OXPY!\/AF=GEP,/WN7?WP<_DE.!F.T MJMM^2L7_76C#D\4]FI\W0?(,-HX!L$[_.$-!TR:)F,*.Q$RI":QNAH:"D5"J MF*EWC78#F@A1DF7YK',:5<^E*;Z'%TDA:*Y94'WH_Y"-)=>!LQP+B,JRJ&M%J!E?S[EAGDX M92S(Y%S1O%2G]Q9ZE5-;ZM-IP?87UU5:KS_",1]%6_>(@D IE5+1KT.Z+ +< MD"F=,:+8C+,YN!,SY9K\IZ *B"(64)Y+9<#)D/?0 [R0]T\B$S)B?TE1&-8DMYUG4ZA_Y*/O8F>;CE/MVV79H^[EHZVX;VDZIMB$+21?D&KO7#(*;I@-=";58 MPL"9A*@(!%">$9HM2)$953#0%$(>&S(!!BE)X4EQ*DA"(RA21*;<$"-=NSL- M,A8QK:E:8).47C,8MR930UD,RL"0 K7&,;!!Q!7$:= ,(C<-FL!R$UB$:$IT M@7]6_>=,L5((&I!R#?$$3K>+[!33.8NL@B@W!]5D#&;"2L.DA(OZ-+1VE-I. M2O5>#*4827@&H$7\KT#:!#Y!)2@/(USX'(DB!IE A!HBFT BCBXA M!QPC!9&:D* L.5;"6l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}2,QO[LAQ3H*3<\7D+6JE2N>\XR^727G9M M(6=,<.FD:L[W""Y$0>U8Q:VC@1[!3TKBH\&<*@)12F1!U0#!Y0C)Z/;BRI_;(-MANEX9.3TNOMN^PE).)S"\&1R$8Q/'LF$WP7%VHHOW .8G$+P:@S3X>7Q\'P\ MM29O7X_?P74Z)F.ZW8>3HF_%X5BR>H+6IQE$(DLHY&.[3+_JI3"AP61J#Y? M@:2YD I$ I?TH^ +1=MPED4V[&BZ/Y[U.AVW/Q)S3-DK\^3U=S$EPZF0<\S9MUI^0"&EXYBBMB(%F,2;M*) M1:YK4Y.\)M*8J/A/B0Q)1@MK&57$9$ M5*& 3)FBEK8G]3.QE"2O9.T>X*K*[I6P.]|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rzlt-20240930x10q_htm.xml IDEA: XBRL DOCUMENT 0001509261 us-gaap:CommonStockMember 2024-07-012024-09-30 0001509261 rzlt:PreFundedWarrants2024Member 2024-07-012024-09-30 0001509261 rzlt:PreFundedWarrants2022Member 2024-07-012024-09-30 0001509261 rzlt:PreFundedWarrants2021Member 2024-07-012024-09-30 0001509261 us-gaap:CommonStockMember 2023-07-012023-09-30 0001509261 rzlt:PreFundedWarrants2022Member 2023-07-012023-09-30 0001509261 rzlt:PreFundedWarrants2021Member 2023-07-012023-09-30 0001509261 us-gaap:AdditionalPaidInCapitalMemberus-gaap:PrivatePlacementMember 2024-07-012024-09-30 0001509261 us-gaap:PrivatePlacementMember 2024-07-012024-09-30 0001509261 us-gaap:CommonStockMemberus-gaap:PrivatePlacementMember 2024-07-012024-09-30 0001509261 us-gaap:PrivatePlacementMember 2024-06-012024-06-30 0001509261 us-gaap:EmployeeStockMember 2024-07-012024-09-30 0001509261 us-gaap:RetainedEarningsMember 2024-09-30 0001509261 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001509261 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-09-30 0001509261 us-gaap:RetainedEarningsMember 2024-06-30 0001509261 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001509261 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0001509261 us-gaap:RetainedEarningsMember 2023-09-30 0001509261 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001509261 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0001509261 us-gaap:RetainedEarningsMember 2023-06-30 0001509261 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001509261 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001509261 us-gaap:CommonStockMember 2024-09-30 0001509261 us-gaap:CommonStockMember 2024-06-30 0001509261 us-gaap:CommonStockMember 2023-09-30 0001509261 us-gaap:CommonStockMember 2023-06-30 0001509261 us-gaap:PrivatePlacementMember 2024-06-30 0001509261 rzlt:HandokInc.Memberus-gaap:RelatedPartyMemberrzlt:UnderwrittenPublicOfferingMember 2024-06-24 0001509261 rzlt:UnderwrittenPublicOfferingMember 2024-06-24 0001509261 2024-04-012024-06-30 0001509261 rzlt:StockOptionVestingTimeBasedMember 2024-09-30 0001509261 rzlt:Year2021PlanMember 2024-09-30 0001509261 rzlt:Year2019PlanMember 2024-09-30 0001509261 rzlt:Year2016PlanMember 2024-09-30 0001509261 rzlt:Year2015PlanMember 2024-09-30 0001509261 rzlt:InducementGrantMember 2024-09-30 0001509261 rzlt:StockOptionVestingTimeBasedMember 2024-07-012024-09-30 0001509261 us-gaap:PrivatePlacementMember 2024-07-012024-07-31 0001509261 rzlt:HandokInc.Memberus-gaap:RelatedPartyMemberrzlt:UnderwrittenPublicOfferingMember 2024-06-242024-06-24 0001509261 rzlt:PreFundedWarrants2024Memberrzlt:UnderwrittenPublicOfferingMember 2024-06-242024-06-24 0001509261 us-gaap:EmbeddedDerivativeFinancialInstrumentsMember 2021-04-142021-04-14 0001509261 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-07-012024-09-30 0001509261 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-012023-09-30 0001509261 us-gaap:RetainedEarningsMember 2024-07-012024-09-30 0001509261 us-gaap:RetainedEarningsMember 2023-07-012023-09-30 0001509261 2023-07-012024-06-30 0001509261 us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember 2024-09-30 0001509261 us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember 2024-09-30 0001509261 us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember 2024-09-30 0001509261 us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember 2024-09-30 0001509261 us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember 2024-09-30 0001509261 us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember 2024-09-30 0001509261 us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember 2024-09-30 0001509261 us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember 2024-09-30 0001509261 us-gaap:FinancialServicesSectorMember 2024-09-30 0001509261 us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember 2024-06-30 0001509261 us-

gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember 2024-06-30 0001509261 us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember 2024-06-30 0001509261 us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember 2024-06-30 0001509261 us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember 2024-06-30 0001509261 us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember 2024-06-30 0001509261 us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember 2024-06-30 0001509261 us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember 2024-06-30 0001509261 us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember 2024-06-30 0001509261 us-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember 2024-06-30 0001509261 us-gaap:EmbeddedDerivativeFinancialInstrumentsMember 2024-09-30 0001509261 us-gaap:EmbeddedDerivativeFinancialInstrumentsMember 2024-06-30 0001509261 us-gaap:EmployeeStockMember 2024-09-30 0001509261 rzlt:PreFundedWarrants2024Member 2024-09-30 0001509261 rzlt:PreFundedWarrants2022Member 2024-09-30 0001509261 rzlt:PreFundedWarrants2021Member 2024-09-30 0001509261 rzlt:PreFundedWarrants2024Member 2024-06-30 0001509261 rzlt:PreFundedWarrants2021Member 2024-06-30 0001509261 rzlt:ExchangePreFundedWarrantsMember 2024-06-30 0001509261 rzlt:PreFundedWarrantsMember 2024-06-30 0001509261 rzlt:PreFundedWarrants2024Memberrzlt:UnderwrittenPublicOfferingMember 2024-06-24 0001509261 rzlt:LegacyWarrantsMember 2024-06-30 0001509261 rzlt:PreFundedWarrants2024Memberrzlt:UnderwrittenPublicOfferingMember 2024-06-17 0001509261 rzlt:PreFundedWarrants2022Member 2022-05-31 0001509261 rzlt:PreFundedWarrants2021Member 2021-10-31 0001509261 rzlt:LegacyWarrantsMember 2020-10-31 0001509261 2023-09-30 0001509261 2023-06-30 0001509261 us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember 2024-09-30 0001509261 us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember 2024-09-30 0001509261 us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember 2024-06-30 0001509261 us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember 2024-06-30 0001509261 us-gaap:USTreasurySecuritiesMember 2024-09-30 0001509261 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2024-09-30 0001509261 us-gaap:CorporateDebtSecuritiesMember 2024-09-30 0001509261 us-gaap:CommercialPaperMember 2024-09-30 0001509261 us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001509261 us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001509261 us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001509261 us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001509261 us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001509261 us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001509261 us-gaap:EmployeeStockOptionMember 2024-07-012024-09-30 0001509261 rzlt:LegacyWarrantsMember 2024-07-012024-09-30 0001509261 us-gaap:EmployeeStockOptionMember 2023-07-012023-09-30 0001509261 rzlt:LegacyWarrantsMember 2023-07-012023-09-30 0001509261 us-gaap:ResearchAndDevelopmentExpenseMember 2024-07-012024-09-30 0001509261 us-gaap:GeneralAndAdministrativeExpenseMember 2024-07-012024-09-30 0001509261 us-gaap:ResearchAndDevelopmentExpenseMember 2023-07-012023-09-30 0001509261 us-gaap:GeneralAndAdministrativeExpenseMember 2023-07-012023-09-30 0001509261 us-gaap:AdditionalPaidInCapitalMember 2023-07-012023-09-30 0001509261 srt:MaximumMemberrzlt:PreFundedWarrantsMemberrzlt:SecuritiesExchangeAgreementMember 2024-07-012024-09-30 0001509261 srt:MaximumMemberrzlt:ExchangePreFundedWarrantsMemberrzlt:SecuritiesExchangeAgreementMember 2024-03-082024-03-08 0001509261 rzlt:ExchangePreFundedWarrantsMemberrzlt:SecuritiesExchangeAgreementMember 2024-05-13 0001509261 rzlt:ExchangePreFundedWarrantsMemberrzlt:SecuritiesExchangeAgreementMember 2024-03-08 0001509261 us-gaap:AdditionalPaidInCapitalMember 2024-07-012024-09-30 0001509261 us-gaap:CommonStockMember 2024-07-012024-09-30 0001509261 rzlt:AtMarketOfferingMember 2024-07-012024-09-30 0001509261 rzlt:AtMarketOfferingMember 2023-11-142023-11-14 0001509261 rzlt:UnderwritersOptionMember 2024-06-24 0001509261 rzlt:HandokInc.Memberrzlt:HandokLicenseAgreementMemberus-gaap:RelatedPartyMember 2024-07-012024-09-30 0001509261 rzlt:HandokInc.Memberrzlt:HandokLicenseAgreementMemberus-gaap:RelatedPartyMember 2020-09-152020-09-15 0001509261 rzlt:SecuritiesExchangeAgreementMember 2024-03-082024-03-08 0001509261 rzlt:UnderwrittenPublicOfferingMember 2024-06-242024-06-24 0001509261 2023-07-012023-09-30 0001509261 rzlt:XomaUsLlcMemberrzlt:ScenarioUponDosingOfLastPatientMemberrzlt:Phase3ClinicalTrialRz358Memberrzlt:XomaLicenseAgreementMember 2024-07-012024-09-30 0001509261 rzlt:ActivesitePharmaceuticalsIncMemberus-gaap:ScenarioPlanMemberrzlt:Phase3ClinicalTrialRz402Memberrzlt:DevelopmentAndLicenseAgreementMember 2024-07-012024-09-30 0001509261 rzlt:XomaUsLlcMemberrzlt:Phase3ClinicalTrialRz358Memberrzlt:XomaLicenseAgreementMember 2024-04-012024-04-30 0001509261 rzlt:ActivesitePharmaceuticalsIncMemberrzlt:Phase2ClinicalTrialRz402Memberrzlt:DevelopmentAndLicenseAgreementMember 2023-02-012023-02-28 0001509261 rzlt:XomaUsLlcMemberrzlt:Phase2ClinicalTrialRz358Memberrzlt:XomaLicenseAgreementMember 2022-01-012022-01-31 0001509261 rzlt:ActivesitePharmaceuticalsIncMemberrzlt:Phase1ClinicalTrialRz402Memberrzlt:DevelopmentAndLicenseAgreementMember 2020-12-012020-12-31 0001509261 rzlt:UnderwritersOptionMember 2024-06-242024-06-24 0001509261 rzlt:XomaUsLlcMembersrt:MaximumMemberrzlt:ScenarioUponClinicalAndRegulatoryMilestonesMemberrzlt:XomaLicenseAgreementMember 2024-09-30 0001509261 rzlt:XomaUsLlcMembersrt:MaximumMemberrzlt:ScenarioAfterClinicalAndRegulatoryMilestonesMemberrzlt:XomaLicenseAgreementMember 2024-09-30 0001509261 rzlt:ActivesitePharmaceuticalsIncMembersrt:MaximumMemberus-gaap:ScenarioPlanMemberrzlt:DevelopmentAndLicenseAgreementMember 2017-08-31 0001509261 rzlt:ActivesitePharmaceuticalsIncMemberrzlt:DevelopmentAndLicenseAgreementMember 2017-08-012017-08-31 0001509261 us-gaap:EmbeddedDerivativeFinancialInstrumentsMember 2021-04-14 0001509261 rzlt:PreFundedWarrantsMember 2024-07-012024-09-30 0001509261 rzlt:ExchangePreFundedWarrantsMember 2024-07-012024-09-30 0001509261 rzlt:ExchangePreFundedWarrantsMemberrzlt:SecuritiesExchangeAgreementMember 2024-03-082024-03-08 0001509261 rzlt:ClassPreFundedWarrantsMember 2022-05-012022-05-31 0001509261 rzlt:ClassBPreFundedWarrantsMember 2022-05-012022-05-31 0001509261 rzlt:LegacyWarrantsMember 2024-09-30 0001509261 rzlt:LegacyWarrantsMember 2024-07-012024-09-30 0001509261 rzlt:PreFundedWarrants2022Memberus-gaap:SubsequentEventMember 2024-11-07 0001509261 rzlt:ExchangePreFundedWarrantsMemberus-gaap:SubsequentEventMember 2024-10-31 0001509261 rzlt:PreFundedWarrantsMember 2024-09-30 0001509261 rzlt:ExchangePreFundedWarrantsMember 2024-09-30 0001509261 rzlt:PreFundedWarrants2022Member 2024-06-30 0001509261 rzlt:ExchangePreFundedWarrantsMemberrzlt:SecuritiesExchangeAgreementMember 2024-05-132024-05-13 0001509261 2024-09-30 0001509261 2024-06-30 0001509261 2024-11-05 0001509261 2024-07-012024-09-30 shares iso4217:USD iso4217:USD shares pure rzlt:subsidiary0001509261--06-302025Q1false 10-Qtrue2024-09-30false001-39683REZOLUTE, INC.NV27-3440894275 Shoreline Drive, Suite 500Redwood CityCA94065650206-4507Common Stock, par value $0.001 per shareRZLTNASDAQYesYesNon-accelerated Filertruefalsefalse5794306610472000703960009780100056478000190500017790001101780001286530009552000263000183800018380001751000679000-344822000-329444000113441000121003000123414000132737000127540001221400041870003700000169410001591400015914000-16941000-15914000157800014040000-15000-14000156300013900000-15378000-14524000368000670000-15010000-14457000-0.22-0.22-0.28-0.28697360006973600051409000514090005324600053000450473000-79000-32944400012100300015000001000599900600000045000430003800930009300014000001400000610000100010000368000368000-15378000-15378000553940005500045791900028900034482200011344100036827000370003777471000-351000-26098500011617200018490001849000670006700014524000-145240003682700037000379320000-284000-27550900010356400015378000-14524000140000018490000-15000-14000129000122000832000-97300080001000020001080009020002194000-836000948000270900016014000-10585000732380001598900023828000185950000-4941000026060007600060000005760005500000-59924000-797900070396000160360001047200080570001840001710001800017000 NOTE 1 — NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Nature of Operations Rezolute, Inc. (the “Company”) is a late-stage rare disease company focused on significantly improving outcomes for individuals with hypoglycemia caused by hyperinsulinism. The Company’s primary clinical assets consist of (i) ersodetug (formerly known as RZ358), which is a potential treatment for all forms of hyperinsulinism, including congenital hyperinsulinism, an ultra-rare pediatric genetic disorder characterized by excessive production of insulin by the pancreas, and (ii) RZ402, which is an oral plasma kallikrein inhibitor (“PKI”) being developed as a potential therapy for the chronic treatment of diabetic macular edema. Basis of Presentation The accompanying unaudited interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”), the rules and regulations of the SEC for interim financial information, and the instructions to Form 10-Q and Article 8 of Regulation S-X. The condensed consolidated balance sheet as of June 30, 2024, has been derived from the Company’s audited consolidated financial statements. The unaudited interim financial statements should be read in conjunction with the Company’s 2024 Form 10-K, which contains the Company’s audited financial statements and notes thereto, together with Management’s Discussion and Analysis of Financial Condition and Results of Operations for the fiscal year ended June 30, 2024. Certain information and footnote

disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all information and footnote disclosures necessary for a comprehensive presentation of financial position, results of operations, and cash flows. It is management's opinion, however, that all material adjustments (consisting of normal recurring adjustments) that are necessary for a fair financial statement presentation have been made. The interim results for the three months ended September 30, 2024, are not necessarily indicative of the financial condition and results of operations that may be expected for any future interim period or for the fiscal year ending June 30, 2025. Consolidation The Company has two wholly owned subsidiaries consisting of Rezolute (Bio) Ireland Limited, and Rezolute Bio UK, Ltd. The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts in the unaudited condensed consolidated financial statements and the accompanying notes. The Company bases its estimates and assumptions on current facts, historical experience, and various other factors that it believes are reasonable under the circumstances, to determine the carrying values of assets and liabilities that are not readily apparent from other sources. The Company's significant accounting estimates include, but are not necessarily limited to, determination if an allowance for credit losses is required for marketable debt securities, the fair value of an embedded derivative liability, fair value of share-based compensation, management's assessment of going concern, and estimates related to clinical trial accrued liabilities. Actual results could differ from those estimates. Risks and Uncertainties The Company's operations may be subject to significant risks and uncertainties including financial, operational, regulatory and other risks associated with a clinical stage company, including the potential risk of business failure discussed in Note 2. Significant Accounting Policies The Company's significant accounting policies are described in Note 1 to the financial statements in Item 8 of the 2024 Form 10-K. Recent Accounting Pronouncements Not Yet Adopted In November 2023, the Financial Accounting Standards Board ("FASB") issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures ("ASU 2023-07"), which improves reportable segment disclosure requirements through enhanced disclosures about significant segment expenses. ASU 2023-07 expands public entities' segment disclosures by requiring disclosure of significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items and interim disclosures of a reportable segment's profit or loss and assets. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods in fiscal years beginning after December 15, 2024. Early adoption is permitted and the amendments should be applied on a retrospective basis to all periods presented. The Company is evaluating the effect of adopting ASU 2023-07 and does not expect the amendments to have a material impact on its consolidated financial statements. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures ("ASU 2023-09"), which expands income tax disclosures including changes in the rate reconciliation and income taxes paid information. This ASU is intended to enhance the transparency and decision usefulness of income tax disclosures. ASU 2023-09 is effective for annual periods beginning after December 15, 2024, and early adoption is permitted. The Company has not determined the timing for adoption of this standard. Other accounting standards that have been issued or proposed by the FASB or other standards-setting bodies that do not require adoption until a future date are not currently expected to have a material impact on the Company's financial statements upon adoption. Nature of Operations Rezolute, Inc. (the "Company") is a late-stage rare disease company focused on significantly improving outcomes for individuals with hypoglycemia caused by hyperinsulinism. The Company's primary clinical assets consist of (i) ersodetug (formerly known as RZ358), which is a potential treatment for all forms of hyperinsulinism, including congenital hyperinsulinism, an ultra-rare pediatric genetic disorder characterized by excessive production of insulin by the pancreas, and (ii) RZ402, which is an oral plasma kallikrein inhibitor ("PKI") being developed as a potential therapy for the chronic treatment of diabetic macular edema. Basis of Presentation The accompanying unaudited interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP"), the rules and regulations of the SEC for interim financial information, and the instructions to Form 10-Q and Article 8 of Regulation S-X. The condensed consolidated balance sheet as of June 30, 2024, has been derived from the Company's audited consolidated financial statements. The unaudited interim financial statements should be read in conjunction with the Company's 2024 Form 10-K, which contains the Company's audited financial statements and notes thereto, together with Management's Discussion and Analysis of Financial Condition and Results of Operations for the fiscal year ended June 30, 2024. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all information and footnote disclosures necessary for a comprehensive presentation of financial position, results of operations, and cash flows. It is management's opinion, however, that all material adjustments (consisting of normal recurring adjustments) that are necessary for a fair financial statement presentation have been made. The interim results for the three months ended September 30, 2024, are not necessarily indicative of the financial condition and results of operations that may be expected for any future interim period or for the fiscal year ending June 30, 2025. Consolidation The Company has two wholly owned subsidiaries consisting of Rezolute (Bio) Ireland Limited, and Rezolute Bio UK, Ltd. The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. 2 Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts in the unaudited condensed consolidated financial statements and the accompanying notes. The Company bases its estimates and assumptions on current facts, historical experience, and various other factors that it believes are reasonable under the circumstances, to determine the carrying values of assets and liabilities that are not readily apparent from other sources. The Company's significant accounting estimates include, but are not necessarily limited to, determination if an allowance for credit losses is required for marketable debt securities, the fair value of an embedded derivative liability, fair value of share-based compensation, management's assessment of going concern, and estimates related to clinical trial accrued liabilities. Actual results could differ from those estimates. Risks and Uncertainties The Company's operations may be subject to significant risks and uncertainties including financial, operational, regulatory and other risks associated with a clinical stage company, including the potential risk of business failure discussed in Note 2. Significant Accounting Policies The Company's significant accounting policies are described in Note 1 to the financial statements in Item 8 of the 2024 Form 10-K. Recent Accounting Pronouncements Not Yet Adopted In November 2023, the Financial Accounting Standards Board ("FASB") issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures ("ASU 2023-07"), which improves reportable segment disclosure requirements through enhanced disclosures about significant segment expenses. ASU 2023-07 expands public entities' segment disclosures by requiring disclosure of significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items and interim disclosures of a reportable segment's profit or loss and assets. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods in fiscal years beginning after December 15, 2024. Early adoption is permitted and the amendments should be applied on a retrospective basis to all periods presented. The Company is evaluating the effect of adopting ASU 2023-07 and does not expect the amendments to have a material impact on its consolidated financial statements. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures ("ASU 2023-09"), which expands income tax disclosures including changes in the rate reconciliation and income taxes paid information. This ASU is intended to enhance the transparency and decision usefulness of income tax

disclosures. ASU 2023-09 is effective for annual periods beginning after December 15, 2024, and early adoption is permitted. The Company has not determined the timing for adoption of this standard. Other accounting standards that have been issued or proposed by the FASB or other standards-setting bodies that do not require adoption until a future date are not currently expected to have a material impact on the Company's financial statements upon adoption. NOTE 2 — LIQUIDITY As a clinical stage business, the Company has not yet generated any revenues and had an accumulated deficit of $344.8 million as of September 30, 2024. For the three months ended September 30, 2024, the Company incurred a net loss of $15.4 million and net cash used in operating activities amounted to $16.0 million. For the fiscal year ended June 30, 2024, the Company incurred a net loss of $68.5 million and net cash used in operating activities amounted to $57.4 million. As of September 30, 2024, the Company's capital resources consist of cash and cash equivalents of $10.5 million, short-term investments in marketable debt securities of $97.8 million and long-term investments in marketable debt securities of $9.6 million. As discussed in Note 7, the Company completed the 2024 Private Placement in July 2024 that resulted in the sale of 1.5 million shares of common stock for net cash proceeds of $6.0 million. As of September 30, 2024, the Company has total liabilities of $10.0 million, including current liabilities of $8.0 million. As discussed in Note 5, the Company is subject to license agreements that provide for future contractual payments upon achievement of various milestone events. Pursuant to the XOMA License Agreement (as defined below), a $5.0 million milestone payment will be due upon dosing of the last patient in a Phase 3 clinical trial for ersodetug. The commitment to pay the last patient dosing milestone of $5.0 million for the ersodetug Phase 3 clinical trial is expected to be recognized as a liability and corresponding expense within 12 months. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Management believes the Company's existing cash and cash equivalents and investments in marketable debt securities will be adequate to meet the Company's contractual obligations and carry out ongoing clinical trials and other planned activities through November 2025, at a minimum.</p>-344800000-15400000-16000000.0-68500000-57400000105000009780000096000001500000600000.010000000.08000000.05000000.05000000.0<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE 3 — INVESTMENTS IN MARKETABLE DEBT SECURITIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Investments in marketable debt securities are accounted for as available-for-sale investments at fair value and consist of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:61.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September 30, </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30, </p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Short-term investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:15.74%;background:#cceeff;margin:0pt;padding:0pt;"> 97,801 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 56,478</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Long-term investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 9,552</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 263</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:15.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 107,353 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:15.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 56,741 </td></tr></table> The Company only invests in

liquid, high quality debt securities. Nonetheless, all of these investments are subject to interest rate and credit risk that may result in fluctuations in the fair value of the investments. To minimize exposure due to an adverse shift in interest rates, the Company generally invests in securities with expected maturities of two years or less while maintaining a weighted average maturity of one year or less. As of September 30, 2024, investments in marketable debt securities with an aggregate fair value of $97.8 million are scheduled to mature during the 12-month period ending September 30, 2025. All remaining investments, with an aggregate fair value of $9.6 million, are scheduled to mature during the 12-month period ending September 30, 2026. During the three months ended September 30, 2024, marketable debt securities for $23.8 million matured and were reinvested in additional marketable debt securities. The Company used $73.2 million of cash and cash equivalents to purchase investments in marketable debt securities of the proceeds during the three months ended September 30, 2024. The Company did not sell any marketable debt securities prior to the scheduled maturity dates for the three months ended September 30, 2024. Accrued interest receivable on all marketable debt securities amounted to $0.5 million and $0.4 million as of September 30, 2024 and June 30, 2024, respectively. Accrued interest receivable is included in other current assets in the accompanying condensed consolidated balance sheets. For the three months ended September 30, 2024, the Company did not recognize any allowance for credit losses or other than temporary impairment related to investments in marketable debt securities. The following table summarizes the cumulative unrealized gains and losses that result in differences between the amortized cost basis and fair value of the Company's marketable debt securities held as of September 30, 2024 (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:31.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:31.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Gross Unrealized </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:31.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Amortized Cost </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Gains </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Losses </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Fair Value </td><td

style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:31.92%;background:#cceeff;margin:0pt;padding:0pt;"> Corporate commercial paper </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 31,485</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"> 37 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"> 31,522 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:31.92%;margin:0pt;padding:0pt;"> Obligations of U.S. government agencies </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"> 5,253 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"> 24 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"> 5,277 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:31.92%;background:#cceeff;margin:0pt;padding:0pt;"> U.S. Treasury obligations </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"> 13,651 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"> 14 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"> (1) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"> 13,664 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:31.92%;margin:0pt;padding:0pt;"> Corporate notes and bonds </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 56,675 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 217 </td><td style="vertical-align:bottom;white-

space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (2) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 56,890 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:31.92%;background:#cceeff;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 107,064</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 292 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 107,353 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr></table> Investments in marketable debt securities are accounted for as available-for-sale investments at fair value and consist of the following (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:61.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.74%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.24%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.01%;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.01%;margin:0pt;padding:0pt;"> June 30, </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.24%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;">   </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.24%;background:#cceeff;margin:0pt;padding:0pt;"> Short-term investments </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 97,801</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:15.74%;background:#cceeff;margin:0pt;padding:0pt;"> 56,478 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.24%;margin:0pt;padding:0pt;"> Long-term investments </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 9,552 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times

New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 263 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.24%;background:#cceeff;margin:0pt;padding:0pt;"> Total investments </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 107,353</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:15.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 56,741 </td></tr>
</table>9780100056478000955200026300010735300056741000P2YP1Y9780000096000002380000073200000500000400000The following table summarizes the cumulative unrealized gains and losses that result in differences between the amortized cost basis and fair value of the Company’s marketable debt securities held as of September 30, 2024 (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:31.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:31.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Gross Unrealized </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:31.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Amortized Cost </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Gains </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Losses </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New

Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> — </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Fair Value </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:31.92%;background:#cceeff;margin:0pt;padding:0pt;"> Corporate commercial paper </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 31,485</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"> 37 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"> 31,522 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:31.92%;margin:0pt;padding:0pt;"> Obligations of U.S. government agencies </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"> 5,253 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"> 24 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"> 5,277 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:31.92%;background:#cceeff;margin:0pt;padding:0pt;"> U.S. Treasury obligations </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"> 13,651 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"> 14 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"> (1) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"> 13,664 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:31.92%;margin:0pt;padding:0pt;"> Corporate notes and bonds </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 56,675 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-

align:center;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 217 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (2) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 56,890 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:31.92%;background:#cceeff;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 107,064</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 292 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 107,353 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr></table>
3148500037000315220005253000240005277000136510001400010001366400056675000217000200056890000107064000292000300010735300

style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE 4 — OPERATING LEASES The carrying values of all right-of-use assets and operating lease liabilities is as follows (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.03%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:62.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.03%;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;">   </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.93%;margin:0pt;padding:0pt;"> June 30, </td></tr><tr><td style="vertical-align:bottom;width:62.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;">   </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;">   </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td></tr><tr><td style="vertical-align:bottom;width:62.02%;background:#cceeff;margin:0pt;padding:0pt;"> Right-of-use assets </td><td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-

space:nowrap;width:14.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,751 </td><td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,880</p></td></tr><tr><td style="vertical-align:bottom;width:62.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">.</p></td></tr><tr><td style="vertical-align:bottom;width:62.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating lease liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:62.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.03%;margin:0pt;padding:0pt;"> 584 </td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 568</p></td></tr><tr><td style="vertical-align:bottom;width:62.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Long-term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,499</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,660</p></td></tr><tr><td style="vertical-align:bottom;width:62.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,083 </td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,228 </td></tr></table> . For the three months ended September 30, 2024 and 2023, operating lease expense is included under the following captions in the accompanying unaudited condensed consolidated statements of operations and comprehensive loss (in thousands): . <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.47%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"> <p

style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:61.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:61.47%;background:#cceeff;margin:0pt;padding:0pt;"> Research and development </td><td style="vertical-align:bottom;white-space:nowrap;width:3.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 119</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;margin:0pt;padding:0pt;"> 131 </td></tr><tr><td style="vertical-align:bottom;width:61.47%;margin:0pt;padding:0pt;"> General and administrative </td><td style="vertical-align:bottom;white-space:nowrap;width:3.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 48 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 42 </td></tr><tr><td style="vertical-align:bottom;width:61.47%;background:#cceeff;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:3.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 167</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 173 </td></tr></table> As of September 30, 2024, the weighted average remaining lease term under operating leases was 3.0 years, and the weighted average discount rate for operating lease liabilities was 7.1%. Future cash payments under all operating lease agreements as of September 30, 2024 are as follows (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:78.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.22%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:78.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Fiscal year ending June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.22%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:78.09%;background:#cceeff;margin:0pt;padding:0pt;"> Remainder of fiscal year 2025 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:16.22%;background:#cceeff;margin:0pt;padding:0pt;"> 564 </td></tr><tr><td style="vertical-align:bottom;width:78.09%;margin:0pt;padding:0pt;"> 2026 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.22%;margin:0pt;padding:0pt;"> 770 </td></tr><tr><td style="vertical-align:bottom;width:78.09%;background:#cceeff;margin:0pt;padding:0pt;"> 2027 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.22%;background:#cceeff;margin:0pt;padding:0pt;"> 750 </td></tr><tr><td style="vertical-

align:bottom;width:78.09%;margin:0pt;padding:0pt;"> Thereafter </td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:16.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 224 </td></tr><tr><td style="vertical-align:bottom;width:78.09%;background:#cceeff;margin:0pt;padding:0pt;"> Total lease payments </td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:16.22%;background:#cceeff;margin:0pt;padding:0pt;"> 2,308 </td></tr><tr><td style="vertical-align:bottom;width:78.09%;margin:0pt;padding:0pt;"> Less imputed interest </td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (225) </td></tr><tr><td style="vertical-align:bottom;width:78.09%;background:#cceeff;margin:0pt;padding:0pt;"> Present value of operating lease liabilities </td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,083</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The carrying values of all right-of-use assets and operating lease liabilities is as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September 30, </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30, </p></td></tr><tr><td style="vertical-align:bottom;width:62.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</p></td></tr><tr><td style="vertical-align:bottom;width:62.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,751 </td><td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,880 </td></tr><tr><td style="vertical-align:bottom;width:62.02%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:14.03%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-

space:nowrap;width:14.03%;margin:0pt;padding:0pt;"> (</td></tr><tr><td style="vertical-align:bottom;width:62.02%;background:#cceeff;margin:0pt;padding:0pt;"> Operating lease liabilities: </td><td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"> (</td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"> (</td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:62.02%;margin:0pt;padding:0pt;"> Current </td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"> (</td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 584</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">(</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.03%;margin:0pt;padding:0pt;"> 568 </td></tr><tr><td style="vertical-align:bottom;width:62.02%;background:#cceeff;margin:0pt;padding:0pt;"> Long-term </td><td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"> (</td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,499 </td><td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"> (</td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,660 </td></tr><tr><td style="vertical-align:bottom;width:62.02%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"> (</td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2,083</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">(</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,228 </td></tr></table>1751000188000058400056800014990001660000208300022280000 For the three months ended September 30, 2024 and 2023, operating lease expense is included under the following captions in the accompanying unaudited condensed consolidated statements of operations and comprehensive loss (in thousands): (<table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.47%;margin:0pt;padding:0pt;"> (</td><td style="vertical-align:bottom;white-space:nowrap;width:3.85%;margin:0pt;padding:0pt;"> (</td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"> (</td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"> (</td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"> (</td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"> (</td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"> (</td></tr><tr><td style="vertical-align:bottom;width:61.47%;margin:0pt;padding:0pt;"> (</td><td style="vertical-align:bottom;white-space:nowrap;width:3.85%;margin:0pt;padding:0pt;"> (</td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:61.47%;background:#cceeff;margin:0pt;padding:0pt;"> Research and development </td><td style="vertical-align:bottom;white-space:nowrap;width:3.85%;background:#cceeff;margin:0pt;padding:0pt;"> (</td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;margin:0pt;padding:0pt;"> 119 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 131</p></td></tr><tr><td style="vertical-align:bottom;width:61.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 48</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 42</p></td></tr><tr><td style="vertical-align:bottom;width:61.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 167 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 173</p></td></tr></table>11900013100048000420001670001730003P3Y0.071Future cash payments under all operating lease agreements as of September 30, 2024 are as follows (in thousands):<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:78.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></div></div></td></tr><tr><td style="vertical-align:bottom;width:78.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Fiscal year ending June 30, </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">.</p></td></tr><tr><td style="vertical-align:bottom;width:78.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Remainder of fiscal year 2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:16.22%;background:#cceeff;margin:0pt;padding:0pt;"> 564 </td></tr><tr><td style="vertical-align:bottom;width:78.09%;margin:0pt;padding:0pt;"> 2026 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:16.22%;margin:0pt;padding:0pt;"> 770 </td></tr><tr><td style="vertical-align:bottom;width:78.09%;background:#cceeff;margin:0pt;padding:0pt;"> 2027 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:16.22%;background:#cceeff;margin:0pt;padding:0pt;"> 750 </td></tr><tr><td style="vertical-align:bottom;width:78.09%;margin:0pt;padding:0pt;"> Thereafter </td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:16.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 224 </td></tr><tr><td style="vertical-align:bottom;width:78.09%;background:#cceeff;margin:0pt;padding:0pt;"> Total lease payments </td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:16.22%;background:#cceeff;margin:0pt;padding:0pt;"> 2,308 </td></tr><tr><td style="vertical-align:bottom;width:78.09%;margin:0pt;padding:0pt;"> Less imputed interest </td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (225) </td></tr><tr><td style="vertical-align:bottom;width:78.09%;background:#cceeff;margin:0pt;padding:0pt;">

Present value of operating lease liabilities </td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:16.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,083 </td></tr></table> $ 5640007700007500002240002308000225000208300 NOTE 5 — LICENSE AGREEMENTS XOMA License Agreement In December 2017, the Company entered into a license agreement (“XOMA License Agreement”) with XOMA Corporation (“XOMA”), through its wholly-owned subsidiary, XOMA (U.S.) LLC, pursuant to which XOMA granted an exclusive global license to the Company to develop and commercialize XOMA 358 (formerly X358 or RZ358, now ersodetug) for all indications. In January 2022, the Company was required to make a milestone payment under the XOMA License Agreement of $2.0 million that became due upon the dosing of the last patient in the Company’s Phase 2b Clinical Trial for ersodetug. In April 2024, the Company was required to make a milestone payment under the XOMA License Agreement of $5.0 million that became due upon dosing of the first patient in the Company’s Phase 3 Clinical Trial for ersodetug. Upon the achievement of certain clinical and regulatory events under the XOMA License Agreement, the Company will be required to make additional milestone payments to XOMA up to $30.0 million. After the clinical and regulatory milestones, the Company will be required, upon the future commercialization of ersodetug, to pay royalties to XOMA based on the net sales of the related products and additional milestone payments to XOMA up to $185.0 million related to annual net sales amounts. There have been no events that would result in any royalty payments owed under the XOMA License Agreement to date. The Company records a liability and corresponding expense for milestone payments under license agreements in the period that the milestone event is achieved. The next milestone payment of $5.0 million will be due upon dosing of the last patient in either of the Phase 3 clinical trials for ersodetug. ActiveSite License Agreement In August 2017, the Company entered into a Development and License Agreement (the “ActiveSite License Agreement”) with ActiveSite Pharmaceuticals, Inc. (“ActiveSite”) pursuant to which the Company acquired the rights to ActiveSite’s Plasma Kallikrein Inhibitor program (“PKI Portfolio”). The Company is initially using the PKI Portfolio to develop an oral PKI therapeutic for diabetic macular edema (RZ402) and may use the PKI Portfolio to develop other therapeutics for different indications. The ActiveSite License Agreement requires various milestone payments up to $46.5 million, if all milestones are achieved. The first milestone payment for $1.0 million was paid in December 2020 after clearance was received for an Initial Drug Application, or IND, filed with the U.S. Food and Drug Administration (“FDA”). The second milestone payment of $3.0 million was paid in February 2023 after dosing of the first patient in a Phase 2 clinical trial for RZ402. The next milestone payment of $5.0 million will be due upon dosing of the first patient in a Phase 3 clinical trial. The Company is also required to pay royalties equal to 2.0% of any sales of products that use the PKI Portfolio. There have been no events that would result in any royalty payments owed under the ActiveSite License Agreement to date. 2000000.05000000.030000000.0185000000.05000000.0465000001000000.03000000.05000000.00.020 NOTE 6 — EMBEDDED DERIVATIVE LIABILITY On April 14, 2021, the Company entered into a $30.0 million Loan and Security Agreement (the “Loan Agreement”) with SLR Investment Corp. and certain other lenders (collectively, the “Lenders”). The Lenders agreed to loan up to $30.0 million but the actual amount borrowed by the Company amounted to $15.0 million. The maturity date of the outstanding borrowings was April 1, 2026 (the “Maturity Date”), but the Company elected to repay the entire amount and terminated the Loan Agreement on June 30, 2022. Concurrently with the execution of the Loan Agreement, the Company entered into an exit fee agreement (the “Exit Fee Agreement”) that provides for a fee of 4.00% of the funded principal balance for a total of $0.6 million in the event certain transactions (defined as “Exit Events”) occur prior to April 13, 2031. The Exit Fee Agreement was not impacted by the termination of the Loan Agreement discussed above. The Company is accounting for the Exit Fee Agreement as an embedded derivative liability with an estimated fair value of $0.5 million as of September 30, 2024 and June 30, 2024. Exit Events include, but are not limited to, sales of substantially all assets, certain mergers, change of control transactions, and issuances of common stock that result in new investors owning more than 35% of the Company’s shares. Fair value of this embedded derivative liability is reassessed at the end of each reporting period with changes in fair value recognized as a non-operating gain or loss.</p>30000000.030000000.015000000.00.040060000050000005000000.35<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 6pt 0pt;">NOTE 7 — SHAREHOLDERS’ EQUITY</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;">Pre-Funded Warrants</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Between October 2021 and June 2024, the Company issued fully vested pre-funded warrants (“PFWs”) exercisable to purchase an aggregate of 21.3 million shares of common stock. As of September 30, 2024, all outstanding PFWs meet the requirements to be classified in shareholders’ equity under the caption <i style="font-style:italic;">additional paid-in capital</i>. The PFWs do not entitle the holders thereof to any voting rights or any of the other rights or privileges to which holders of common stock are entitled. The exercise prices of the PFWs are subject to adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting holders of common stock. In the event of certain fundamental corporate transactions, the holders of the PFWs are entitled to receive the kind and amount of securities, cash or other property that the holders would have received had they exercised the PFWs immediately prior to such transaction. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The PFWs are exercisable at any time, subject to the then effective ownership blocker percentage (the “OBP”) as elected by each of the holders of PFWs. The OBP is a percentage designated by the holders whereby the PFWs cannot be exercised if, after giving effect thereto, the holder would beneficially own more than the designated OBP. However, upon at least 61 days’ prior notice to the Company, any holder of PFWs may elect to increase or decrease the OBP to any other percentage not to exceed 19.99%. Assuming the holders </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;margin:0pt;">comply with the respective OBP terms, all of the PFWs may be exercised at any time by paying the respective exercise price or electing to exercise on a cashless basis. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 6pt 0pt;">As of June 30, 2024, the Company had an aggregate of 15,020,371 PFWs that were outstanding. The following table summarizes PFW activity for the three months ended September 30, 2024:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;">$ <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:51.26%;margin:0pt;padding:0pt;"> $</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"> $</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"> $</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"> $</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"> <p

style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.26%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"> 2021 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"> 2022 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"> Exchange </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.26%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:7.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> PFWs </td><td style="vertical-align:bottom;width:1.54%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:8.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> PFWs </td><td style="vertical-align:bottom;width:1.54%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:8.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> PFWs </td><td style="vertical-align:bottom;width:1.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:8.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> PFWs </td><td style="vertical-align:bottom;width:1.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:9.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.26%;background:#cceeff;margin:0pt;padding:0pt;"> Outstanding, June 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;background:#cceeff;margin:0pt;padding:0pt;"> 123,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"> ⁽¹⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;background:#cceeff;margin:0pt;padding:0pt;"> 8,147,371 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"> ⁽²⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;background:#cceeff;margin:0pt;padding:0pt;"> 3,000,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"> ⁽³⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;background:#cceeff;margin:0pt;padding:0pt;"> 3,750,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"> ⁽⁴⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;margin:0pt;padding:0pt;"> 15,020,371 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.26%;margin:0pt;padding:0pt;"> Cashless exercise of PFWs: </td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.26%;background:#cceeff;margin:0pt;padding:0pt;"> Shares surrendered for exercise price </td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;background:#cceeff;margin:0pt;padding:0pt;"> (131) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:9.44%;background:#cceeff;margin:0pt;padding:0pt;"> (131) </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.26%;margin:0pt;padding:0pt;"> Shares of common stock issued </td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (610,273) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (610,273) </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.26%;background:#cceeff;margin:0pt;padding:0pt;"> Outstanding, September 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 123,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 8,147,371 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,389,596 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 3,750,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 14,409,967 </td></tr></table> <table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;">In connection with an underwritten offering in October 2021, PFWs were issued to purchase 1,661,461 shares of common stock at an issuance price of $6.49 per share (the “2021 PFWs”). The exercise price of the 2021 PFWs is $0.01 per share.</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;">In connection with a registered direct offering in May 2022, the Company issued 1,973,684 Class A PFWs and 10,947,371 Class B PFWs to purchase an aggregate of 12,921,055 shares of common stock at an issuance price of $3.799 per warrant (the “2022 PFWs”). The exercise price of the 2022 PFWs is $0.001 per share. For the fiscal year ended June 30, 2024, the holders elected cashless exercises for a total of 4,773,684 of the 2022 PFWs resulting in 8,147,371 shares that remained outstanding as of June 30, 2024. The 2022 PFWs were classified within shareholders’ equity for the entirety of the fiscal quarter ended September 30, 2024 and the fiscal year ended June 30, 2024.</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;">As discussed below under the caption Exchange Agreement, the Company issued 3,000,000 Exchange PFWs on March 8, 2024. The exercise price of the Exchange PFWs is $0.001 per share. The Exchange PFWs were initially classified as a derivative liability until May 13, 2024 when the terms were amended to permit reclassification within shareholders’ equity.</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt 0pt 12pt 0pt;">(4)</td><td style="padding:0pt 0pt 12pt 0pt;">As discussed below under the caption 2024 Underwritten Offering, the Company issued 2024 PFWs for the purchase of 3,750,000 shares of common stock on June 17, 2024. The exercise price of the 2024 PFWs is $0.001 per share.</td></tr></table> 2024 Private Placement In June 2024, the Company entered into a securities purchase agreement (the “2024 SPA”) with Handok, Inc. and one other investor relating to a private placement (the “2024 Private Placement”), pursuant to which 1,500,000 shares of common stock were issued at a purchase price of $4.00 per

share. Closing of the 2024 Private Placement occurred in July 2024, resulting in net proceeds of $6.0 million after deduction of offering costs. 2024 Underwritten Offering On June 13, 2024, the Company entered into an underwriting agreement with Jefferies LLC and Cantor Fitzgerald & Co. (the "Underwriters") for the planned issuance and sale of equity securities in an underwritten public offering (the "2024 Underwritten Offering"). The 2024 Underwritten Offering provided for the issuance of (i) 11,250,000 shares of common stock at a price of $4.00 per share for gross proceeds of $45.0 million, and (ii) pre-funded warrants to purchase 3,750,000 shares of common stock at a public offering price of $3.999 per pre-funded warrant (the "2024 PFWs") for gross proceeds of $15.0 million. The Company granted the 2024 Underwriters a 30-day option to purchase up to an additional 2,250,000 shares of its common stock in the 2024 Underwritten Offering at a public offering price of $4.00 per share, less underwriting commissions (the "2024 Underwriters' Option"). The Underwriters' Option was partially exercised for 1,786,589 shares of common stock for gross proceeds of $7.1 million. Closing occurred on June 24, 2024, whereby the aggregate gross proceeds from the 2024 Underwritten Offering amounted to $67.1 million before deductions for underwriting commissions of 6.0% of the gross proceeds and other offering costs of approximately $0.5 million. After deducting total offering costs of $4.5 million, the net proceeds of the 2024 Underwritten Offering amounted to approximately $62.6 million. Exchange Agreement On March 8, 2024, the Company entered into a securities exchange agreement (the "Exchange Agreement") with certain of its stockholders (the "Exchanging Shareholders"), whereby the Company purchased 3,000,000 shares of common stock representing approximately 7% of outstanding shares with an aggregate fair value of $5,700,000 (the "Retired Shares") from the Exchanging Shareholders. The Retired Shares were immediately cancelled whereby they will remain as authorized shares for future issuance in accordance with Nevada law. Consideration for the acquisition of the Retired Shares consisted of (i) a cash payment to the Exchanging Shareholders of $3,000, and (ii) the issuance of pre-funded warrants (the "Exchange PFWs") to the Exchanging Shareholders with an estimated fair value of $5,697,000. The Exchange PFWs do not expire and are exercisable to purchase an aggregate of 3,000,000 shares of the Company's outstanding common stock at an exercise price of $0.001 per share. As required pursuant to the Exchange Agreement, the Company filed a registration statement in August 2024 to register the shares issuable upon the exercise of the Exchange PFWs. The Exchange PFWs originally required approval by the Company's shareholders if the exercise of the Exchange PFWs resulted in aggregate beneficial ownership by the holders in excess of 19.99%. Even though the Exchange PFWs only entitled the holders to purchase 7% of the Company's outstanding shares of common stock, the requirement to obtain shareholder approval for ownership in excess of 19.99% resulted in the treatment of the exchange PFWs as a warrant derivative liability of $5.7 million as of the issuance date. The fair value of this warrant derivative liability increased by approximately $2.9 million, for a total of approximately $8.5 million as of May 13, 2024 when the Exchange PFWs were amended to permit equity classification. Accordingly, the derivative liability was reclassified to shareholders' equity on May 13, 2024. Jefferies Open Market Sales Agreement On November 14, 2023, the Company and Jefferies LLC (the "Agent") entered into an open market sales agreement (the "Sales Agreement") that provides for an "at the market" offering for the sale of up to $50.0 million in shares of the Company's common stock (the "Placement Shares") through the Agent. The Agent is acting as sales agent and is required to use commercially reasonable efforts to sell all of the Placement Shares requested to be sold by the Company, consistent with the Agent's normal trading and sales practices, on mutually agreed terms between the Agent and the Company. The Sales Agreement will terminate when all of the Placement Shares have been sold, or earlier upon the election of either the Company or the Agent. The Company has no obligation to sell any of the Placement Shares under the Sales Agreement. The Company intends to use the net proceeds, if any, from amounts sold under the Sales Agreement for general corporate purposes, including working capital. Under the terms of the Sales Agreement, the Company agreed to pay the Agent a commission equal to 3.0% of the gross sales price of the Placement Shares plus certain expenses incurred by the Agent in connection with the offering. For the three months ended September 30, 2024, the Company did not elect to sell any shares of its common stock pursuant to the Sales Agreement. Accordingly, the maximum amount remaining for sale under the Sales Agreement amounts to $50.0 million as of September 30, 2024. 213000000.199915020371The following table summarizes PFW activity for the three months ended September 30, 2024: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:51.26%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.26%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"> 2021 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"> 2022 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"> Exchange </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-

space:nowrap;width:51.26%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:7.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> PFWs </td><td style="vertical-align:bottom;width:1.54%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:8.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> PFWs </td><td style="vertical-align:bottom;width:1.54%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:8.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> PFWs </td><td style="vertical-align:bottom;width:1.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:8.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> PFWs </td><td style="vertical-align:bottom;width:1.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:9.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.26%;background:#cceeff;margin:0pt;padding:0pt;"> Outstanding, June 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;background:#cceeff;margin:0pt;padding:0pt;"> 123,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"> ⁽¹⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;background:#cceeff;margin:0pt;padding:0pt;"> 8,147,371 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"> ⁽²⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;background:#cceeff;margin:0pt;padding:0pt;"> 3,000,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"> ⁽³⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;background:#cceeff;margin:0pt;padding:0pt;"> 3,750,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"> ⁽⁴⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;margin:0pt;padding:0pt;"> 15,020,371 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.26%;margin:0pt;padding:0pt;"> Cashless exercise of PFWs: </td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;margin:0pt;padding:0pt;"> - </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.26%;background:#cceeff;margin:0pt;padding:0pt;"> Shares surrendered for exercise price </td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;background:#cceeff;margin:0pt;padding:0pt;"> (131) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;margin:0pt;padding:0pt;"> (131) </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.26%;margin:0pt;padding:0pt;"> Shares of common stock issued </td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (610,273) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (610,273) </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.26%;background:#cceeff;margin:0pt;padding:0pt;"> Outstanding, September 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 123,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;background:#ccceff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 8,147,371 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;background:#ccceff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,389,596 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;background:#ccceff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 3,750,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;background:#ccceff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 14,409,967 </td></tr></table> <table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;">In connection with an underwritten offering in October 2021, PFWs were issued to purchase 1,661,461 shares of common stock at an issuance price of $6.49 per share (the “2021 PFWs”). The exercise price of the 2021 PFWs is $0.01 per share.</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;">In connection with a registered direct offering in May 2022, the Company issued 1,973,684 Class A PFWs and 10,947,371 Class B PFWs to purchase an aggregate of 12,921,055 shares of common stock at an issuance price of $3.799 per warrant (the “2022 PFWs”). The exercise price of the 2022 PFWs is $0.001 per share. For the fiscal year ended June 30, 2024, the holders elected cashless exercises for a total of 4,773,684 of the 2022 PFWs resulting in 8,147,371 shares that remained outstanding as of June 30, 2024. The 2022 PFWs were classified within shareholders’ equity for the entirety of the fiscal quarter ended September 30, 2024 and the fiscal year ended June 30, 2024.</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;">As discussed below under the caption Exchange Agreement, the Company issued 3,000,000 Exchange PFWs on March 8, 2024. The exercise price of the Exchange PFWs is $0.001 per share. The Exchange PFWs were initially classified as a derivative liability until May 13, 2024 when the terms were amended to permit reclassification within shareholders’ equity.</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt 0pt 12pt 0pt;">(4)</td><td style="padding:0pt 0pt 12pt 0pt;">As discussed below under the caption 2024 Underwritten Offering, the Company issued 2024 PFWs for the purchase of 3,750,000 shares of common stock on June 17, 2024. The exercise price of the 2024 PFWs is $0.001 per share.</td></tr>
</table>1230008147371300000037500001502037113113161027361027312300081473712389596375000014409967166146164900.011973684109447736848147371300000000.00137500000.00115000004.006000000.0112500004.0045000000.037500003.99915000000.022500004.00178658971000 NOTE 8 — SHARE-BASED COMPENSATION AND WARRANTS Stock Option Plans Presented below is a summary of the number of shares outstanding, authorized, and available for future grants under the Company’s stock option plans and an inducement grant not associated with a stock option plan as of September 30, 2024 (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.81%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:10.54%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:62.81%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Number of Shares as of September 30, 2024 </td></tr><tr><td style="vertical-align:bottom;width:62.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Description </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Authorized </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Outstanding </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Available </td></tr><tr><td style="vertical-align:bottom;width:62.81%;background:#cceeff;margin:0pt;padding:0pt;"> 2015 Plan </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"> 17 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"> 17 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:62.81%;margin:0pt;padding:0pt;"> 2016 Plan </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"> 123 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"> 123 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:62.81%;background:#cceeff;margin:0pt;padding:0pt;"> 2019 Plan </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"> 200 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"> 200 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:62.81%;margin:0pt;padding:0pt;"> 2021 Plan </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"> 10,580 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"> 10,160 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"> 420 </td></tr><tr><td style="vertical-align:bottom;width:62.81%;background:#cceeff;margin:0pt;padding:0pt;"> Inducement Grant </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 275 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 275 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:62.81%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 11,195 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 10,775 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:10.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 420 </td></tr></table> 2022 Employee Stock Purchase Plan On June 16, 2022, the Company's shareholders approved the adoption of the 2022 Employee Stock Purchase Plan (the "2022 ESPP"). The 2022 ESPP provides an opportunity for employees to purchase the Company's common stock through accumulated payroll deductions. The 2022 ESPP has consecutive offering periods that begin approximately every 6 months commencing on the first trading day on or after July 1 and terminating on the last trading day of the offering period ending on December 31 and commencing on the first trading day on or after January 1 and terminating on the last trading day of the offering period ending on June 30. The 2022 ESPP reserves 0.5 million shares for purchases. There have been no offering periods under the 2022 ESPP through September 30, 2024. Stock Options Outstanding For the three months ended September 30, 2024, the following table sets forth a summary of the combined activity under the Company's stock option plans and an inducement grant not associated with a stock option plan (shares in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:62.19%;margin:0pt;padding:0pt;"> 0 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Shares </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Price ⁽¹⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Term ⁽²⁾ </td></tr><tr><td style="vertical-align:bottom;width:62.19%;background:#cceeff;margin:0pt;padding:0pt;"> Outstanding, June 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"> 10,891 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"> 0 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"> 3.82 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"> 0 </td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"> 8.1 </td></tr><tr><td style="vertical-align:bottom;width:62.19%;margin:0pt;padding:0pt;"> Grants to employees </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"> 0 </td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"> 240 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"> 0 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"> 0 </td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"> 4.73 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"> 0 </td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"> 0 </td></tr><tr><td style="vertical-align:bottom;width:62.19%;background:#cceeff;margin:0pt;padding:0pt;"> Exercises </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"> 0 </td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"> (38) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"> ⁽³⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"> 0 </td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"> 2.44 </td><td style="vertical-align:bottom;white-

space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:62.19%;margin:0pt;padding:0pt;"> Forfeited </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (318) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"> 2.61 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:62.19%;background:#cceeff;margin:0pt;padding:0pt;"> Outstanding, September 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 10,775 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"> ⁽⁴⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"> 3.88 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"> 7.7 </td></tr><tr><td style="vertical-align:bottom;width:62.19%;margin:0pt;padding:0pt;"> Vested, September 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 5,525 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"> ⁽⁵⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"> 5.07 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"> 7.2 </td></tr></table> <table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;">Represents the weighted average exercise price.</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;">Represents the weighted average remaining contractual term for the number of years until the stock options expire.</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;">The total intrinsic value (the amount by which the fair market value exceeded the exercise price) of stock options exercised during the three months ended September 30, 2024, was $0.1 million.</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(4)</td><td style="padding:0pt;">As of September 30, 2024, the intrinsic value of outstanding options was approximately $19.2 million.</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(5)</td><td style="padding:0pt;">As of September 30, 2024, the aggregate intrinsic value of vested stock options was approximately $7.5 million.</td></tr></table> For the three months ended September 30, 2024, the aggregate fair value of stock options granted for approximately 0.2 million shares of common stock amounted to $0.8 million or approximately $3.45 per share as of the grant dates. Fair value was computed using the Black-Scholes-Merton (“BSM”) option-pricing model and will result in the recognition of compensation cost ratably over the expected vesting period of the stock options. For the three months ended September 30, 2024, the fair value of stock options was estimated on the respective dates of grant, with the following weighted-average assumptions: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:81.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-

word;position:relative;"> </td></tr><tr><td style="vertical-align:bottom;width:81.15%;background:#cceeff;margin:0pt;padding:0pt;"> Market price of common stock on grant date </td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 4.73</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:81.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 84</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:81.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:81.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 6.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:81.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:12pt 0pt 0pt 0pt;">Share-based compensation expense for the three months ended September 30, 2024 and 2023 is included under the following captions in the unaudited condensed consolidated statements of operations and comprehensive loss (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:72.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;margin:0pt;padding:0pt;"> 712 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 840</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:72.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 688</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,009</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:72.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,400 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,849 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr></table> Unrecognized share-based compensation expense is approximately $10.4 million as of September 30, 2024. This amount is expected to be recognized over a weighted average period of 1.8 years. Pre-Funded Warrants PFWs are outstanding for a total of 14.4 million shares as of September 30, 2024. Please refer to Note 7 for additional information about outstanding PFWs. Legacy Warrants In connection with an equity financing in October 2020, the Company issued warrants entitling the holders to purchase approximately 0.8 million shares of common stock. The warrants are exercisable at $19.50 per share for a period of seven years, may be exercised on a cash or cashless basis at the election of the holders, and the holders are entitled to share in any dividends or distributions payable to holders of common stock on an as-converted basis (“the Participating Warrants”). Additionally, the Company has issued warrants in conjunction with various debt and equity financings and for services. As of September 30, 2024, all of the warrants were vested. The Participating Warrants and other warrants are collectively referred to as the “Legacy Warrants.” For the three months ended September 30, 2024, no Legacy Warrants were granted or exercised. The following table sets forth a summary of all Legacy Warrants for the three months ended September 30, 2024 (shares in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:60.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Shares </td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Price ⁽¹⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Term ⁽²⁾ </td></tr><tr><td style="vertical-align:bottom;width:60.99%;background:#cceeff;margin:0pt;padding:0pt;"> Outstanding, June 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;margin:0pt;padding:0pt;"> 861 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;margin:0pt;padding:0pt;"> 20.28 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;margin:0pt;padding:0pt;"> 3.2 </td></tr><tr><td style="vertical-align:bottom;width:60.99%;margin:0pt;padding:0pt;"> Expirations </td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (10) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"> 52.00 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:60.99%;background:#cceeff;margin:0pt;padding:0pt;"> Outstanding, September 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 851 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;margin:0pt;padding:0pt;"> 19.90 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;margin:0pt;padding:0pt;"> 3.0 </td></tr></table> <table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;">Represents the weighted average exercise price.</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;">Represents the weighted average remaining contractual term for the number of years until the warrants expire.</td></tr></table> Presented below is a summary of the number of shares outstanding, authorized, and available for future grants under the Company’s stock option plans and an inducement grant not associated with a stock option plan as of September 30, 2024 (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.81%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:62.81%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Number of Shares as of September 30, 2024 </td></tr><tr><td style="vertical-align:bottom;width:62.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Description </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Authorized </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Outstanding </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Available </td></tr><tr>

<td style="vertical-align:bottom;width:62.81%;background:#cceeff;margin:0pt;padding:0pt;"> 2015 Plan </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"> 17 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"> 17 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:62.81%;margin:0pt;padding:0pt;"> 2016 Plan </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"> 123 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"> 123 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:62.81%;background:#cceeff;margin:0pt;padding:0pt;"> 2019 Plan </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"> 200 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"> 200 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:62.81%;margin:0pt;padding:0pt;"> 2021 Plan </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"> 10,580 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"> 10,160 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"> 420 </td></tr><tr><td style="vertical-align:bottom;width:62.81%;background:#cceeff;margin:0pt;padding:0pt;"> Inducement Grant </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 275 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 275 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:62.81%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 11,195 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 10,775 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 420 </td></tr>
</table>1700017000123000123000200000200000105800001016000042000027500027500011195000107750004200005000000 For the three months ended September 30, 2024, the following table sets forth a summary of the combined activity under the Company’s stock option plans and an inducement grant not associated with a stock option plan (shares in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.19%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"> <p

style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:62.19%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Shares </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;">   </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Price ⁽¹⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Term ⁽²⁾ </td></tr><tr><td style="vertical-align:bottom;width:62.19%;background:#cceeff;margin:0pt;padding:0pt;"> Outstanding, June 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"> 10,891 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"> 3.82 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"> 8.1 </td></tr><tr><td style="vertical-align:bottom;width:62.19%;margin:0pt;padding:0pt;"> Grants to employees </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"> 240 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"> 4.73 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;">   </td></tr><tr><td style="vertical-align:bottom;width:62.19%;background:#cceeff;margin:0pt;padding:0pt;"> Exercises </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"> (38) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"> ⁽³⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"> 2.44 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;">   </td></tr><tr><td style="vertical-align:bottom;width:62.19%;margin:0pt;padding:0pt;"> Forfeited </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (318) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"> 2.61 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;">   </td></tr><tr><td style="vertical-align:bottom;width:62.19%;background:#cceeff;margin:0pt;padding:0pt;"> Outstanding, September 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 10,775 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"> ⁽⁴⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"> 3.88 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-

space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"> 7.7 </td></tr><tr><td style="vertical-align:bottom;width:62.19%;margin:0pt;padding:0pt;"> Vested, September 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ 5,525 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"> ⁽⁵⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"> $ 5.07 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"> 7.2 </td></tr></table> <table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;">Represents the weighted average exercise price.</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;">Represents the weighted average remaining contractual term for the number of years until the stock options expire.</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;">The total intrinsic value (the amount by which the fair market value exceeded the exercise price) of stock options exercised during the three months ended September 30, 2024, was $0.1 million.</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(4)</td><td style="padding:0pt;">As of September 30, 2024, the intrinsic value of outstanding options was approximately $19.2 million.</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(5)</td><td style="padding:0pt;">As of September 30, 2024, the aggregate intrinsic value of vested stock options was approximately $7.5 million.</td></tr></table>
108910003.82P8Y1M6D2400004.73380002.443180002.61107750003.88P7Y8M12D55250005.07P7Y2M12D10000019200000750000020000008 style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">For the three months ended September 30, 2024, the fair value of stock options was estimated on the respective dates of grant, with the following weighted-average assumptions: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:81.15%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.03%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:81.15%;background:#cceeff;margin:0pt;padding:0pt;"> Market price of common stock on grant date </td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.03%;background:#cceeff;margin:0pt;padding:0pt;"> 4.73 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:81.15%;margin:0pt;padding:0pt;"> Expected volatility </td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.03%;margin:0pt;padding:0pt;"> 84 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"> % </td></tr><tr><td style="vertical-align:bottom;width:81.15%;background:#cceeff;margin:0pt;padding:0pt;"> Risk free interest rate </td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.03%;background:#cceeff;margin:0pt;padding:0pt;"> 3.7 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"> % </td></tr><tr><td style="vertical-align:bottom;width:81.15%;margin:0pt;padding:0pt;"> Expected term (years) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-

align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 6.1 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"> ‌ </td></tr><tr><td style="vertical-align:bottom;width:81.15%;background:#cceeff;margin:0pt;padding:0pt;"> Dividend yield </td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.03%;background:#cceeff;margin:0pt;padding:0pt;"> 0 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"> % </td></tr></table>4.730.840.037P6Y1M6D0 Share-based compensation expense for the three months ended September 30, 2024 and 2023 is included under the following captions in the unaudited condensed consolidated statements of operations and comprehensive loss (in thousands): ‌ <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.14%;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> ‌ </td></tr><tr><td style="vertical-align:bottom;width:72.14%;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> ‌ </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> ‌ </td></tr><tr><td style="vertical-align:bottom;width:72.14%;background:#cceeff;margin:0pt;padding:0pt;"> Research and development </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 712</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">‌</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;margin:0pt;padding:0pt;"> 840 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> ‌ </td></tr><tr><td style="vertical-align:bottom;width:72.14%;margin:0pt;padding:0pt;"> General and administrative </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 688 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,009 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> ‌ </td></tr><tr><td style="vertical-align:bottom;width:72.14%;background:#cceeff;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">‌</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,849 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td></tr>
</table>712000840000688000100900014000001849000104000000P1Y9M18D1440000080000019.50P7Y For the three months ended September 30, 2024, no Legacy Warrants were granted or exercised. The following table sets forth a summary of all Legacy Warrants for the three months ended September 30, 2024 (shares in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:60.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Shares </td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Price ⁽¹⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Term ⁽²⁾ </td></tr><tr><td style="vertical-align:bottom;width:60.99%;background:#cceeff;margin:0pt;padding:0pt;"> Outstanding, June 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;margin:0pt;padding:0pt;"> 861 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;margin:0pt;padding:0pt;"> 20.28 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;margin:0pt;padding:0pt;"> 3.2 </td></tr><tr><td style="vertical-align:bottom;width:60.99%;margin:0pt;padding:0pt;"> Expirations </td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (10) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"> 52.00 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:60.99%;background:#cceeff;margin:0pt;padding:0pt;"> Outstanding, September 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 851 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;margin:0pt;padding:0pt;"> 19.90 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;margin:0pt;padding:0pt;"> 3.0 </td></tr></table> <table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;">Represents the weighted average exercise price.</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-

align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;">Represents the weighted average remaining contractual term for the number of years until the warrants expire.</td></tr></table> 086100020.28P3Y2M12D1000052.0085100019.90P3Y NOTE 9 — COMMITMENTS AND CONTINGENCIES Licensing Commitments Please refer to Note 5 for further discussion of commitments to make milestone payments and to pay royalties under license agreements with XOMA and ActiveSite. Legal Matters From time to time, the Company may be involved in litigation relating to claims arising out of operations in the normal course of business. At each reporting period, the Company evaluates known claims to determine whether a potential loss amount or a potential range of loss is probable and reasonably estimable under ASC 450, Contingencies. As of September 30, 2024, there were no pending or threatened lawsuits that could reasonably be expected to have a material effect on the Company's results of operations. Legal fees are expensed as incurred. NOTE 10 — RELATED PARTY TRANSACTIONS Related Party Licensing Agreement On September 15, 2020, the Company and Handok entered into an exclusive license agreement (the "Handok License") for the territory of the Republic of Korea. The Handok License relates to pharmaceutical products in final dosage form containing the pharmaceutical compounds developed or to be developed by the Company, including those related to ersodetug and RZ402. The Handok License is in effect for a period of 20 years after the first commercial sale of each product and requires (i) milestone payments to the Company of $0.5 million upon approval of a New Drug Application ("NDA") for each product in the territory, and (ii) the Company will sell products ordered by Handok at a transfer price equal to 70% of the net selling price of the products. To date, no milestone payments have been earned by the Company. Investors in 2024 Private Placement Handok was an investor in the 2024 Private Placement discussed in Note 7 for which the Company issued 1,250,000 shares of common stock at a purchase price of $4.00 resulting in gross proceeds of $5.0 million. P20Y5000000.70012500004.005000000.0 NOTE 11 — INCOME TAXES Income tax expense during interim periods is based on applying an estimated annualized effective income tax rate applied to the respective quarterly periods, adjusted for discrete tax items in the period in which they occur. The computation of the annualized estimated effective tax rate for each interim period requires certain estimates and significant judgment including, but not limited to, the expected operating results for the year, projections of the proportion of income earned and taxed in various jurisdictions, permanent and temporary differences, and the likelihood of recovering deferred income tax assets generated in the current year. The accounting estimates used to compute the provision for income taxes may change as new events occur, more experience is obtained, additional information becomes known or as the tax environment changes. For the three months ended September 30, 2024 and 2023, the Company did not recognize any income tax benefit due to a full valuation allowance on its deferred income tax assets. The Company did not have any material changes to its conclusions regarding valuation allowances for deferred income tax assets or uncertain tax positions for the three months ended September 30, 2024 and 2023. NOTE 12 — NET LOSS PER SHARE Basic net loss per share is computed by dividing net loss by the weighted average number of outstanding shares of common stock and PFWs during periods when the PFWs are accounted for as equity instruments. Common shares associated with PFWs that are accounted for as equity instruments are included in the computation of basic and diluted net loss per share since the exercise price is negligible and all of the PFWs are fully vested and exercisable. Accordingly, the weighted average number of shares outstanding for basic and diluted net loss per share is computed as follows for the three months ended September 30, 2024 and 2023 (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:73.87%;background:#cceeff;margin:0pt;padding:0pt;"> Common Stock </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"> 55,167 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"> 36,827 </td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"> 2021 PFWs </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 123 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> 1,661 </td></tr><tr><td style="vertical-align:bottom;width:73.87%;background:#cceeff;margin:0pt;padding:0pt;"> 2022 PFWs </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"> 8,147 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"> 12,921 </td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"> Exchange PFWs </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> 2,549 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:73.87%;background:#cceeff;margin:0pt;padding:0pt;"> 2024 PFWs </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,750 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 69,736 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 51,409 </td></tr></table> . For the three months ended September 30, 2024 and 2023, basic and diluted net loss per share were the same since all other common stock equivalents were anti-dilutive. As of September 30, 2024 and 2023, the following outstanding potential common stock equivalents were excluded from the computation of diluted net loss per share since the impact of inclusion was anti-dilutive (in thousands): . <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:80.4%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:80.4%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:80.4%;background:#cceeff;margin:0pt;padding:0pt;"> Stock options </td><td style="vertical-align:bottom;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 10,775 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"> 9,109 </td></tr><tr><td style="vertical-align:bottom;width:80.4%;margin:0pt;padding:0pt;"> Legacy warrants </td><td style="vertical-align:bottom;width:1.62%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 851 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 888 </td></tr><tr><td style="vertical-align:bottom;width:80.4%;background:#cceeff;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 11,626 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 9,997 </td></tr></table> . Accordingly, the weighted average number of shares outstanding for basic and diluted net loss per share is computed as follows for the three months ended September 30, 2024 and 2023 (in thousands): . <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:73.87%;background:#cceeff;margin:0pt;padding:0pt;"> Common Stock </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"> 55,167 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"> 36,827 </td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"> 2021 PFWs </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> 123 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> 1,661 </td></tr><tr><td style="vertical-align:bottom;width:73.87%;background:#cceeff;margin:0pt;padding:0pt;"> 2022 PFWs </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"> 8,147 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-

space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"> 12,921 </td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"> Exchange PFWs </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> 2,549 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:73.87%;background:#cceeff;margin:0pt;padding:0pt;"> 2024 PFWs </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,750 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 69,736 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 51,409 </td></tr>
</table>551670005516700036827000368270001230001230001661000166100081470008147000129210001292100025490002549000375000037500

As of September 30, 2024 and 2023, the following outstanding potential common stock equivalents were excluded from the computation of diluted net loss per share since the impact of inclusion was anti-dilutive (in thousands):

<table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;">
<tr style="height:1pt;">
<td style="vertical-align:bottom;white-space:nowrap;width:80.4%;margin:0pt;padding:0pt;"> . </td>
<td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"> . </td>
<td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"> . </td>
<td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"> . </td>
<td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"> . </td></tr>
<tr>
<td style="vertical-align:bottom;white-space:nowrap;width:80.4%;margin:0pt;padding:0pt;"> . </td>
<td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"> . </td>
<td style="vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td>
<td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"> . </td>
<td style="vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr>
<tr><td style="vertical-align:bottom;width:80.4%;background:#cceeff;margin:0pt;padding:0pt;"> Stock options </td><td style="vertical-align:bottom;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"> 10,775 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"> 9,109 </td></tr><tr><td style="vertical-align:bottom;width:80.4%;margin:0pt;padding:0pt;"> Legacy warrants </td><td style="vertical-align:bottom;width:1.62%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 851 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 888 </td></tr><tr><td style="vertical-align:bottom;width:80.4%;background:#cceeff;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 11,626 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 9,997 </td></tr></table> 1077500091090008510008880001162600009997000 NOTE 13 — FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS Fair Value Measurements Fair value is defined as the price that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants on the measurement date. When determining fair value, the Company considers the principal or most advantageous market in which it transacts and considers assumptions that market participants would use when pricing the asset or liability. The Company applies the following fair value hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement: Level 1—Quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date. Level 2—Other than quoted prices included in Level 1 that are observable for the asset and liability, either directly or indirectly through market corroboration, for substantially the full term of the asset or liability. Level 3—Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any market activity for the asset or liability at the measurement date. The following table presents information about the Company’s financial assets measured at fair value on a recurring basis and indicates the fair value hierarchy classification as of September 30, 2024 and June 30, 2024 (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:39.83%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"> | </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.83%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> | </td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:58.42%;margin:0pt;padding:0pt;"> | </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.83%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> | </td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:58.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Fair Value Measurement of Assets as of September 30, 2024 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.83%;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> | </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> | </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Level 1 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> | </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Level 2 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> | </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Level 3 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.83%;background:#cceeff;margin:0pt;padding:0pt;"> Cash and cash equivalents: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> | </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> | </td><td style="vertical-

align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.83%;margin:0pt;padding:0pt;"> Money market funds </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,894</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"> 5,894 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.83%;background:#cceeff;margin:0pt;padding:0pt;"> Marketable debt securities: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.83%;margin:0pt;padding:0pt;"> Corporate commercial paper </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"> 31,522 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"> 31,522 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.83%;background:#cceeff;margin:0pt;padding:0pt;"> U.S. Government agencies </td><td style="vertical-align:bottom;white-

space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"> 5,277 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;margin:0pt;padding:0pt;"> 5,277 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.83%;margin:0pt;padding:0pt;"> U.S. Government treasuries </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"> 13,664 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"> 13,664 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.83%;background:#cceeff;margin:0pt;padding:0pt;"> Corporate notes and bonds </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 56,890 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 56,890 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.83%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 113,247</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 5,894 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 107,353</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt

0pt;">— </td></tr></table> <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:39.83%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.83%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> . </td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:58.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Fair Value Measurement of Assets as of June 30, 2024 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.83%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Level 1 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Level 2 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Level 3 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.83%;background:#cceeff;margin:0pt;padding:0pt;"> Cash and cash equivalents: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.83%;margin:0pt;padding:0pt;"> Money market funds </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-

align:right;margin:0pt 3pt 0.05pt 0pt;"> 61,249 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"> 61,249 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.83%;background:#cceeff;margin:0pt;padding:0pt;"> Marketable debt securities: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20,929</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,997</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,997</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Corporate commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20,929</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">U.S. Government agencies</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,997</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.83%;margin:0pt;padding:0pt;"> U.S. Government treasuries </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;">

</td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"> 2,720 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"> 2,720 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.83%;background:#cceeff;margin:0pt;padding:0pt;"> Corporate notes and bonds </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"> 30,832 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;margin:0pt;padding:0pt;"> 30,832 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.83%;margin:0pt;padding:0pt;"> Asset-backed securities </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 263 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 263 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:39.83%;background:#cceeff;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 117,990</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 61,249 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 56,741</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td></tr></table> <p style="font-

family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:12pt 0pt 12pt 0pt;">Marketable debt securities classified as Level 2 within the valuation hierarchy generally consist of U.S. government agency securities, corporate bonds, and commercial paper. The Company determines the fair value of marketable debt securities based upon valuations obtained from third-party pricing sources. Except for the amounts shown in the table above, the Company did not have any other assets measured at fair value on a recurring basis as of September 30, 2024 and June 30, 2024. The Company's embedded derivative liability discussed in Note 6 is classified under Level 3 of the fair value hierarchy and is required to be measured and recorded at fair value on a recurring basis. Fair value is determined based on management's assessment of the probability and timing of occurrence for the Exit Events discussed in Note 6 using a discount rate equal to the effective interest rate under the Loan Agreement. The following table sets forth changes in the fair value of the Company's embedded derivative liability measured at fair value liability for the three months ended September 30, 2024 and 2023 (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:72.11%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:72.11%;background:#cceeff;margin:0pt;padding:0pt;"> Fair value, beginning of period </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 468</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;margin:0pt;padding:0pt;"> 412 </td></tr><tr><td style="vertical-align:bottom;width:72.11%;margin:0pt;padding:0pt;"> Changes in fair value </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 15 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 14 </td></tr><tr><td style="vertical-align:bottom;width:72.11%;background:#cceeff;margin:0pt;padding:0pt;"> Fair value, end of period </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 483</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 426 </td></tr></table> Except for the embedded derivative liability, the Company did not have any other liabilities measured at fair value on a recurring basis as of September 30, 2024 and June 30, 2024. Due to the relatively short maturity of the respective instruments, the fair value of cash, accounts payable, and accrued liabilities approximated their carrying values as of September 30, 2024 and June 30, 2024. The Company's policy is to recognize asset or liability transfers among Level 1, Level 2 and Level 3 as of the actual date of the events or change in circumstances that caused the transfer. During the three months ended September 30, 2024 and 2023, the Company did not have any transfers of its assets or liabilities between levels of the fair value hierarchy. Significant Concentrations Financial instruments that subject the Company to concentrations of credit risk consist primarily of cash, cash equivalents and investments in marketable debt securities. The Company maintains cash in demand deposit accounts at a high-quality financial institution. As of and for the three months ended September 30, 2024 and 2023, cash deposits have exceeded the amount of insurance provided on such deposits by the Federal Deposit Insurance Corporation. As of September 30, 2024, the Company has an aggregate of $41.3 million invested in the debt securities of issuers in the banking and financial services industries. While the Company's investment policy requires investments in highly rated securities, a wide variety of broad economic factors and issuer-specific factors could result in credit agency downgrades below the Company's minimum credit rating requirements that could result in losses regardless of whether the Company elects to sell the securities or hold them until maturity. To date, the Company has not experienced any credit losses or impairments of marketable debt securities due to credit rating agency downgrades. The following table presents information about the Company's financial assets measured at fair value on a recurring basis and indicates the fair value hierarchy classification as of September 30, 2024 and June 30, 2024 (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:39.83%;margin:0pt;padding:0pt;"> <p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:58.42%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:58.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Fair Value Measurement of Assets as of September 30, 2024 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Level 1 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Level 2 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Level 3 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.83%;background:#cceeff;margin:0pt;padding:0pt;"> Cash and cash equivalents: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.83%;margin:0pt;padding:0pt;"> Money market funds </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-

align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,894</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"> 5,894 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.83%;background:#cceeff;margin:0pt;padding:0pt;"> Marketable debt securities: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.83%;margin:0pt;padding:0pt;"> Corporate commercial paper </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"> 31,522 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"> 31,522 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.83%;background:#cceeff;margin:0pt;padding:0pt;"> U.S. Government agencies </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"> 5,277 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;margin:0pt;padding:0pt;"> 5,277 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt

6pt;">U.S. Government treasuries </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"> 13,664 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"> 13,664 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.83%;background:#cceeff;margin:0pt;padding:0pt;"> Corporate notes and bonds </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 56,890 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 56,890 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:39.83%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 113,247</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 5,894 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 107,353</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td></tr></table> <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:39.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> <div

style="bottom:0pt;position:absolute;width:100%;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.83%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> . </td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:58.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Fair Value Measurement of Assets as of June 30, 2024 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.83%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Level 1 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Level 2 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Level 3 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.83%;background:#cceeff;margin:0pt;padding:0pt;"> Cash and cash equivalents: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.83%;margin:0pt;padding:0pt;"> Money market funds </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 61,249</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"> 61,249 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.83%;background:#cceeff;margin:0pt;padding:0pt;"> Marketable debt securities: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"> . </td>

<td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;margin:0pt;padding:0pt;">) </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.83%;background:#cceeff;margin:0pt;padding:0pt;"> U.S. Government agencies </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;margin:0pt;padding:0pt;">) </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.83%;background:#cceeff;margin:0pt;padding:0pt;"> U.S. Government treasuries </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;">) </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.83%;background:#cceeff;margin:0pt;padding:0pt;"> Corporate commercial paper </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;margin:0pt;padding:0pt;">) </td></tr>

space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"> 30,832 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;margin:0pt;padding:0pt;"> 30,832 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.83%;margin:0pt;padding:0pt;"> Asset-backed securities </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 263 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 263 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 263 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 263 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:39.83%;background:#cceeff;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 117,990</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 61,249 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 56,741</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td></tr>
</table>5894000589400031522000315220005277000527700013664000136640005689000056890000113247000589400010735300061249000612400style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table sets forth changes in the fair value of the Company’s embedded derivative liability measured at fair value liability for the three months ended September 30, 2024 and 2023 (in thousands): . <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.11%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:72.11%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p

style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:72.11%;background:#cceeff;margin:0pt;padding:0pt;"> Fair value, beginning of period </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 468</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;margin:0pt;padding:0pt;"> 412 </td></tr><tr><td style="vertical-align:bottom;width:72.11%;margin:0pt;padding:0pt;"> Changes in fair value </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 15 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 14 </td></tr><tr><td style="vertical-align:bottom;width:72.11%;background:#cceeff;margin:0pt;padding:0pt;"> Fair value, end of period </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 483</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 426 </td></tr>
</table>468000412000150001400048300042600 0Financial instruments that subject the Company to concentrations of credit risk consist primarily of cash, cash equivalents and investments in marketable debt securities. The Company maintains cash in demand deposit accounts at a high-quality financial institution. As of and for the three months ended September 30, 2024 and 2023, cash deposits have exceeded the amount of insurance provided on such deposits by the Federal Deposit Insurance Corporation. 41300000 NOTE 14 — SUBSEQUENT EVENTS Exchange PFW Warrant Exercises In October 2024, holders of Exchange PFWs provided notice of cashless exercises of the remaining 2,389,596 Exchange PFWs outstanding, which resulted in the issuance of 2,389,111 shares of common stock. 2022 PFW Warrant Exercise On November 7, 2024, a holder of certain 2022 PFWs provided notice of cashless exercises of 2,526,318 Class B PFWs, which will result in the issuance of 2,525,883 shares of common stock in November 2024. 2389596238911125263182525883falsefalsefalsefalse '

*)*L^W&36?B7%?*1G&23W+VE%1$L51)\;?F=:Q\Z+G.B M43DNPW {'<^I?+)#+0M26BD4XKXU2K[=J/SV0S1{L1 1&>I,L[4%#(Z M#W6FA190?6>-!X%.'X3 7I]O?0Z"O1GV>6YZ.8'<[!^O'SBN<1*K]C)P6*2 M[PG.4)(',&H"Z-^#=9URK)-MT)V M3;%V;1$>T4%&7'MNG%9TH$L*+JJ^?FJ==5J8#2KY=J4M"J%V;V"+C4BKPOK6 M0CDV_^VCWZ<3X&(PHG" G#H)1B^:^J36R>F)C;9M4\T(&*>$3#O1RL:S F3] M6RK.SXF-OG.(WJHP>28$Q;1(N-,$W()4TLPR+-68Q[X3(.BS"+KZ2G,'CDK$ M'*4 GY2R*K3BJM">#PI"=^Q;,\LW1R5N2[L

"
=